<SEC-DOCUMENT>0001615774-17-003091.txt : 20170612
<SEC-HEADER>0001615774-17-003091.hdr.sgml : 20170612
<ACCEPTANCE-DATETIME>20170609173710
ACCESSION NUMBER:		0001615774-17-003091
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20170612
DATE AS OF CHANGE:		20170609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-215204
		FILM NUMBER:		17903911

	BUSINESS ADDRESS:	
		STREET 1:		PO BOX 8694
		CITY:			ARMADALE, VICTORIA
		STATE:			C3
		ZIP:			3143
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		PO BOX 8694
		CITY:			ARMADALE, VICTORIA
		STATE:			C3
		ZIP:			3143
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>s106515_424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(4)</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right"><B>File No. 333-215204</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 12pt"><B>$6,100,000
of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 12pt"><B>American
Depositary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 12pt"><B>and
Warrants</B></FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="logo_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immuron Limited</B></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering 610,000 American Depositary
Shares (each, an &ldquo;ADS&rdquo; and, collectively the &ldquo;ADSs&rdquo;) and warrants to purchase 610,000 (each a &ldquo;Warrant&rdquo;
and, collectively the &ldquo;Warrants&rdquo;). Each ADS will represent forty (40) of our ordinary shares. Each Warrant has an per
ADS exercise price of $10.00, is exercisable immediately and expire five years from the date of issuance. The initial public offering
price for each ADS is $9.99 and $0.01 per Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, the ADSs have not
been listed on any stock exchange. As of June 9, 2017, the ADSs and Warrants are listed on The NASDAQ Capital Market under the
symbol &ldquo;IMRN&rdquo; and &ldquo;IMRNW&rdquo;, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ordinary shares are listed on the
Australian Securities Exchange under the symbol &ldquo;IMC.&rdquo; On June 7, 2017, the closing price of our ordinary shares on
the Australian Securities Exchange was AUD$0.50 per ordinary share, equivalent to $15.08 per ADS based on an exchange rate of
AUD$1.00 to $0.7540 (as published by the Reserve Bank of Australia as of June 7, 2017).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are an &ldquo;emerging growth
company,&rdquo; as that term is used in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and, as such, we have elected
to comply with certain reduced public company reporting requirements for future filings. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our ordinary shares
in the form of ADSs involves a high degree of risk. See &ldquo;<U>Risk Factors</U>&rdquo; beginning on page 10 of this prospectus.
</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Neither the Securities and Exchange
Commission nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per ADS</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Warrant</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-indent: -10pt; padding-left: 10pt">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9.99</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.01</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.6993</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Does not include a non-accountable expense allowance
equal to 1% of the gross proceeds of this offering payable to Joseph Gunnar &amp; Co., and Rodman &amp; Renshaw, a unit of H.C.
Wainwright &amp; Co., the representatives of the underwriters. See &lsquo;&lsquo;Underwriting&rsquo;&rsquo; for a description of
compensation payable to the underwriters.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have granted a 45-day option to the
representatives of the underwriters to purchase up to 91,500 ADSs and/or 91,500 Warrants solely to cover over-allotments, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0">The underwriters expect to deliver our ADSs and Warrants to the purchasers on or about June 14, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 18pt"><B>Joseph Gunnar &amp; Co.</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 18pt"><B>Rodman &amp; Renshaw,</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt"><P STYLE="margin: 0pt 0"><B>a unit of H.C. Wainwright &amp; Co.</B></P>


</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 11pt"><B>WallachBeth
Capital, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Prospectus dated June 9, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_002">Industry and Market Data</A></TD>
    <TD STYLE="text-align: center">ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_003">Trademarks and Tradenames</A></TD>
    <TD STYLE="text-align: center">ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_004">Prospectus Summary</A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_005">The Offering</A></TD>
    <TD STYLE="text-align: center">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006">Summary Historical Consolidated Financial Data</A></TD>
    <TD STYLE="text-align: center">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_007">Risk Factors</A></TD>
    <TD STYLE="text-align: center">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008">Cautionary Note Regarding Forward-Looking Statements</A></TD>
    <TD STYLE="text-align: center">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_009">Use of Proceeds</A></TD>
    <TD STYLE="text-align: center">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_010">Price Range of Ordinary Shares</A></TD>
    <TD STYLE="text-align: center">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_011">Dividend Policy</A></TD>
    <TD STYLE="text-align: center">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_012">Exchange Rate Information</A></TD>
    <TD STYLE="text-align: center">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_013">Capitalization</A></TD>
    <TD STYLE="text-align: center">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_014">Dilution</A></TD>
    <TD STYLE="text-align: center">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_015">Selected Historical Consolidated Financial Data</A></TD>
    <TD STYLE="text-align: center">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_016">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD STYLE="text-align: center">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_017">Business</A></TD>
    <TD STYLE="text-align: center">61</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_018">Directors and Management</A></TD>
    <TD STYLE="text-align: center">88</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_019">Principal Shareholders</A></TD>
    <TD STYLE="text-align: center">96</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_020">Related Party Transactions</A></TD>
    <TD STYLE="text-align: center">97</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_021">Description of Share Capital</A></TD>
    <TD STYLE="text-align: center">101</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_022">Description Of American Depositary Shares</A></TD>
    <TD STYLE="text-align: center">109</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#d_0032">Description of the Warrants</A></TD>
    <TD STYLE="text-align: center">116</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_023">Shares Eligible for Future Sale</A></TD>
    <TD STYLE="text-align: center">116</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_024">Taxation</A></TD>
    <TD STYLE="text-align: center">117</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_025">Underwriting</A></TD>
    <TD STYLE="text-align: center">125</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_026">Expenses Relating to This Offering</A></TD>
    <TD STYLE="text-align: center">128</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_027">Legal Matters</A></TD>
    <TD STYLE="text-align: center">128</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_028">Experts</A></TD>
    <TD STYLE="text-align: center">129</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_029">Enforceability of Civil Liabilities</A></TD>
    <TD STYLE="text-align: center">129</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_030">Where You Can Find Additional Information</A></TD>
    <TD STYLE="text-align: center">129</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_031">Index to Consolidated Financial Statements</A></TD>
    <TD STYLE="text-align: center">F-1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">You may rely only
on the information contained in this prospectus. Neither we nor any of the underwriters have authorized anyone to provide information
different from that contained in this prospectus. When you make a decision about whether to invest in the ADSs and Warrants, you
should not rely upon any information other than the information in this prospectus. Neither the delivery of this prospectus nor
the sale of ADSs and Warrants means that information contained in this prospectus is correct after the date of this prospectus.
This prospectus is not an offer to sell or solicitation of an offer to buy the ADSs and Warrants in any circumstances under which
the offer of solicitation is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">We have not taken
any action to permit a public offering of the ADSs and Warrants outside the United States or to permit the possession or distribution
of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must
inform themselves about and observe any restrictions relating to the offering of the ADSs and Warrants and the distribution of
this prospectus outside of the United States.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>CONVENTIONS THAT
APPLY TO THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Unless otherwise
indicated or the context implies otherwise:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">&ldquo;we,&rdquo;
                                         &ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;Immuron&rdquo; refers to Immuron Limited,
                                         an Australian corporation;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">&ldquo;shares&rdquo;
                                         or &ldquo;ordinary shares&rdquo; refers to our ordinary shares;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">&ldquo;ADSs&rdquo;
                                         refers to American Depositary Shares, each of which represents 40 ordinary shares;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">&ldquo;ADRs&rdquo;
                                         refers to American Depositary Receipts, which evidence the ADSs; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0">Warrants&rdquo;
                                         refers to warrants to purchase ADSs.</P>


</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our reporting
and functional currency is the Australian dollar. Solely for the convenience of the reader, this prospectus contains translations
of some Australian dollar amounts into U.S. dollars at specified rates. Except as otherwise stated in this prospectus, all translations
from Australian dollars to U.S. dollars are based on the rate published by the Reserve Bank of Australia on the date indicated.
See &ldquo;Exchange Rate Information.&rdquo; No representation is made that the Australian dollar amounts referred to in this
prospectus could have been or could be converted into U.S. dollars at such rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Unless otherwise noted,
all industry and market data in this prospectus, including information provided by independent industry analysts, is presented
in U.S. dollars. Unless otherwise noted, all other financial and other data related to Immuron Limited in this prospectus is presented
in Australian dollars. All references to &ldquo;$&rdquo; in this prospectus (other than in our audited consolidated financial
statements) refer to U.S. dollars. All references to &ldquo;AUD$&rdquo; or &ldquo;AUD&rdquo; in this prospectus mean Australian
dollars.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our fiscal year
end is June&nbsp;30. References to a particular &ldquo;fiscal year&rdquo; are to our fiscal year ended June&nbsp;30 of that calendar
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Unless otherwise
indicated, the consolidated financial statements and related notes included in this prospectus have been prepared in accordance
with International Accounting Standards (IAS) and also comply with International Financial Reporting Standards, or IFRS, and interpretations
issued by the International Accounting Standards Board, or IASB, which differ in certain significant respects from Generally Accepted
Accounting Principles in the United States, or GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_002"></A><B>INDUSTRY
AND MARKET DATA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">This prospectus
includes information with respect to market and industry conditions and market share from third-party sources or based upon estimates
using such sources when available. We believe that such information and estimates are reasonable and reliable. We also believe
the information extracted from publications of third-party sources has been accurately reproduced. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>TRADEMARKS AND
TRADENAMES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We have rights
to trademarks and tradenames (both registered and unregistered) used in this prospectus which are important to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These trademarks are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt">-</TD><TD>Immuron (registration in process)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt">-</TD><TD>Travelan (registration in U.S., Australia and China)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt">-</TD><TD>Protectyn (registration in Australia and Europe)</TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt">-</TD><TD>IMM-124E (unregistered)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt">-</TD><TD>IMM-529 (unregistered)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Solely for convenience,
trademarks and trade names referred to in this prospectus appear without the &ldquo;<FONT STYLE="font-size: 10pt"><SUP>&reg;</SUP></FONT>&rdquo;
or &ldquo;&trade;&rdquo; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the
fullest extent possible under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade
names. We do not intend our use or display of other companies&rsquo; trade names, trademarks or service marks to imply a relationship
with, or endorsement or sponsorship of us by, any other companies. Each trademark, trade name or service mark of any other company
appearing in this prospectus is the property of its respective holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 99%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>PROSPECTUS SUMMARY
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>This summary
provides a brief overview of information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed
information and the financial statements and notes thereto included elsewhere in this prospectus. This summary does not contain
all of the information that you should consider before investing in the ADSs and Warrants. You should read the entire prospectus
carefully before making an investment decision, including the information presented under the headings &ldquo;Risk Factors,&rdquo;
&ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; and the historical consolidated financial statements and the related notes to those
financial statements included elsewhere in this prospectus. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We are a clinical-stage
biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class
of immunomodulator polyclonal antibodies that we believe can address significant unmet medical needs. Immunomodulator polyclonol
antibodies are blood proteins that are produced by the immune system to attack foreign substances such as bacteria and can be
specifically utilized to increase and/or decrease the activity of the immune system. &nbsp;Our oral polyclonal antibodies offer
targeted delivery within the gastrointestinal (GI) track but do not cross into the bloodstream. We believe that our two lead immunomodulator
product candidates, IMM-124E and IMM-529, have the potential to transform the existing treatment paradigms for NASH (Non Alcoholic
Steatohepatitis) and for Clostridium difficile (C. difficile), respectively. We also market an OTC product, Travelan, has been
designated by the Therapeutic Goods Administration (&ldquo;TGA&rdquo;) in Australia and Health Canada as being preventative to
Traveler&rsquo;s Diarrhea&nbsp;. Travelan is also based on the same technology. Generally Regarded as Safe&nbsp; (&ldquo;GRAS&rdquo;)
is a Food and Drug Administration (&ldquo;FDA&rdquo;) designation which designates a chemical or substance that is added to food
as &ldquo;safe&rdquo; by experts exempting such chemical or substance from Federal Food, Drug and Cosmetic Act (&ldquo;FFDCA&rdquo;)
food additive tolerance requirements. We previously submitted a GRAS notification to the FDA as part of our investigational new
drug (&ldquo;IND&rdquo;) &nbsp;application with respect to IMM-124E which designation, to date, has not challenged by the FDA.
The safety profile of our compounds, which has a GRAS status, enables us to commercialize our platform-derived products through
a range of regulatory pathways, including prescription (Rx), medical foods, over-the-counter (OTC) medicines and dietary supplements.
As of December 31, 2016 and June 30, 2016, our accumulated deficit was AUD$46,175,581 and AUD$42,821,357, respectively&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Lipopolysaccharide
(&ldquo;LPS&rdquo;) is the&nbsp; major component of the outer membrane of Gram-negative bacteria, and IMM-124E is a first-in-class
oral anti-LPS polyclonal antibody and a powerful regulator agent of regulatory T-cells. IMM-124E is currently in Phase 2 clinical
trial in the United States, Australia and Israel for the treatment of nonalcoholic steatohepatitis (NASH). We expect that top
line results will be available in the second half of 2017. IMM-124E is also the investigational drug of two National Institute
of Health (&ldquo;NIH&rdquo;) sponsored Phase 2 clinical trials in alcoholic steatohepatitis (ASH) and Pediatric NASH. NIH is
an agency of the United States Department of Health and is one of the world&rsquo;s foremost medical research centers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">IMM-529 targets
the C. difficile bacterium and contains polyclonal antibodies to the Toxin B, the spores and the vegetative cells. We successfully
completed our pre-clinical program in January 2016 and are currently preparing our clinical supplies to support our Phase 1/2
clinical trials, which will enroll as many as 60 patients. We plan to initiate our Phase 1/2 clinical trial in Israel in the second
quarter of 2017. As the clinical trial will be conducted outside of the United States, specifically, in Israel, the Company is
not required to apply for an IND.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Because our assets
target different biological pathways and act on diseases in completely novel ways, we believe that both IMM-124E and IMM-529 have
the potential to be the backbone therapies in their respective fields.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 99%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Major Markets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our two lead assets
target two prevalent diseases with major unmet need: NASH and C. <I>difficile</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">NASH, which is
now an epidemic of global proportion, is driven by obesity and a &ldquo;western lifestyle&rdquo;. NASH is a severe disease of
the liver caused by chronic inflammation and a buildup of fat in the liver, and is one of the most severe manifestations of NAFLD
(nonalcoholic fatty-liver disease). The presentation of NASH resembles alcoholic liver disease but occurs in people who drink
little or no alcohol. Current estimates place NASH prevalence at approximately 24 million people in the United States, or approximately
7% of the population, with similar prevalence in other major developed markets. There are currently no approved therapies for
the treatment of NASH, making this disease one of the largest unmet medical needs in the world today, and a key therapeutic area
(TA) targeted by large pharmas. A major analyst report by Deutche Bank in 2014, forecasted a $35B-$40B market by 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Clostridium <I>difficile</I>,
or C. <I>difficile</I>, is a gram-positive, toxin-producing, spore-forming bacterium that generally causes severe and persistent
diarrhea in infected individuals, but can also lead to more severe outcomes, including in the most serious cases, death. C. <I>difficile
</I>infection (CDI) is most often associated with the prior use of antibiotics. The U.S. Centers for Disease Control has identified
CDI as one of the top three most urgent antibiotic-resistant bacterial threats in the United States. It is the most common cause
of hospital acquired infection in the United States and has overtaken methicillin-resistant Staphylococcus aureus in prevalence
with an estimated 450,000 acute infections per year, and nearly 100,000 cases of first recurrences. CDI is responsible for the
death of approximately 29,000 Americans each year.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The versatility
of our platform allows us to target other immune mediated diseases such as Inflammatory Bowel Disease (IBD) and infectious agents
such as shigella and campylobacter. Both therapeutic areas ecompass millions of potential patients and present significant unmet
medical needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Immuron&rsquo;s
platform technology is based on producing antigen targeted, hyper-immune bovine colostrum powder (BCP) suitable for pharmaceutical
use. Polyclonal antibodies are collected from the first milking of a cow after calving. Prior to calving, cows are immunized with
proprietary vaccines to ensure maximum immunogenicity and after calving, the first milk is harvested and purified. This proprietary
process ensures that the colostrum contains a high concentration of antibodies and high concentrations of Immunoglobulin G1. The
technology is safe (classified as GRAS by the FDA), low cost, and can be applied to a variety of diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The underlying
nature of Immuron&rsquo;s platform technology enables the development of medicines across a large range of diseases, including
infectious diseases and immune mediated disorders. The platform can be used to influence the cell-mediated immune system through
regulatory T cell populations, or it can directly block viruses or bacteria at mucosal surfaces (such as the GI tract) and neutralize
the toxins they produce. Additionally, the dairy origins of Immuron&rsquo;s antibodies enables us to commercialize our platform
through most regulatory pathways, including prescription (Rx), medical foods, over-the-counter medicines, and dietary supplements.
The GRAS status of our technology platform allow us to advance our preclinical programs into clinical trials faster relative to
other companies due to the platform&rsquo;s proven safety profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">IMM-124E is currently
in an ongoing Phase 2 clinical study for the treatment of NASH. Over 100 patients have been recruited to date out of a target
of 120. We estimate that top line results will be available in the second half of 2017. The mechanism of action for IMM-124E is
unique and acts on multiple pathways to significantly reduce inflammation in the liver by (1) targeting the gut innate immune
system to upregulate regulatory T cell (Treg) populations and (2) by neutralizing intestinal bacterial-LPS, thereby decreasing
the translocation of these toxins into the liver, and thus reducing pro-inflammatory burden in the gut and in the liver.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 99%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In addition to
NASH, <B>IMM-124E</B> is also in <B>two NIH-sponsored</B> Phase 2 clinical trials for the treatment of <B>ASH</B>, in collaboration
with Dr. Arun Sanyal at the University of Virginia, and in <B>Pediatric NASH</B>, in collaboration with Dr. Miriam Vos at Emory
University. We are unaware of another company in the field of fatty-liver diseases with such a comprehensive set of Phase 2 trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>IMM-529
</I></B>has successfully completed its pre-clinical program in <B>CDI </B>and we estimate that we will begin Phase 1/2 trials
in Israel in the second quarter of 2017. IMM-529 which was developed in collaboration with world leading C. <I>difficile </I>researcher
Dr. Dena Lyras and her team at Monash University, targets the virulent Toxin B, the spores and the vegetative cells. It is a three
pronged approach that is unique and which has yielded exceptional results in the pre-clinical studies including (1) Prevention
of primary disease, (2) Treatment of primary disease and (3) Suppression of recurrence. To our knowledge, it is to date the only
investigational drug that has showed therapeutic benefits in all three phases of the disease.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to
these programs, we also have two research collaborations with the U.S. Department of Defense including with the <B>U.S. Navy</B>
and with the <B>U.S. Army</B>, for the study of <B>shigella, campylobacter and Enterotoxigenic Escherichia coli (&ldquo;ETEC&rdquo;)
vaccines</B>. ETEC is a type of E-coli and is&nbsp;one of the leading bacterial&nbsp; causes of diarrhea in the developing world,
as well as the most common cause of travelers&rsquo; diarrhea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We also started
a pre-clinical program in <B>IBD,</B> in collaboration with renowned IBD KOL, Professor Gerhard Rogler, MD, PhD. and the university
of Zurich, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="pg8img1_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We believe that
the breath/depth of our assets and the support we are receiving from the NIH and the DoD, makes us truly a unique and attractive
player in the TAs that we target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Marketed Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>Travelan &ndash;
A Unique OTC:</B> Travelan is the only product currently on the market designated by TGA and Health Canada for the prevention
of Traveler&rsquo;s Diarrhea (TD). Travelan uses hyperimmune BCP from cows vaccinated against various strains of ETEC to protect
against TD and to reduce the risk of TD, along with the symptoms of minor gastrointestinal disorders. Two independent, double-blinded,
placebo-controlled clinical trials in Europe in 90 healthy volunteers showed protection of up to 90% against infection with the
type of E. coli that causes TD, along with indicating a significant reduction in abdominal cramps and stomach pain. There were
no reported side effects in the clinical trials. Importantly, because Travelan is not an antibiotic, it does not have the side-effect
profile of antibiotics and also does not contribute to the worldwide concerns about bacterial drug resistance. Sales in fiscal
year 2016 were AUD$1.0M.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Travelan is now
marketed in four countries: Australia, U.S.A, China and Canada (with our partner Paladin Labs, a branch of Endo Pharmaceuticals
that sells products for the Canadian Market), and we plan to launch the products in additional countries. &nbsp;Effective February
23, 2017, the Company terminated its marketing and distribution agreement with Paladin for failure to purchase the minimum quantities
of product pursuant to the agreement; <I>provided, however</I>, that Paladin shall be entitled to continue selling existing inventory
in the Territory (as defined in the agreement) for a period of 6 months from the date of termination. The Company may, but is
not required to, repurchase any inventory from Paladin. After termination of the agreement with Paladin, the Company will continue
to sell Travelan in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 99%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>Protectyn &ndash;
For Gut Dysbiosis.</B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During fiscal year 2016, we launched
Protectyn in Australia, which is an OTC targeting LPS bacteria in the gut to prevent gut dysbiosis, improve bacterial clearance,
reduce chronic inflammation and improve immune function. This product has been formulated to help maintain healthy digestive function
and help support the liver. The product was launched in late 2015 and is currently in its market ramp up phase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our goal is to
become one of the leading biopharmaceutical company developing and commercializing therapeutics to address increased unmet medical
needs in inflammation-mediated diseases and anti-infectious diseases. The critical components of our strategy include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Rapidly
                                         advance</B> our two lead oral polyclonal antibodies, IMM-124E and IMM-529:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify"><B>IMM-124E/NASH: </B>Continue
                                         progressing our IMM-124E Phase 2 for the treatment of NASH with a target for top line
                                         read-out of second half of 2017; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify"><B>IMM-529/CDI: </B>Finalize
                                         development of clinical supplies and Phase 1/2 protocol with a target Phase 1/2 start
                                         in second quarter of 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Leverage
                                         our technology platform and our collaborations to expand</B> our differentiated polyclonal-based
                                         product pipeline across multiple indications including ASH, Pediatric NASH and various
                                         novel and potentially game-changing anti-infective programs with the DoD (U.S. Army and
                                         U.S. Navy).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Partner
                                         our fatty-liver programs </B>at the right time and with the right commercial / development
                                         partner(s) for NASH, ASH and pediatric NASH.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Continue
                                         investing in and growing Travelan Worldwide</B> including in the U.S., Australia, Canada
                                         and China, and in new markets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Continue
                                         investing in mechanism of action studies</B> that expands our understanding of our unique
                                         MOA across our targeted diseases and conditions, and potentially identify new opportunities
                                         for investment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Protect
                                         and leverage</B> our intellectual property portfolio and patents. We believe that our
                                         intellectual property protection strategy, grounded in securing composition of matter
                                         patents on the biologics we develop, as well as broader patents to protect our technology
                                         platform, has best positioned us to gain broad and strong protection of our assets. We
                                         have 13 issued patents and 23 pending patent applications worldwide. We have been issued
                                         patents in the U.S., Australia, Canada, India, Japan and New Zealand.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Management Team </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our management
and development team has extensive experience in designing and developing therapeutics, ensuring a stable manufacturing supply
chain and bringing products to the market (either in partnerships/BD or organically), gained across both large pharmas (e.g.,
Pfizer) and leading and emerging biotechnology companies (e.g., CSL).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our advisory Board
includes some of the foremost experts in the their field including Dr. Arun Sanyal in NASH and Professor Dena Lyras in C. <I>difficile</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dual Listing - Australian Securities
Exchange and The NASDAQ Capital Market</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ordinary shares
are currently listed on the Australian Securities Exchange, or ASX under the symbol &ldquo;IMC&rdquo;, and the ADSs and Warrants
are listed on The NASDAQ Capital Market under the symbol &ldquo;IMRN&rdquo; and &ldquo;IMRNW&rdquo;, respectively. The investor
in our convertible notes issued in February 2016 has the right to require that we delist from NASDAQ at any time when our primary
listing is not on the ASX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risk Factors</B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt; background-color: white">You
should carefully consider the risks described under the &ldquo;Risk Factors&rdquo; section beginning on page 10. Some of these
risks are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Risk
                                         associated with our profitability including, but not limited to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 99%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         have incurred operating losses since we began operations and may not be profitable in
                                         the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Risk
                                         associated with clinical trials, the development of our products and acceptance in the
                                         market of our products including, but not limited to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Clinical
                                         trials are expensive and time consuming, and their outcome is uncertain;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         may experience delays in our clinical trials that could adversely affect our business
                                         and operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         rely on third parties to conduct our preclinical studies and clinical trials and if such
                                         third parties do not meet our deadlines or otherwise conduct the studies as required,
                                         we may be delayed in progressing, or ultimately may not be able to progress, product
                                         candidates to clinical trials, our clinical development programs could be delayed or
                                         unsuccessful, and we may not be able to commercialize or obtain regulatory approval for
                                         our product candidates when expected, or at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         may not be able to secure and maintain research institutions to conduct our future trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         have limited large scale manufacturing experience with our product candidates.&nbsp;&nbsp;Delays
                                         in manufacturing sufficient quantities of such materials to the required standards for
                                         pre-clinical and clinical trials may negatively impact our business and operations;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         may not be able to complete the development of IMM-124E or develop other pharmaceutical
                                         products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         may need to prioritize the development of our most promising candidates at the expense
                                         of the development of other products;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Physicians,
                                         patients, third-party payors or others in the medical community may not be receptive
                                         to our product candidates, and we may not generate any future revenue from the sale or
                                         licensing of our product candidates; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">If
                                         healthcare insurers and other organizations do not pay for our products, or impose limits
                                         on reimbursement, our future business may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Risks
                                         associated with intellectual property including, but not limited to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">We may not be successful in obtaining
                                         or maintaining other necessary rights necessary to the development of our pipeline through
                                         acquisitions and in-licenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Risks
                                         associated with competition and manufacturing including, but not limited to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         face competition from entities that have developed or may develop product candidates
                                         for our target disease indications, including companies developing novel treatments and
                                         technology platforms based on modalities and technology similar to ours; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         depend upon a sole manufacturer of our lead compound and on a sole manufacturer to encapsulate
                                         the compound and could incur significant costs and delays if we are unable to promptly
                                         find a replacement for either of them.&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Risks
                                         associated with government regulation including, but not limited to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">If
                                         we do not obtain the necessary governmental approvals, we will be unable to commercialize
                                         our pharmaceutical products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">We
                                         will not be able to commercialize any current or future product candidates if we fail
                                         to adequately demonstrate their safety, efficacy and superiority over existing therapies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Even
                                         if we obtain regulatory approval for a product candidate, our products may remain subject
                                         to regulatory scrutiny; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Healthcare
                                         reform measures and other statutory or regulatory changes could adversely affect our
                                         business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Risk
                                         associated with the ADSs, Warrants and this Offering including, but not limited to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">If
                                         we are classified as a &ldquo;passive foreign investment company,&rdquo; our U.S. shareholders
                                         could suffer adverse tax consequences as a result;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 99%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The
                                         market price and trading volume of the ADSs and Warrants may be volatile and may be affected
                                         by economic conditions beyond our control;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Investors
                                         purchasing the ADSs will suffer immediate and substantial dilution;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Currency
                                         fluctuations may adversely affect the price of our ordinary shares, ADSs and Warrants;
                                         and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The
                                         dual listing of our ordinary shares and the ADSs following this offering may adversely
                                         affect the liquidity and value of the ADSs, and the investor in our convertible notes
                                         issued in February 2016 has the right to require&nbsp; that we delist from NASDAQ at
                                         any time when our primary listing is not on the ASX.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
and other risks described in this prospectus could materially and adversely impact our business, financial condition, operating
results and cash flow, which could cause the trading price of our ADSs and Warrants to decline and could result in a loss of your
investment.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Immuron Limited
was incorporated under the laws of Australia in 1994 and has been listed on the Australian Securities Exchange, or ASX, since
April 30, 1999.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our headquarters
are located at Suite 1, 1233 High Street, Armadale, Victoria, Australia 3143. Our telephone number is +61 (0)3 9824 5254. Our
website address is www.immuron.com. Information on our website and the websites linked to it do not constitute part of this prospectus
or the registration statement to which this prospectus forms a part. Our agent for service of process in the United States is
Delaney Corporate Services Ltd., 99 Washington Avenue, Suite 805A, Albany, New York 12210</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Implications of Being an Emerging
Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a company with less than $1.0 billion in revenue during our last fiscal year, with less than $1 billion in </FONT>non-convertible
debt securities issued in the past three years, and that is pursuing a first registered equity offering in the United States,
we qualify as an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS
Act. An emerging growth company may avail itself of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies. For example, we have elected to rely on an exemption from the
auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, relating to
internal control over financial reporting, and we will not provide such an attestation from our auditors for as long as we qualify
as an emerging growth company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">We will remain an emerging growth company
until the earliest of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the end
                                         of the fiscal year in which the fifth anniversary of the completion of this offering
                                         occurs;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the end
                                         of the first fiscal year in which the market value of our ordinary shares held by non-affiliates
                                         exceeds US $700 million as of the end of the second quarter of such fiscal year;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the end
                                         of the first fiscal year in which we have total annual gross revenues of at least US
                                         $1&nbsp;billion; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the date
                                         on which we have issued more than US $1 billion in non-convertible debt securities in
                                         any rolling three-year period.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Once we cease
to be an emerging growth company, we will not be entitled to the exemptions provided for by the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Implications of Being a Foreign Private
Issuer</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We are also considered
a &ldquo;foreign private issuer&rdquo; pursuant to Rule 405 under the Securities Act of 1933, as amended<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
or the Securities Act. In our capacity as a foreign private issuer, we are exempt from certain rules under the Securities Exchange
Act of 1934, as amended, or the Exchange Act, that impose certain disclosure obligations and procedural requirements for proxy
solicitations under Section&nbsp;14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt
from the reporting and &ldquo;short-swing&rdquo; profit recovery provisions of Section&nbsp;16 of the Exchange Act and the rules
under the Exchange Act with respect to their purchases and sales of our ordinary shares. Moreover, we are not required to file
periodic reports and financial statements with the U.S. Securities and Exchange Commission, or SEC, as frequently or as promptly
as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation
FD, which restricts the selective disclosure of material information. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We may take advantage
of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer
at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances
applies: (1)&nbsp;the majority of our executive officers or directors are U.S. citizens or residents; (2)&nbsp;more than 50% of
our assets are located in the United States; or (3)&nbsp;our business is administered principally in the United States. We are
required to determine our status as a foreign private issuer on an annual basis at the end of our second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</DIV>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>THE OFFERING
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">Securities
    &nbsp;offered by us </FONT></TD>
    <TD STYLE="width: 62%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">610,000 ADSs (or up to&nbsp;701,500 ADSs
if the underwriters exercise their option to purchase additional ADSs in full) at a combined purchase price for each ADS and Warrant
of $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0">Warrants to purchase&nbsp;610,000 ADSs. Each Warrant will have a per ADS exercise price of $10.00, will
be exercisable immediately and will expire five years from the date of issuance. To better understand the terms of the Warrants,
you should carefully read the section in this prospectus entitled &ldquo;Description of the Warrants.&rdquo;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">ADSs to be outstanding
    immediately after this offering </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">610,000 ADSs (or 701,500 ADSs if the underwriters exercise their option to purchase additional ADSs in
full), excluding ADSs underlying the Warrants.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">Ordinary shares
    to be outstanding immediately after this offering, including shares underlying ADSs</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">128,041,417&nbsp;ordinary shares (or 131,701,417 ordinary shares if the underwriters exercise their option
to purchase additional ADSs in full), excluding ordinary shares underlying the Warrants.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">Underwriters&rsquo; option to purchase
    additional ADSs &nbsp;and/or Warrants</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have granted the underwriters a 45-day option to purchase up to an additional 91,500 ADSs and/or 91,500
Warrants to cover overallotments, if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">The ADSs</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each ADS represents 40 ordinary shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">The depositary (as identified below)
    will be the holder of the ordinary shares underlying the ADSs and you will have the rights of an ADS holder as provided in
    the deposit agreement among us, the depositary and holders and beneficial owners of ADSs from time to time.</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">You may surrender your ADSs to the depositary
    to withdraw the ordinary shares underlying your ADSs. The depositary will charge you a fee for such an exchange.</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We may amend or terminate the deposit
    agreement for any reason without your consent. Any amendment that imposes or increases fees or charges or which materially
    prejudices any substantial existing right you have as an ADS holder will not become effective as to outstanding ADSs until
    30&nbsp;days after notice of the amendment is given to ADS holders. If an amendment becomes effective, you will be bound by
    the deposit agreement as amended if you continue to hold your ADSs.</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">To better understand the terms of the
    ADSs, you should carefully read the section in this prospectus entitled &ldquo;Description of American Depositary Shares.&rdquo;
    We also encourage you to read the deposit agreement, which is an exhibit to the registration statement to which this prospectus
    forms&nbsp;a part.</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">Depositary</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Bank of New York Mellon.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
    Price</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10.00 per ADS and Warrant. See &ldquo;Underwriting&rdquo;
    for a discussion of factors considered in determining the price of public ADSs.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">Shareholder approval
    of offering</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Under Australian law, certain steps necessary for the consummation
    of this offering require the approval of our shareholders voting at a general meeting of shareholders. We expect to receive
    all such required approvals from our shareholders prior to the completion of this offering.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="width: 62%; text-align: justify"><FONT STYLE="font-size: 10pt">The net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions
and estimated offering expenses payable by us, will be approximately $4,800,000.&nbsp;&nbsp;We intend to use the net proceeds from
this offering to advance our products and platform technologies&nbsp;and for working capital and for general corporate purposes.
See &ldquo;Use of Proceeds&rdquo; for a description of the intended use of proceeds from this offering.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You should carefully read and consider the information in
    this prospectus under the heading &nbsp;&ldquo;Risk Factors&rdquo; beginning on page 10 and other information included in
    this prospectus before deciding to invest in the ADSs.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">NASDAQ Capital Market</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our ADSs and Warrants are listed on NASDAQ under the symbol &ldquo;IMRN&rdquo; and &ldquo;IMRNW&rdquo;,
respectively</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12.2pt; text-indent: -12.2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12.2pt; text-indent: -12.2pt"><FONT STYLE="font-size: 10pt">Lock-up Agreements</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We and our directors and executive officers have agreed with the underwriters, subject to certain exceptions,
not to sell or transfer &nbsp;any of the ordinary shares, the ADSs or securities convertible into or exchangeable or exercisable
for ordinary shares or ADSs for a period of (i) three months after the date of this prospectus in the case of our directors and
officers and (ii) 180 days after the date of this prospectus in the case of the Company without the prior written consent of the
representatives of the underwriters. See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The number of ordinary shares shown
above that will be outstanding immediately following the completion of this offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">is based on 103,641,417 ordinary shares outstanding as of June 7, 2017; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0">excludes an aggregate 34,177,523 of ordinary shares issuable upon the exercise of options outstanding
at June 7, 2017, at a weighted average exercise price of AUD$0.543, of which options to purchase 33,177,523 ordinary shares were
vested at a weighted average exercise price of AUD$0.544.</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Except as otherwise indicated herein, all information in this prospectus assumes no exercise by the underwriters
of their option to purchase up to 91,500 additional ADSs and/or 91,500 Warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 24.5pt"><B>&nbsp;</B></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 24.5pt"><A NAME="a_006"></A><B>SUMMARY
                                         HISTORICAL CONSOLIDATED FINANCIAL DATA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The following tables set forth summary
historical consolidated financial data for the periods indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The consolidated
statement of profit or loss and other comprehensive income data for the years ended June&nbsp;30, 2016, 2015 and 2014 and consolidated
statement of financial position data as of June&nbsp;30, 2016 and 2015 are derived from the audited consolidated financial statements
included in this prospectus. The consolidated statement of profit or loss and other comprehensive income data for the six months
ended December 31, 2016 and 2015 and consolidated statement of financial position data as of the six months ended December 31,
2016 are derived from the unaudited consolidated financial statements included in this prospectus.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our consolidated
financial statements have been prepared in Australian dollars and in accordance with International Accounting Standards and IFRS,
as issued by the IASB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">You should read the
summary historical consolidated financial data in conjunction with our consolidated financial statements and related notes beginning
on page&nbsp;F-1 of this prospectus, and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations&rdquo; included elsewhere in this prospectus. Our historical results do not necessarily indicate our expected results
for any future periods. Financial results for the year ended June 30, 2016 and the six months ended December 31, 2016 are not
necessarily indicative of the results that may be expected for the year ending June 30, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the year ended
    June&nbsp;30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the six months
    ended <BR>
    December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2015</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2014</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2015</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Consolidated Statement of Profit or Loss and Other Comprehensive Income Data:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 8.8pt">Revenue:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1pt">Operating Revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">1,001,077</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">1,002,380</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">981,051</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">703,099</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">497,220</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Total Operating Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,001,077</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,002,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">981,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">703,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">497,220</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cost of Goods Sold</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(301,435</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(316,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(277,928</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(223,394</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(153,640</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Gross Profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">699,642</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">686,252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">703,123</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">479,705</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">343,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Sales and Marketing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(133,781</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,794</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(79,796</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(93,520</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52,659</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Freight Costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(134,967</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(116,379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(114,278</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(62,590</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(61,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Gross Profit less Direct Selling Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">430,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">493,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">509,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,595</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,622</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 8.8pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,539,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,591,021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">804,477</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">816,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">763,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 8.8pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -8.8pt; padding-left: 8.8pt">Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Amortisation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(680,587</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Consulting, Employee and Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,840,037</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(728,140</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(555,487</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(907,390</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,113,214</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Corporate Administration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,320,570</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(557,422</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(492,465</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(790,103</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(708,625</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,719</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,989</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,975</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,944</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(341,600</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(463,685</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,183</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Impairment of Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,340</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,204</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(135,170</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Marketing and Promotion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(487,591</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(304,687</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(235,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(471,735</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,724</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,623,961</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,018,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,289,675</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,117,867</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,839,990</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Travel and Entertainment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(416,849</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(128,318</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(37,327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(112,453</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(195,605</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss before income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,068,767</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,691,820</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,495,069</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,409,349</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,068,086</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 8.8pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,068,767</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,691,820</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,495,069</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,409,349</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,068,086</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 8.8pt">Other Comprehensive Income
    / (Losses)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,846</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41,425</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Comprehensive Loss for the Period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,059,921</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,704,401</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,495,069</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,450,774</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,072,867</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.2pt">Loss per share, basic and diluted (cent per share)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.065</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.2pt">Weighted-average number of shares outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,435,993</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,935,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,955,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,328,491</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,470,006</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June&nbsp;30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR>
    December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2015</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Consolidated Statement of Financial
    Position Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,290,639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,116,074</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,103,683</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,809,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,998,898</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,837,834</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,827,484</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,018,412</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,855,801</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,886,921</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,207,810</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,302,621</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,886,921</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,207,810</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,302,621</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Total equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,940,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,810,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,553,180</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

</DIV>
<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>RISK FACTORS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>An investment
in the ADSs involves significant risks. You should carefully consider the risks described below and the other information in this
prospectus, including our consolidated financial statements and related notes included elsewhere in this prospectus, before you
decide to invest in the ADSs. If any of the following risks actually occurs, our business, prospects, financial condition and
results of operations could be materially and adversely affected, the trading price of the ADSs could decline and you could lose
all or part of your investment. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Financial Condition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have incurred operating losses
since we began operations and may not be profitable in the future. We will need to secure additional financing and may not be
successful in obtaining sufficient funding.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We have incurred
losses in every period since we began operations in 1994 and reported net losses of AUD$7,068,767, AUD$2,691,820 and AUD$2,495,069
during the fiscal years ended June 30, 2016, 2015 and 2014, respectively. For the six-month periods ended December 31, 2016 and
2015, the reported net losses were AUD$3,409,349 and AUD$3,068,086, respectively.&nbsp;&nbsp;As of December 31, 2016 and June
30, 2016, our accumulated deficit was AUD$46,175,581 and AUD$42,821,357, respectively.&nbsp;&nbsp;We expect to continue to incur
additional operating losses over at least the next several years as we expand our research and development activities in fatty-liver
diseases and new trials for our product candidate IMM-529 for C. <I>difficile</I>, and potential other assets/indications. We
may never be able to achieve or maintain profitability.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our actual cash
requirements may vary materially from those now planned and will depend upon numerous factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the continued
                                         progress of our research and development programs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the timing,
                                         scope, results and costs of pre-clinical studies and clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the cost,
                                         timing and outcome of regulatory submissions and approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>determinations
                                         as to the commercial potential of our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>spending
                                         on our marketed assets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability
                                         to successfully expand our contract manufacturing services;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability
                                         to establish and maintain collaborative arrangements; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the status
                                         and timing of competitive developments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">As of December
31, 2016 and June 30, 2016, our cash and cash equivalents were AUD$3,103,683 and AUD$2,290,639. Developing prescription products
is expensive and we will need to secure additional financing in order to continue to meet our longer term business objectives,
including advancement of our research and development programs. We may also require additional funds to pursue regulatory clearances,
defend our intellectual property rights, establish commercial scale manufacturing facilities, develop marketing and sales capabilities
and fund operating expenses.&nbsp;&nbsp;We intend to seek such additional funding through public or private financings and/or
through licensing of our assets or strategic alliances or other arrangements with corporate partners. The global economic climate
could adversely impact our ability to obtain such funding, license our assets or enter into alliances or other arrangements with
corporate partners.&nbsp;&nbsp;Any shortfall in funding could result in our having to curtail or cease our operations, including
our research and development activities, which would be expected to adversely affect our business, financial condition and results
of operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have never generated any revenue
from prescription product sales and may never be profitable. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our ability to
generate significant revenue from prescription products and achieve profitability depends on our ability to, alone or with strategic
collaboration partners, successfully complete the development of and obtain the regulatory approvals for our prescription product
candidates, to manufacture sufficient supply of our product candidates, to establish a sales and marketing organization or suitable
third-party alternative for the marketing of any approved products and to successfully commercialize any approved products on
commercially reasonable terms. All of these activities will require us to raise sufficient funds to finance business activities.
Currently, we do not expect any milestone payments from our collaborative partners to be significant in the foreseeable future
however we are actively pursuing potential partner collaboration. In addition, we do not anticipate generating revenue from commercializing
product candidates for the foreseeable future, if ever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our ability to
generate future revenues from commercializing Company owned IP assets depends heavily on our success in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">establishing
                                         proof of concept in preclinical studies and clinical trials for our product candidates;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">successfully
                                         completing clinical trials of our product candidates;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">obtaining
                                         regulatory and marketing approvals for product candidates for which we complete clinical
                                         trials;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">maintaining,
                                         protecting and expanding our intellectual property portfolio, and avoiding infringing
                                         on intellectual property of third parties;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">establishing
                                         and maintaining successful licenses, collaborations and alliances with third parties;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&bull;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">developing a sustainable, scalable, reproducible and transferable
    manufacturing process for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">establishing
                                         and maintaining supply and manufacturing relationships with third parties that can provide
                                         products and services adequate, in amount and quality, to support clinical development
                                         and commercialization of our product candidates, if approved;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">launching
                                         and commercializing any product candidates for which we obtain regulatory and marketing
                                         approval, either by collaborating with a partner or, if launched independently, by establishing
                                         a sales, marketing and distribution infrastructure;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">obtaining
                                         market acceptance of any product candidates that receive regulatory approval as viable
                                         treatment options;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">obtaining
                                         favorable coverage and reimbursement rates for our products from third-party payors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">addressing
                                         any competing technological and market developments;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">identifying
                                         and validating new product candidates; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">negotiating
                                         favorable terms in any collaboration, licensing or other arrangements into which we may
                                         enter.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The process of
developing product candidates for fatty-liver and anti-infective conditions contains a number of inherent risks and uncertainties,
including clinical and regulatory risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Even if one or
more of our product candidates is approved for commercial sale, we may incur significant costs associated with commercializing
any approved product candidate. As one example, our expenses could increase beyond expectations if we are required by the Food
and Drug Administration, or FDA, or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition
to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may
not become profitable and may need to obtain additional funding to continue operations, which could have an adverse effect on
our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are a development stage company of pharmaceutical
products and our success is uncertain.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We are a development
stage company of our pharmaceutical products which are designed to treat a range of anti-inflammatory and anti-infectives. Other
than Travelan product, we have not sufficiently advanced the development of any of our products, including our current lead product
candidate, IMM-124E, to market or generate revenues from their commercial application.&nbsp;&nbsp;Our current or any future product
candidates, if successfully developed, may not generate sufficient or sustainable revenues to enable us to be profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We receive Australian government
research and development income tax concession refunds. If our research and development expenditures are not deemed to be eligible
for the refund, we may encounter difficulties in the funding of future research and development projects, which could harm our
operating results. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We have historically
received, and expect to continue to receive, refunds from the Australian Federal Government&rsquo;s Research and Development Tax
Incentive program, under which the government provides a cash refund for the 45% of eligible research and development expenditures
by small Australian entities, which are defined as Australian entities with less than AUD$20 million in revenue, having a tax
loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The Research and Development
Tax Incentive refund is made by the Australian federal government for eligible research and development purposes based on the
filing of an annual application. We received Research and Development Tax Concession Incentive refunds in the fiscal years ended
June 30, 2014, June 30, 2015 and June 30, 2016 of AUD$713,632, AUD$1,478,581 and AUD$1,512,840 respectively. This refund is available
for our research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based
expenses relate to our activities in Australia, do not exceed half the expenses for the relevant activities and are approved by
the Australian government. To the extent our research and development expenditures are deemed to be &ldquo;ineligible,&rdquo;
then our refunds would decrease. In addition, the Australian government may in the future modify the requirements of, reduce the
amounts of the refunds available under, or discontinue the Research and Development Tax Incentive program. Any such change in
the Research and Development Tax Incentive program would have a negative effect on our future cash flows.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related To Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are faced with uncertainties related to our research.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our research programs
are based on scientific hypotheses and experimental approaches that may not lead to desired results.&nbsp;&nbsp;In addition, the
timeframe for obtaining proof of principle and other results may be considerably longer than originally anticipated, or may not
be possible given time, resource, financial, strategic and collaborator scientific constraints.&nbsp;&nbsp;Success in one stage
of testing is not necessarily an indication that the particular program will succeed in later stages of testing and development.&nbsp;&nbsp;It
is not possible to predict whether any of the drugs designed for these programs will prove to be safe, effective, and suitable
for human use.&nbsp;&nbsp;Each drug will require additional research and development, scale-up, formulation and extensive clinical
testing in humans.&nbsp;&nbsp;Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon
our commitment to that program or to the lead compound or product candidate being tested. The discovery of toxicities, lack of
sufficient efficacy, unacceptable pharmacology, inability to increase scale of manufacture, market attractiveness, regulatory
hurdles, competition, as well as other factors, may make our targets, lead therapies or product candidates unattractive for further
development or unsuitable for human use, and we may abandon our commitment to that program, target, lead therapy or product candidate.
Any delay in obtaining or failure to obtain required approvals could materially and adversely affect our ability to generate revenue
from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact
the price of the ADSs. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated
uses for which we may market the product. These limitations may limit the size of the market for the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clinical trials are expensive and time consuming, and
their outcome is uncertain.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In order to obtain
approvals to market a new drug product, we or our potential partners must demonstrate proof of safety and efficacy in humans.
To meet these requirements, we or our potential partners will have to conduct extensive preclinical testing and &ldquo;adequate
and well-controlled&rdquo; clinical trials. Conducting clinical trials is a lengthy, time-consuming and expensive process. The
length of time may vary substantially according to the type, complexity, novelty and intended use of the product candidate, and
often can be several years or more per trial. Even if we obtain positive results from preclinical or initial clinical trials,
we may not achieve the same success in future trials. Clinical trials may not demonstrate statistically sufficient safety and
effectiveness to obtain the requisite regulatory approvals for product candidates employing our technology. The failure of clinical
trials to demonstrate safety and efficacy for a particular desired indication could harm development of that product candidate
for other indications as well as other product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We expect to commence
new clinical trials from time to time in the course of our business as our product development work continues. Any change in,
or termination of, our clinical trials could materially harm our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We rely on third parties to conduct
our preclinical studies and clinical trials. If these third parties do not meet our deadlines or otherwise conduct the studies
as required, we may be delayed in progressing, or ultimately may not be able to progress, product candidates to clinical trials,
our clinical development programs could be delayed or unsuccessful, and we may not be able to commercialize or obtain regulatory
approval for our product candidates when expected, or at all. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We do not have
the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. We are dependent on third parties
to conduct the clinical trials for IMM-124E and IMM-529, and preclinical studies for our other product candidates, and therefore
the timing of the initiation and completion of these trials and studies is reliant on third parties and may occur at times substantially
different from our estimates or expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">If we cannot contract
with acceptable third parties on commercially reasonable terms, or if these third parties do not carry out their contractual duties,
satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines,
our clinical development programs could be delayed or discontinued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We may experience delays in our clinical trials that
could adversely affect our business and operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We do not know
whether planned clinical trials will begin on time or whether we will complete any of our clinical trials on schedule or at all
or within budget.&nbsp;&nbsp;Our ability to commence and complete clinical trials may be delayed by many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">government
                                         or regulatory delays, including delays in obtaining approvals from applicable hospital
                                         ethics committees and internal review boards;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">slower
                                         than expected patient enrollment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         inability to manufacture sufficient quantities of our new proprietary compound or our
                                         other product candidates or matching controls;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">unforeseen
                                         safety issues; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">lack
                                         of efficacy or unacceptable toxicity during the clinical trials or non-clinical studies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Patient enrollment
is a function of, among other things, the nature of the clinical trial protocol, the existence of competing protocols, the size
and longevity of the target patient population, and the availability of patients who comply with the eligibility criteria for
the clinical trial.&nbsp;&nbsp;Delays in planned patient enrollment may result in increased costs, delays or termination of the
clinical trials.&nbsp;&nbsp;&nbsp;Moreover, we rely on third parties such as clinical research organizations to assist us in clinical
trial management functions including; clinical trial database management, statistical analyses, site management and monitoring.&nbsp;&nbsp;&nbsp;Any
failure by these third parties to perform under their agreements with us may cause the trials to be delayed or result in a failure
to complete the trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">If we experience
delays in testing or approvals or if we need to perform more, larger or more complex clinical trials than planned, our product
development costs may increase.&nbsp;&nbsp;Significant delays could adversely affect the commercial prospects of our product candidates
and our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may not be successful in obtaining
or maintaining other necessary rights necessary to the development of our pipeline through acquisitions and in-licenses. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our product candidates
may require specific formulations to work effectively and efficiently and rights to such formulations may be held by others. We
may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property
rights from third parties that we identify on terms that we find acceptable, or at all. The licensing and acquisition of third-party
intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to
license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have
a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">For example, we
sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under
written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to
any of the institution&rsquo;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation
for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable
to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking
our ability to pursue our program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In addition, companies
that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire
third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are
unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and
prospects for growth could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We rely on research institutions
to conduct our clinical trials and we may not be able to secure and maintain research institutions to conduct our future trials.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We rely on research
institutions to conduct our clinical trials.&nbsp;&nbsp;Our reliance upon research institutions, including public and private
hospitals and clinics, provides us with less control over the timing and cost of clinical trials, clinical study management personnel
and the ability to recruit subjects. If we are unable to reach agreements with suitable research institutions on acceptable terms,
or if any resulting agreement is terminated, we may be unable to secure, maintain or quickly replace the research institution
with another qualified institution on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We grant licenses to our collaborators
to use our hyper-immune colostrum technology exclusively for the development of product candidates for certain conditions. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We may out-license
to our collaborators the right to use our hyper-immune colostrum technology for the development of product candidates for certain
conditions, so long as our collaborators comply with certain requirements. That means that once our technology is licensed to
a collaborator for a specified condition, we are generally prohibited from developing product candidates for that condition and
from licensing the to any third party for that condition. The limitations imposed by these exclusive licenses could prevent us
from expanding our business and increasing our development of product candidates with new collaborators, both of which could adversely
affect our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may not be able to complete the
development of IMM-124E; IMM-529 or develop other pharmaceutical products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We may not be
able to progress with the development of our current or any future pharmaceutical product candidates to a stage that will attract
a suitable collaborative partner for the development of any current or future pharmaceutical product candidates.&nbsp;&nbsp;The
projects initially specified in connection with any such collaboration and any associated funding may change or be discontinued
as a result of changing interests of either the collaborator or us, and any such change may change the budget for the projects
under the collaboration.&nbsp;&nbsp;Additionally, our research may not lead to the discovery of additional product candidates,
and any of our current and future product candidates may not be successfully developed, prove to be safe and efficacious in clinical
trials, meet applicable regulatory standards and receive regulatory approval, be capable of being produced in commercial quantities
at reasonable costs, or be successfully or profitably marketed, either by us or a collaborative partner.&nbsp;&nbsp;The products
we develop may not be able to penetrate the potential market for a particular therapy or indication or gain market acceptance
among health care providers, patients and third-party payers.&nbsp;&nbsp;We cannot predict if or when the development of IMM-124E,
IMM-529 or any future pharmaceutical product will be completed or commercialized, whether funded by us, as part of a collaboration
or through a grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may need to prioritize the development
of our most promising candidates at the expense of the development of other products.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We may need to
prioritize the allocation of development resources and/or funds towards what we believe to be our most promising product or products.&nbsp;&nbsp;The
nature of the drug development process is such that there is a constant availability of new information and data which could positively
or adversely affect a product in development.&nbsp;&nbsp;We cannot predict how such new information and data may impact in the
future the prioritization of the development of our current or future product candidates or that any of our products, regardless
of its development stage or the investment of time and funds in its development, will continue to be funded or developed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our research and development efforts
will be seriously jeopardized if we are unable to retain key personnel and cultivate key academic and scientific collaborations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our future success
depends to a large extent on the continued services of our senior management and key scientific personnel, including Thomas Liquard,
our Chief Executive Officer, Dr. Jerry Kanellos (PhD), Chief Operating and Scientific Officer and Dr. Dan Peres (MD), Medical
Director.&nbsp;&nbsp; The loss of their services could negatively affect our business.&nbsp;&nbsp;Competition among biotechnology
and pharmaceutical companies for qualified employees is intense, including competition from larger companies with greater resources,
and we may not be able to continue to attract and retain qualified management, technical and scientific personnel critical to
our success.&nbsp;&nbsp;Our success is highly dependent on our ability to develop and maintain important relationships with leading
academic institutions and scientists who conduct research at our request or assist us in formulating our research and development
strategies.&nbsp;&nbsp;These academic and scientific collaborators are not our employees and may have commitments to, or consulting
or advisory contracts with, other entities that may limit their availability to us.&nbsp;&nbsp;In addition, these collaborators
may have arrangements with other companies to assist such companies in developing technologies that may prove competitive to ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we are unable to successfully
keep pace with technological change or with the advances of our competitors, our technology and products may become obsolete or
non-competitive.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The biotechnology
and pharmaceutical industries are subject to rapid and significant technological change.&nbsp;&nbsp;Our competitors are numerous
and include major pharmaceutical companies, biotechnology firms, universities and other research institutions.&nbsp;&nbsp;These
competitors may develop technologies and products that are more effective than any that we are developing, or which would render
our technology and products obsolete or non-competitive.&nbsp;&nbsp;Many of these competitors have greater financial and technical
resources and manufacturing and marketing capabilities than we do.&nbsp;&nbsp;In addition, many of our competitors have much more
experience than we do in pre-clinical testing and human clinical trials of new or improved drugs, as well as in obtaining regulatory
approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We know that competitors
are developing or manufacturing various technologies or products for the treatment of diseases that we have targeted for product
development.&nbsp;&nbsp;Some of these competitive products use therapeutic approaches that compete directly with our product candidates.&nbsp;&nbsp;Our
ability to further develop our products may be adversely affected if any of our competitors were to succeed in obtaining regulatory
approval for their competitive products sooner than us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Physicians, patients, third-party
payors or others in the medical community may not be receptive to our product candidates, and we may not generate any future revenue
from the sale or licensing of our product candidates. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Even if we obtain
approval for a product candidate, we may not generate or sustain revenue from sales of the product if the product cannot be sold
at a competitive cost or if it fails to achieve market acceptance by physicians, patients, third-party payors or others in the
medical community. These market participants may be hesitant to adopt a novel treatment based on hyper-immune colostrum technology,
and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement
for, any product candidates developed by us or our existing or future collaborators. Market acceptance of our product candidates
will depend on, among other factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><P STYLE="margin: 0pt 0; text-align: justify">the
                                         establishment and demonstration of the safety and clinical efficacy of our product candidates
                                         and their potential advantages over existing therapeutics and technologies;</P> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability
                                         to offer our products for sale at competitive prices;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the relative
                                         convenience and ease of administration of our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the prevalence
                                         and severity of any adverse side effects associated with our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><P STYLE="margin: 0pt 0">the
                                         receipt, timing and terms of regulatory approvals and the countries in which approvals
                                         are obtained;</P> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limitations
                                         or warnings contained in any labeling approved by the FDA or comparable foreign regulatory
                                         authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">conditions
                                         upon the approval imposed by FDA or comparable foreign regulatory authorities, including,
                                         but not limited to, a REMS;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         willingness of patients to try new treatments and of physicians to prescribe these treatments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the availability
                                         of government and other third-party payor coverage and adequate reimbursement; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">availability
                                         of alternative effective treatments for the disease indications our product candidates
                                         are intended to treat and the relative risks, benefits and costs of those treatments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Additional risks
apply in relation to any disease indications we pursue which are classified as rare diseases and allow for orphan drug designation
by regulatory agencies in major commercial markets, such as the United States or European Union. If pricing is not approved or
accepted in the market at an appropriate level for any approved product for which we pursue and receive an orphan drug designation,
such product may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization despite
any benefits received from the orphan drug designation, such as market exclusivity, for a period of time. Orphan exclusivity could
temporarily delay or block approval of one of our products if a competitor obtains orphan drug designation for its product first.
However, even if we obtain orphan exclusivity for one of our products upon approval, our exclusivity may not block the subsequent
approval of a competitive product that is shown to be clinically superior to our product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Market size is
also a variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication
may be materially different from what we discover to exist at the time we commence commercialization, if any, for a product, which
could result in significant changes in our business plan and have a material adverse effect on our business, financial condition,
results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We face competition from entities
that have developed or may develop product candidates for our target disease indications, including companies developing novel
treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies
or product candidates more rapidly than we do or their technologies, including delivery technologies, are more effective, our
ability to develop and successfully commercialize product candidates may be compromised. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The development
and commercialization of pharmaceutical products is highly competitive. We compete with a variety of multinational pharmaceutical
companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions.
Our competitors have developed, are developing or could develop product candidates and processes competitive with our product
candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community,
patients and third-party payors, and any new treatments that enter the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We believe that
a significant number of products are currently under development, and may become commercially available in the future, for the
treatment of conditions for which we are developing, and may in the future try to develop, product candidates. We are aware of
multiple companies that are working in the field of fatty-liver diseases and C. <I>difficile</I> therapeutics, including Intercept,
Gilead, Genfit, Tobira, Galmed are all developing therapeutics for fatty-liver diseases and Seres, Synthetic Biotechnology and
Assembly Biotechnology for C. <I>difficile</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have limited large scale manufacturing
experience with our product candidates.&nbsp;&nbsp;Delays in manufacturing sufficient quantities of such materials to the required
standards for pre-clinical and clinical trials may negatively impact our business and operations.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">While we have
extensive experience in producing therapeutic colostrum, we may not be able to manufacture sufficient quantities of our product
candidates in a cost-effective or timely manner.&nbsp;&nbsp;Manufacturing includes the production, formulation and stability testing
of an active pharmaceutical ingredient and its formulation into pharmaceutical products, such as capsules or tablets.&nbsp;&nbsp;Any
delays in production would delay our pre-clinical and human clinical trials, which could adversely affect our business, financial
condition and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We may be required
to enter into contracting arrangements with third parties to manufacture our product candidates for large-scale, pre-clinical
and/or clinical trials.&nbsp;&nbsp;We may not be able to make the transition from laboratory-scale to development-scale or from
development-scale to commercial production.&nbsp;&nbsp;We may need to develop additional manufacturing resources, enter into collaborative
arrangements with other parties who have established manufacturing capabilities, or have third parties manufacture our products
on a contract basis.&nbsp;&nbsp;We may not have access on acceptable terms to the necessary and substantial financing that would
be required to scale-up production and develop effective commercial manufacturing processes and technologies.&nbsp;&nbsp;We may
not be able to enter into collaborative or contracting arrangements on acceptable terms with parties that will meet our requirements
for quality, quantity and timeliness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We expect that
we will be required to design and develop new synthetic pathways for most, if not all, of the product candidates that we currently
intend to develop or may develop in the future.&nbsp;&nbsp;We cannot predict the success of such efforts, the purity of the products
that may be obtained or the nature of the impurities that may result from such efforts.&nbsp;&nbsp;If we are not able to obtain
an acceptable purity for any product candidate or an acceptable product specification, pre-clinical and clinical trials would
be delayed, which could adversely affect the priority of the development of our product candidates, our business, financial condition
and results of operations.&nbsp;&nbsp;We also cannot guarantee that the active pharmaceutical ingredient will be suitable for
high throughput encapsulation to produce drug products.&nbsp;&nbsp;This may adversely impact the cost of goods or feasibility
of market scale manufacture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our product candidates and the process
for administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent
their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following
any potential marketing approval. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Treatment with
our product candidates may produce undesirable side effects or adverse reactions or events. If any such adverse events occur,
our clinical trials could be suspended or discontinued and the FDA or comparable foreign regulatory authorities could order us
to cease further development or deny approval of our product candidates for any or all targeted indications. The product-related
side effects could affect patient recruitment or the ability of enrolled patients to complete the trial. If we elect or are required
to delay, suspend or discontinue any clinical trial of any of our product candidates, the commercial prospects of such product
candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or
eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Currently we depend upon a sole
manufacturer of our lead compound and on a sole manufacturer to encapsulate the compound and could incur significant costs and
delays if we are unable to promptly find a replacement for either of them.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">At this time,
we are relying on a single manufacturer to develop Good Manufacturing Practice, processes for our lead compounds.&nbsp;&nbsp;Our
lead compound, IMM-124E, is manufactured by Synlait based in New Zealand. This manufacturer enables efficient large scale manufacture
of colostrum to provide drug substance for the current and prospective trials in fatty-liver and c. <I>difficile</I> patients.
&nbsp;&nbsp;We also rely on a sole manufacturer Catalent Australia, to encapsulate all of our marketed and investigational drug
products.&nbsp;&nbsp;We are actively seeking an additional and back up manufacturer but may be unsuccessful in our efforts, or
may incur material additional costs and substantial delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The failure to establish sales,
marketing and distribution capability would materially impair our ability to successfully market and sell our pharmaceutical products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We currently have
<FONT STYLE="font-family: Times New Roman, Times, Serif">limited </FONT>experience in marketing, sales or distribution of pharmaceutical
products.&nbsp;&nbsp;If we develop any commercially marketable pharmaceutical products and decide to perform our own sales and
marketing activities, we will require additional management, will need to hire sales and marketing personnel and will require
additional capital.&nbsp;&nbsp;Qualified personnel may not be available in adequate numbers or at a reasonable cost.&nbsp;&nbsp;Further,
our sales staff may not achieve success in their marketing efforts.&nbsp;&nbsp;Alternatively, we may be required to enter into
marketing arrangements with other parties who have established appropriate marketing, sales and distribution capabilities.&nbsp;&nbsp;We
may not be able to enter into marketing arrangements with any marketing partner, or if such arrangements are established, our
marketing partners may not be able to commercialize our products successfully.&nbsp;&nbsp;Other companies offering similar or
substitute products may have well-established and well-funded marketing and sales operations in place that will allow them to
market their products more successfully.&nbsp;&nbsp;Failure to establish sufficient marketing capabilities would materially impair
our ability to successfully market and sell our pharmaceutical products.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If healthcare insurers and other
organizations do not pay for our products, or impose limits on reimbursement, our future business may suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The drugs we hope
to develop may be rejected by the marketplace due to many factors, including cost.&nbsp;&nbsp;The continuing efforts of governments,
insurance companies, health maintenance organizations and other payors of healthcare costs to contain or reduce healthcare costs
may affect our future revenues and profitability and those of our potential customers, suppliers and collaborative partners, as
well as the availability of capital.&nbsp;&nbsp;In Australia and certain foreign markets, the pricing or profitability of prescription
pharmaceuticals is already subject to government control.&nbsp;&nbsp;We expect initiatives for similar government control at both
the state and federal level to continue in the United States and elsewhere.&nbsp;&nbsp;The adoption of any such legislative or
regulatory proposals could adversely affect our business and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our ability to
commercially exploit our products successfully will depend in part on the extent to which reimbursement for the cost of our products
and related treatment will be available from government health administration authorities, private health coverage insurers and
other organizations.&nbsp;&nbsp;Third-party payors, such as government and private health insurers, are increasingly challenging
the price of medical products and services.&nbsp;&nbsp;Uncertainty exists as to the reimbursement status of newly approved health
care products and in foreign markets, including the United States.&nbsp;If third-party coverage is not available to patients for
any of the products we develop, alone or with collaborators, the market acceptance of these products may be reduced, which may
adversely affect our future revenues and profitability.&nbsp;&nbsp;In addition, cost containment legislation and reductions in
government insurance programs may result in lower prices for our products and could materially adversely affect our ability to
operate profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may be exposed to product liability
claims, which could harm our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The testing, marketing
and sale of human health care products also entails an inherent risk of product liability.&nbsp;&nbsp;We may incur substantial
liabilities or be required to limit development or commercialization of our products if we cannot successfully defend ourselves
against product liability claims.&nbsp;&nbsp;We have historically obtained no fault compensation insurance for our clinical trials
and intend to obtain similar coverage for future clinical trials. Such coverage may not be available in the future on acceptable
terms, or at all.&nbsp;&nbsp;This may result in our inability to pursue further clinical trials or to obtain adequate protection
in the event of a successful claim.&nbsp;&nbsp;We may not be able to obtain product liability insurance in the event of the commercialization
of a product or such insurance may not be available on commercially reasonable terms.&nbsp;&nbsp;Even if we have adequate insurance
coverage, product liability claims or recalls could result in negative publicity or force us to devote significant time, attention
and financial resources to those matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Breaches of network or information
technology security, natural disasters or terrorist attacks could have an adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Cyber-attacks
or other breaches of network or information technology (IT) security, natural disasters, terrorist acts or acts of war may cause
equipment failures or disrupt our research and development operations.&nbsp;&nbsp;In particular, both unsuccessful and successful
cyber-attacks on companies have increased in frequency, scope and potential harm in recent years.&nbsp;&nbsp;Such an event may
result in our inability, or the inability of our partners, to operate the research and development facilities, which even if the
event is for a limited period of time, may result in significant expenses and/or significant damage to our experiments and trials.
&nbsp;In addition, a failure to protect employee confidential data against breaches of network or IT security could result in
damage to our reputation. Any of these occurrences could adversely affect our results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">To date, we have
not had any such occurrence of cyber-attacks <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to our
networks and IT infrastructure through cyber-attack, malware, computer viruses and other means of unauthorized access or other
cyber incidents, individually or in the aggregate, however, should this occur in the future, it may result in a material impact
to our operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We expect to expand our drug development,
regulatory and business development capabilities, and as a result, we may encounter difficulties in managing our growth, which
could disrupt our operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We expect to experience
significant growth in the number of our employees and consultants and the scope of our operations, particularly in the areas of
drug development, regulatory affairs and business development. To manage our anticipated future growth, we must continue to implement
and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional
qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company
with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional
qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business
development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations,
and have a materially adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preliminary positive results from
the clinical trial of our leading product candidate, IMM-124E, are not necessarily predictive of the final results of the trial,
and positive results from preclinical studies of our product candidates are not necessarily predictive of the results of our planned
clinical trials of our product candidates. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In 2012, 10 biopsy-proven
NASH patients were dosed for 30 days with IMM-124E in a Phase 1 study aimed to assess the safety of IMM-124E in NASH patients.
The preliminary results from this trial are not necessarily predictive of the final results of the trial. The biological effect
observed in this trial has been observed in only those 10 patients, is not statistically significant and might not be observed
in any other patients treated with IMM-124E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In addition, positive
results in preclinical proof-of-concept and animal studies of our product candidates may not result in positive results in clinical
trials in humans. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical
trials after achieving positive results in preclinical development or early stage clinical trials, and we cannot be certain that
we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical
trials were underway or safety or efficacy observations made in clinical trials, including adverse events. Moreover, preclinical
and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product
candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory
authority approval. If we fail to produce positive results in our clinical trials of our product candidates, the development timeline
and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial
prospects, would be negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our future prospects may also be
dependent on our or our collaborators&rsquo; ability to successfully develop a pipeline of additional product candidates, and
we and our collaborators may not be successful in efforts to use our platform technologies to identify or discover additional
product candidates. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The success of
our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technology.
We only have two product candidates currently in clinical development (IMM-124E) or ready to start clinical development trials
phase (IMM-529).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our other product
candidates derived from our platform technology may not successfully complete IND-enabling studies, and our research programs
may fail to identify other potential product candidates for clinical development for a number of reasons. Our and our collaborators&rsquo;
research methodology may be unsuccessful in identifying potential product candidates, our potential product candidates may not
demonstrate the necessary preclinical outcomes to progress to clinical studies, or our product candidates may be shown to have
harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing
approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">If any of these
events occur, we may be forced to discontinue our development efforts for a program or programs. Research programs to identify
new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on
potential programs or product candidates that ultimately prove to be unsuccessful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may not be able to obtain orphan
drug exclusivity for some of our product candidates. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Of our current
product candidates, the only one designed for treatment of an indication that would likely qualify for rare disease status is
IMM-529 for the treatment of recurrent C. <I>difficile</I>. Regulatory authorities in some jurisdictions, including the United
States and the European Union, may designate drugs or biological products for relatively small patient populations as orphan drugs.
Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a product intended to treat a rare disease
or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States.
The FDA may also designate a product as an orphan drug if it is intended to treat a disease or condition of more than 200,000
individuals in the United States and there is no reasonable expectation that the cost of developing and making a drug or biological
product available in the United States for this type of disease or condition will be recovered from sales of the product candidate.
Under the European Union orphan drug legislation, a rare disease or condition means a disease or condition which affects not more
than five in ten thousand persons in the European Union at the time of the orphan drug designation application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Generally, if
a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has
such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another
marketing application for the same drug for that time period. During the marketing exclusivity period, in the European Union,
the European Medicines Agency, or the EMA, is precluded from approving a similar drug with an identical therapeutic indication.
The applicable period is seven years in the United States and ten years in the European Union. The European Union exclusivity
period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently
profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the
drug to meet the needs of patients with the rare disease or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Even if we obtain
orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different
drugs can be approved for the same condition, and the same drug could be approved for a different condition. Even after an orphan
drug is approved, the FDA can subsequently approve the same drug, made by a competitor, for the same condition if the FDA concludes
that the competitive product is clinically superior in that it is shown to be safer, more effective or makes a major contribution
to patient care. In the European Union, the EMA can approve a competitive product if the orphan drug no longer meets the criteria
for orphan designation (including sufficient profitability), if the competitive product is safer, more effective or otherwise
clinically superior, or if the orphan drug cannot be supplied in sufficient quantities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have not entered into agreements
with any third-party manufacturers to support commercialization of our pharmaceutical product candidates. Additionally, no manufacturers
have experience producing our product candidates at commercial levels, and any manufacturer that we work with may not achieve
the necessary regulatory approvals or produce our product candidates at the quality, quantities, locations and timing needed to
support commercialization. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We have not yet
secured manufacturing capabilities for commercial quantities of our product candidates or established facilities in the desired
locations to support commercialization of our product candidates. We intend to rely on third-party manufacturers for commercialization,
and currently we have only entered into agreements with such manufacturers to support our clinical trials for IMM-124E. We may
be unable to negotiate agreements with third-party manufacturers to support our commercialization activities on commercially reasonable
terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We may encounter
technical or scientific issues related to manufacturing or development that we may be unable to resolve in a timely manner or
with available funds. Currently, we do not have the capacity to manufacture our product candidates on a commercial scale. In addition,
our product candidates are novel, and no manufacturer currently has experience producing our product candidates on a large scale.
If we are unable to engage manufacturing partners to produce our product candidates on a larger scale on reasonable terms, our
commercialization efforts will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Even if we timely
develop a manufacturing process and successfully transfer it to the third-party manufacturers of our product candidates, if such
third-party manufacturers are unable to produce the necessary quantities of our product candidates, or do so in compliance with
cGMP or with pertinent foreign regulatory requirements, and within our planned time frame and cost parameters, the development
and sales of our product candidates, if approved, may be impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our auditors have identified certain
matters involving our internal controls over our financial reporting that are material weaknesses under standards established
by the PCAOB. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Material weaknesses
were identified in some aspects of our internal control over financial reporting for the fiscal years ended June 30, 2014, 2015,
and 2016 and for the six months ended December 31, 2016 and 2015. Given these material weaknesses, management concluded that we
did not maintain effective internal control over financial reporting. Once identified, we commenced the evaluation of the material
weaknesses noted in our internal control over financial reporting specifically surrounding the assessment of certain significant
transactions and properly performing certain reviews and monitoring controls in the preparation of the financial statements in
accordance with IFRS, as promulgated by IASB. This resulted in the restatements disclosed in the financial statements. In order
to address the Company&rsquo;s internal control over financial reporting material weaknesses the Company has improved the training
of its finance team with respect to the applicable financial reporting requirements during fiscal 2017. The cost of implementing
the improved internal control process was negligible because the additional training was incorporated into the existing training
programs at no additional cost.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The elements of
our remediation plan can only be proven over time and we can offer no assurance that these initiatives will ultimately have the
intended effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Any failure to
maintain such internal controls could adversely impact our ability to report our financial results on a timely and accurate basis,
which could result in our inability to satisfy our reporting obligations or result in material misstatements in our financial
statements. If our financial statements are not accurate, investors may not have a complete understanding of our operations or
may lose confidence in our reported financial information, which could result in a material adverse effect on our business or
have a negative effect on the trading price of our common stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we do not obtain the necessary
governmental approvals, we will be unable to commercialize our pharmaceutical products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our ongoing research
and development activities are, and the production and marketing of our pharmaceutical product candidates derived from such activities
will be, subject to regulation by numerous international regulatory authorities. &nbsp;Prior to marketing, any therapeutic product
developed must undergo rigorous pre-clinical testing and clinical trials and, to the extent that any of our pharmaceutical products
under development are marketed abroad, by the relevant international regulatory authorities. For example, in Australia, principally
the Therapeutics Goods Administration, or TGA; <FONT STYLE="font-family: Times New Roman, Times, Serif">the FDA</FONT>, in the
United States; the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom; the Medical Products Agency,
or MPA, in Sweden; and the European Medicines Agency, or EMA.&nbsp;&nbsp;These processes can take many years and require the expenditure
of substantial resources.&nbsp;&nbsp;Governmental authorities may not grant regulatory approval due to matters arising from pre-clinical
animal toxicology, safety pharmacology, drug formulation and purity, clinical side effects or patient risk profiles, or medical
contraindications.&nbsp;&nbsp;Failure or delay in obtaining regulatory approvals would adversely affect the development and commercialization
of our pharmaceutical product candidates.&nbsp;&nbsp;We may not be able to obtain the clearances and approvals necessary for clinical
testing or for manufacturing and marketing our pharmaceutical product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We will not be able to commercialize
any current or future product candidates if we fail to adequately demonstrate their safety, efficacy and superiority over existing
therapies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Before obtaining
regulatory approvals for the commercial sale of any of our pharmaceutical products, we must demonstrate through pre-clinical testing
and clinical studies that our product candidates are safe and effective for use in humans for each target indication. Results
from early clinical trials may not be predictive of results obtained in large-scale, later-stage clinical testing.&nbsp;&nbsp;Even
though a potential drug product shows promising results in clinical trials, regulatory authorities may not grant the necessary
approvals without sufficient safety and efficacy data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We may not be
able to undertake further clinical trials of our current and future product candidates as therapies for fatty-liver disease, C.
<I>difficile </I>or other indications or to demonstrate the safety and efficacy or superiority of any of these product candidates
over existing therapies or other therapies under development, or enter into any collaborative arrangement to commercialize our
current or future product candidates on terms acceptable to us, or at all.&nbsp;&nbsp;Clinical trial results that show insufficient
safety and efficacy could adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Even if we obtain regulatory approval
for a product candidate, our products may remain subject to regulatory scrutiny. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Even if we obtain
regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses
or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market
surveillance. For example, the holder of an approved biologics license application (BLA) is obligated to monitor and report to
the FDA adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must
also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling
or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition
to other potentially applicable foreign, federal and state laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">If we fail to
comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issue
                                         a warning letter asserting that we are in violation of the law;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">seek
                                         an injunction or impose civil or criminal penalties or monetary fines;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspend
                                         or withdraw regulatory approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspend
                                         any ongoing clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse
                                         to permit government reimbursement of our product by government-sponsored third-party
                                         payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse
                                         to approve a pending BLA or supplements to a BLA submitted by us for other indications
                                         or new product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">seize
                                         our product; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse
                                         to allow us to enter into or continue supply contracts, including government contracts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Any government
investigation of alleged violations of law could require us to expend significant time and resources in response and could generate
negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product
candidates and generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Healthcare reform measures and other
statutory or regulatory changes could adversely affect our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In both the United
States and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the healthcare
system in ways that could impact our business. For example, the Patient Protection and Affordable Care Act and the Health Care
and Education Affordability Reconciliation Act of 2010 (collectively, the &ldquo;ACA&rdquo;), enacted in March 2010, substantially
changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical
industry. With regard to pharmaceutical products, among other things, the ACA is expected to expand and increase industry rebates
for drugs covered under Medicaid programs and make changes to the coverage requirements under the Medicare D program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">If we obtain FDA
approval for any of our product candidates and begin commercializing those products in the United States, our operations may be
directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation,
the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The pharmaceutical
and biotechnology industries are subject to extensive regulation, and from time to time legislative bodies and governmental agencies
consider changes to such regulations that could have significant impact on industry participants. For example, in light of certain
highly-publicized safety issues regarding certain drugs that had received marketing approval, the U.S. Congress has considered
various proposals regarding drug safety, including some which would require additional safety studies and monitoring and could
make drug development more costly. Additional legislation or regulation, if any, relating to safety or other aspects of drug development
may be enacted in the future, which could have an adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our product candidates are based
on our hyper-immune colostrum technology. Currently, no prescription product candidates utilizing our technology have been approved
for commercial sale and our approach to the development of our technology may not result in safe, effective or marketable products.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We have concentrated
our product research and development efforts on our hyper-immune colostrum technology, and our future success depends on successful
clinical development of this technology. We plan to develop a pipeline of product candidates using our technology and deliver
therapeutics for a number of chronic and life-threatening conditions, including fatty-liver diseases and C. <I>difficile</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The scientific
research that forms the basis of our efforts to develop product candidates is based on the pre-clinical and clinical data in conditions
such as Traveler&rsquo;s Diarrhea, NASH and C. <I>difficile</I>, and the identification, optimization and delivery of <FONT STYLE="font-family: Times New Roman, Times, Serif">hyper-immune
</FONT>colostrum-based product candidates is relatively new. The scientific evidence to support the feasibility of successfully
developing therapeutic treatments based on our is preliminary and limited. There can be no assurance that any development and
technical problems we experience in the future will not cause significant delays or unanticipated costs, or that such development
problems can be solved. We may be unable to reach agreement on favorable terms, or at all, with providers of vectors needed to
optimize delivery of our product candidates to target disease cells and we may also experience unanticipated problems or delays
in expanding our manufacturing capacity or transferring our manufacturing process to commercial partners, any of which may prevent
us from completing our clinical trials or commercializing our products on a timely or profitable basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Only a few product
candidates based on our technology have been tested in either animals or humans. We may discover that the applications of IMM-124E
and IMM-529 do not possess properties required for a therapeutic benefit, such as the ability to sufficiently suppress the immune
system for the period of time required to be approved as a NASH therapeutic. In addition, application of hyper-immune-based products
in humans may result in safety problems. We currently have only limited long-term data, and no conclusive evidence, to suggest
that we can effectively produce effective therapeutic treatments using our hyper<FONT STYLE="font-family: Times New Roman, Times, Serif">-immune
</FONT>colostrum technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are early in our product development
efforts and have only two product candidates in early-stage (Phase 1 ready) and mid-stage (Phase 2) clinical trials. All of our
other current product candidates are still in preclinical development. We have no late-stage clinical trials (post-proof of concept)
and may not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The research,
testing, manufacturing, labeling, approval, selling, marketing and distribution of biologics is subject to extensive regulation
by the FDA and other regulatory authorities, and these regulations differ from country to country. We do not have any products
on the market and are early in our development efforts. We have only one product candidate in clinical trials and all of our other
product candidates are in preclinical development. All of our current and future product candidates are subject to the risks of
failure typical for development of biologics. The development and approval process is expensive and can take many years to complete,
and its outcome is inherently uncertain. In addition, the outcome of preclinical testing and early clinical trials may not be
predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We have not submitted
an application, or received marketing approval, for any of our product candidates and will not submit any applications for marketing
approval for several years. We have limited experience in conducting and managing clinical trials necessary to obtain regulatory
approvals for prescription product candidates. To receive approval, we must, among other things, demonstrate with evidence from
clinical trials that the product candidate is both safe and effective for each indication for which approval is sought, and failure
can occur in any stage of development. Satisfaction of the approval requirements typically takes several years and the time needed
to satisfy them may vary substantially, based on the type, complexity and novelty of the pharmaceutical product. We cannot predict
if or when we might receive regulatory approvals for any of our product candidates currently under development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The FDA and foreign
regulatory authorities also have substantial discretion in the pharmaceutical product approval process. The numbers, types and
sizes of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the product
candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular
product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change
during the course of a product candidate&rsquo;s clinical development and may vary among jurisdictions, and there may be varying
interpretations of data obtained from preclinical studies or clinical trials, any of which may cause delays or limitations in
the approval or the decision not to approve an application. <FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory
agencies can delay, limit or deny approval of a product candidate for many reasons, including: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         FDA or comparable foreign regulatory authorities may disagree with the design or implementation
                                         of our clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory
                                         authorities that a product candidate is safe and effective for its proposed indication;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         results of clinical trials may not meet the level of statistical or clinical significance
                                         required by the FDA or comparable foreign regulatory authorities for approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         patients recruited for a particular clinical program may not be sufficiently broad or
                                         representative to assure safety in the full population for which we seek approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         results of clinical trials may not confirm the positive results from earlier preclinical
                                         studies or clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         may be unable to demonstrate that a product candidate&rsquo;s clinical and other benefits
                                         outweigh its safety risks;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         FDA or comparable foreign regulatory authorities may disagree with our interpretation
                                         of data from preclinical studies or clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         data collected from clinical trials of our product candidates may not be sufficient to
                                         the satisfaction of FDA or comparable foreign regulatory authorities to support the submission
                                         of a biologics license application, or BLA, or other comparable submission in foreign
                                         jurisdictions or to obtain regulatory approval in the United States or elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         FDA or comparable foreign regulatory authorities may only agree to approve a product
                                         candidate under conditions that are so restrictive that the product is not commercially
                                         viable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                         agencies might not approve or might require changes to our manufacturing processes or
                                         facilities; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                         agencies may change their approval policies or adopt new regulations in a manner rendering
                                         our clinical data insufficient for approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Any delay in obtaining
or failure to obtain required approvals could materially and adversely affect our ability to generate revenue from the particular
product candidate, which likely would result in significant harm to our financial position and adversely impact the price of the
ADSs and Warrants. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses
for which we may market the product. These limitations may limit the size of the market for the product.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We are not permitted
to market our product candidates in the United States or in other countries until we receive approval of a BLA from the FDA or
marketing approval from applicable regulatory authorities outside the United States. Obtaining approval of a BLA can be a lengthy,
expensive and uncertain process. If we fail to obtain FDA approval to market our product candidates, we will be unable to sell
our product candidates in the United States, which will significantly impair our ability to generate any revenues. In addition,
failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, if any, subject
us to administrative or judicially imposed sanctions, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">restrictions
                                         on our ability to conduct clinical trials, including full or partial clinical holds on
                                         ongoing or planned trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">restrictions
                                         on the products, manufacturers or manufacturing process;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">warning
                                         letters;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">civil
                                         and criminal penalties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">injunctions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspension
                                         or withdrawal of regulatory approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">product
                                         seizures, detentions or import bans;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">voluntary
                                         or mandatory product recalls and publicity requirements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">total
                                         or partial suspension of production;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">imposition
                                         of restrictions on operations, including costly new manufacturing requirements; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refusal
                                         to approve pending BLAs or supplements to approved BLAs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Even if we do
receive regulatory approval to market a product candidate, any such approval may be subject to limitations on the indicated uses
for which we may market the product. It is possible that none of our existing product candidates or any product candidates we
may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators
to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us
from commercializing our product candidates, generating revenues and achieving and sustaining profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We could be adversely affected by
violations of the U.S. Foreign Corrupt Practices Act.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our business operations
may be subject to anti-corruption laws and regulations, including restrictions imposed by the U.S. Foreign Corrupt Practices Act
<FONT STYLE="font-family: Times New Roman, Times, Serif">the FCPA. </FONT>The FCPA and similar anti-corruption laws in other jurisdictions
generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of
obtaining or retaining business. We cannot provide assurance that our internal controls and procedures will always protect us
from criminal acts committed by our employees or third parties with whom we work. If we are found to be liable for violations
of the FCPA or similar anti-corruption laws in international jurisdictions, either due to our own acts or out of inadvertence,
or due to the acts or inadvertence of others, we could suffer from criminal or civil penalties which could have a material and
adverse effect on our results of operations, financial condition and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our success depends upon our ability
to protect our intellectual property and our proprietary technology, to operate without infringing the proprietary rights of third
parties and to obtain marketing exclusivity for our products and technologies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Any future success
will depend in large part on whether we can:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">obtain
                                         and maintain patents to protect our own products and technologies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">obtain
                                         orphan designation for our products and technologies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">obtain
                                         licenses to the patented technologies of third parties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">operate
                                         without infringing on the proprietary rights of third parties; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">protect
                                         our trade secrets, know-how and other confidential information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Patent matters
in biotechnology are highly uncertain and involve complex legal and factual questions.&nbsp;&nbsp;Accordingly, the availability
and breadth of claims allowed in biotechnology and pharmaceutical patents cannot be predicted.&nbsp;&nbsp;Any of the pending or
future patent applications filed by us or on our behalf may not be approved, we may not develop additional proprietary products
or processes that are patentable, or we may not be able to license any other patentable products or processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our products may
be eligible for orphan designation for particular therapeutic indications that are of relatively low prevalence and for which
there is no effective treatment. Orphan drug designation affords market exclusivity post marketing authorization for a product
for a specified therapeutic utility.&nbsp;&nbsp;The period of orphan protection is dependent on&nbsp;&nbsp;jurisdiction, for example,
seven years in the United States and ten years in Europe. The opportunity to gain orphan drug designation depends on a variety
of requirements specific to each marketing jurisdiction and can include; a showing of improved benefit relative to marketed products,
that the mechanism of action of the product would provide plausible benefit and the nature of the unmet medical need within a
therapeutic indication. It is uncertain if our products will be able to obtain orphan drug designation for the appropriate indications
and in the jurisdictions sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our commercial
success will also depend, in part, on our ability to avoid infringement of patents issued to others.&nbsp;&nbsp;If a court determines
that we were infringing any third party patents, we could be required to pay damages, alter our products or processes, obtain
licenses or cease certain activities.&nbsp;&nbsp;Licenses required under patents held by third parties may not be made available
on terms acceptable to us or at all.&nbsp;&nbsp;To the extent that we are unable to obtain such licenses, we could be foreclosed
from the development, export, manufacture or commercialization of the product requiring such license or encounter delays in product
introductions while we attempt to design around such patents, and any of these circumstances could adversely affect our business,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We may have to
resort to litigation to enforce any patents issued or licensed to us or to determine the scope and validity of third party proprietary
rights.&nbsp;&nbsp;We may have to defend the validity of our patents in order to protect or enforce our rights against a third
party.&nbsp;&nbsp;Third parties may in the future assert against us infringement claims or claims that we have infringed a patent,
copyright, trademark or other proprietary right belonging to them.&nbsp;&nbsp;Any infringement claim, even if not meritorious,
could result in the expenditure of significant financial and managerial resources and could negatively affect our profitability.&nbsp;&nbsp;While
defending our patents, the scope of the claim may be reduced in breadth and inventorship of the claimed subject matter, and proprietary
interests in the claimed subject matter may be altered or reduced. Some of our competitors may be able to sustain the costs of
such litigation or proceedings more effectively than we can because of their substantially greater financial resources.&nbsp;Any
such litigation or <FONT STYLE="font-family: Times New Roman, Times, Serif">proceedings, regardless </FONT>of outcome, could be
expensive and time consuming, and adverse determinations in any such litigation or proceedings could prevent us from developing,
manufacturing or commercializing our products and could adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The patents for
our product candidates have varying expiration dates and, if these patents expire, we may be subject to increased competition
and we may not be able to recover our development costs or market any of our approved products profitably. In some of the larger
potential market territories, such as the United States and Europe, patent term extension or restoration may be available to compensate
for time taken during aspects of the product&rsquo;s development and regulatory review or by procedural delays before the relevant
patent office. However, such an extension may not be granted, or if granted, the applicable time period or the scope of patent
protection afforded during any extension period may not be sufficient. In addition, even though some regulatory authorities may
provide some other exclusivity for a product under their own laws and regulations, we may not be able to qualify the product or
obtain the exclusive time period. If we are unable to obtain patent term extension/restoration or some other exclusivity, we could
be subject to increased competition and our opportunity to establish or maintain product revenue could be substantially reduced
or eliminated. Furthermore, we may not have sufficient time to recover our development costs prior to the expiration of our U.S.
and non-U.S. patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may face difficulties in certain
jurisdictions in protecting our intellectual property rights, which may diminish the value of our intellectual property rights
in those jurisdictions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The laws of some
jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States and the European
Union, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions.
If we or our collaboration partners encounter difficulties in protecting, or are otherwise precluded from effectively protecting,
the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished
and we may face additional competition from others in those jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Many countries
have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many
countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced
to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired
and our business, financial condition and results of operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual property rights do not address all potential
threats to our competitive advantage.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The degree of
future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Others
                                         may be able to make products that are similar to ours but that are not covered by the
                                         claims of the patents that we own.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Others
                                         may independently develop similar or alternative technologies or otherwise circumvent
                                         any of our technologies without infringing our intellectual property rights.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                         or any of our collaboration partners might not have been the first to conceive and reduce
                                         to practice the inventions covered by the patents or patent applications that we own,
                                         license or will own or license.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                         or any of our collaboration partners might not have been the first to file patent applications
                                         covering certain of the patents or patent applications that we or they own or have obtained
                                         a license, or will own or will have obtained a license.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">It
                                         is possible that our pending patent applications will not lead to issued patents.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Issued
                                         patents that we own may not provide us with any competitive advantage, or may be held
                                         invalid or unenforceable, as a result of legal challenges.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                         competitors might conduct research and development activities in countries where we do
                                         not have patent rights, or in countries where research and development safe harbor laws
                                         exist, and then use the information learned from such activities to develop competitive
                                         products for sale in our major commercial markets.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                         patents of third parties or pending or future applications of third parties, if issued,
                                         may have an adverse effect on our business.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Compulsory
                                         licensing provisions of certain governments to patented technologies that are deemed
                                         necessary for the government to access.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in patent laws or patent
jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products or product
candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">As is the case
with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents involves both technological complexity and legal complexity and is costly, time-consuming and inherently
uncertain. In addition, the America Invents Act was recently enacted in the United States, resulting in significant changes to
the U.S. patent system. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of
patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition
to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the
U.S. Patent and Trademark Office, <FONT STYLE="font-family: Times New Roman, Times, Serif">or USPTO, the </FONT>laws and regulations
governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing
patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has
also increased in recent years. In addition, the European patent system is relatively stringent with regard to the type of amendments
that are allowed during prosecution. These changes could limit our ability to obtain new patents in the future that may be important
for our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Confidentiality agreements with
employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We consider proprietary
trade secrets and/or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets
and/or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited
value. However, trade secrets and/or confidential know-how can be difficult to maintain as confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">To protect this
type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors
and advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors
and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements
may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that
a third-party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable.
The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Failure to obtain
or maintain trade secrets and/or confidential know-how trade protection could adversely affect our competitive position. Moreover,
our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection
in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets
and/or confidential know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to the ADSs, Warrants and this Offering
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The market price and trading volume
of the ADSs and Warrants may be volatile and may be affected by economic conditions beyond our control. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The market price of
the ADSs and Warrants may be highly volatile and subject to wide fluctuations. In addition, the trading volume of the ADSs and
Warrants may fluctuate and cause significant price variations to occur. If the market price of the ADSs or Warrants declines significantly,
you may be unable to resell your ADSs or Warrants at or above the purchase price, if at all. We cannot assure you that the market
price of the ADSs and Warrants will not fluctuate or significantly decline in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Some specific factors
that could negatively affect the price of the ADSs and Warrants or result in fluctuations in their price and trading volume include:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actual
                                         or expected fluctuations in our operating results;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes
                                         in market valuations of similar companies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes
                                         in our key personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes
                                         in financial estimates or recommendations by securities analysts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">trading
                                         prices of our ordinary shares on the ASX;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes
                                         in trading volume of ADSs or Warrants on The NASDAQ Capital Market, or NASDAQ, and of
                                         our ordinary shares on the ASX;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sales
                                         of the ADSs or ordinary shares by us, our executive officers or our shareholders in the
                                         future; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">conditions
                                         in the financial markets or changes in general economic conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An active trading market for the ADSs
and Warrants may not develop or be liquid enough for you to sell your ADSs and Warrants quickly or at market price.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Prior to this offering,
there has not been any public market in the United States for the ADSs or Warrants. If an active public market in the United States
for the ADSs and Warrants does not develop after this offering, the market price and liquidity of the ADSs and Warrants may be
adversely affected. While the ADSs and Warrants are listed on NASDAQ, a liquid public market in the United States for the ADSs
and Warrants may not develop or be sustained after this offering. The public offering price for the ADSs and Warrants will be
determined by negotiation among us and the underwriters, and the price at which the ADSs and Warrants are traded after this offering
may decline below the initial public offering price, which means you may experience a decrease in the value of your ADSs and Warrants
regardless of our operating performance or prospects. In the past, following periods of volatility in the market price of a company&rsquo;s
securities, shareholders often instituted securities class action litigation against that company. If we were involved in a class
action suit, it could divert the attention of senior management and, if adversely determined, could have cause us significant
financial harm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><B>Following
this offering, the market value of the Warrants is uncertain and there can be no assurance that the market value of the Warrants
will equal or exceed their public offering price.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Warrants offered
in this offering do not confer any rights of ordinary share ownership on their holders, such as voting rights or the right to
receive dividends, but rather merely represent the right to acquire shares of the ADS at a fixed price for a limited period of
time. Specifically, commencing on the date of issuance, holders of the Warrants may exercise their right to acquire ADS and pay
a per ADS exercise price of $10.00, prior to five years from the date of issuance, after which date any unexercised Warrants will
expire and have no further value. Moreover, following this offering, the market value of the Warrants is uncertain and there can
be no assurance that the market value of the Warrants will equal or exceed their public offering price. There can be no assurance
that the market price of the ADS will ever equal or exceed the exercise price of the Warrants, and consequently, whether it will
ever be profitable for holders of the Warrants to exercise the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investors purchasing the ADSs will
suffer immediate and substantial dilution. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The public offering
price for the ADSs will be substantially higher than the net tangible book value per ADS of the underlying ordinary shares immediately
after this offering. If you purchase ADSs in this offering, you will incur substantial and immediate dilution in the net tangible
book value of your investment. Net tangible book value per ADS represents the amount of total tangible assets less total liabilities,
divided by the number of ordinary shares then outstanding, multiplied by forty, the number of ordinary shares underlying each
ADS. To the extent that options or any convertible securities that are currently outstanding are exercised or converted, there
will be further dilution to your investment. We may also issue additional ordinary shares, ADSs, performance rights, options and
other securities in the future that may result in further dilution of your ADSs. See &ldquo;Dilution&rdquo; for a calculation
of the extent to which your investment will be diluted.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The dual listing of our ordinary
shares and the ADSs following this offering may adversely affect the liquidity and value of the ADSs. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Following this
offering and after the ADSs are listed on NASDAQ, our ordinary shares will continue to be listed on the ASX. We cannot predict
the effect of this dual listing on the value of our ordinary shares and ADSs. However, the dual listing of our ordinary shares
and ADSs may dilute the liquidity of these securities in one or both markets and may impair the development of an active trading
market for the ADSs in the United States. The trading price of the ADSs could also be adversely affected by trading in our ordinary
shares on the ASX. The investor in our convertible notes issued in February 2016 has the right to require that we delist from
NASDAQ at any time when our primary listing is not on the ASX.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Future sales of our ordinary shares
or ADSs, or the perception that such sales may occur, could depress the trading price of our ordinary shares and ADSs. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">After the completion of this offering, based on an offering price of $9.99 per ADS and $0.01 per Warrant,
we will have 610,000 (or 701,500 ADSs if the underwriters exercise their option to purchase additional ADSs in full), excluding
ADSs underlying the Warrants and 128,041,417&nbsp;ordinary shares (or 131,701,417 ordinary shares if the underwriters exercise
their option to purchase additional ADSs in full), excluding ordinary shares underlying the Warrants, which may be resold in the
public market immediately after this offering. We and all of our directors and executive officers have signed lock-up agreements
for a period of (i) three months after the date of this prospectus in the case of our directors and officers and (ii) 180 days
after the date of this prospectus in the case of the Company without the prior written consent of the representatives of the underwriters
subject to specified exceptions. See &ldquo;Underwriting.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The underwriters
may, in their sole discretion and without notice, release all or any portion of the ordinary shares or ADSs subject to lock-up
agreements. As restrictions on resale end, the market price of our ADSs and ordinary shares could drop significantly if the holders
of these ADSs or ordinary shares sell them or are perceived by the market as intending to sell them. These factors could also
make it more difficult for us to raise additional funds through future offerings of our ordinary shares, ADSs or other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>As a foreign private issuer, we are
permitted and we expect to follow certain home country corporate governance practices in lieu of certain NASDAQ requirements applicable
to domestic issuers. This may afford less protection to holders of the ADSs and Warrants. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">As a foreign private
issuer whose ADSs and Warrants are listed on NASDAQ, we are permitted to follow certain home country corporate governance practices
in lieu of certain NASDAQ requirements. For example, we may follow home country practice with regard to the composition of the
board of directors and quorum requirements applicable to shareholder meetings. A foreign private issuer must disclose in its annual
reports filed with the SEC the requirements with which it does not comply followed by a description of its applicable home country
practice. The Australian home country practices described above may afford less protection to holders of the ADSs and Warrants
than that provided under NASDAQ rules. See &ldquo;Description of Share Capital&mdash;Exemptions from Certain NASDAQ Corporate
Governance Rules.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>As a foreign private issuer, we
are permitted to file less information with the SEC than a company incorporated in the United States. Accordingly, there may be
less publicly available information concerning us than there is for companies incorporated in the United States. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">As a foreign private
issuer, we are exempt from certain rules under the Exchange Act, that impose disclosure requirements as well as procedural requirements
for proxy solicitations under Section&nbsp;14 of the Exchange Act. In addition, our officers, directors and principal shareholders
are exempt from the reporting and &ldquo;short-swing&rdquo; profit recovery provisions of Section&nbsp;16 of the Exchange Act.
Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as a
company that files as a U.S. company whose securities are registered under the Exchange Act, nor are we required to comply with
the SEC&rsquo;s Regulation&nbsp;FD, which restricts the selective disclosure of material non-public information. Accordingly,
there may be less information publicly available concerning us than there is for a company that files as a domestic issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We are an emerging growth company as
defined in the JOBS Act and the reduced disclosure requirements applicable to emerging growth companies may make the ADSs less
attractive to investors and, as a result, adversely affect the price of the ADSs and result in a less active trading market for
the ADSs and Warrants. </B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We are an emerging
growth company as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies. For example, we have elected to rely on
an exemption from the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act relating to internal control
over financial reporting, and we will not provide such an attestation from our auditors for so long as we qualify as an emerging
growth company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We may avail ourselves
of these disclosure exemptions until we are no longer an emerging growth company. We cannot predict whether investors will find
the ADSs less attractive because of our reliance on some or all of these exemptions. If investors find the ADSs less attractive,
it may cause the trading price of the ADSs and Warrants to decline and there may be a less active trading market for the ADSs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">We will cease to be an emerging growth
company upon the earliest of:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the end of
                                         the fiscal year in which the fifth anniversary of completion of this offering occurs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the end of
                                         the first fiscal year in which the market value of our ordinary shares held by non-affiliates
                                         exceeds $700&nbsp;million as of the end of the second quarter of such fiscal year;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the end of
                                         the first fiscal year in which we have total annual gross revenues of at least $1&nbsp;billion;
                                         and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date on
                                         which we have issued more than $1&nbsp;billion in non-convertible debt securities in
                                         any rolling three-year period.<FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.5pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we fail to establish and maintain
proper internal financial reporting controls, our ability to produce accurate <FONT STYLE="font-family: Times New Roman, Times, Serif">consolidated
</FONT>financial statements or comply with applicable regulations could be impaired. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Section&nbsp;404(a)
of the Sarbanes-Oxley Act requires that, beginning with our second annual report after the completion of this offering, our management
assess and report annually on the effectiveness of our internal controls over financial reporting and identify any material weaknesses
in our internal controls over financial reporting. Although Section&nbsp;404(b) of the Sarbanes-Oxley Act requires our independent
registered public accounting firm to issue an annual report that addresses the effectiveness of our internal controls over financial
reporting, we have opted to rely on the exemptions provided in the JOBS Act, and consequently will not be required to comply with
SEC rules that implement Section&nbsp;404(b) of the Sarbanes-Oxley Act until such time as we are no longer an emerging growth
company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our first Section&nbsp;404(a)
assessment will take place beginning with our second annual report after the completion of this offering. The presence of material
weaknesses could result in financial statement errors which, in turn, could lead to errors in our financial reports and/or delays
in our financial reporting, which could require us to restate our operating results. We might not identify one or more material
weaknesses in our internal controls in connection with evaluating our compliance with Section&nbsp;404(a) of the Sarbanes-Oxley
Act. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal controls over financial
reporting, we will need to expend significant resources and provide significant management oversight. Implementing any appropriate
changes to our internal controls may require specific compliance training of our directors and employees, entail substantial costs
in order to modify our existing accounting systems, take a significant period of time to complete and divert management&rsquo;s
attention from other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal
control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">If we are unable to conclude
that we have effective internal controls over financial reporting, investors may lose confidence in our operating results, the
price of the ADSs and Warrants could decline and we may be subject to litigation or regulatory enforcement actions. In addition,
if we are unable to meet the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, the ADSs and Warrants may not be able
to remain listed on NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ADS and Warrant holders may be subject
to additional risks related to holding ADSs and Warrants rather than ordinary shares. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">ADS and Warrant holders
do not hold ordinary shares directly and, as such, are subject to, among others, the following additional risks:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">As
                                         an ADS or Warrant holder, we will not treat you as one of our shareholders and you will
                                         not be able to exercise shareholder rights, except through the ADR depositary as permitted
                                         by the deposit agreement.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">distributions
                                         on the ordinary shares represented by your ADSs will be paid to the ADR depositary, and
                                         before the ADR depositary makes a distribution to you on behalf of your ADSs, any withholding
                                         taxes that must be paid will be deducted. Additionally, if the exchange rate fluctuates
                                         during a time when the ADR depositary cannot convert the foreign currency, you may lose
                                         some or all of the value of the distribution.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                         and the ADR depositary may amend or terminate the deposit agreement without the ADS holders&rsquo;
                                         consent in a manner that could prejudice ADS holders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You must act through the ADR depositary
to exercise your voting rights and, as a result, you may be unable to exercise your voting rights on a timely basis. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">As a holder of ADSs
(and not the ordinary shares underlying your ADSs), we will not treat you as one of our shareholders, and you will not be able
to exercise shareholder rights. The ADR depositary will be the holder of the ordinary shares underlying your ADSs, and ADS holders
will be able to exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the
deposit agreement relating to the ADSs. There are practical limitations on the ability of ADS holders to exercise their voting
rights due to the additional procedural steps involved in communicating with these holders. For example, holders of our ordinary
shares will receive notice of shareholders&rsquo; meetings by mail and will be able to exercise their voting rights by either
attending the shareholders meeting in person or voting by proxy. ADS holders, by comparison, will not receive notice directly
from us. Instead, in accordance with the deposit agreement, we will provide notice to the ADR depositary of any such shareholders
meeting and details concerning the matters to be voted upon at least 30&nbsp;days in advance of the meeting date. If we so instruct,
the ADR depositary will mail to holders of ADSs the notice of the meeting and a statement as to the manner in which voting instructions
may be given by holders as soon as practicable after receiving notice from us of any such meeting. To exercise their voting rights,
ADS holders must then instruct the ADR depositary as to voting the ordinary shares represented by their ADSs. Due to these procedural
steps involving the ADR depositary, the process for exercising voting rights may take longer for ADS holders than for holders
of ordinary shares. The ordinary shares represented by ADSs for which the ADR depositary fails to receive timely voting instructions
will not be voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we are classified as a &ldquo;passive
foreign investment company,&rdquo; then our U.S. shareholders could suffer adverse tax consequences as a result. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Generally, if, for
any taxable year, at least 75% of our gross income is passive income (including our pro rata share of the gross income of our
25% or more owned corporate subsidiaries) or at least 50% of the average quarterly value of our gross assets (including our pro
rata share of the gross assets of our 25% or more owned corporate subsidiaries) is attributable to assets that produce passive
income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment
company, or PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive income includes dividends, interest,
and gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received
from unrelated parties in connection with the active conduct of a trade or business. If we are characterized as a PFIC, a U.S.
holder of our ordinary shares or ADSs may suffer adverse tax consequences, including having gains recognized on the sale of our
ordinary shares or ADSs treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable to
dividends received on our ordinary shares or ADSs by individuals who are U.S. holders, and having interest charges added to their
tax on distributions from us and on gains from the sale of our ordinary shares or ADSs. See &ldquo;Taxation&mdash;U.S. Federal
Income Tax Considerations&mdash;<I>Passive Foreign Investment Company</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Since cash is viewed
by U.S. tax authorities as a passive asset, our status as a PFIC may also depend, in part, on how quickly we utilize the cash
proceeds from this offering in our business. Since PFIC status depends on the composition of our income and the composition and
value of our assets, which may be determined in large part by reference to the market value of our ordinary shares or ADSs, which
may be volatile, there can be no assurance that we will not be a PFIC for any taxable year. While we expect that we will not be
a PFIC for our taxable year ending June 30, 2017, since the PFIC tests are applied only at the end of a taxable year no assurance
of our PFIC status can be provided for such taxable year or future taxable years. Prospective U.S. investors should discuss the
issue of our possible status as a PFIC with their tax advisors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Currency fluctuations may adversely
affect the price of our ordinary shares, ADSs and Warrants. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our ordinary shares
are quoted in Australian dollars on the ASX and the ADSs and Warrants are quoted in U.S. dollars on NASDAQ. Movements in the Australian
dollar/U.S. dollar exchange rate may adversely affect the U.S. dollar price of the ADSs and Warrants. In the past year the Australian
dollar has generally weakened against the U.S. dollar. However, this trend may not continue and may be reversed. If the Australian
dollar weakens against the U.S. dollar, the U.S. dollar price of the ADSs and Warrants could decline, even if the price of our
ordinary shares in Australian dollars increases or remains unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We have never declared or paid dividends
on our ordinary shares and we do not anticipate paying dividends in the foreseeable future. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We have never declared
or paid cash dividends on our ordinary shares. For the foreseeable future, we currently intend to retain all available funds and
any future earnings to support our operations and to finance the growth and development of our business. Any future determination
to declare cash dividends will be made at the discretion of our board of directors, subject to compliance with applicable laws
and covenants under current or future credit facilities, which may restrict or limit our ability to pay dividends, and will depend
on our financial condition, operating results, capital requirements, general business conditions and other factors that our board
of directors may deem relevant. We do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future.
As a result, a return on your investment will only occur if our ADS or Warrant price appreciates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You may not receive distributions on
our ordinary shares represented by the ADSs or any value for such distribution if it is illegal or impractical to make them available
to holders of ADSs. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">While we do not anticipate
paying any dividends on our ordinary shares in the foreseeable future, if such a dividend is declared, the depositary for the
ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or
other deposited securities after deducting its fees and expenses. You will receive these distributions in proportion to the number
of our ordinary shares your ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it
may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action
to permit the distribution of the ADSs, ordinary shares, rights or anything else to holders of the ADSs. This means that you may
not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them
available to you. These restrictions may have a material adverse effect on the value of your ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Australian takeover laws may discourage
takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares, ADSs or
Warrants. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We are incorporated in
Australia and are subject to the takeover laws of Australia. Among other things, we are subject to the Australian Corporations
Act 2001, or the Corporations Act. Subject to a range of exceptions, the Corporations Act prohibits the acquisition of a direct
or indirect interest in our issued voting shares if the acquisition of that interest will lead to a person&rsquo;s voting power
in us increasing to more than 20%, or increasing from a starting point that is above 20% and below 90%. Australian takeover laws
may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares.
This may have the ancillary effect of entrenching our board of directors and may deprive or limit our shareholders&rsquo;, ADS
holders&rsquo; or Warrant holders&rsquo; opportunity to sell their ordinary shares, ADSs or Warrants and may further restrict
the ability of our shareholders and ADS and Warrant holders to obtain a premium from such transactions. See &ldquo;Description
of Share Capital&mdash;Change of Control.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Constitution and Australian laws
and regulations applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">As an Australian
company, we are subject to different corporate requirements than a corporation organized under the laws of the states of the United
States. Our Constitution, as well as the Australian Corporations Act, set forth various rights and obligations that are unique
to us as an Australian company. These requirements may operate differently than those of many U.S. companies. You should carefully
review the summary of these matters set forth under the section entitled, &ldquo;Description of Share Capital&rdquo; as well as
our Constitution, which is included as an exhibit to this registration statement to which this prospectus forms&nbsp;a part, prior
to investing in the ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You will have limited ability to bring
an action against us or against our directors and officers, or to enforce a judgment against us or them, because we are incorporated
in Australia and certain of our directors and officers reside outside the United States.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We are incorporated
in Australia, certain of our directors and officers reside outside the United States and substantially all of the assets of those
persons are located outside the United States. As a result, it may be impracticable or at least more expensive for you to bring
an action against us or against these individuals in Australia in the event that you believe that your rights have been infringed
under the applicable securities laws or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You may not be able to participate
in rights offerings and may experience dilution of your holdings as a result.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We may from time
to time distribute rights to our shareholders, including rights to acquire our securities. However, we may not, and under the
Deposit Agreement for the ADSs, the depositary will not, offer those rights to ADS holders unless both the rights and the underlying
securities to be distributed to ADS holders are registered under the Securities Act, or the distribution of them to ADS holders
is exempted from registration under the Securities Act with respect to all holders of ADSs. We are under no obligation to file
a registration statement with respect to any such rights or underlying securities or to endeavor to cause such a registration
statement to be declared effective. In addition, we may not be able to rely on an exemption from registration under the Securities
Act to distribute such rights and securities. Accordingly, holders of the ADSs may be unable to participate in our rights offerings
and may experience dilution in their holdings as a result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You may be subject to limitations on
transfer of the ADSs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The ADSs are only
transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to
time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver,
transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we
or the depositary deem it advisable to do so because of any requirement of law or of any government or governmental body, or under
any provision of the Deposit Agreement, or for any other reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 36; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Australian companies may not be able
to initiate shareholder derivative actions, thereby depriving shareholders of the ability to protect their interests.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Australian companies
may not have standing to initiate a shareholder derivative action in a federal court of the United States. The circumstances in
which any such action may be brought, and the procedures and defenses that may be available in respect to any such action, may
result in the rights of shareholders of an Australian company being more limited than those of shareholders of a company organized
in the United States. Accordingly, shareholders may have fewer alternatives available to them if they believe that corporate wrongdoing
has occurred. Australian courts are also unlikely to recognize or enforce against us judgments of courts in the United States
based on certain liability provisions of U.S. securities law and to impose liabilities against us, in original actions brought
in Australia, based on certain liability provisions of U.S. securities laws that are penal in nature. There is no statutory recognition
in Australia of judgments obtained in the United States, although the courts of Australia may recognize and enforce the non-penal
judgment of a foreign court of competent jurisdiction without retrial on the merits, upon being satisfied about all the relevant
circumstances in which that judgment was obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-takeover provisions in our Constitution
and our right to issue preference shares could make a third-party acquisition of us difficult.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Some provisions of
our Constitution may discourage, delay or prevent a change in control of our company or management that shareholders may consider
favorable, including provisions that only require one-third of our board of directors to be elected annually and authorize our
board of directors to issue an unlimited number of shares of capital stock and preference shares in one or more series and to
designate the price, rights, preferences, privileges and restrictions of such preference shares by amending the Constitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><A NAME="a_008"></A><B>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">This prospectus contains
forward looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. All
statements, other than statements of historical fact included in this prospectus, regarding our strategy, future operations, financial
position, projected costs, prospects, plans and objectives of management are forward looking statements. When used in this prospectus,
the words &ldquo;could,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;continue,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; &ldquo;project,&rdquo;
or the negative of these terms, and similar expressions are intended to identify forward looking statements, although not all
forward looking statements contain such identifying words. These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis
for each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination
of facts and important factors currently known by us and our expectations of the future, about which we cannot be certain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Forward-looking statements
may include statements about:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         plans to develop and potentially commercialize our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         timing of the initiation and completion of preclinical studies and clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         timing of patient enrollment and dosing in clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         timing of the availability of data from clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         timing of expected regulatory filings;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expectations
                                         about the plans of licensees of our technology;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">potential
                                         future out-licenses and collaborations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         expectations regarding expenses, ongoing losses, future revenue, capital needs and needs
                                         for additional financing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         use of proceeds from this offering;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         length of time over which we expect our cash and cash equivalents and the proceeds from
                                         this offering to be sufficient; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         intellectual property position and the duration of our patent portfolio.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">All forward-looking
statements speak only as of the date of this prospectus. You should not place undue reliance on these forward-looking statements.
Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements
we make in this prospectus are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will
be achieved. We disclose important factors that could cause our actual results to differ materially from our expectations under
&ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>The
forward-looking statements made in this prospectus relate only to events or information as of the date on which the statements
are made in this prospectus. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made
or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our net proceeds
from this offering will be approximately $4.8 million (after deducting underwriting discounts and commissions and estimated
offering expenses payable by us) or approximately $5.7 million if the underwriters exercise their over-allotment option in
full, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Each $1.00
increase (decrease) in the public offering price of $10.00 for the ADS and Warrants) would increase (decrease) the net
proceeds to us from this offering by approximately $567,300, or approximately $652,395 if the underwriter exercise their
over-allotment option in full, assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We currently estimate
that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">approximately $2 million to advance the
    clinical development of IMM-124E for the treatment of fatty-liver diseases, which we expect will be sufficient to complete
    our Phase II clinical programs in NASH, ASH and Pediatric NASH;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approximately $1 million to advance development of IMM-529 and
    complete our planned Phase I/II in the prevention of CDI recurrence in patients suffering from recurrent CDI;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approximately $0.5 million to support other programs including our colitis pre-clinical program and our collaboration with the US Army and US Navy; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approximately $377,000 to pay off amounts due on the R&amp;D Tax Incentive Prepayment Loan Facility Agreement with Grandlodge Capital Pty. Ltd.; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the remainder of approximately $0.923 million, to fund
    manufacturing costs of clinical supplies and Travelan, marketing initiatives for Travelan in the United States and Australia,
    current and feature research and development activities, &nbsp;for working capital and other general corporate
    purposes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>


<!-- Field: Page; Sequence: 38; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">This expected use
of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. We may
also use a portion of the net proceeds to in-license, acquire, or invest in additional businesses, technologies, products or assets,
although currently we have no specific agreements, commitments or understandings in this regard. As of the date of this prospectus,
we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering
or the amounts that we will actually spend on the uses set forth above. Predicting the cost necessary to develop product candidates
can be difficult and we anticipate that we will need additional funds to complete the development of IMM-124E, IMM-529 and any
other product candidates we identify. The amounts and timing of our actual expenditures and the extent of clinical development
may vary significantly from our expectations depending upon numerous factors, including the progress of our research and development
efforts, progress of our clinical trial, our operating costs and factors described under &ldquo;Risk Factors&rdquo; in this prospectus.
Accordingly, we will retain broad discretion over the allocation of the net proceeds from this offering and we reserve the right
to change the allocation of the net proceeds described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; text-align: justify">Pending our use of
the net proceeds from this offering, we intend to invest the net proceeds from this offering in investment-grade, interest-bearing
instruments and U.S. government securities or certificates of deposit.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_010"></A><B>PRICE
RANGE OF ORDINARY SHARES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">The following table presents, for the
periods indicated, the high and low market prices for our ordinary shares reported on the ASX, under the symbol IMC. All prices
are in Australian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">AUD$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">AUD$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Annual:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; padding-left: 9pt; text-align: left">Fiscal year ended June 30,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 0.25in">2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.08</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Quarterly:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; padding-left: 9pt; text-align: left">Fiscal year ending June 30, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.38</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; padding-left: 9pt; text-align: left">Fiscal year ending June 30, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.18</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.18</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; padding-left: 9pt; text-align: left">Fiscal year ended June 30, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.28</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Most Recent Six Months:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">May 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">April 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">0.57</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">0.40</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">March 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">February 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.29</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">January 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">December 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">On June 7, 2017, the
closing price of our ordinary shares as traded on the ASX was AUD$0.50 per ordinary share ($0.38 per share based on the foreign
exchange rate of AUD$1.00 to $0.7540 as published by the Reserve Bank of Australia as of such date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">As of June 7, 2017,
the Company had 105,641,417 ordinary shares issued and 103,641,417 ordinary shares outstanding held by a total of 1,386 shareholders
and 34,177,523 options over ordinary shares outstanding. Of the total shares on issue, 256,011 of these issued ordinary shares
were held in the U.S. by 6 holders on this date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">A large number of
our ordinary shares are held in nominee companies so we cannot be certain of the identity of those beneficial owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_011"></A><B>DIVIDEND POLICY </B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We have not declared
or paid any dividends on our ordinary shares, and we do not anticipate paying any dividends in the foreseeable future. Our board
of directors presently intends to reinvest all earnings in the continued development and operation of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Payment of dividends
in the future, if any, will be at the discretion of our board of directors. If our board of directors elects to pay dividends,
the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general
financial conditions, contractual restrictions and other factors that our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_012"></A><B>EXCHANGE RATE INFORMATION
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The Australian dollar
is convertible into U.S. dollars at freely floating rates. There are no legal restrictions on the flow of Australian dollars between
Australia and the United States. Any remittances of dividends or other payments by us to persons in the United States are not
and will not be subject to any exchange controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our consolidated
financial statements are prepared and presented in Australian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The table below sets
forth for the periods identified the number of U.S. dollars per Australian dollar as published by the Reserve Bank of Australia.
We make no representation that any Australian dollar or U.S. dollar amounts could have been, or could be, converted into U.S.
dollars or Australian dollars, as the case may be, at any particular rate, the rates stated below, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">At&nbsp;Period<BR> End <BR> AUD$</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average<BR> Rate <BR> AUD$</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">High<BR> AUD$</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Low<BR> AUD$</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt; text-align: left">Fiscal year ended June 30,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; padding-left: 9pt">2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.7426</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.7265</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.7812</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.6867</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.8288</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9458</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7590</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9420</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9148</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9672</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.8716</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0239</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9202</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0191</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0362</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.1055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0739</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9990</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0939</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.8366</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt; text-align: left">Month ended:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left">May 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7434</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7539</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7352</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left">April 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0">$</P>


</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">0.7475</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0">$</P>


</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">0.7533</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">0.7602</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0">$</P>


</TD><TD STYLE="text-align: right">0.7475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left">March, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7644</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7624</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7514</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left">February, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7688</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7668</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7717</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7566</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left">January, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7567</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7453</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7576</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7234</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;December, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7236</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7497</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7202</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left">November, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7474</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7536</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7324</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left">October, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7613</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7616</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7537</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left">September, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7595</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7698</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7469</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left">August, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7514</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7711</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7514</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left">July, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7522</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7626</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7436</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left">June, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7533</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7239</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Determined by averaging
                                         the published rate on the last day of each full month during the fiscal year.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The following table sets
forth our cash and cash equivalents and our capitalization as of December 31, 2016 presented in U.S. dollars:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">on an actual basis; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 96%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">on a pro-forma, as adjusted, basis to also give effect to: our sale of 610,000 ADSs and warrants to purchase 610,000 ADSs in this offering at an initial public offering price of $9.99 per ADS and $0.01 per Warrant. You should read this table in conjunction with &ldquo;Selected Financial Data,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our financial statements and related notes included elsewhere in this prospectus.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify">The data below is based on the December
31, 2016 exchange rate of $1.00 = AUD$0.7236:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of December 31, 2016</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As Adjusted</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>USD$</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>USD$</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,245,825</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">7,045,825</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Other financial liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">490,601</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">490,601</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Shareholders&rsquo; equity:</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Issued capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34,360,653</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">39,160,653</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Reserves</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,623,079</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,623,079</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Accumulated losses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(33,412,650</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(33,412,650</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Total shareholders&rsquo; equity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>2,571,082</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>7,371,082</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total capitalization</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,061,683</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">7,861,683</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A $1.00 increase (decrease) in the aggregate
public offering price of $9.99 per ADS and $0.01 per Warrant, would increase (decrease) the as adjusted amount of each of cash
and cash equivalents and total shareholders' equity by approximately $567,300, assuming that the number of ADSs and Warrants offered
by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A 100,000 ADS increase in the number of
ADSs offered by us together with a concomitant $1.00 increase in the aggregate public offering price of $9.99 per ADS and $0.01
per Warrant, would increase our as adjusted cash and cash equivalents by approximately $1.6 million after deducting estimated underwriting
discounts and estimated offering expenses payable by us. Conversely, a 100,000 ADS decrease in the number of ADSs and warrants
offered by us together with a concomitant $1.00 decrease in the aggregate public offering price of $9.99 per ADS and $0.01 per
Warrant, would decrease our as adjusted cash and cash equivalents by approximately $1.4 million after deducting estimated underwriting
discounts and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">The number of
ordinary shares that will be outstanding immediately after this offering is based on 128,041,417 ordinary shares outstanding as
of June 7, 2017. This number excludes, as of such date:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 21px"></TD><TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify">excludes an aggregate of 34,177,523 ordinary shares issuable upon the exercise of options outstanding
at June 7, 2017, at a weighted average exercise price of AUD$0.543, of which 33,177,523 ordinary shares were vested at a weighted
average exercise price of AUD$0.544;</TD>
</TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 21px; text-align: left"></TD><TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2,000,000
                                         escrow restricted treasury shares issued to a convertible loan holder as collateral over
                                         any future potential convertible loan repayment defaults;</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 21px; text-align: left"></TD><TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary
                                         shares underlying the ADSs issuable upon exercise of the warrants issued in the offering;
                                         and</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 21px; text-align: left"></TD><TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary
                                         shares underlying the ADSs issuable upon the exercise of the underwriter warrants.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise indicated, all information in this prospectus
assumes or gives effect to no exercise of outstanding options or warrants described above and the underwriters&rsquo; over-allotment
option.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_014"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">If you purchase ADSs in
this offering, your ownership interest in us will be diluted to the extent of the difference between the public offering price
per ADSs you will pay in this offering and the pro forma net tangible book value per ADS after this offering. Such calculation
does not reflect any dilution associated with the sale and exercise of the warrants. Dilution results from the fact that the initial
public offering price per ordinary share is substantially in excess of the book value per ordinary share attributable to the existing
shareholders for our presently outstanding ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">Our historical net tangible
book value as of December 31, 2016, was approximately AUD$3.553 million, or $2.571 million, corresponding to a net tangible book
value of AUD$ 0.0343 or $0.0248 per ordinary share or $0.99 per ADS (using the ratio of 40 ordinary shares to one ADS), as of such
date. We calculate our historical net tangible book value per share or per ADS by taking the amount of our total tangible assets,
subtracting the amount of our total liabilities, and then dividing the difference by the actual total number of ordinary shares
or ADSs outstanding, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">The pro forma as adjusted
net tangible book value per share as of December 31, 2016 was AUD$0.0796 or $0.0576 per ordinary share or $2.30 per ADS (using
the ratio of 40 ordinary shares to one ADS). The pro forma as adjusted net tangible book value per share gives effect to the sale
and issuance of the ADSs in this offering at an offering price of $9.99 per ADS and $0.01 per Warrant, after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">The pro forma as adjusted
net tangible book value per share after the offering is calculated by dividing the pro forma net tangible book value of AUD$10.2
million or $7.4 million, by 128,041,417, which is equal to our pro forma issued and outstanding ordinary shares. The difference
between the public offering price and the pro forma net tangible book value per share represents an immediate increase in the net
tangible book value of AUD$0.0453, or $0.0328 per ordinary share or $1.31 per ADS to existing shareholders and immediate dilution
of AUD$0.2659, or $0.1924 per share, or $7.70 per ADS to new investors purchasing the ADSs in this offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The following table illustrates this dilution
on an ADS basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>AUD$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>USD$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%">Initial public offering price</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">13.82</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">10.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Actual net tangible book value as at December 31, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.37</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.99</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Increase in net tangible book value per ADS attributable to purchasers purchasing ADSs in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.81</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.31</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Pro forma net tangible book value per ADS, as adjusted to give effect to this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.18</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.30</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Dilution per ADS to purchasers in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.64</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.70</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">A $1.00 increase (decrease)
in the initial public offering price of $9.99 per ADS and $0.01 per Warrant, would increase (decrease) our pro forma net tangible
book value per ADS after this offering by AUD$0.24, $0.18 and the dilution per ADS to new investors by AUD$1.13, $0.82 assuming
the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number
of ADSs we are offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 42; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">The following table
summarizes, on a pro forma as adjusted basis as of June 7, 2017, the differences between the number of ordinary shares purchased
from us (treating each ADS as 40 ordinary shares), the total consideration paid to us and the average price per ordinary share
paid by existing holders of our ordinary shares and by investors in this offering (treating each ADS as 40 ordinary shares) in
purchases of the ADSs from us and by purchasers in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">The table below is based
on 128,041,417 ordinary shares outstanding immediately after the consummation of this offering (including those represented by
the ADSs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">The table below is based
upon a public offering price of $9.99 per ADS and $0.01 per Warrant, excluding underwriting discounts and commissions and estimated
offering expenses payable by us, and assuming no exercise of the underwriters&rsquo; over-allotment option and does not take into
account any warrants to be sold in this offering:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares Purchased</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Consideration</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Average Price</B><BR>
        <B>Per Share </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(USD$)</B></P></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>%</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(USD$)</B></P></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>%</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Existing shareholders</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">103,641,417</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">80.94</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">34,360,653</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">84.92</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">0.3315</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Purchasers in this offering</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">24,400,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">19.06</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6,100,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">15.08</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">%</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">0.2500</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">128,041,417</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100.00</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">40,460,653</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100.00</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">0.3160</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A><B>SELECTED HISTORICAL
CONSOLIDATED FINANCIAL DATA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The following tables
set forth selected historical consolidated financial data for the periods indicated. <FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The consolidated statement
of profit or loss and other comprehensive income data for the fiscal years ended June&nbsp;30, 2016, 2015 and 2014 are derived
from the audited consolidated financial statements included in this prospectus. The consolidated statement of profit or loss and
other comprehensive income data for the six months ended December 31, 2016 and 2015 are derived from the unaudited consolidated
financial statements included in this prospectus. In our management&rsquo;s opinion, these consolidated financial statements include
all adjustments necessary for the fair presentation of our financial condition as of such dates and our results of operations
for such periods.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our consolidated
financial statements have been prepared in Australian dollars and in accordance with International Accounting Standards. Our consolidated
financial statements comply with IFRS, as issued by the IASB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">You should read the
selected consolidated financial data in conjunction with our consolidated financial statements and related notes beginning on
page&nbsp;F-1 of this prospectus, and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations&rdquo; included elsewhere in this prospectus. Our historical results do not necessarily indicate our expected results
for any future periods. Financial results for the year ended June 30, 2016 and six months ended December 31, 2016 are not necessarily
indicative of the results that may be expected for the full fiscal year ending June&nbsp;30, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the year ended June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the six months ended Dec
    31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<BR> AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015<BR> AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014<BR> AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<BR> AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015<BR> AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0.2pt">Consolidated Statement of Profit or Loss and Other Comprehensive
    Income Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 8.8pt">Revenue:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: left; padding-bottom: 1pt">Operating Revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: right">1,001,077</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: right">1,002,380</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: right">981,051</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: right">703,099</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: right">497,220</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Total Operating Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,001,077</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,002,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">981,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">703,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">497,220</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cost of Goods Sold</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(301,435</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(316,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(277,928</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(223,394</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(153,640</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Gross Profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">699,642</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">686,252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">703,123</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">479,705</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">343,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Sales and Marketing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(133,781</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,794</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(79,796</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(93,520</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52,659</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Freight Costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(134,967</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(116,379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(114,278</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(62,590</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(61,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Gross Profit less Direct Selling Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">430,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">493,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">509,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,595</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,622</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 8.8pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,539,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,591,021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">804,477</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">816,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">763,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 8.8pt">Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(680,587</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Consulting, Employee and Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,840,037</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(728,140</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(555,487</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(907,390</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,113,214</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Corporate Administration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,320,570</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(557,422</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(492,465</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(790,103</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(708,625</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,719</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,989</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,975</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,944</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(341,600</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(463,685</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,183</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Impairment of Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,340</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,204</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(135,170</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Marketing and Promotion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(487,591</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(304,687</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(235,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(471,735</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,724</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,623,961</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,018,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,289,675</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,117,867</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,839,990</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Travel and Entertainment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(416,849</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(128,318</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(37,327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(112,453</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(195,605</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss before income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,068,767</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,691,820</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,495,069</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,409,349</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,068,086</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 8.8pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,068,767</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,691,820</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,495,069</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,409,349</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,068,086</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 8.8pt">Other Comprehensive Income / (Losses)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,846</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41,425</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total Comprehensive Loss for the Period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,059,921</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,704,401</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,495,069</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,450,774</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,072,867</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.2pt">Loss per share, basic and diluted (cent per share)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.065</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.2pt">Weighted-average number of shares outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,435,993</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,935,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,955,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,328,491</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,470,006</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 44; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_016"></A><B>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>You should read
the following discussion and analysis of our financial condition and results of operations in conjunction with the section entitled
&ldquo;Selected Historical Consolidated Financial Data&rdquo; and our consolidated financial statements and related notes included
elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual
results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as
a result of various factors, including, but not limited to, those set forth under &ldquo;Risk Factors&rdquo; and elsewhere in
this prospectus. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Our financial
statements have been prepared in Australian dollars and in accordance with International Financial Reporting Standards (IFRS).
Our financial statements comply with IFRS, as issued by the IASB. Our fiscal year end is June&nbsp;30. References to a particular
&ldquo;fiscal year&rdquo; are to our fiscal year ended June&nbsp;30 of that year. </I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We are a clinical-stage
publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on developing a novel class
of biological polyclonal antibodies. Our first-in-class oral polyclonal antibodies drugs can target specific antigens to directly
block bacteria at mucosal surfaces and/or to influence the cell-mediated immune system through regulatory T-cell populations.
These unique antibodies can target a large range of human diseases, including infectious diseases and immune mediated disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We are advancing our
lead asset, IMM-124E, in several Phase 2 clinical trials for NASH, ASH and pediatric NASH. Both the Phase 2s in ASH and Pediatric
are funded by the NIH, highlighting the potentially of our technology. The success of any of these human trials would be a key
step toward therapeutic use and toward ultimately commercializing the product if it achieves approval. In addition to IMM-124E,
we are pursuing other programs in the pre-clinical or Phase I stage such as IMM-529, which is a C. <I>difficile</I> ToxinB antagonist,
and a shigella vaccine, that is currently in development with the Department of Defense (DoD). Currently, we are selling over-the-counter
Travelan product, the only preventative treatment targeting Traveler&rsquo;s Diarrhea (TD). In the future, we also expect to earn
revenues from commercializing our primary therapeutic product candidates in our targeted markets, if they receive approval.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Since we were incorporated
in 1994, we have devoted the majority of our resources to development efforts relating to oral immunotherapy for human beings.
We have funded our operations primarily from public offerings in Australia and private placements of ordinary shares. We have
also been awarded research and development tax incentive refunds for eligible research and development expenditure from the Australian
federal government, totaling nearly AUD$1.6 million for the fiscal year ended June 30, 2016. We are currently collaborating with
the U.S. Department of Defense for the research of Shigella, Campylobacter and ETEC vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We have incurred losses
from operations in each year since inception. Our net losses were AUD$3.4 million and AUD$3.1 million for the six-month periods
ended December 31, 2016 and 2015 respectively, and AUD$7.1 million, AUD$2.7&nbsp;million, and AUD$2.5 million for the fiscal years
ended June&nbsp;30, 2016, 2015, and 2014 respectively. The majority of our net losses resulted from costs incurred in connection
with our research and development programs and from general and administrative costs associated with our operations. We expect
to continue to incur significant expenses and increasing operating losses for at least the next several years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We generated AUD$0.7
million and AUD$0.5 million of revenue from the sale of our existing consumer product Travelan for the six-month periods ended
December 31, 2016 and 2015 respectively, and AUD$1.0 million for the fiscal years ended June&nbsp;30, 2016 and 2015, and AUD$981K
for fiscal year 2014. We are not currently, but may in the future, generate revenue from licensing programs, strategic alliances,
and collaboration arrangement with other pharmaceutical companies for the use of our pipeline products. Whilst we do not have
any of these arrangements in place, it is likely that these possibilities will manifest as our pipeline products become more advanced
following our ongoing research efforts. We do not expect to generate revenue from our current clinical trial products until we
have successfully completed sufficient clinical development having also obtained the necessary regulatory approvals, which we
expect will take a number of years, which is subject to significant uncertainty and may never occur.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We expect that the
net proceeds from this offering, and our existing cash and cash equivalents, will be sufficient to enable us to advance the planned
preclinical programs and clinical trials for certain of our key product candidates for approximately the next 24 months. See &ldquo;Use
of Proceeds.&rdquo; In addition, we will continue to pursue licensing programs, strategic alliances, and collaboration arrangements
with major pharmaceutical companies, governmental entities, and universities to assist us to fund our trial development and commercialization
process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis of Preparation &ndash; For the
audited consolidated financial statements</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The financial report
is a general-purpose financial report, which has been prepared in accordance with the requirements of International Financial
Reporting Standards (IFRS), required for a for-profit entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The financial report
has been prepared on an accruals basis and is primarily based on historical costs. The financial report is presented in Australian
dollars, which is the Company&rsquo;s functional and presentation currency. All values are rounded to the nearest dollar unless
otherwise stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Management is required
to make judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily apparent from
other sources. The estimates and associated assumptions are based on historical experience and various other factors that are
believed to be reasonable under the circumstance, the results of which form the basis of making the judgements. Actual results
may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting
estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period
of the revision and future periods if the revision affects both current and future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Judgements made by
management in the application of IFRS that have significant effects on the financial statements and estimates with a significant
risk of material adjustments in the next year are disclosed, where applicable, in the relevant notes to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 46; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Accounting policies
are selected and applied in a manner which ensures that the resulting financial information satisfies the concepts of relevance
and reliability, thereby ensuring that the substance of the underlying transactions or other events is reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Statement of Compliance</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our consolidated
financial statements comply with the International Financial Reporting Standards (&quot;IFRS&quot;) as issued by the International
Accounting Standards Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>New, revised or amending Accounting
Standards and Interpretations adopted</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The Company has adopted
all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards
Board ('IASB') that are mandatory for the current reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">There were no significant
new standards adopted during the reporting periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Management has determined
that the standards that have been adopted in fiscal year 2017 have not had a material impact on the Group. Management is currently
assessing the impact of the standards to be adopted in fiscal year 2018 and forward on the Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Critical Accounting Policies</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The following is
a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting
policies have been consistently applied, unless otherwise stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Basis of Consolidation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The consolidated
financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries)
referred to as &lsquo;the Group&rsquo; in the financial statements. Control is achieved where the consolidated entity is exposed
to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through
its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred
to the consolidated entity. They are de-consolidated from the date that control ceases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">A list of controlled
entities is contained in Note 11 to the financial statements. All controlled entities have a June 30 financial year-end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">All intra-group transactions,
balances, income and expenses are eliminated in full on consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Accounting policies
of subsidiaries have been changed where necessary to ensure consistency with those policies applied by the parent entity. Subsidiaries
are accounted for at cost in the parent entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The results of subsidiaries
acquired or disposed of during the year are included in profit or loss from the effective date of acquisition or up to the effective
date of disposal, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Revenue Recognition</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Revenue is measured
at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances,
rebates and amounts collected on behalf of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The Company recognizes
revenue when the amount of the revenue can be reliably measured, it is probable that the future economic benefits will flow to
the entity and specific criteria have been met for each of the activities as described below. The amount of the revenue is not
considered to be reliably measured until all contingencies relating to the sale have been resolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The following specific
revenue criteria must be met before revenue is recognized:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 94%; border-collapse: collapse; margin-left: 0.31in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">(i)</TD>
    <TD STYLE="width: 25%">Sale of Goods and services</TD>
    <TD STYLE="width: 5%; text-align: justify">&ndash;</TD>
    <TD STYLE="width: 65%; text-align: justify">Significant risks and rewards of ownership of goods has passed to the buyer and
    an invoice for the goods or services is issued;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(ii)</TD>
    <TD STYLE="text-align: justify">Interest</TD>
    <TD STYLE="text-align: justify">&ndash;</TD>
    <TD STYLE="text-align: justify">Interest income is recognized using the effective interest rate method;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(iii)</TD>
    <TD STYLE="text-align: justify">R &amp; D Tax Refunds</TD>
    <TD STYLE="text-align: justify">&ndash;</TD>
    <TD STYLE="text-align: justify">Income is recognized in the year the research and development expenses were incurred.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: -156.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">A difference of AUD$644,149
in the Accumulated losses balance at June 30, 2013 between the consolidated financial statements appearing elsewhere in this prospectus
and the original statement lodged with ASX relates to the previous recognition of fiscal year 2013 R&amp;D refund in fiscal year
2014, which does not significantly affect the overall financial position and results presented in the original statement. For
the fiscal year 2014, 2015 and 2016, the Company has reassessed and made changes to the amount of R&amp;D Tax Refund recognized
as Other Income for the period as compared to the previous statements lodged with the ASX. Effectively, these changes resulted
in an increase of AUD$49,481 and AUD$756,131 in Other Income, resulting in a related decrease in the net loss, for the period
on the Consolidated Statement of Profit or Loss and Other Comprehensive Income for the fiscal year 2014 and 2015. These changes
also resulted in a decrease in Other Income of AUD$1,469,763, and a related increase in Net Loss, for the period on the Consolidated
Statement of Profit or Loss and Other Comprehensive Income for fiscal year 2016.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">These adjustments
were the result of additional information being made available to the Company subsequent to the previous lodgements with ASX which,
as a result, changed the timing of recognition, but not the actual amount of the R&amp;D Refund received.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: -156.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The Company has worked
with experienced advisors to improve its internal process on advanced findings of the R&amp;D activities, which includes determining
and evaluating the eligibility of R&amp;D related expenditure to support its submission of the R&amp;D Tax Refund claim.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: -156.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.25in"><I><U>Intangible
Assets - Research &amp; Development</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Expenditure on research
activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in
the statement of profit or loss and other comprehensive income as an expense when it is incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Expenditure on development
activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially
improved products or services before the start of commercial production or use, is capitalized if it is probable that the product
or service is technically and commercially feasible, will generate probable economic benefits and adequate resources are available
to complete development and cost can be measured reliably. Other development expenditure is recognized in the statement of profit
or loss and other comprehensive income as an expense as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Interest Bearing Loans and Borrowings</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Generally, loans
and borrowings are initially recognized at cost, being the fair value of the consideration received net of issue costs associated
with the borrowing. After initial recognition, interest bearing loans and borrowings are subsequently measured at amortized cost
using the effective interest method. Amortized cost is calculated by taking into account any issue costs and any discount or premium
on settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The component of
the convertible notes that were issued in connection with the February 2016 financing arrangement, that exhibits characteristics
of a liability is recognised as a liability in the statement of financial position. On the date of issuance and each subsequent
reporting period, the Company records the entire hybrid instrument as measured at fair value through profit and loss. The associated
transaction costs have also been expensed as incurred and are recorded as Finance and Termination costs in the Statement of Profit
or Loss and Other Comprehensive Income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Fair Value of Convertible Notes</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The convertible notes
were measured and disclosed as a level 3 instrument, using a three level hierarchy, based on the lowest level of input that is
significant to the entire fair value measurement, as defined below:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                         1: Quoted price (unadjusted) in active markets for identical assets or liabilities that
                                         the entity can access at the measurement date</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                         2: Inputs other than quoted prices included within Level 1 that are observable for the
                                         asset and liability, either directly or indirectly</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                         3: Unobservable inputs for the asset or liability</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">No transfers between
the levels of the fair value hierarchy occurred during the current year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 48; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Inventories</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">Raw materials, work
in progress and finished goods are stated at the lower of cost and net realizable value. Where appropriate, cost comprises direct
materials, direct labor and an appropriate proportion of variable and fixed overheads expenditure, the latter being allocated
on the basis of normal operating capacity. The Company classifies inventory as a current asset as all amounts are held for the
purpose of trading. Costs are assigned to individual items of inventory on basis of weighted average costs. Net realizable value
is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs
necessary to make the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">The Company&rsquo;s
Inventory balance increased from AUD$1,146,267 as of June 30, 2015 to AUD$ 2,056,067 as of June 30, 2016 as the Company increased
its stocks of raw colostrum to ensure there would be sufficient supply of product available to ensure no stock-outs occurred from
the increase in sales volumes expected from the Company&rsquo;s expansion into the new geographic markets of USA and China.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Share-based payments</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Share-based compensation
benefits may be provided through the issue of fully paid ordinary shares under the Immuron Employee Share and Option Plan. Options
are also granted to employees and consultants in accordance with the terms of their respective employment and consultancy agreements.
Any options granted are made in accordance with the terms of the Company&rsquo;s Employee Share and Option Plan (ESOP).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The fair value of
options granted under employment and consultancy agreements are recognized as an employee benefit expense with a corresponding
increase in equity. The fair value is measured at grant date and recognized over the period during which the employees become
unconditionally entitled to the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The fair value at
grant date is determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the
option, the vesting and performance criteria, the impact of dilution, the non-tradeable nature of the option, the share price
at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate
for the term of the option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The fair value of
the options granted excludes the impact of any non-market vesting conditions (for example, profitability and sales growth targets).
Non-market vesting conditions are included in assumptions about the number of options that are expected to become exercisable.
At each reporting date, the entity revises its estimate of the number of options that are expected to become exercisable. The
employee benefit expense recognized each period takes into account the most recent estimate. The impact of the revision to original
estimates, if any, is recognized in the statement of profit or loss and other comprehensive in come with a corresponding adjustment
to equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Upon the exercise of options, the balance
of the share-based payments reserve relating to those options is transferred to contributed equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Previously issued Financial Statements</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Reclassification:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The Company has reclassified
certain items in the statement of profit or loss and other comprehensive income for the years ended June 30, 2015 and 2014 to
conform with the current year presentation and reclassified certain items in the statement of change in equity for the year ended
June 30, 2016, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 49; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Statement of profit or loss and other comprehensive income:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-style: italic; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-style: italic; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right; border-bottom: Black 1pt solid">Previously<BR> Issued</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-style: italic; text-align: right; border-bottom: Black 1pt solid">Reclassification</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-style: italic; text-align: right; border-bottom: Black 1pt solid">Previously<BR> Issued</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-style: italic; text-align: right; border-bottom: Black 1pt solid">Reclassification</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: left">Cost of Goods Sold</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(316,128</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(316,128</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(332,686</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">54,758</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(277,928</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sales and Marketing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(360,073</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">* 283,279</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,794</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(401,811</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">** 322,015</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(79,796</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Freight Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(116,379</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(116,379</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(38,445</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(75,833</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(114,278</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Amortisation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(680,567</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(680,587</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Consulting, Employee and Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(728,140</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(728,140</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(555,487</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(555,487</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Corporate Administration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(557,422</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(557,422</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(367,514</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(124,951</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(492,465</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,719</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,719</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,010</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,989</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(588,636</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(463,685</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Impairment of Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,340</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,340</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,204</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,204</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Marketing and Promotion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(142,735</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(161,952</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(304,687</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52,085</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(183,091</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(235,176</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,018,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,018,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,285,121</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,554</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,289,675</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Travel and Entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(128,318</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(128,318</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,326</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,327</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Amount includes AUD121,327
                                         that has been reflected as a restatement to decrease both Operating revenue and Sales
                                         and Marketing Costs.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: justify">Amount includes AUD63,091
                                         that has been reflected as a restatement to decrease both Operating revenue and Sales
                                         and Marketing Costs.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Statement of change in equity:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-style: italic; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-style: italic; text-align: right; border-bottom: Black 1pt solid">Previously Issued</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-style: italic; text-align: right; border-bottom: Black 1pt solid">Reclassification</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%">Shares issued, net of costs</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,658,504</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(71,875</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,586,629</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71,875</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reclassifications had no impact on
the net loss for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restatement:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Company revised all customer discounts and allowances previously recognized as Selling
                                         and Marketing Costs as reduction to Operating revenue. These revisions resulted in decreases
                                         in both Operating revenue and Selling and Marketing Costs of AUD$154,446, AUD$121,327
                                         and AUD$63,091 for the fiscal year ended June 30, 2016, 2015 and 2014, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         the previously issued financial statements, the basic and diluted loss per share was
                                         5.705 cents, 4.603 cents, 3.398 cents and the weighted average number of ordinary shares
                                         outstanding was 76,944,879, 74,907,491, 74,891,316 for the years ended 30 June 2016,
                                         2015 and 2014, respectively. The revised basic and diluted loss per share and the weighted
                                         average number of ordinary shares outstanding were 9.248 cents, 3.592 cents, 5.947 cents
                                         and 76,435,993, 74,935,902, 41,955,199 for the years ended 30 June 2016, 2015 and 2014,
                                         respectively. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
                                         adjustment was made in relation to the treasury shares which resulted in a decrease of
                                         AUD$800,000 in Non-current assets and Equity as compared to the previous statement lodged
                                         with ASX.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
                                         adjustment of AUD$1,209,338 was made to the Total reserves balance at 30 June 2016 as
                                         compared to the previous statement lodged with ASX, as a result of a change in volatility
                                         assessment. Effectively, this resulted in an increase in Consulting, Employee and Director
                                         expense and the Loss for the period on the Statement of Profit or Loss and Other Comprehensive
                                         income.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
                                         were made to the Consolidated Statement of Cash Flows for the year 2016 as compared to
                                         the previous statement lodged with ASX, details as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Previously
    issued</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Restatement</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Receipts from customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,242,884</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(128,288</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,114,596</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payments to suppliers and employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,639,088</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71,909</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,710,997</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Interest and other costs of finance paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(43,863</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(43,863</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Used In Operating Activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,914,276</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(244,060</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(5,158,336</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issues of securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,282,861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,482,861</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Repayment of borrowings</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,121,080</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,860</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,077,220</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Provided By Financing Activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,091,482</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">243,860</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,335,342</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net increase/(decrease) in cash and cash equivalents</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(825,235</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(200</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(825,435</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Effects of exchange rate changes on cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
                                         were made to the Consolidated Statement of Cash Flows for the year 2014 as compared to
                                         the previous statement lodged with ASX, details as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Previously
    issued</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Restatement</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Proceeds from borrowings</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">420,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">420,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Repayment of borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,485,001</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(420,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,905,001</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In addition to these
restatements, the Company has made revisions to Notes 1, 3, 4, 7, 8, 9, 13, 15, 16, 19, 21, 22, 23,24</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Critical Accounting Estimates and
Judgments </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Management evaluates
estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information.
Estimates assume a reasonable expectation of future events are based on current trends and economic data, obtained both externally
and within the group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21.3pt"><I>(i)</I></TD><TD STYLE="text-align: justify"><I>Share-based Payments</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">The value attributed to share
options and remunerations shares issued is an estimate calculated using an appropriate mathematical formula based on an option
pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood
and timing of the conversion of the options to shares and the value of volatility of the price of the underlying shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21.3pt"><I>(ii)</I></TD><TD STYLE="text-align: justify"><I>Impairment of Inventories</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">The provision for impairment
of inventories assessment requires a degree of estimation and judgment. The level of the provision is assessed by taking into
account the recent sales experience, the ageing of inventories and in particular the shelf life of inventories that affects obsolescence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21.3pt"><I>(iii)</I></TD><TD STYLE="text-align: justify"><I>Fair value measurement
                                         hierarchy</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 22.5pt">The preparation
of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts
in the financial statements. Management continually evaluates its judgments, estimates in relation to assets, liabilities, contingent
liabilities, revenue and expenses. Management bases its judgments, estimates, and assumptions on historical experience and on
other various factors, including expectations of future events, management believes to be reasonable under the circumstances.
The resulting accounting judgments and estimates will seldom equal the related actual results. The judgments, estimates and assumptions
that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next
financial year are discussed within the relevant sections where applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 22.5pt">The fair
value of convertible note classified as level 3 is determined by the use of valuation model. These include discounted cash flow
analysis and the use of observable inputs that required significant adjustments based on unobservable inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 23.7pt">As at
June 30, 2016, management has assessed the terms of the convertible notes and determined that in their view the fair value of
the debt component is equal to the proceeds such that there is no residual amount to be allocated to an equity component. In making
this determination, management is of the view that the value of the consideration received, net of costs, provided reliable evidence
of the fair value of the debt component of the convertible note. Fair value has been determined by the income approach based on
a discounted cash flow analysis, with the most significant inputs being the discount rate that reflects the investors credit risk.
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A slight increase or decrease in the discount rate used
would not be material to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Basis of Preparation &ndash; For the unaudited
consolidated financial statements</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">The general
purpose financial report for the interim six months reporting periods ended December, 31 2016 and 2015 have been prepared in accordance
with International Accounting Standard (IAS) 134 Interim Financial Reporting, under the International Financial Reporting Standards,
as issued by the International Accounting Standards Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">This half
year financial report does not include all notes of the type normally included in an annual financial report. Accordingly, this
report is to be read in conjunction with the annual report for the years ended June 30, 2016, 2015 and 2014 included in the Form
F-1 and any public announcements made by Immuron Limited and its controlled entities (the &ldquo;Group&rdquo;), during the interim
reporting periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">The half year
financial report reflects all adjustments which are, in the opinion of management, necessary to a fair statement of the results
for the interim periods presented. All adjustments are of a normal recurring nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Critical Accounting Policies</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">All accounting
policies adopted are consistent with the most recent Annual Financial Report for the years ended June 30, 2016, 2015 and 2014.
The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the
International Accounting Standards Board ('IASB') that are mandatory for the current reporting period. The adoption of these Accounting
Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated
entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Fair value measurement</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">Due to the
nature of the Group&rsquo;s operating profile, the Directors and management do not consider that the fair values of the Group&rsquo;s
financial assets and liabilities are materially different from their carrying amounts at December, 31 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Going Concern </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">For the six
months ended December, 31 2016 the Company experienced a net cash outflow of AUD$2,256,539 (2015: AUD$3,454,247) from operating
activities. Net loss for the period was AUD$3,409,349 which included AUD$2,117,867 of expenditures associated with research, development
and commercialization programs predominantly surrounding the Non- Alcoholic Steatohepatitis (NASH) Clinical Trial (2015: AUD$3,068,086
and AUD$1,839,990, respectively). These factors raise substantial doubt on the Company&rsquo;s ability to continue as a going
concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt"></P>

<!-- Field: Page; Sequence: 52; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">Whilst the
Company is projecting further net losses and a net cash outflow from operations for the remainder of the 2017 financial year,
management is in the process of enhancing its internal cost control procedures to further reduce operating costs. Additionally,
the Company also plans to raise additional capital from domestic or oversea market. The following historical successes achieved
in the past 6 months further support the Company&rsquo;s position in future capital raising and cost reduction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt"></TD><TD STYLE="width: 14.15pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">successfully
                                         completion of an oversubscribed AUD$6.32M Right Issue Capital Raising (before costs);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -14.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt"></TD><TD STYLE="width: 14.15pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">completion
                                         of patient recruitment in the Company&rsquo;s (NASH) IMM-124E Phase 2 clinical trial.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">Notwithstanding
the above discussion, there exists a degree of uncertainty in the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">Having considered
all the above, the Directors have prepared the financial statements on a going concern basis. &nbsp;As such, the financial statements
do not include any adjustments as to the recoverability and classification of recorded asset amounts or to the amounts and classification
of liabilities that might be necessary should the entity not continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Restatements:</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">The Company
has restated certain items in the previously issued financial statements as at and for the six months ended December 31, 2015,
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Consolidated statement
of profit or loss and other comprehensive income:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">Previously<BR> Issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Adjustments</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Other income*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,476,906</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(713,343</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">763,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sales and Marketing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(242,150</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189,491</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52,659</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Marketing and Promotion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,233</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(189,491</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,724</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Consolidated statement
of changes in equity:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">Previously<BR> Issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Adjustments</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Balance at June 30, 2015 / Accumulated losses*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(37,542,572</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,469,762</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(36,072,810</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Lapse or exercise of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,615</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Shares issued, net of costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">480,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">422,264</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Consolidated statement
of cash flows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">Previously<BR> Issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Adjustments</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Receipts from customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">613,528</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(60,122</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">553,406</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payments to suppliers and employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,074,918</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,122</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,014,796</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">* These adjustments were the result
of the timing of the recognition of the R&amp;D refund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: 23.7pt">Restatements
were also made to the Consolidated Statement of Cash Flows for the six months ended December 31, 2016 as compared to the previous
statement lodged with ASX, details as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Previously
    issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Adjustments</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Receipts from customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">664,900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">108,576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">773,476</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payments to suppliers and employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,423,797</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(148,497</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,572,294</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Cash Flows Used In Operating Activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,216,618</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(39,921</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,256,539</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Capital raising costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(120,285</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,634</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(149,919</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Repayment of borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,271,555</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,555</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,202,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Cash Flows Provided By Financing Activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,031,394</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">39,921</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,071,315</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">As described in Note
8, the Company has restated its previously issued financial statements for the six months ended December 31, 2016. In addition
to these restatements, the Company has made revisions to Notes 3, 6, 7 and 9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Results of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The following discussion
relates to our consolidated results of operations, financial condition and capital resources. You should read this discussion
in conjunction with our consolidated financial statements and the notes thereto contained elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 53; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Comparison of the six-month periods ended December 31,
2016 and 2015 </I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Revenue and Other income </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For
                                         the six months ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>December
                                         31,</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Increase/</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Decrease</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-indent: -12pt; padding-left: 12pt">Revenue:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-indent: -12pt; padding-left: 0.5in">Sale of goods</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 12%; text-align: right">703,099</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 12%; text-align: right">497,220</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 12%; text-align: right">205,879</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left; text-indent: -12pt; padding-left: 12pt">Other income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Australian Federal R&amp;D Tax Concession Refund</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">779,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">756,420</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,406</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,143</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(352</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,315</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,315</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Total Revenue and Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,520,031</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,260,783</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">259,248</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Revenues received
from the sale of goods remain increased in the fiscal half year 2016 in comparison to the fiscal hand year of 2015. This increase
in revenues can be attributed to the establishment and maturing of our U.S. sales channel as we achieved a major advancement by
releasing the Company&rsquo;s flagship product Travelan in the U.S. by means of sales through customers such as PassportHealth
and Medique, whilst also opening a new distribution channels into the Chinese market. The Company does not have any formal agreements
with PassportHealth for the sale of Travelan. There was also an increase in sales in the Canada market. Whilst our Australian
product sales remained constant, we applied our resources and marketing spend to these new emerging market opportunities in the
US and China, whilst instigated programs to reengage the Australian consumers. As these new markets mature over the coming 12
months, when combined with our existing market presence in Australia, we anticipate that revenues received from the sale of our
Travelan product to increase.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Our R&amp;D tax concession
refund for the fiscal half year 2016 appears to be slightly higher in comparison to fiscal half year 2015 by AUD$23 thousand due
to the higher R&amp;D expenditures recognized during the fiscal half year 2016 as compared to that of fiscal half year 2015. This
research and development increase was predominantly due to the increased expenditures of our major Phase 2 NASH clinical trial
as the program recruitment accelerated and more patients entered the trial.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Cost of Goods Sold, Gross Profit
and Direct Selling Costs</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For
                                         the six months ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>December
                                         31,</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Increase/</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2015</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Decrease</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -12pt; padding-left: 12pt">Total Operating Revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">703,099</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">497,220</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">205,879</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cost of Goods Sold</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(223,394</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(153,640</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(69,754</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Gross Profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">479,705</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">343,580</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">136,125</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Less Direct Selling Costs:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Sales and Marketing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(93,520</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52,659</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,861</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Freight Costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(62,590</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(61,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,291</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total Gross Profit less Direct Selling Costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">323,595</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">229,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">93,973</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Immuron&rsquo;s strong
mature relationships with its key manufacturing partners for the Company&rsquo;s flagship consumer product Travelan, has enabled
the Company maintain consistent Cost of Goods Sold ratios across the two fiscal half years for 2016 and 2015 of 32% and 31% respectively.
These key manufacturing partners provide Immuron with steady, reliable product for a known price which from a strategic point
of view provides certainty around the manufacturing margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">These strong manufacturing
partnerships have also given rise to greater efficiencies in the manufacturing processes which not only resulted in the improvement
in Gross Profit ratio but also an overall increase in Gross Profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Sales and Marketing Costs
increased by AUD$40 thousand in fiscal half years for 2016 compared fiscal half years for 2015 due to increased marketing activities
in oversea markets. Freight Costs, despite the increased number of sales, remained constant due to our more established logistical
channels for shipping Travelan from Australia to the overseas countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I><U>Expenses </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For
                                         the six months ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>December
                                         31,</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Increase/</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2015</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Decrease</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: left; text-indent: -12pt; padding-left: 0.5in">Consulting, Employee and Director</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(907,390</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(1,113,214</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">205,824</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Corporate Administration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(790,103</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(708,625</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(81,478</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,975</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,944</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Finance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,183</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,183</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in">Impairment of Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(135,170</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(135,001</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Marketing and Promotion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(471,735</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,724</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(270,011</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,117,867</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,839,990</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(277,877</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">Travel and Entertainment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(112,453</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(195,605</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,152</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Total expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,549,876</TD><TD STYLE="padding-bottom: 1pt; text-align: left">))</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,061,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(488,605</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 54; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Consulting, Employee
and Director.&nbsp;&nbsp;&nbsp;&nbsp;</I>Consulting, Employee and Director expense decreased by AUD$0.21 million from the six
months ended December 31, 2015 to the six months ended December 31, 2016 due primarily to the fact the company issued options
to directors during the 2015 half year resulting in a higher expense. Director fees and staff salaries have remained constant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Corporate Administration.&nbsp;&nbsp;&nbsp;&nbsp;</I>Corporate
Administration expense increased by AUD$0.08 million, or 11.50%, from the six months ended December 31, 2015 to the six months
ended December 31, 2016 due to both a general increase in the size of the business in combination with additional resources being
implemented to assist the Company for its growth, as well as the cost of additional specialized services required to initiate
the NASDAQ listing including additional legal, accounting and audit costs which were not present during the 2015 fiscal half year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Finance Costs.&nbsp;&nbsp;&nbsp;&nbsp;</I>Finance
Costs incurred by the Company in the six months ended December 31, 2016 of AUD$0.01 million which is directly attributable to
the finance costs associated with the SBI Investment Fund Convertible Loan Facility which the Company executed in February 2016.
This facility provided Immuron with the short to medium-term cash flow requirements it needed to ensure the Company&rsquo;s momentum
surrounding its pipeline research programs was not diminished. In comparison, there were no Finance Costs incurred in the six
months ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Impairment of Inventory.&nbsp;&nbsp;&nbsp;&nbsp;</I>Impairment
of Inventory incurred by the Company in the six months ended December 31, 2016 of AUD$0.14 million related to the writing down
of Colostrum from the Company&rsquo;s inventory balance as it reached expiry date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Marketing and Promotion.&nbsp;&nbsp;&nbsp;&nbsp;</I>Marketing
and Promotion expenses increased by AUD$0.27 million from the six months ended December 31, 2015 to the six months ended December
31, 2016 as the Company increased its promotional efforts of its existing flagship consumer product Travelan. These increased
costs included costs associated with the expansion of the product&rsquo;s reach via a launch in both the US and China consumer
markets. We hope to see the benefits of these expansions come to fruition during calendar year 2017 as these groundwork costs
incurred mature into increased revenue in these large new markets. The higher Marketing and Promotional Costs incurred during
the fiscal half year 2016 in comparison to the fiscal half year 2015, can also be attributed to the Company increasing both its
investor relations and public relations profiles ahead of the NASDAQ listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Research and Development.&nbsp;&nbsp;&nbsp;&nbsp;</I>Research
and Development expense increased by AUD$0.28 million from the six months ended December 31, 2015 to the six months ended December
31, 2016, primarily due to the significant increase in the Company&rsquo;s Phase 2 NASH clinical trial, together with the advancement
of its other early pipeline products.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">During fiscal year 2016,
Immuron brought the management of its Phase 2 NASH clinical trial program in-house through the appointment of Medical Director
another clinical trial support staff member, thereby alleviating the need for some of the external outsourced management whilst
also providing Immuron with greater control over the program.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Whilst costs were reduced
by bringing the management of the trial in-house, the ramping up of this trial from development to extensive patient recruitment
and testing, began to see the majority of the costs of the trial coming through causing an expected increase in the overall research
and development expenditures of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">There were also some
additional costs incurred through the establishment of additional clinical trial sites in a bid to lift the clinical trial recruitment
rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Travel and Entertainment</I>.
&nbsp;Travel and Entertainment expense decreased by AUD$0.08 million from fiscal from the six months ended December 31, 2015 to
the six months ended December 31, 2016 as the Company&rsquo;s management reduced its frequency of travel due to being required
to remain in their base-countries due to necessary projects which needed to be delivered locally, whilst also ensure cash conservation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Loss for the period</I>.&nbsp;&nbsp;&nbsp;&nbsp;As
a result of the foregoing, our loss for the period after income tax benefit increased by AUD$0.34 million, or 11.12%, from AUD$3.07
&nbsp;million in the six months ended December 31, 2015 to AUD$3.41 million in the six months ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Given our, and our subsidiaries&rsquo;
history of recent losses, we have not recognized a deferred tax asset with regard to unused tax losses and other temporary differences,
as it has not been determined whether we, or our subsidiaries, will generate sufficient future taxable income against which we
can utilized these unused tax losses and any uncalculated potential deferred tax assets, together with any other temporary differences.
Should the need arise, the Company can, and will, revisit this position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Comparison of the fiscal years ended June&nbsp;30, 2016 and
2015 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I><U>Revenue and Other income </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the
    fiscal year ended</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>June&nbsp;30,</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Increase/</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2016</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2015</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Decrease</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 12pt; text-decoration: underline; text-indent: -12pt"><FONT STYLE="font-size: 10pt"><U>Revenue:</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 55%; padding-left: 0.5in; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Sale of goods</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1,001,077</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1,002,380</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">(1,303</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -12pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 12pt; text-decoration: underline; text-indent: -12pt"><FONT STYLE="font-size: 10pt"><U>Other income:</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Australian Federal R&amp;D Tax Concession
    Refund</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,512,840</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,478,581</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34,259</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.5in; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Interest income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12,165</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">112,440</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(100,275</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.5in; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Other</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">14,010</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">14,010</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Total Revenue and Other
    income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,540,092</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,593,401</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(53,309</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 55; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Revenues received
from the sale of goods remain consistent for fiscal 2015 and 2016. Whilst there appears to be no real perceived growth in our
revenues, our geographic sales mix has changed as we achieved a major advancement by releasing the Company&rsquo;s flagship product
Travelan in the U.S. by means of sales through customers such as PassportHealth and Medique, whilst also opening a new distribution
channels into the Chinese market. The Company does not have any formal agreements with PassportHealth for the sale of Travelan.
Whilst our Australian product sales remained constant, we applied our resources and marketing spend to these new emerging market
opportunities in the US and China, we have instigated programs to reengage the Australian consumers. As these new markets mature
over the coming 12 months, when combined with our existing market presence in Australia, we anticipate that revenues received
from the sale of our Travelan product to increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">R&amp;D tax concession
refund increased by AUD$0.03 million, or 2.32%, from AUD$1.48 million in fiscal 2015 to AUD$1.51 million in fiscal 2016 due to
an increased level of eligible research and development expenditures being incurred during the fiscal 2016. This research and
development increase was predominantly due to the increased expenditures of our major Phase 2 NASH clinical trial as the program
recruitment accelerated and more patients entered the trial.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Interest income decreased
by AUD$0.10 million or 89.18%, from AUD$0.11 million in fiscal 2015 to AUD$0.01 million in fiscal 2016 as we depleted our cash
reserves through applying our financial resources to the increased areas of expenditure within the Company. The lower cash reserves
therefore generated and received less interest revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Cost of Goods Sold, Gross Profit
and Direct Selling Costs</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the
    fiscal year ended</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>June&nbsp;30,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Increase/</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2016</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2015</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Decrease</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 55%; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Total Operating Revenue</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1,001,077</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1,002,380</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">(1,303</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Cost of Goods Sold</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(301,435</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(316,128</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">14,693</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Gross Profit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">699,642</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">686,252</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">13,390</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Less Direct Selling Costs:</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Sales and Marketing Costs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(133,781</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(76,794</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(56,987</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Freight Costs</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(134,967</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(116,379</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(18,588</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total Gross Profit less Direct Selling Costs</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">430,894</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">493,079</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(62,185</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Immuron&rsquo;s strong
mature relationships with its key manufacturing partners for the Company&rsquo;s flagship consumer product Travelan, has enabled
the Company maintain consistent Cost of Goods Sold ratios from 32% of Operating Revenue, and then down to 30% of Operating Revenue,
for the 2015 and 2016 fiscal years, respectively. These key manufacturing partners provide Immuron with steady, reliable product
for a known price which from a strategic point of view provides certainty around the manufacturing margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">These strong manufacturing
partnerships have also given rise to greater efficiencies in the manufacturing processes which not only resulted in the improvement
in Gross Profit ratio but also an overall increase in Gross Profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The Company&rsquo;s push
of its Travelan product into the new overseas markets of the US and China required greater Sales and Marketing support to ensure
it gained traction. The expenditure to support this expansion resulted in a AUD$57 thousand increase in Sales and Marketing Costs
in fiscal year 2016 in comparison to fiscal year 2015, and also a AUD$19 thousand increase in Freight Costs through the additional
logistical implications of shipping Travelan from Australia to the overseas countries.</P>










<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 56; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Expenses </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the fiscal year ended<BR>
    June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Increase/</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<BR>
    AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015<BR>
    AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Decrease</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AUD$</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in">Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -12pt; padding-left: 0.5in">Consulting, Employee and Director</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(2,840,037</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(728,140</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(2,111,897</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Corporate Administration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,320,570</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(557,422</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(763,148</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,719</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(173</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Finance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(341,600</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(341,600</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in">Impairment of Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,340</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,164</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Marketing and Promotion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(487,591</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(304,687</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(182,904</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,623,961</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,018,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(605,667</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">Travel and Entertainment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(416,849</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(128,318</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(288,531</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -12pt; padding-left: 12pt; padding-bottom: 1pt"><FONT STYLE="font-weight: normal; font-style: normal">Total
    expenses</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-weight: normal; font-style: normal">AUD$</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-weight: normal; font-style: normal">(9,038,676</FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-weight: normal; font-style: normal">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-weight: normal; font-style: normal">AUD$</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-weight: normal; font-style: normal">(4,775,920</FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-weight: normal; font-style: normal">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-weight: normal; font-style: normal">AUD$</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-weight: normal; font-style: normal">(4,262,756</FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-weight: normal; font-style: normal">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Consulting, Employee
and Director.&nbsp;&nbsp;&nbsp;&nbsp;</I>Consulting, Employee and Director expense increased by AUD$2.11 million from fiscal 2015
to fiscal 2016 due primarily to the Company employing more permanent full-time senior management, and additional operational employees
within the organization due to the Company&rsquo;s expansion, which was offset by the use of less part-time consulting and advisory
providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Following the appointment
of an additional Director in May 2015, who subsequently became Executive Vice Chairman, this resulted in an increase in the overall
Director&rsquo;s fees paid during fiscal year 2016, in comparison to fiscal year 2015 as the Company went from three to four directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">On top of this increase,
there was a AUD$1.6 million share-based payments expense realized during fiscal year 2016 which was not present in fiscal year
2015, which pertained to the issuance of 6 million unlisted options in the company exercisable at AUD$0.50 per option expiring
on November 27, 2019 to the four Directors of the Company. The unlisted options were issued to the Directors in lieu of cash payment
for additional services each director has performed which were deemed to be far over and above those services usually performed
by Non-Executive Directors of a company of Immuron&rsquo;s positioning. The issuance of these options was designed to also encapsulate
the additional services the Director&rsquo;s will be required to perform over the subsequent 12 &ndash; 24 month period as the
Company matures through a number of key milestone inflection points, where their guidance will be regularly required, during both
the 2017 and 2018 fiscal years.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Corporate Administration.&nbsp;&nbsp;&nbsp;&nbsp;</I>Corporate
Administration expense increased by AUD$0.76 million, or 137%, from fiscal 2015 to fiscal 2016 due to the general increase in
the size of the business in combination with increases in consequent expenses due to additional resources being implemented to
assist the Company for its growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The increase was
also the result of an increase in a number of back-office support costs, fees associated with the Company&rsquo;s OTCQB listing,
legal fees surrounding the initial U.S. NASADAQ listing and additional programs and contracts required for the organization as
it employed new employees and raised further capital whilst generally expanding, and increased conference and seminar costs as
the Company lifted its public profile around the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">There was also a significant
increase in the company&rsquo;s foreign currency realized losses as the overseas expenditure, predominantly in $, became more
expensive for our AUD$ financially denominated Company as the $ strengthened against the AUD$ throughout the fiscal year 2016,
in comparison to the relative strength of the AUD$ against the $ in fiscal year 2015, where the AUD$ was either on parity of at
times even above parity.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 57; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Finance Costs.&nbsp;&nbsp;&nbsp;&nbsp;</I>Finance
Costs incurred by the Company in fiscal 2016 of AUD$0.34 million which directly pertained to the establishment of the SBI Investment
Fund Convertible Loan Facility in February 2016. This facility provided Immuron with the short to medium-term cash flow requirements
it needed to ensure the Company&rsquo;s momentum surrounding its pipeline research programs was not diminished. In comparison,
there were no Finance Costs incurred in fiscal 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Marketing and Promotion.&nbsp;&nbsp;&nbsp;&nbsp;</I>Marketing
and Promotion expenses increased by AUD$0.18 million from fiscal 2015 to fiscal 2016 as the Company increased its promotional
efforts of its existing flagship consumer product Travelan. These increased costs included costs associated with the expansion
of the product&rsquo;s reach via a launch in both the US and China consumer markets. We hope to see the benefits of these expansions
come to fruition during calendar year 2017 as these groundwork costs incurred mature into increased revenue in these large new
markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Research and Development.&nbsp;&nbsp;&nbsp;&nbsp;</I>Research
and Development expense increased by AUD$0.61 million from fiscal 2015 to fiscal 2016, primarily due to the significant increase
in the Company&rsquo;s Phase 2 NASH clinical trial, together with the advancement of its other early pipeline products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">During fiscal year 2016,
Immuron brought the management of its Phase 2 NASH clinical trial program in-house through the appointment of Medical Director
another clinical trial support staff member, thereby alleviating the need for some of the external outsourced management whilst
also providing Immuron with greater control over the program.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Whilst costs were reduced
by bringing the management of the trial in-house, the ramping up of this trial from development to extensive patient recruitment
and testing, began to see the majority of the costs of the trial coming through causing an expected increase in the overall research
and development expenditures of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Travel and Entertainment</I>.
&nbsp;Travel and Entertainment expense increased by AUD$0.3 million from fiscal 2015 to fiscal 2016 as the Company&rsquo;s activities
expanded into the US through the appointment of a U.S.-based Chief Executive Officer and US Sales Director, as well as an Israeli-based
Medical Director. These overseas appointments were critical for the Company to begin its expansion into the U.S. capital markets
through the initial OTCQB listing, and now into the NASDAQ as part of this offering, and into the product markets for Travelan&rsquo;s
expansion into the US. Having an Israeli-based Medical Director also brought us within close proximity to our major-research collaboration
partner Hadasit Hospital in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Loss for the period</I>.&nbsp;&nbsp;&nbsp;&nbsp;As
a result of the foregoing, our loss for the period after income tax benefit increased by AUD$4.38 million, or 163%, from AUD$2.69&nbsp;million
in fiscal 2015 to AUD$7.07 million in fiscal 2016.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Given our, and our
subsidiaries&rsquo; history of recent losses, we have not recognized a deferred tax asset with regard to unused tax losses and
other temporary differences, as it has not been determined whether we, or our subsidiaries, will generate sufficient future taxable
income against which we can utilized these unused tax losses and any uncalculated potential deferred tax assets, together with
any other temporary differences. Should the need arise, the Company can, and will, revisit this position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Comparison of the fiscal years ended June&nbsp;30, 2015
and 2014 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Revenue and Other income </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the fiscal year ended<BR>
    June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Increase/</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Decrease</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-indent: -12pt; padding-left: 12pt">Revenue:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-indent: -12pt; padding-left: 0.5in">Sale of goods</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 10%; text-align: right">1,002,380</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 10%; text-align: right">981,051</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 10%; text-align: right">21,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left; text-indent: -12pt; padding-left: 12pt">Other income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Australian Federal R&amp;D Tax Concession Refund</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,478,581</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">713,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">764,949</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,440</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,095</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Total Revenue and Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,593,401</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,785,528</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">807,873</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Sale of Goods.&nbsp;&nbsp;&nbsp;&nbsp;</I>Revenues
received from the sale of goods increased by AUD$0.02 million, from AUD$981 thousand in fiscal 2014 to AUD$1 million in fiscal
2015. Fiscal year 2013 and into 2014 were proving to be a slow sales years for the Company&rsquo;s flagship product Travelan as
Immuron&rsquo;s licensee selling Travlean went through a period of internal restructuring. Accordingly, in June 2013 Immuron terminated
the license agreement with the third party and commenced a new direct-to-wholesaler sales strategy in Australia and New Zealand
which achieved immediate results in fiscal years 2014 and 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Australian Federal
R&amp;D Tax Concession Refund</I> The Company&rsquo;s R&amp;D tax concession refund more than doubled from AUD$714 thousand in
fiscal year 2014, to AUD$1.48 million in fiscal 2015. This significant increase in the R&amp;D Tax Concession refund was the direct
result of the significant increase in research and development expenditures as the Company commenced its major Phase 2 NASH clinical
trial program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Interest Income </I>Interest
income increased marginally from AUD$88 thousand in fiscal year 2014 to AUD$0.1 million in fiscal 2015 as the company increased
its cash reserves during 2015 through the completion of a capital consolidation followed by a AUD$9.66 million (before costs)
Rights Issue capital raising. The higher cash reserves held by the Company, following such a significant rights issue capital
raising, generated an increase in the interest revenue paid to Immuron for the cash reserves.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Cost of Goods Sold, Gross Profit
and Direct Selling Costs</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the fiscal year ended<BR>
    June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Increase/</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Decrease</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -12pt; padding-left: 12pt">Total Operating Revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 10%; text-align: right">1,002,380</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 10%; text-align: right">981,051</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 10%; text-align: right">21,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cost of Goods Sold</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(316,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(277,928</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Gross Profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">686,252</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">703,123</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,871</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Less Direct Selling Costs:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Sales and Marketing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,794</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(79,796</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,002</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Freight Costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(116,379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(114,278</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total Gross Profit less Direct Selling Costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">493,079</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">509,049</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,970</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Following its shift
to a direct-to-consumer wholesale sales model in early fiscal year 2014, Immruon&rsquo;s Gross Profit ratio increased from just
41% in fiscal year 2013, to 72% in fiscal year 2014, and 68% in fiscal year 2015 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">This improved Gross
Profit margin was a combination of a shift to the direct-to-consumer wholesale sales model, and also the establishment of a relationship
with a major new colostrum supplier in New Zealand who provided certainty not only to the level of colostrum powder they could
manufacture for Immuron&rsquo;s flagship product Travelan, but also the quality GMP processes the new supplier were able to offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The variances in
Sales and Marketing and Freight costs between fiscal year 2014 and 2015 were negligible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 59; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Expenses </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the fiscal year ended<BR>
    June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Increase/</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015<BR>
    AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014<BR>
    AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Decrease</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AUD$</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-indent: -12pt; padding-left: 0.5in">Amortization</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(680,587</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">680,587</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Consulting, Employee and Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(728,140</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(555,487</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(172,653</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Corporate Administration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(557,422</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(492,465</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64,957</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,719</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,989</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Finance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(463,685</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">463,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in">Impairment of Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,340</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,204</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,864</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Marketing and Promotion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(304,687</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(235,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(69,511</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.5in">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,018,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,289,675</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,728,619</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">Travel and Entertainment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(128,318</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(37,327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(90,991</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Total expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,775,920</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,808,595</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">AUD$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(967,325</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; text-align: justify"><I>Amortization.&nbsp;&nbsp;&nbsp;</I>In
fiscal year 2014 the Company expensed the remaining amortization of the intellectual property it acquired through its platform
technologies from Hadasit Hospital, Israel in 2009. At the end of fiscal year 2012, the estimated useful life of the intellectual
property was reviewed, in accordance with the application of accounting standards, and it was determined that the Intellectual
Property had a finite remaining useful life of two years. Accordingly, there was no amortization expense in any subsequent fiscal
years after 2014 as the intellectual property asset had been fully provided for.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Consulting, Employee
and Director.&nbsp;&nbsp;&nbsp;&nbsp;</I>Consulting, Employee and Director expense increased by AUD$173 thousand from fiscal 2014
to fiscal 2015 as the Company employed some additional staff and consultants to assist in the areas of manufacturing and research
and development ahead of the Phase 2 clinical trial commencement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Corporate Administration.&nbsp;&nbsp;&nbsp;&nbsp;</I>Corporate
Administration expense increased by AUD$0.06 million from fiscal 2014 to fiscal 2015 due to the general increase in the size of
the business in combination with an increase in consequent expenses due to additional resources being implemented to assist the
company for its growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The increase was
also the result of an increase in a number of back-office support costs, consultant and advisory fees associated with the planning
and implementation of the Company&rsquo;s clinical trials and other research and development programs. Additional expenses were
also incurred through the necessary legal and compliance costs surrounding the capital restructuring and subsequent significant
capital raising program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Finance Costs.&nbsp;&nbsp;&nbsp;&nbsp;</I>Following
the company significant rights issue capital raising in February 2014 (fiscal year 2014) the Company was able to extinguish its
outstanding convertible note loan liability due to Paladin which in turn removed any further finance expense from being incurred
in fiscal year 2014 and no financing costs being incurred in fiscal year 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Marketing and
Promotion.&nbsp;&nbsp;&nbsp;&nbsp;</I>Marketing and Promotion expenses increased by AUD$70 thousand from fiscal 2014 to fiscal
2015 as the Company marginally extended some of the marketing campaigns surrounding the Company&rsquo;s flagship consumer product
Travelan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Research and Development.&nbsp;&nbsp;&nbsp;&nbsp;</I>Research
and Development expenses more than doubled between fiscal years 2014 and 2015 from AUD$1.3 million to AUD$3 million as the Company
began the clinical trial program commencement for the Company&rsquo;s Phase 2 NASH clinical trial, together with the advancement
of its other early pipeline products. The research and development program leader, together with the other members of their team,
were all contracted advisors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Travel and Entertainment.
&nbsp;</I>Travel and Entertainment expense increased from AUD$37 thousand in fiscal 2014 to AUD$0.128 million in fiscal 2015 as
the Company promoted the commencement of the trial overseas, and also travels to establish new overseas markets for Travelan from
which Canadian, Korean, and Chinese opportunities arose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Loss for the period</I>.&nbsp;&nbsp;&nbsp;&nbsp;
As a result of the above areas, our loss for the period after income tax benefit increased by almost AUD$0.2 million, to AUD$2.7
million. Whilst the increase has an overall negative affect on the Company, the change in direction of the Company throughout
fiscal year 2015 resulted in a stronger balance sheet, with increased cash reserves, no convertible note debt, and also the completion
of any ongoing amortization expenditures. This overall resulted in a much stronger, recapitalized and re-focused Company by the
end of fiscal year 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Given our, and our
subsidiaries&rsquo; history of recent losses, we have not recognized a deferred tax asset with regard to unused tax losses and
other temporary differences, as it has not been determined whether we, or our subsidiaries, will generate sufficient future taxable
income against which we can utilized these unused tax losses and any uncalculated potential deferred tax assets, together with
any other temporary differences. Should the need arise, the Company can, and will, revisit this position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 60; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We have incurred
cumulative losses and negative cash flows from operations since the Company&rsquo;s inception in 1994, and as of June 30, 2016
we had accumulated losses of AUD$42.8 million. We anticipate for the foreseeable future that we will continue to incur losses
for at least the next several years. We expect that as we continue research efforts and the development of our product candidates,
hire additional staff, including clinical, scientific, operational, financial and management personnel, and incur additional costs
associated with being both an Australian and NASDAQ public company and, as a result, we will need additional capital to fund our
operations, which we may raise through a combination of equity offerings, debt financings, other third-party funding and other
collaborations, strategic alliances and licensing arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We plan to continue
to fund losses from operations and capital funding needs through future debt and equity financing, as well as potential additional
collaborations or strategic partnerships with other companies or through non-dilutive financings. The sale of additional equity
or convertible debt could result in additional dilution to our stockholders. The incurrence of indebtedness would result in debt
service obligations and could result in operating and financing covenants that would restrict our operations. We can provide no
assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. I f we are not able
to secure adequate additional funding we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate
assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm our business</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We have had nil and AUD$1.90
million of net borrowings/repayments in fiscal 2015 and fiscal 2016 respectively, and do not currently have any credit facilities
in place.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt; background-color: white">As
of June&nbsp;30, 2016, we had cash and cash equivalents of AUD$2.29 million. Additionally, the Company also recognized a total
of AUD$4,387,772 in receivables, including a AUD$1,512,840 related to R&amp;D Tax Concession, which was received in November 2016.
On this basis, even though the company has been in loss making position historically, management is satisfied that the Group is
a going concern and are of the opinion that no asset is likely to be realized for an amount lower than the amount at which it
is recorded in the Consolidated Statement of Financial Position at June 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We estimate that our
net proceeds from this offering will be approximately $4.8 million after deducting the underwriting discounts and commissions
and estimated offering expenses payable by us. Along with our existing cash and cash equivalents of AUD$2.3 million as of June
30, 2016, we expect that the net proceeds from this offering will be sufficient to fund our capital requirements for at least
24 &nbsp;months from the issuance date of the financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash flows </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">The following table sets forth the primary
sources and uses of cash for each of the periods set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>For
    the year ended</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>June&nbsp;30,</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="vertical-align: top; border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For
                                         the six months ended</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>December 31,</B></P></TD>
    <TD NOWRAP STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2016</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2015</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2014</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2016</B></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2015</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; width: 45%; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Net
    cash used in operating activities</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">(5,158,336</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">(3,020,933</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">(2,650,577</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">(2,256,539</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; vertical-align: bottom">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">(3,454,247</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left; vertical-align: bottom">)</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Net cash used
    in investing activities</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">(2,441</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">(3,168</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">(15,901</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">(1,879</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">(2,441</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; vertical-align: bottom">)</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Net cash provided
    by (used in) financing activities</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">4,335,342</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">(1,614</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">7,361,555</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">3,071,315</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">1,334,765</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Comparison of the six months ended December 31, 2016 and 2015
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Operating activities.&nbsp;&nbsp;&nbsp;&nbsp;</I>For
the six months ended December 31, 2016 and 2015, net cash used in operating activities decreased by AUD$1.20 million from AUD$3.45
million to AUD$2.26 million respectively. The use of net cash in all periods resulted from our ordinary business operations. Cash
flows from operating activities for the six months ended December, 2016 and 2015 also included inflows of AUD$1.59 million and
AUD$ nil, respectively in relation to refunds received through the Australian Federal Government&rsquo;s Research and Development
Income Tax Incentive program for eligible expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Investing
activities.&nbsp;&nbsp;&nbsp;&nbsp;</I>Net cash used in investing activities in the six months ended December 31, 2016 and 2015
were AUD$1,879 and AUD$2,441, which solely pertains to purchases of office equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Financing activities.&nbsp;&nbsp;&nbsp;&nbsp;</I>For
the six months ended December 31, 2016, net cash provided by financing activities was AUD$3.07 million, which comprised of (i)
proceeds from issue of securities and exercise of options of AUD$4.27 million, net of capital raising costs, (ii) repayments of
borrowing principal of AUD$1.20 million<I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>For the six months ended December 31, 2015, net cash provided
by financing activities of AUD$1.33 million comprised of (i) proceeds from issue of securities and exercise of options of AUD$0.33
million and (ii) proceeds from borrowings of AUD$1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Comparison of the fiscal years ended June&nbsp;30, 2016 and
2015 </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Operating activities.&nbsp;&nbsp;&nbsp;&nbsp;</I>For
the twelve months ended June 30, 2016 and 2015, net cash used in operating activities increased by AUD$2.14 million from AUD$3.02
million to AUD$5.16 million respectively. The use of net cash in all periods resulted from our ordinary business operations. Cash
flows from operating activities for the year ended 2016 and 2015 also included inflows of AUD$1.47 million and AUD$0.72 million,
respectively in relation to refunds received through the Australian Federal Government&rsquo;s Research and Development Income
Tax Incentive program for eligible expenditure. As discussed earlier, the major increase of net cash outflows surrounding Operating
Activities, results from the significant increase in the costs associated with the Company&rsquo;s research and development programs,
as well as the Company&rsquo;s overall general internal expansion and shift to overseas markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Investing activities.&nbsp;&nbsp;&nbsp;&nbsp;</I>Net
cash used in investing activities in fiscal 2016 and 2015 was AUD$2,441 and AUD$3,168, which solely pertains to purchases of office
equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Financing activities.&nbsp;&nbsp;&nbsp;&nbsp;</I>For
the twelve months ended June 30, 2016, net cash provided by financing activities was AUD$4.34 million, which comprised of (i)
proceeds from issue of securities and exercise of options of AUD$2.46 million, net of capital raising costs, (ii) proceeds from
the issuance of convertible notes pertaining to the convertible loan funding arrangement established in February 2016, and other
borrowings of AUD$2.95 million less repayments of AUD$1.08 million related to these borrowings. In the fiscal year ended June
30, 2015, net cash used in financing activities of AUD$1,614 was related to the payment of minor subsequent capital raising costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Comparison of the fiscal years ended June&nbsp;30, 2015
and 2014 </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Operating activities.&nbsp;&nbsp;&nbsp;&nbsp;</I>For
the twelve months ended June 30, 2015 and 2014, net cash used in operating activities increased by AUD$370 thousand from AUD$2.65
million to AUD$3 million respectively. The use of net cash in all periods resulted from our ordinary business operations. The
significant increase of AUD$0.86 million in receipts from customers from fiscal year 2014 to fiscal year 2015 was the direct result
of moving Immuron's sales strategy from a license agreement for selling Travelan through a third party, to a direct to wholesaler
consumer distribution model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">This significant
increase in receipts from customers between fiscal years 2014 to 2015 from increased sales allowed Immuron, combined with the
large capital raising the company performed in February 2014 which gave the company the confidence to increase its expenditures
associated with the Company&rsquo;s research and development programs as it commenced the major clinical trial program for which
the funds from the February raising were applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Cash inflows in operating
activities included inflows in fiscal year 2014 and 2015 of AUD$0.67 million and AUD$0.72 million in relation to refunds received
through the Australian Federal Government&rsquo;s Research and Development Income Tax Incentive program for eligible expenditure.
Interest received also increased between the periods by AUD$24 thousand following receipt of funds from the February 2014 major
rights issue capital raising being invested in cash term deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Investing activities.&nbsp;&nbsp;&nbsp;&nbsp;</I>The
variance in the difference of cash flows used in investing activities in fiscal years 2014 and 2015 were negligible and solely
pertains to purchases of office equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>Financing activities.&nbsp;&nbsp;</I>&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were negligible net financing cash flows in fiscal year 2015 as Immuron had performed its significant rights issue capital raising
during fiscal year 2014 resulting in a total net cash inflow of AUD$7.4M. The funds raised from the capital raising were also
supported from a short-term loan the Company received. This inflows were off-set by the repayment of this short-term loan, and
also repayment of the convertible loan totaling AUD$1.9 million</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Operating capital requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In the future, we
expect our revenue streams will be generated mostly through a combination of sales from our flagship consumer product Travelan
as the US and China expansion plans come to fruition, and through opportunities which arise from the maturing of our pipeline
portfolio products through collaboration, license, partnership or sale with major pharmaceutical or investment companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We have based our
projections of operating capital requirements on assumptions, that may prove to be incorrect, and we may use all of our available
capital resources sooner than we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our future funding
requirements will depend on many factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 22.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and costs of our planned clinical trials for our product candidates; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and costs of our planned preclinical studies for our product candidates; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of product candidates that we pursue; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing and costs of seeking regulatory approvals; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue
    received from commercial sales of any of our product candidates that may receive regulatory approval; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing,
    prosecution, defense and enforcement of any patents or other intellectual property rights; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights
    and defending against intellectual property related claims; and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we need to in-license or acquire other products and technologies. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-balance sheet arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We did not have over
the past three fiscal years, and we currently do not have, any off-balance sheet arrangements as defined in the rules and regulations
of the Securities and Exchange Commission. To the extent we have any contingent assets or liabilities, these have been captured
and audited within the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Quantitative and qualitative disclosures
about market risks </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We are exposed to
market risk related to changes in interest rates and exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">As of December 31, 2016,
we had cash and cash equivalents of AUD$3.1M, primarily held in bank accounts and term deposits. Our primary exposure to market
risk is interest rate sensitivity, which is affected primarily by changes in the general level of Australian interest rates. The
Company is exposed to interest rate risks via the cash and cash equivalents and borrowings that it holds. Interest rate risk is
the risk that a financial instruments value will fluctuate as a result of changes in market interest rates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We are exposed to
fluctuations in foreign currencies that arise from foreign currencies held in bank accounts and the translation of results from
our operations outside Australia. Our foreign exchange exposure is primarily the U.S. dollar and New Zealand dollar. Foreign currency
risks arising from commitments in foreign currencies are managed by holding cash in that currency. Foreign currency translation
risk is not hedged. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_017"></A><B>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We are a clinical-stage
biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies
to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. Our lead product candidate,
IMM-124E, is a proprietary immunomodulator agent targeted at GI immune mediated diseases including fatty-liver diseases. We are
developing IMM-124E for the treatment of nonalcoholic steatohepatitis, or NASH, for which we are currently in Phase 2. IMM-124E
is also the investigational drug of two NIH-sponsored Phase 2 clinical trials in alcoholic steatohepatitis (ASH) and Pediatric
NASH. Dr. Arun Sanyal, one of NASH&rsquo;s foremost thought leaders, is the principal investigator of our NASH Phase 2 trial.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">IMM-124E is a first
in class oral, LPS antibody, with strong anti-inflammatory and anti-fibrotic properties, making NASH an ideal target for this
compound. IMM-124E binds to the LPS receptors of gram-negative bacteria and influence the cell-mediated immune system through
regulatory T cell populations, creating a downstream decrease of liver inflammation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">NASH is a severe type
of nonalcoholic fatty liver disease (NAFLD). NAFLD is the most common liver disease and is associated with obesity and type-2
diabetes, and is characterized by the accumulation of fat in the liver with no other apparent causes. Approximately 10%-20% of
people with NAFLD will progress to NASH. Current estimates place NASH prevalence at approximately 24 million people in the United
States, or 7% of the population, with similar prevalence in other major developed markets.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">There are currently
no treatment approved for NASH and other compounds in development target primarily one biological pathway believed to impact NASH.
However, NASH is now increasingly recognized as a multi-factorial disease, creating a unique opportunity for IMM-124E given our
broad and upstream anti-inflammatory properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Our second lead compound,
IMM-529, targets the C. <I>difficile</I> bacterium and contains polyclonal antibodies to the Toxin B, the spores and the vegetative
cells. We recently successfully completed our pre-clinical program, and we plan to initiate a Phase 1/2 clinical trial in Israel
in the second quarter of 2017. As the clinical trial will be conducted outside of the United States, specifically, in Israel,
the Company is not required to apply for an IND. IMM-529 was developed and tested extensively in pre-clinical models at Monash
University, Australia in collaboration with Dr. Dena Lyras, one of the world&rsquo;s foremost expert in C. <I>difficile</I>. Although
the Company entered into an agreement with Monash University with respect to the development and pre-clinical testing of IMM-529,
the agreement expired in February 2016, and the Company currently has no collaboration agreements with either Dr. Lyras or Monash&nbsp;
University.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Clostridium <I>difficile</I>,
or C. <I>difficile</I>, is a gram-positive, toxin-producing, spore-forming bacterium that generally causes severe and persistent
diarrhea in infected individuals, but can also lead to more severe outcomes, including in the most serious cases, death. C. <I>difficile
</I>infection (CDI) is most often associated with the prior use of antibiotics. The U.S. Centers for Disease Control has identified
CDI as one of the top three most urgent antibiotic-resistant bacterial threats in the United States. It is the most common cause
of hospital acquired infection in the United States and has overtaken methicillin-resistant Staphylococcus aureus in prevalence.
CDI is responsible for the death of approximately 29,000 Americans each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We also market an OTC
product, Travelan, in Australia, Canada (with our partner Paladin Labs, a branch of Endo Pharmaceuticals that sells products for
the Canadian market) and in the U.S., for the prevention of Traveler&rsquo;s Diarrhea. Travelan has been shown to be up to 90%
effective in the prevention of diarrhea in several E-coli challenge placebo controlled studies. Travelan is based in the same
platform and targets 13 strains of E-coli. Travelan sales for FY2016 were AUD$1.0M.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In addition to these
two programs, we are also targeting other anti-infectious and anti-inflammation diseases such as shigella, campylobacter and colitis.
These early programs are pursued in cooperation with some of the leading research institutions in the world including the U.S.
Army, U.S. Navy and Zurich University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Below is our clinical
and pre-clinical pipeline. Of note, Immuron has successfully put together one of the most comprehensive portfolio of fatty-liver
disease programs in the industry, with three Phase 2 clinical trials including NASH, ASH and Pediatric NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="pg64img1_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our goal is to become
one of the leading biopharmaceutical company developing and commercializing therapeutics to address increased unmet medical needs
in inflammation-mediated diseases and anti-infectives. The critical components of our strategy include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Rapidly
                                         advance</B> our two lead oral polyclonal antibodies, IMM-124E and IMM-529:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><B>IMM-124E/NASH</B>:
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue progressing
                                         our IMM-124E Phase 2 for the treatment of NASH with a target for top line read-out of
                                         second half of 2017;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>IMM-529/CDI: </B>Finalize development of
    clinical supplies Phase 1/2 protocol with a target Phase 1/2 start in the second quarter of 2017;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Leverage
                                         our technology platform and our collaborations to expand</B> our differentiated polyclonal-based
                                         product pipeline across multiple indications including ASH, Pediatric NASH and various
                                         novel and potentially game-changing anti-infective programs with the DoD (U.S. Army and
                                         U.S. Navy)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Partner
                                         our fatty-liver programs </B>at the right time and with the right commercial / development
                                         partner(s) for NASH, ASH and pediatric NASH</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Continue
                                         investing in and growing Travelan Worldwide</B> including in the U.S., Australia, Canada
                                         and China, and in new markets</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Continue
                                         investing in mechanism of action studies</B> that expands our understanding of our unique
                                         MOA across our targeted diseases and conditions, and potentially identify new opportunities
                                         for investment</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Protect
                                         and leverage our intellectual property portfolio and patents. </B>We believe that our
                                         intellectual property protection strategy, grounded in securing composition of matter
                                         patents on the biologics we develop, as well as broader patents to protect our technology
                                         platform, has best positioned us to gain broad and strong protection of our assets. We
                                         have 13 issued patents and 23 pending patent applications worldwide. We have been issued
                                         patents in the U.S., Australia, Canada, India, Japan and New Zealand.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fatty-Liver Diseases Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">NASH is a severe type
of nonalcoholic fatty liver disease (NAFLD) and is characterized by the accumulation of fat in the liver with no other apparent
causes. The rising prevalence of obesity-related disorders has contributed to a rapid rise in the prevalence of NASH and NAFLD.
In the United States, NAFLD affects approximately 27%-34% of the population, or an estimated 86 million to 108 million people.
Approximately 10%-20% of people with NAFLD will progress to NASH. Current estimates place NASH prevalence at approximately 24
million people in the United States, or approximately 7% of the population, with similar prevalence in other major developed markets.
Prevalence is also rising in developing regions, likely due to the adoption of a more sedentary lifestyle and westernized diet
consisting of processed food with high fat and fructose content.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">NASH is a progressive
disease that displays an increasing burden of liver fibrosis as the disease gets progressively worse. It is estimated that 63%
of all NASH patients, or approximately 15 million people, have either no scaring of the liver (F0) or present with evidence of
mild fibrosis (F1). The other 37%, or approximately 9M people, will present with either moderate (F2) or severe fibrosis (F3).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The high level of
investment activity in the space, including licensing and M&amp;A (collectively, &ldquo;LM&amp;A&rdquo;), is indicative of the
high level of unmet need. This is driven by a few factors including the size of the population that might need interventional
agents, the increasing recognition that NASH is a severe disease that needs to be treated and the belief that because NASH is
a multi-factorial disease, there will be room for multiple therapies to offer choices to physicians and patients. An often-quoted
analysts report by Deutche Bank estimate that the NASH market will be $35B by 2025. This is not unreasonable given that the statin
branded market peaked at nearly $30B worldwide and span multiple blockbuster drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Since 2014, there
have been multiple LM&amp;A transactions and we expect this LM&amp;A trend to continue in 2017&nbsp;&nbsp; and beyond, especially
as the increasing rates of obesity and type-2 diabetes around the world continue driving the prevalence of NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                         2014, Shire acquired Lumena Pharmaceuticals for $260 million. Lumena had two Phase 2
                                         assets for NASH and cholestatic liver disease</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                         2015, Boehringer Ingelheim acquired Pharmaxis Limited&rsquo;s NASH asset in Phase 1 for
                                         AUD$39 million. Total potential deal value of AUD$600 million including milestones.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                         2015, Gilead acquired Phenex Pharmaceutical&rsquo;s NASH asset in Phase 2 for $470 million.
                                         Undisclosed upfront fees and milestones payments.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                         2016, Allergan acquired Tobira Therapeutics for approximately $330 million and up to
                                         $1.7 billion in total payments.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                         2016, Allergan licensed Akarna Therapeutics&rsquo; pre-clinical NASH asset for approximately
                                         $50 million upfront plus other undisclosed milestones payments.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                         2016, BMS acquired the worldwide rights to Nitto Denko&rsquo;s NASH asset, ND-L02-s0201,
                                         for $100 million upfront plus additional undisclosed clinical and regulatory milestone
                                         payments, royalties, sales-based milestone payments as well as option exercise payments
                                         for other indications.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                         2016, Novartis announced that it paid $50 million upfront plus undisclosed milestones
                                         and other payments for the exclusive rights to Conatus Pharmaceuticals&rsquo; Emricasan,
                                         a Phase 2 pan-caspase inhibitor for the treatment of NASH with advanced fibrosis scarring
                                         and cirrhosis.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                         2017, JNJ entered into a collaboration and option agreement with Bird Rock Bio which
                                         is evaluating a Cannabinoid receptor 1 (CB1)-targeting antibody, namacizumab, which is
                                         in Phase 1 clinical trial. JNJ will collaborate with Bird Rock Bio during the trial and
                                         has the exclusive right to acquire the Bird Rock Bio following the Phase 1 data readout.
                                         Specific terms of the transaction were not disclosed.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pathophysiology of NASH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">NAFLD/NASH is a disease
that can evolve over time as the liver is subjected to an increasing amount of injury, which deepens liver inflammation and fibrosis,
and can eventually lead to end-stage liver failure and liver cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Inflammation plays
a key role in the pathogenesis of NASH as conditions linked to the metabolic syndrome, including obesity, are all associated with
an elevated state of chronic inflammation that cause damage to organs such as the pancreas and the liver. The pathogenesis is
thought to be multi-factorial, and is a multiple-hit process involving insulin resistance, oxidative stress, apoptosis, and adipokines
brought on by fatty diet, obesity, sedentary lifestyle and genetic pre-disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In addition to the
elevated state of inflammation suffered by NASH patients which perpetuates liver injury, it has also been shown that fatty diets,
sugar and obesity are linked to an overgrowth of gram-negative bacteria within the gut. These gram-bacteria produce LPS (LipoPolySaccharides)
products that elicit strong innate and cell-mediated immune responses in animals and humans, both from within the gut and through
circulating endotoxins, particularly via Toll-like Receptor 4 on cells. The intraluminal LPS concentration is additionally thought
to increase gut permeability, also known as &quot;leaky gut&quot;, enabling passage of endotoxins into the bloodstream and increasing
the inflammatory response especially within the liver since 75% of the liver&rsquo;s blood supply comes from the portal vein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The importance of
this LPS-driven inflammatory process is unfortunately often overlooked since there are no therapeutics that can effectively block
gram-negative bacteria in the gut, except for broad-spectrum antibiotics which are not an option for long-term use in NASH patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The immune and inflammatory
response to liver cell damage caused by these insults is mediated through a well-described signaling network of liver and immune
cells. Kupffer cells, also known as resident liver macrophages, sense tissue injury and are the first responders to liver cell
damage. Activated Kupffer cells initiate an inflammatory response to the liver injury and can activate HSCs (Hematopoietic Stem
Cells) to transdifferentiate into myofibroblasts, the primary collagen-producing cell type responsible for liver fibrosis. The
extent of this fibrosis can vary, and it is described in several stages. A normal liver is at a stage between F0 and F1. Stage
F2 denotes light fibrosis, and F3 is severe fibrosis. Cirrhosis is defined from stage F4, when scar tissue exists throughout the
liver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Pediatric NASH is
also a growing concern in many countries, and similar to NASH, Pediatric NASH is a progressive form of liver disease associated
with excessive fat storage in the liver together with inflammation, which can then lead to liver fibrosis and cirrhosis. Pediatric
NASH is believed to affect up to 5% - 10% of the US pediatric population. A U.S. landmark study that examined the incidence of
disease in 742 autopsy children who had died of an accident, found that 17.3% of the children aged 15 to 19 years had NAFLD. There
are currently no approved drug therapies for pediatric NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">ASH is one of the
hepatitis manifestation of alcohol abuse and typically occurs in an individual with long-standing history of alcohol intake. As
in NASH, inflammation plays a key part in the development and worsening of ASH. More than 90% of heavy drinkers have steatosis,
10% to 35% have ASH, and 8% to 20% have alcoholic cirrhosis. While the consumption of alcohol is certainly a driving factor, especially
if intake is high, other factors can contribute to the development of ASH in these patients, including diet, age and ethnicity.
It is estimated that the prevalence of alcoholism in the U.S. is 8% of the U.S. population, or more than 15 million people. It
is thought that at least 20% of patients with alcoholism have ASH or 3 million people in the U.S. alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IMM-124E for the treatment of fatty-liver
diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">IMM-124E, which is
made of LPS polyclonal antibodies, is manufactured from colostrum which is harvested from dairy cows that have been immunized
against bacterial LPS of the most common strains of Enterotoxigenic Escherichia coli (ETEC). Such inoculation activates a generalized
immune response in the host animal to produce antibody clones which recognize and bind with the bacterial cell-surface epitopes
presented. These antibodies are present in high concentration within our raw material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">IMM-124E contains at
least 40% immunoglobulins (Ig), composed mainly of IgG (mostly IgG1), some IgA with small concentrations of IgM and IgE. Our studies
have shown that these antibodies bind to bacterial LPS specific sites, as per the method by which they were designed and produced.
It had been additionally demonstrated that these antibodies cross react with other types of bacteria such as shigella and salmonella.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The pre-clinical evidence
gathered so far supports IMM-124E&rsquo;s MOA as well the Company's position that IMM-124E is a unique investigational therapeutic
for fatty-liver diseases including NASH, ASH and Pediatric NASH. This has been shown given this agent's anti-fibrotic and anti-inflammatory
properties.</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pre-Clinical and Clinical Studies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">An IND was initially
filed for the commencement of clinical trials for IMM-124E on November 11, 2011 and was sponsored by the Company. The subject
of the IND was protocol number IMM-124E-2001, a Phase 2, randomized, double-blind, placebo-controlled study of IMM-124E for patients
with NASH.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Oral administration of
IMM-124E has been tested in a Carbon-tetrachloride (CCl4) fibrosis model and in a NASH ob/ob metabolic model. Results of this
pre-clinical study demonstrate that IMM-124E has strong anti-fibrotic and anti-inflammatory effects on the liver and is associated
with multiple biomarkers showing a similar response. IMM-124E had also been tested in a Phase 1 study of 10 (ten) biopsy-proven
NASH and diabetes patients, conducted by investigators at Hadassah Medical Center, Jerusalem, Israel.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Powerful Anti-Fibrotic and Anti-Inflammatory
Effect Shown in CCl4 Mice Models</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">IMM-124E was tested
in a Carbon-Tetrachloride (CCl4) mouse model to determine the efficacy of orally administered IMM-124E to prevent hepatic inflammation
and. 4 groups of mice (n = 6/8 per group) were utilized for the study as follow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify">Group A: (Positive
                                         Control) Intraperitoneal (IP) CCl4</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Group B: IMM-124E (negative control) administered
    to na&iuml;ve mice to assess the safety of IMM-124E in &quot;healthy&quot; mice</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Group C: IP CCl4 + IMM-124E: IMM-124E initiated
    in proximity to the CCl4 insult.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Group D: IP CCl4 + IMM-124E (IMM-124E was administered
    two weeks before initiation of CCl4). It is customary to assess the effectiveness of investigational treatments to prevent
    the disease, especially in acute models such as the one presented.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The IMM-124E treatment
group (Group C) demonstrated the following when compared to Control Group (Group A):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Statistically significantly (p&lt;0.05 and
    p&lt;0.03) reduction and near-normal Alanine aminotransferase&nbsp; (&ldquo;ALT&rdquo;) and Aspartate aminotransferase (&ldquo;AST&rdquo;)
    respectively at days 21 and 30 post insult. ALT is an enzyme found in various body tissues, and elevated serum levels of ALT
    suggest liver injury. AST is an enzyme found in various body tissues, and elevated serum levels of AST, most commonly together
    with serum ALT, suggest liver injury.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Statistically significant (p&lt;0.0001) reduction
    in serum bilirubin levels compared to positive control group (Group A). Bilirubin is a compound used to process waste products
    by the liver, and elevated serum levels of Bilirubin suggest liver injury.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Statistically significant (P&lt;0.0009) in
    decreased METAVIR Score and reduced inflammation on liver histology. METAVIR Score is a standardized scoring system used to
    describe the level of liver fibrosis and inflammation found within a given liver biopsy. Fibrosis is scored on a range from
    0 to 4 and level of inflammation is scored on a range from 0 to 3. An increased METAVIR Score describes a more advanced and
    active liver disease. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liver weight of treated mice,
        suggesting of level of fibrosis, was noted as significantly lower higher than Group A.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Spleen weight of treated mice
        was significantly lower than Group A suggesting spleens were less enlarged in this group (spleen enlargement is associated
        with cirrhosis).</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify">Reduction in
                                         activated Macrophages F4/80<SUP>high </SUP>on liver tissue FACS analysis and Immunohistochemistry
                                         (IHC) staining.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The p-value is the
probability that the results achieved would be false. It is customary, in statistical terms and in discussions with the FDA, to
define p lower than 0.05 as sign of acceptable evidence, also known as &quot;significance&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kuppfer Cells 4/80 Flow Cytometry and
IHC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg67img1_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">A representative
macroscopic views of the livers from Group A (Positive Control) demonstrates the widespread fibrotic liver associated with this
chemical insult, while the liver from the IMM-124E treated group (Group C) shows a normal liver, demonstrating the protective
effect of IMM-124E even with the most aggressive of fibrosis models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg68img1_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, when
comparing the treated Group A to the negative control B, no statistically significant differences were noted apart from the histological
fibrosis score (METAVIR) and histological inflammation. This proves the treated mice were near normal despite the insult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Group
D did not show differentiation from Group A in any of the labs or macroscopic parameters (spleen/liver weight) suggesting the
insult did propagate an extensive necroinflammatory response. However, this group did demonstrate a statistically significant
lower METAVIR score when compared to Group A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The effect of this
anti-fibrotic effect is evident both macroscopically as well as histology and on liver associated labs all pointing to the potential
mechanism by which fibrosis is halted.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Ob/Ob Mice Models Show Significant
and Sustained Anti-Inflammatory and Anti-Metabolic Effects</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We also conducted
a study using ob/ob mice, which are a well-accepted mouse model for the metabolic syndrome showing insulin resistance, dyslipidemia,
liver steatosis and elevated liver enzymes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><I>4 groups of ob/ob
</I>mice were fed for 6 weeks with either IMM-124E or immunoglobulins purified from IMM-124E (3 doses). A positive Control was
also established in parallel to the treatment groups. Mice were evaluated for their liver injury (serum ALT) metabolic state and
immunological / inflammatory response using Flow cytometry to determine alterations in regulatory T-cell (Treg) and cytokines.
Mice were also followed for liver enzymes, glucose levels, glucose tolerance test (GTT), hepatic and serum triglycerides (TGs)
levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">High
                                         dose of IMM-124E derived immunoglobulins demonstrated a statistically significant reduction
                                         in serum ALT&nbsp;(P&lt;0.05)&nbsp;and liver/serum TG levels&nbsp;<FONT STYLE="color: #007F00"><B>(</B></FONT>P&lt;0.05
                                         for cf ddH20 and P&lt;0.01 for cf Normal Colostrum)&nbsp;over&nbsp;controls which&nbsp;did
                                         not reach statistical significance;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">High
                                         dose of IMM-124E derived immunoglobulins ameliorated glucose intolerance (P&lt;0.05 cf
                                         ddH20 and P&lt;0.01 cf Normal Colostrum);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Glucose
                                         tolerance test (GTT) was improved within this group but did&nbsp;not reach statistical
                                         significance (P&gt;0.05<FONT STYLE="color: #007F00"><B>);</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">IMM-124E
                                         demonstrated a similar metabolic effect, with significant reduction in hepatic&nbsp;<FONT STYLE="color: #007F00"><B>(</B></FONT>P&lt;0.05)&nbsp;and
                                         serum triglycerides levels&nbsp;(P&lt;0.05)&nbsp;and an increase in CD3+NK1.1+ cells&nbsp;(P&lt;0.05
                                         cf ddH20 and Normal Colostrum); and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">IMM-124E
                                         demonstrated a similar metabolic effect, with statistically significant reduction in
                                         hepatic and serum triglycerides levels&nbsp;(P&lt;0.05)&nbsp;&nbsp;and an increase in
                                         CD4-CD25-FoxP3 cells&nbsp;(P&gt;0.05) &ndash; Not statistically significant.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Phase 1/2 - IMM-124E Demonstrated
Safety and Significant Anti-Metabolic Effect in Patients with Biopsy-Proven NASH and Impaired Glucose Metabolism (i.e. type II
DM or Insulin resistance) </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The company conducted
a Phase 1/2 clinical trial to evaluate the safety and preliminary efficacy of IMM-124E in humans. This study was an open-label,
single-center, 10 patient trial, conducted in subjects with impaired glucose tolerance and biopsy-proven NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">All patients were
treated for 30 days and were monitored for their liver enzymes, glucose metabolism markers, serum lipids and metabolic associated
hormonal signals such as Adiponectin and GLP-1. Inflammation associated cytokines and regulatory immune cells were evaluated as
well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The primary endpoint
of the study was safety and all patients completed the study according to protocol. No treatment related adverse events were reported
by the investigators for any of the clinical or laboratory parameters during the treatment and follow-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We also observed
multiple impact on the underlying disease relevant parameters including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">All patients exhibited a clinically meaningful
    reduction in the hemoglobin A1c by day 30 of treatment of at least 0.5 constituting 14.8% reduction on average. Since all
    10 subjects demonstrated significant change such reduction was deemed statistically significant when comparing baseline to
    day 30 (p&lt;0.03).</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">7 out of 10 subjects demonstrated at least
    10% reduction in one or more enzymes (AST/ALT) between the two time points (0 and 30 days) but did not reach significance.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Five patients demonstrated lower fasting blood
    glucose levels at day 30. 6.3 vs. 5.8 mmol/L for days 1 and 30 respectively, however did not demonstrate statistical significance.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">A decrease in serum cholesterol and LDL levels was noted in the 9 of the
    10 patients treated with IMM-214E. The mean total serum cholesterol was 5.3 &mu;M/dl at Baseline and 4.7 &mu;M/dl at day 30.
    8 out of 10 subjects were noted to improve their serum LDL with the mean serum LDL level reduced from 3.92 &mu;M/dl to 3.13
    &mu;M/dl at baseline and day 30, respectively.</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">An increase in adiponectin and GLP-1 was recorded
    in 8 and 6 subjects respectively showing a serum level increase 6181 vs. 7069 ng/mL and 6.31 vs. 6.78 &times; 104 pM respectively,
    however both did not reach statistical significance. </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Peripheral blood mononuclear cells (PBMCs)
    were isolated from all subjects and analyzed using flow cytometry. Levels of regulatory T-cells were measured in the isolates.
    CD4+CD25+, CD4+CD25+HLA-DR+, CD4+CD25+FOXP3+ and CD4+CD62L+ were numerically increased in the majority of patients for all
    cell types, however did not reach significance.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The combined results
of these pre-clinical studies have clearly shown that IMM-124E exerts an immunomodulatory and anti-inflammatory effects resulting
in metabolic and liver related biomarkers improvements, and showed strong inhibition of fibrosis. We believe that the combination
of the pre-clinical and the clinical studies, as well as the supporting literature linking LPS to NASH, establishes IMM-124E as
a unique and potentially paradigm-changing option for NASH patients. In a publication of our phase 1/2 study of 10 subjects, which
was reported in the Journal of Inflammation Research, the authors concluded that no treatment-related adverse events were noted.&nbsp;
The Company&rsquo;s Phase 2 randomized, placebo controlled and double-blinded study is ongoing under an IND in the USA, Australia
and Israel. As per regulatory requirements, we have been periodically reporting on safety and progression of the study to the
FDA. Our latest report to the FDA was dated April 7th, 2017 and reported progress up to February 28th, 2017. The report noted
that 124 subjects were randomized to either IMM-124E or a placebo. There were no serious adverse events. There were 2 moderate
adverse events (diarrhea and intermittent upper right quadrant abdominal pain) considered by the investigator as &quot;probably
related to treatment&quot; and 97 adverse events considered as &quot;possibly related to treatment&quot;. &nbsp;The most common
adverse events noted were loose stools, nausea and flatulence, the majority of which were mild. As the Phase 2 is still ongoing,
blinding had yet to be broken, and data yet to be fully monitored and verified, rendering the relationship of these reported adverse
events to the drug or other factors unknown until the data is finalized and blinding is lifted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Global Phase 2 Clinical Trial in NASH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In November 2014,
Immuron initiated its global Phase 2, multicenter, double blind placebo control, randomized clinical study with sites in the U.S.A,
Australia and Israel. The study's goal is to assess the safety and effectiveness of IMM-124E for the treatment of NASH. A total
of 120 biopsy-proven NASH patients are being enrolled comparing 2 doses of IMM-124E to placebo within a 6 month treatment period.
The study design had been reviewed by the FDA and finalized under the agency&rsquo;s recommendation. The top line results of the
study are expected by second half of 2017. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The trial Principal
Investigator is Dr. Arun Sanyal, one of the world&rsquo;s foremost leaders in NASH. Dr. Sanyal is Professor of Medicine and Former
Chairman of the Division of Gastroenterology, Hepatology and Nutrition at VCU Medical Center, Virginia, U.S.A. Dr. Sanyal is an
internationally renowned expert in liver diseases. He is a former President of the AASLD (American Association for the Study of
Liver Diseases) and is the current Chair of the Liver Study Section at the NIH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">To date, 134 subjects
have been randomized into the study, at 24 active sites. We have completed enrollment and expect to have top-line data by the
second half of 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NIH Funded Phase 2 Clinical Trials
in ASH and in Pediatric NASH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In addition to the
Company's phase 2 clinical study for the treatment of NASH, 2 studies evaluating IMM-124E were chosen to be funded by the American
National Institute of Health (NIH):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><B>The first
                                         is a Phase 2 clinical study for the treatment of Alcoholic SteatoHepatitis (ASH), </B>in
                                         collaboration with Dr. Arun Sanyal at Virginia Commonwealth University (VCU). The trial
                                         is a 66 patient, randomized to placebo. The study is expected to generate safety as well
                                         as preliminary efficacy data and should be completed in 2018.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><B>The second,
                                         is also a Phase 2 clinical study for the treatment of Pediatric NASH,</B> in collaboration
                                         with Dr. Miriam Vos at Emory University, Atlanta. This Phase 2 trial aims to enroll 40
                                         pediatric patients for three months treatment and aims at determining the safety and
                                         exploratory efficacy of IMM-124 in Pediatric NASH patients.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IMM-124E &ndash; Competitive Advantage</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We believe that IMM-124E
has a significant competitive advantage when compared to other assets in development:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><B><I>Multi-Factorial
                                         / Broad Anti-Inflammatory Upstream Effect</I></B> &ndash; It is now increasingly acknowledged
                                         that NASH is a multi-factorial disease, and that targeting only one or two pathways is
                                         likely to only have a marginal effect on the disease. IMM-124E offers hope for long-lasting
                                         effects because of its broad upstream anti-inflammatory effects which induces the release
                                         of regulatory T-cells and anti-inflammatory cytokines while decreasing levels of pro-inflammatory
                                         cytokines.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Attractive Profile for Long-Term Chronic
    Use &ndash;</I></B> Because of its tolerable safety profile, which is derived from a GRAS (Generally Regarded as Safe) platform,
    we believe that data will support the use of IMM-124E as a chronic / long-term treatment, providing a unique advantage over
    other NASH therapies as some have already shown significant side effect profile (e.g., increased cholesterol).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Potential for Use as Backbone Agent for
    both Early and Severe Disease &ndash;</I></B> While other more toxic agents in development are likely to be confined to severe
    populations, we believe that IMM-124E will be able to be used in all NASH patients, including for those with mild fibrosis
    (F1) / no scarring (F0), and potentially in NAFLD patients as well, to reduce their elevated inflammation state. We believe
    that this will be unique to IMM-124E, hence potentially putting nearly 15 million of mild NASH patients within reach of IMM-124E
    but out of reach of our competition.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Potential for Use in Combination Therapy
    &ndash; </I></B>Because of its delivery method and GRAS profile, it is likely that IMM-124E can not only be used as monotherapy,
    but also in combination with other NASH agents, if these are approved, and if physicians feel that this is warranted for their
    patients. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>C. <I>difficile</I> Infections (CDI)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Clostridium <I>difficile</I>,
or C. <I>difficile</I>, is a gram-positive, toxin-producing, spore/vegetative cells-forming bacterium that can cause symptoms
ranging from diarrhea to life-threatening inflammation of the colon. In the most serious cases, CDIs can lead to fulminant colitis,
megacolon and even death from colon perforation and peritonitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">C <I>difficile </I>is
acquired from contact with humans or objects harboring these bacteria. It can be commonly acquired during hospitalization with
up to 30% of those who have spent a prolonged period in the hospital leaving carrying these bacteria in the bowel flora, especially
if antibiotics have been administered. This is because CDI is most often associated with the prior use of broad-spectrum antibiotics,
which decrease the natural resistance of the body to C. <I>difficile</I>. Chronic CDI is estimated to occur in perhaps 15-30%
of those infected. In some, reinfections can occur with the same or with a different strain. Risk factors for relapse include
the number of previous episodes, the need to use antibiotics recurrently, and older age groups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Human infection occurs
through ingestion and if the bacterium survives acid and bile on its passage into the bowel, it may be eradicated by the normal
bowel flora since the microbes that collectively make up the flora provide colonization resistance against pathogenic species
through competition for essential nutrients and attachment sites to the gut wall. However, if the bowel flora is suppressed because
of concomitant use of antibiotics, or if the bowel flora has a deficiency, C. <I>difficile</I> can colonize the flora and remain
with the patient. In some individuals, it seems that antibiotics are not required for colonization to take place, which may be
related to inadequate defense of the naturally occurring flora within the bowel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">When C. <I>difficile
</I>takes hold, the toxins produced by the bacterium, especially Toxin B, act by inactivation of Rho GTPases leading to cell death,
and stimulation of an inflammatory cascade that exacerbates tissue damage, diarrhea, and pseudomembranous colitis. When faced
with a CDI infection, the standard of care are either a course of Vancomycin or metronidazole, both of which are broad spectrum
antibiotics. While these agents are very effective at treating the primary infections, they also severely impact the rest of the
gut flora, creating an ideal environment for the C. <I>difficile</I> spores to once again take hold. This creates a vicious cycle,
as more courses of antibiotic treatments worsen recurrence. Vancomycin and metronidazole are plagued by increasing rate of CDI
recurrences, underscoring the need for new treatments. There is also growing concern of resistance to Vancomycin treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">C. <I>difficile </I>is
a very hardy organism most likely because it shed spores and these spores are unable to be eradicated by any known antibiotics.
Since C. <I>difficile</I> spores are able to survive for long periods of time outside of the body, and because healthcare settings
are often sites of significant antibiotic use, CDI transmission rates in hospitals, long-term acute care facilities and nursing
homes have been increasing. CDI is also a cause of morbidity and mortality among hospitalized cancer patients and bone marrow
transplant patients, as their immune systems are suppressed by cytotoxic drugs and sometimes by antibiotics that are administered
to prevent opportunistic infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The U.S. Centers
for Disease Control has identified CDI as one of the top three most urgent antibiotic-resistant bacterial threats in the United
States and is now the most common cause of hospital acquired infection in the U.S. CDI is responsible for approximately 29,000
deaths in the U.S. annually. The prevalence of CDI is estimated at more than 450,000 infections annually, with nearly 100,000
cases of first recurrences. Research suggests that the risk of recurrence is approximately 25% after the primary occurrence of
CDI, 40% after a first recurrence and greater than 60% for those experiencing two or more recurrences. CDI leads to an increased
length of hospitalization and an estimated $1.1 billion in health care costs annually in the U.S. The rise of community-acquired
CDI is now a growing problem and led to the recognition that CDI is not simply limited to just hospitals. This increase in CDI
incidence, which is now a growing problem worldwide due to the widespread and increase use of antibiotics, is the driver behind
a growing market for C. <I>difficile</I> therapeutics, which is estimated to reach $1.5B by 2024, up from $350M today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IMM-529 &ndash; A Potentially Revolutionary
Treatment for CDI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">IMM-529 is an oral
biologic which does not destroy the microbiome like antibiotic treatments, allowing the microbiome to return to a healthy state,
while treating the virulent CDI. The antibodies in IMM-529 have been demonstrated to be cross-reactive with a variety of human
and animal C. <I>difficile</I> isolates and to their associated Toxin B, vegetative cells and spore components.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The antibodies in
IMM-529 have also been shown to neutralize Toxin B from a historical C. <I>difficile</I> strain (630), and from a hypervirulent
(HV) strain which caused recent worldwide outbreaks. Immunoglobulin G comprised almost 90% of total immunoglobulin present in
IMM-529, with major subclass IgG1 making up over 65% of total immunoglobulins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">IMM-529 has successfully
completed its pre-clinical program in CDI. IMM-529, which was developed in collaboration with world-leading C. <I>difficile</I>
Key Opinion Leader (&ldquo;KOL&rdquo;) Dr. Dena Lyras and her team at Monash University, has a unique Triple-Action MOA (antibodies
to Toxin B + Spores + Vegetative Cells):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg72img1_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">It is a three pronged
approach that is unique and which has yielded exceptional results in the pre-clinical studies including (1) Prevention of primary
disease, (2) Treatment of primary disease and (3) Suppression of recurrence. To our knowledge, it is to date the only investigational
drug that has showed positive therapeutic benefits in all three phases of the disease. All results were highly statistically significant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Prevention of C. <I>difficile</I> infection:
    Mice treated with IMM-529 demonstrated a significant increase in survival rates (P&lt;0.0001) compared to untreated controls
    of approximately 70% (17/24) survival vs. 0% survival in the control groups. Mice that were untreated or treated with non-hyperimmune
    colostrum succumbed rapidly to infection with no significant difference in survival observed (P=0.3511):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Control group #1 (0/14) treated
                                         with water</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Control group #2 (0/15) treated
                                         with non-hyperimmune colostrum</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><IMG SRC="pg72img2_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Treatment: Mice treated with IMM-529 demonstrated
    a significant increase in survival rates (P&lt;0.0001) compared to untreated controls of approximately 80% survival (11/14)
    vs. &lt;7% survival in the control groups. Mice that were untreated or treated with non-hyperimmune colostrum showed no significant
    difference in survival with 0% or 6.7% survival rates (P=0.3178), respectively:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Control group #1 (0/14): Treated
                                         with water alone following vancomycin treatment</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Control group #2 (1/15): Treated
                                         with non-hyperimmune colostrum following vancomycin treatment</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><IMG SRC="pg72img3_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Relapse: Mice treated with IMM-529 demonstrated
    a significant increase in survival rates (P&lt;0.0027) compared to mice treated with only vancomycin of approximately 90%
    survival in IMM-529 + vancomycin group (n=7/9); vs. 11% survival in the control group which received vancomycin alone (n=1/9)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><IMG SRC="pg73img1_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We have submitted
these results for peer review and for publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We are currently in the
process of manufacturing clinical supplies for our Phase 1/2 and are finalizing the Phase 1/2 protocol. We aim to start our Phase
1/2 in Israel in the second quarter of 2017. As the clinical trial will be conducted outside of the United States, specifically,
in Israel, the Company is not required to apply for an IND.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IMM-529 &ndash; Competitive Advantage</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We believe that IMM-529
has a unique competitive advantage:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Triple
                                         Mechanism of Action &ndash;</I></B> IMM-529 not only <B><I>targets the Toxin B</I></B>,
                                         but it also contains antibodies to the <B>spores and the vegetative cells.</B> This is
                                         unique among all assets currently in development.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Effective
                                         vs Virulent Strains &ndash;</I></B> As discussed above, IMM-529 has been shown to be
                                         effective vs both the normal strains as well as the virulent strains of CDI, providing
                                         a strong Proof-of-Concept (POC) model that IMM-529 can be a front line agent in the battle
                                         vs hypervirulent and difficult to treat strains.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Effective
                                         in All phases of the Disease</I></B> &ndash; IMM-529 has shown that it can be an effective
                                         agent in all phases of the disease including prevention of infection, treatment of primary
                                         disease and recurrence. This is unique among all of our competitors and indicate a much
                                         larger potential use than current development programs which primarily target recurrence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Oral
                                         Therapy &ndash;</I></B> IMM-529 is an <B><I>oral therapy</I></B> lessening costs/burden
                                         on the patient, hospitals and the healthcare system overall.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Not
                                         an Antibiotic &ndash;</I></B> IMM-529 is <B><I>not an antibiotic</I></B>, and hence is
                                         only targeted at C. <I>difficile</I> its Toxin B, spores and vegetative cells. It therefore
                                         does not negatively impact the rest of the flora and allows the flora to return to normal,
                                         while fighting the primary infection / recurrence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We are excited about
the future prospects of this asset given the lack of treatment options that are available for this devastating disease. One of
our major competitors, Seres Therapeutics, recently announced the interim results of a phase 2 with their SER-109 CDI therapeutic
which failed to achieve the primary endpoint of reducing the risk of CDI recurrence. SER-109 (an ecology of bacterial spores enriched
and purified from healthy, screened human donors) does not specifically target Toxin B, which has been proved time and again,
especially through the work of Dr. Dena Lyras, to be the main driver of disease morbidity and mortality. We are confident in the
long-term success of IMM-529 given its unique triple-action MOA which targets the Toxin B, the spores and the vegetative cells.
We look forward to more data in the years ahead as we continue to develop this highly differentiated asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Development Programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In addition to the
IMM-124E and IMM-529 programs, we also have two research collaborations ongoing with the U.S. Department of Defense including
one with the <B>U.S. Army</B> and a second collaboration with the <B>U.S. Navy</B>, for the study of <B>shigella, campylobacter
and ETEC vaccines</B>. We also started a pre-clinical program targeting <B>Irritable Bowel Diseases (IBD),</B> in collaboration
with renowned IBD KOL, Dr. Gerhard Rogler and the university of Zurich, Switzerland, and a pre-clinical Autism study with several
universities / hospitals in Australia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>Pre-Clinical
- Colitis:</I></B> The University of Zurich&rsquo;s world renowned inflammatory bowel diseases researcher, Professor Gerhard Rogler,
has teamed with Immuron to launch a pre-clinical development program in colitis. The three stage program will use well-known acute
and chronic colitis models and will take place throughout 2016/2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Colitis, manifesting
as a group of inflammatory bowel conditions, including Crohn&rsquo;s Disease and Ulcerative Colitis, affects millions of people
around the world. The global market for treatments of IBD, of which colitis is a significant component, is expected to reach an
annual U.S. $10 billion by 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Professor Rogler
is Professor of Gastroenterology and Hepatology and Consultant Gastroenterologist at Zurich University Hospital Switzerland. He
is also principal investigator of the Swiss Irritable Bowel Diseases cohort study, and the author of 200 original peer-reviewed
articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>Collaborations
with U.S. Army and U.S. Navy:</I></B> Our collaborations with the DoD are a powerful validation of the potential of our platform
to develop novel anti-infectives. These collaborations also open the door to explore and develop potentially low risk / low cost
therapeutics with some of the most advanced research facilities in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>U.S. Army &ndash;
</I></B>In June 2016, Immuron signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to develop a vaccine
for a form of dysentery that kills up to one million people a year. WRAIR is the largest and most diverse biomedical research
laboratory in the Department of Defense. Immuron will provide the clinical supply for the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The project aims
to develop a vaccine for shigellosis, a severe form of dysentery that affects about 165 million people a year, mostly children,
and causes up to a million deaths. Symptoms of shigellosis, also known as bacillary dysentery, include severe and bloody diarrhea,
fever, and stomach cramps. WRAIR aims to develop the vaccine for both civilian and military use in areas where endemic diseases
such as shigellosis can compromise the health and readiness of the local community, travelers, contractors and defense personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In May 2017, we
announced that the agreement with the U.S. Army will be expanded to include the development of 3 new Shigella therapeutics. In
addition, non-human primate (NHP) studies will be added and the Armed Forces Research Institute of Medical Sciences (AFRIMS) will
also join the project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>U.S. Navy
</I></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;In August 2016, we signed an agreement
with the U.S. Navy to test the reactivity and therapeutic effectiveness of Travelan against campylobacter and Enterotoxigenic
Escherichia coli (ETEC), two common gram-negative bacterium. The next step would be to develop new vaccines. Immuron will provide
the clinical supply for the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Campylobacter&rsquo;s
main reservoir is poultry, however humans can contract the disease from contaminated food. At least a dozen species of Campylobacter
have been implicated in human disease, with C. jejuni and C. coli being the most common. C. jejuni is now recognized as one of
the main causes of bacterial foodborne disease in many developed countries as well as developing countries were poultry is common.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Enterotoxigenic Escherichia
coli (ETEC) is a type of Escherichia coli (E-coli) and one of the leading bacterial causes of diarrhea in the developing world,
as well as the most common cause of travelers' diarrhea. Conservative estimates suggest that each year, about 157,000 deaths occur,
mostly in children, from ETEC, but no vaccines exist, highlighting the need for new treatment modalities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>Autism: </I></B>In
July 2016, we announced a strategic partnership with three leading Australian research institutes focused on understanding how
the genetic basis underlying Autism Spectrum Disorder (ASD) relates to changes to the gut, and how Immuron&rsquo;s anti-LPS IMM-124E
compound affects changes in mouse models for autism. This effort involves the University of Melbourne, La Trobe University and
Murdoch Children&rsquo;s Hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Except for clinical
supplies, this unique collaboration involves very little R&amp;D investment from Immuron, but has the potential for tremendous
upside given that are no treatments approved for autism, and very few assets in development. This could also potentially open
the door for other development partnerships in Central Nervous System (CNS) conditions such as Alzheimer&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In summary, we believe
that the breath/depth of our assets and the support we are receiving from the NIH, the DoD and other leading institutions and
KOL, demonstrates the importance of our platform and makes us truly a unique and attractive player in the therapeutic areas we
target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Advisory Board</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The company&rsquo;s
programs are supported by world-renowned KOLs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.
Arun Sanyal (MD) &ndash;</I></B> University of Virginia. Professor of Medicine and Former Chairman of the Division of Gastroenterology,
Hepatology and Nutrition, VCU Medical Center. Dr. Sanyal is an internationally renowned expert in liver diseases. He is a former
President of the AASLD (American Association for the Study of Liver Diseases) and is the current Chair of the Liver Study Section
at the NIH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.
Stephen Harrison (MD) &ndash;</I></B> Professor of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland;
Physician, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas. Chief of Residents, Internal Medicine, Brooke
U.S. Army Medical Center. Dr. Harrison is an internationally renowned expert in NASH and his group has published seminal work
on many aspects in the field. Dr. Harrison is the Principal Investigator of Galectin&rsquo;s GR-MD-02&rsquo;s Phase 2 trial and
hold's key roles in other leading clinical NASH studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.
Manal Abdelmalek (MD) &ndash;</I></B> Duke University Medical Center. Dr. Abdelmalek is Associate Professor of Medicine at Duke
Medical University Medical Center, Division of Gastroenterology &amp; Hepatology, Section of Hepatobiliary Diseases &amp; Liver
Transplantation. Dr. Abdelmalek is a leading investigator in the field of NASH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.
Gerhard Rogler (MD, PhD)</I></B> &ndash; Zurich University. Dr. Rogler is the Chairman of the Scientific Advisory Board of the
University of Zurich and Professor of Gastroenterology and Hepatology and Consultant Gastroenterologist at the Division of Gastroenterology
&amp; Hepatology, Department of Medicine, Z&uuml;rich University Hospital, Switzerland. Prof. Rogler is a leader in the field
of Colitis and has authored approximately 200 original peer-reviewed articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.
Miriam Vos (MD) &ndash;</I></B> Emory University. Dr. Vos is an associate professor of pediatrics at the Emory University School
of Medicine, and an attending Hepatologist at Children&rsquo;s Healthcare of Atlanta. She specializes in the treatment of gastrointestinal
disease in children as well as fatty liver disease and obesity. Dr. Vos is also the author of The No-Diet Obesity Solution for
Kids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.
Dena Lyras (PhD) &ndash;</I></B> Monash University. Dr. Lyras is associate professor at Monash University, is one of the world&rsquo;s
leading expert in C. <I>difficile</I>. Dr. Lyras has spent her research career developing world-leading knowledge of C. <I>difficile</I>.
She was the lead author of a seminal study published in Nature in 2009, which shed new light on the essential role specific toxins
play in causing disease, a discovery that disproved prevailing opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We believe that we
will face competition in differing levels of intensity in all of the areas in which we are conducting research.&nbsp;&nbsp;Our
competitors, which are located worldwide, are numerous and include, among others, major pharmaceutical companies such as Gilead;
biotechnology firms such as Intercept with its product, obeticholic acid, Genfit, with its product Elafibrinor, Tobira with its
product Cenicriviroc, Seres with its product SER-109 and Synthetic Biologics with its product ribaxamase; universities and other
research institutions.&nbsp;&nbsp;These competitors may develop technologies and&nbsp; products that are more effective than any
that we are developing, or which would render our technology and products obsolete or non-competitive.&nbsp;&nbsp;Many of these
competitors have greater financial, research and screening capabilities, technical resources and manufacturing and marketing capabilities
than we do.&nbsp;&nbsp;In addition, many of our competitors have much more experience than we do in pre-clinical testing and human
clinical trials of new or improved drugs, as well as in obtaining FDA, EMA, TGA and other regulatory approvals.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Marketed Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><B>Travelan &ndash; A
Unique Product:</B> Travelan is the only product currently sold for the prevention of Traveler&rsquo;s Diarrhea (TD). Travelan
uses hyperimmune BCP from cows vaccinated against various strains of ETEC to protect against TD and reduces the risk of TD, along
with the symptoms of minor gastrointestinal disorders. Travelan prevents TD by up to 90%. Travelan is not an antibiotic and so
it does not have the side-effect profile of antibiotics and does not contribute to the worldwide concerns about bacterial drug
resistance. Two independent, double-blinded, placebo-controlled clinical trials in Europe in 90 healthy volunteers showed protection
of up to 90% against infection with the type of E.coli that causes TD, along with indicating a significant reduction in abdominal
cramps and stomach pain. There were no reported side effects in the clinical trials. Sales in FY2016, were AUD$1.0M.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Travelan is now marketed
in four countries including Australia, U.S.A, China and Canada (with our partner Paladin Labs, a branch of Endo Pharmaceuticals
that sells products for the Canadian market), and we planned to launched the products in additional countries. In Australia, Canada
and China, Travelan is regulated as an OTC had therefore has disease claims. In the United States, Travelan is sold as a dietary
supplement and as such does not require approval of a biologics license application from the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Our marketing and sales
strategies vary by territory. In Australia, Travelan is sold within most pharmacies, and we utilize trade promotions strategies,
as well as a contracted field force, to ensure that our products are appropriately distributed throughout our partner pharmacies.
In the United States, we are heavily focused on driving demand through the travel clinics market, such as PassportHealth, and
also by partnering with large distributors such as Medique. In Canada, our partner Paladin Labs, a branch of Endo Pharmaceuticals
that sells products for the Canadian market will actively promote Travelan in both retail and pharmacies until approximately August
23, 2017. In China, our partner QBID, has an extensive presence on JD.com and Travelan is sold through their online stores. In
all of our markets, we invest in social media marketing, trade marketing, traditional media marketing and PR to drive awareness
and pull through of Travelan.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Overall, over 50 million
people from developed nations travel to developing countries each year and 35%-50% of people traveling to developing countries
will suffer from TD while 70% of these TD episodes will be caused by Enterotoxigenic Escherichia coli (ETEC). TD is the most common
health problem faced by these travelers; given this, we believe that an expanded sales and marketing campaign for Travelan would
lead to a strong increase in sales. We are in the process of finding partners for other priority markets outside of Australia,
the U.S. and Canada. Our market research has shown that TD is a $600M market worldwide including therapeutics approved for the
treatment of TD, off-label use of non-TD approved therapeutics such as antibiotics and OTCs. As the only preventative treatment
on the market, we believe that the potential worldwide peak sales for Travelan is 20% of the worldwide TD market, or $120M per
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Distribution and License Agreement with
Paladin Labs Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Effective November 28,
2011, we entered into a Distribution and License Agreement (the &ldquo;Distribution Agreement&rdquo;) with Paladin Labs Inc. (&ldquo;Paladin&rdquo;)
pursuant to which we appointed Paladin as our exclusive distributor for marketing and selling Travelan in certain territories
(the &ldquo;Paladin Territories&rdquo;). In addition to marketing, promoting, importing and selling Travelan in the Paladin Territories,
Paladin has (i) the right to manufacture packs of Travelan and engage in clinical development and associated activities in connection
with obtaining regulatory approvals in the Paladin Territories and (ii) grant sublicenses to its affiliates with respect to the
foregoing rights. The term of the Distribution Agreement is 15 years after the first commercial sale of Travelan, which sale occurred
in 2015, unless earlier terminated in accordance with the terms of the Distribution Agreement. Pursuant to the terms of the Distribution
Agreement, Paladin (i) advanced the Company a secured facility in the amount of up to CAD $1,500,000, (ii) paid the Company a
non-refundable fee of CAD$10,000 for the use of the Travelan trademark and (iii) paid the Company CAD$490,000 for exclusive distribution
rights in the Paladin Territories. These amounts were paid in fiscal year 2012. Moreover, Paladin will pay the Company, the following
amounts, as one-time milestone payments within 30 days of the end of the year in which Paladin first obtains certain aggregate
Net Sales (as defined in the Distribution Agreement); <I>provided, however, </I>that the maximum amount of milestone payments
shall not exceed CAD$115,250,000:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 77; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone
    Payment (all expressed</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>in Canadian dollars)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone
    the first time</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>that Net Sales in the</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Paladin Territory in a calendar</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>year are equal or greater</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>than</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 48%; font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 47%; font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">100,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">1,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">150,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">1,500,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">200,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">250,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2,250,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">300,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">3,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">500,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">5,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">750,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">7,500,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">1,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">10,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">20,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">5,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">30,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">10,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">40,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">10,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">50,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">10,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">60,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">15,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">70,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">15,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">80,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">15,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">100,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">15,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">125,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">15,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">150,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Paladin must order Product
from the Company in multiples of a minimum of 20,000 packs. Paladin is to use commercially reasonable efforts to retain required
regulatory approvals as set forth in the Distribution Agreement, and is responsible for sales and marketing expenses. To date,
no milestones have been met under the Distribution Agreement. &ldquo;Product&rdquo; means hyper-immune bovine colostrum enriched
with antibodies that are reactive to Enterotoxigenic E. Coli and all improvements thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Effective February
23, 2017, the Company terminated the Distribution Agreement for Paladin&rsquo;s for failure to purchase the minimum quantities
of product pursuant to the agreement; <I>provided, however</I>, that Paladin shall be entitled to continue selling existing inventory
in the Paladin Territories for a period of 6 months from the date of termination. The Company may, but is not required to, repurchase
any inventory from Paladin.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Marketing and Master Distribution Agreement
with UniFirst-First Aid Corporation d/b/a Medique Products</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Effective June 28, 2016,
the Company entered into a Marketing and Master Distribution Agreement (the &ldquo;Marketing Agreement&rdquo;) with UniFirst-First
Aid Corporation d/b/a Medique Products (&ldquo;Medique&rdquo;) pursuant to which Medique was appointed as the exclusive marketing
representative and exclusive distributor to certain parties in the U.S. as identified in the Marketing Agreement. The term of
the Marketing Agreement is two years which will automatically be extended for additional one year periods unless earlier terminated
in accordance with the terms of the Marketing Agreement. Pursuant to the Marketing Agreement, Medique will (i) assist the Company
in the development of marketing, advertising and sales plans for certain of the Company&rsquo;s products, (ii) implementing such
plans, (iii) establishing customer relations, (iv) assisting the Company with receiving and responding to customer complaints
and (v) performing such other services and providing such other assistance as may be reasonably requested by the Company. The
prices that the Company will charge Medique for products will be equal to the Company&rsquo;s wholesale prices for the products
being charged to third parties, which prices may be increased one annually upon written notice to Medique. In addition, Medique
has been granted the nontransferable right to use the Company&rsquo;s trade names, trademarks and copyrights to distribute the
products in the markets as contemplated by the Marketing Agreement. Medique shall have no right to manufacture any of the Company&rsquo;s
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The Marketing Agreement
may be terminated sooner than the end of the term immediately upon the giving of notice to the non-defaulting party if any of
the following occur:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         assignment of the Marketing Agreement, or any transfer or attempted transfer by the defaulting
                                         party of&nbsp;&nbsp;the&nbsp;&nbsp;Marketing Agreement; or transfer by operation of&nbsp;&nbsp;law
                                         or otherwise of the principal assets of the defaulting party that are required to permit
                                         the defaulting party to perform its obligations under the Marketing Agreement; or change
                                         in the direct or indirect ownership of a controlling interest in the voting securities
                                         or operating management of the defaulting party however accomplished without the prior
                                         written consent of the non-defaulting party;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.3in; text-align: justify; text-indent: -21.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any misrepresentation by the defaulting party
    in obtaining the&nbsp;&nbsp;Marketing Agreement or in obtaining any refund, credit, rebate, incentive, allowance, discount,
    reimbursement or payment from the non-defaulting party or submission by the defaulting party of any false or fraudulent application,
    claim or report in connection with its sales operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If the defaulting party is insolvent, unable
    to meet its debts as they mature, files a petition or answer consenting to or acquiescing in a petition against it in bankruptcy
    or under any chapter of the Bankruptcy Reform Act of 1978 or any similar law for the relief of debtors, federal or state,
    whether now existing or hereafter enacted, or suffers such a petition to be filed against it which is not vacated or stayed
    within 60 days, has a receiver appointed for or execution levied upon all or a material part of its business or assets, makes
    any arrangement with its creditors generally, goes into liquidation or dissolution, or fails for any other reason to function
    as a going business;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any act by the defaulting party or any person
    involved in the ownership or operations of the defaulting party which violates any law and adversely affects the defaulting
    party&rsquo;s operations or the Company&rsquo;s&nbsp;&nbsp;products covered under the Marketing Agreement or any conduct or
    unfair business practice by the defaulting party or any person involved in the ownership or operations of the defaulting party
    which adversely affects the defaulting party&rsquo;s operations or the goodwill and reputation of the defaulting party, the
    non-defaulting party or the products; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Failure by the defaulting party to fulfill
    any of its other obligations or agreements with respect to or arising under this Marketing Agreement and such failure continues
    for a period of 30 days or is repeated after written notice thereof is given by the non-defaulting party to the defaulting
    party.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>Protectyn &ndash;
For Gut Dysbiosis.</B> This year we launched Protectyn in Australia, an health product targeting LPS bacteria in the gut to prevent
gut dysbiosis, improve bacterial clearance, reduce chronic inflammation and improve immune function. This product has been formulated
to help maintain healthy digestive function and help support the liver. Protectyn is currently only sold through the Natural Healthcare
Practitioners (Naturopath).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 78; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Technology Platform &ndash; Targeted Polyclonal Antibodies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Immuron&rsquo;s hyper-immune
platform technology is safe (GRAS rated), low cost, and can be applied to a variety of diseases. Immuron&rsquo;s platform technology
is based on producing antigen targeted, hyper-immune bovine colostrum powder (BCP) suitable for pharmaceutical use. Polyclonal
antibodies are collected from the first milking of a cow after calving. Prior to calving, cows are immunized with proprietary
vaccines to ensure immunogenicity and after calving, the first milk is harvested. This proprietary process ensures that the colostrum
contains a high concentration of antibodies and high concentration of Immunoglobulin G.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The underlying nature
of Immuron&rsquo;s platform technology enables the development of medicines across a large range of diseases, including infectious
diseases and immune-mediated disorders. The platform can be used to influence the cell-mediated immune system through regulatory
T cell populations, or it can directly block viruses or bacteria at mucosal surfaces (such as the GI tract) and neutralize the
toxins they produce. Additionally, the dairy origins of Immuron&rsquo;s antibodies enables us to commercialize our platform through
most regulatory pathways, including prescription (Rx), medical foods, over-the-counter medicines, and dietary supplements. The
GRAS status of our technology platform will allow us to advance our preclinical programs into clinical trials in other diseases
faster relative to other companies due to these characteristics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">In general, Immuron&rsquo;s
immunotherapy uses the inherent ability of the gastrointestinal tract&rsquo;s immune system to control unwanted systemic immune
responses by using specific antigens to induce the release of regulatory T-cells and anti-inflammatory cytokines while decreasing
levels of pro-inflammatory cytokines. These T-cells fight systemic inflammation and restore inflammation to a normalized level.
While our compound produces an anti-inflammatory effect, it does not involve general immune suppression, thus does not lead to
potential serious side effects such as increased infection susceptibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Technology Platform &ndash; Targeted Polyclonal Antibodies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Immuron&rsquo;s active
ingredient is Bovine Colostrum Powder (BCP) purified from dairy cows that have been immunized with patented vaccines to produce
very high levels of specific antibodies against targeted antigens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">These antibodies
have powerful anti-inflammatory effect and work through two modes of action:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><I>Passive Immunity:</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Immuron&rsquo;s active ingredient
targets a specific antigen. When bound by polyclonal antibodies, the antigens are prevented from infecting the cells of the patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><I>Active Immunity:</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Immuron&rsquo;s active ingredient
modulates the body&rsquo;s own immune system by boosting the right T-cells and suppressing &ldquo;unwanted&rdquo; T-cells through
a cell-mediated immune response that functions against the antigen. The antibodies, once orally ingested, are presented in the
peyers patches to the lymph system's dendritic cells which sample the antibodies, thereby eliciting the cell mediated immune response.
This response is associated with increased distribution of T regulatory lymphocytes and anti-inflammatory cytokines and decreased
levels of pro-inflammatory cytokines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg77img1_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Manufacturing Process</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Effective June 28, 2013,
we entered into a Development and Supply Agreement, as amended on June 21, 2016 (the &ldquo;Development Agreement&rdquo;) with
Synlait Milk Ltd., a New Zealand company which specializes in the processing of infant formula and special milk powders with expertise
in on-farm manipulation of milk (including colostrum), processing technologies, product development and marketing. Pursuant to
the terms of the Development Agreement, we obtain our lead compound, IMM-124E, from Synlait.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Our lead compound, IMM-124E,
is obtained from Synlait. Immuron&rsquo;s&nbsp; active ingredient is manufactured under full cGMP conditions in an Australian
TGA-licensed facility. Many of the active ingredients are the same as those of normal cow&rsquo;s milk. However, the main differentiation
between milk and Immuron&rsquo;s active ingredient constituents is the presence of antibodies in the order of 35-45% by weight
of dry colostrum powder. The main classes of immunoglobulins found in the active ingredient are IgG with smaller amounts of IgM
and IgA. The major class of immunoglobulin found in bovine colostrum is IgG1 making up between 65% and 90% of total immunoglobulins,
in contrast to milk which comprises predominantly IgA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The Development Agreement
shall expire on July 21, 2018 unless extended or earlier terminated by the parties.in accordance with the Development Agreement.
Pursuant to the terms of the Development Agreement, the Company granted Synlait a non-exclusive, non-transferable license to use
the Company&rsquo;s intellectual property for vaccination of dairy herds with the Company&rsquo;s vaccines and for collection
and production of hyper-immune bovine colostrum (&ldquo;HIC&rdquo;) in the South Island of New Zealand. The Company shall supply
Synlait with vaccines ready to use for formulation and/or component parts that are required for the production of HIC and information
required by Synlait to enable it to attain regulatory registration within New Zealand for the lawful vaccination of dairy cows
for the production of HIC. The Company paid Synlait NZ$260,000 in relation to its purchase of product in fiscal year 2014 for
the Development (as defined in the Development Agreement)<I>; provided, however, </I>Synlait will discount the purchase price
of HIC in the first year by an amount equal to the foregoing fee. During the first year of the Development Agreement, the Company
will pay Synlait as follows for HIC: (i) 10% of the expected order price upon the Company placing an order for HIC, (ii) 40% of
the expected order price within two weeks of Synlait delivering written notice to the Company with respect to the commencement
of processing the HIC and (ii) 50% of the expected order price within 30 days from the date the Company receives export documentation
with respect to its order. After the first year, the Company will pay Synlait as follows for HIC: (i) 30% of the expected order
price within two weeks of Synlait delivering written notice to the Company with respect to the commencement of processing the
HIC and (ii) 70% of the expected order price within 30 days from the date the Company receives export documentation with respect
to its order.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">If any party is in material
default or breach of any of terms of the Development Agreement, including payments due under the Development Agreement, and such
breach or default s not remedied within 30 days after written notice thereof is provided by the other party, such other party
may, in its sole discretion, terminate the Development Agreement in its entirety by delivering 30 days&rsquo; written notice to
such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In the event Synlait
breaches the Development Agreement, the Company shall also be entitled to terminate the license granted to Synlait to the extent
that it relates to the production of HIC on Synlait&rsquo;s behalf. Additionally, each party may terminate the Development Agreement
by giving written notice to the other party to such effect if such other party shall make an arrangement for the benefit of creditors,
or if proceedings a party enters voluntary or involuntary liquidation or bankruptcy, or if a receiver or trustee of the property
of such party shall be appointed, or if any proceedings are commenced by or against such party and in respect of such party under
any provisions of any law relating to bankruptcy, liquidation or insolvency, or, in the case of Synlait, if its agreement with
Bright Dairy is amended with respect to Bright Dairy&rsquo;s access to Synlait&rsquo;s and/or the Company&rsquo;s intellectual
property or with respect to its control over Synlait&rsquo;s operations that use the Company&rsquo;s intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Upon termination of the
Development Agreement, Synlait shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt">(a)</TD><TD STYLE="text-align: justify">immediately cease all activities
                                         permitted under the licenses and all rights granted to Synlait thereunder shall revert
                                         to the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt">(b)</TD><TD STYLE="text-align: justify">immediately deliver to the Company
                                         all vaccine that the Company supplied to Synlait and all the Company&rsquo;s trade secrets
                                         related to the production of HIC; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt">(c)</TD><TD STYLE="text-align: justify">remain liable to the Company for
                                         all HIC ordered by the Company prior to the date of termination.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Vaccination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The active drug substance
is prepared using the first milking colostrum of dairy cows that have been immunized with a patented vaccine to produce very high
levels of specific antibodies against selected surface antigens. Pregnant dairy cows at Australian commercial dairy farms are
immunized through a proprietary process that is approved by an independent animal ethics committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Colostrum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The colostrum which
is sourced from Synlait is harvested from immunized Holstein Friesian and Jersey cows. They are all Australian government registered
for milk production for human consumption and at the time of harvesting are free from antibiotics. They are not given steroids
at any stage of the process. Colostrum is harvested at the first milking which will be within twelve hours of calving, leaving
plenty for the calf to feed on.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Risk management on
the source of colostrum must focus on assurance of freedom from Bovine Spongiform Encephalopathy (BSE or commonly known as Mad
Cow Disease) of the liquid raw product. A small number of countries, including Australia and New Zealand, have been judged by
the World Organization for Animal Health (OIE) to have the highest BSE free rating on the basis that they have never experienced
BSE at any time. The definition of this status means that both Australia and New Zealand are currently certified as BSE free countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Once harvested, preparation
of the active ingredient complies with processes that are regulated by Dairy Safe standards in addition to the TGA, which is a
Federal requirement and known globally for its stringent criteria. The raw colostrum material is centrifuged using a milk separator
to remove somatic cells, cell debris, some bacteria and fat. It is then pasteurized, cooled and subjected to membrane ultra-filtration,
removing much of the water, salts and lactose. The colostrum wet concentrate is then lyophilized to produce a powder, which is
milled to 200 microns. The processes are typical for the dairy industry and for production of dairy foods. After freeze drying,
the active ingredient is ready for further processing into the oral dosage form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Tableting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The product excipients
are all standard, FDA acceptable oral compounds that are granulated, milled and finally compressed into caplets and blister packaged
(pharmaceutical grade packaging materials).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Batch Consistency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The Ab% component
of Immuron&rsquo;s active ingredient ranges between 36% and 40%. The parameters are stable within batches and across batches.
Immuron&rsquo;s product is stable according to ICH guidelines and the IgG component of Immuron&rsquo;s active ingredient is stable
over time. The IgG component is also stable across batches primarily as a function of harvesting colostrum from at least 100s
of dairy cattle for any one batch, thereby attaining consistency by reason of averaging over a population. Furthermore, Immuron&rsquo;s
active ingredient is manufactured under full cGMP conditions with all associated QA and QC processes ensuring the stability of
these parameters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulatory</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our clinical assets
are regulated as biologics by the FDA conferring it 12 years of market exclusivity in the U.S. New products in Europe have 10
years of market exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Worldwide, we have
13 issued patents and 23 pending patent applications. We have been issued patents in the U.S., Australia, Canada, India, Japan
and New Zealand. All of these patents are owned by Immuron and are not licensed. These patents enhance the market exclusivity
offered by the fact that our compounds are classified as biologics by the FDA.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 22%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 24%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 24%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 24%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Expiry</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Composition and Method for the Treatment
    and Prevention of Enteric Bacterial Infections</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2004216920</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4 March 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">0408085-8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Brazil</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4 March 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2,517,911</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4 March 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">102698258</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4 March 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">230664 B</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">India</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4 March 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">542088</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">New Zealand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4 March 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">9,402,902</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4 March 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">8,637,025</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">25 February 2028 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7"><FONT STYLE="font-size: 10pt"><B>Immuno-Modulating Compositions for the Treatment of Immune-Mediated
    Disorders</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2009222965</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11 March 2029</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2,718,381</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11 March 2029</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">EP 2268669</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Europe</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11 March 2029</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">587901</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">New Zealand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11 March 2029</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">13/715,371</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11 March 2029</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7"><FONT STYLE="font-size: 10pt"><B>Method and Apparatus for the Collection of Fluids</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2,527,260</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 June 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2004244673</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 June 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">544198</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">New Zealand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 June 2024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7"><FONT STYLE="font-size: 10pt"><B>Anti LPS Enriched Immunoglobulin for the Treatment and/or Prophylaxis
    of a Pathologic Disorder</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2010243205</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2760096</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">13/265,252</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2424890</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Europe</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">12103554.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Hong Kong </FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Published</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">315924</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Israel</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">5740390</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Japan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">10-2011-7027634</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Korea</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">335793</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Mexico</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">201171304</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Eurasia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7"><FONT STYLE="font-size: 10pt"><B>Anti LPS Enriched Immunoglobulin Preparation For Use In Treatment
    and/or Prophylaxis of a Pathologic Disorder</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2011290478</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2808361</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2605791</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Europe</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Granted</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">13/817,414</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">1185016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Hong Kong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Published</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27 April 2030</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP COLSPAN="7" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Methods and Compositions for the Treatment
    and/or Prophylaxis of Clostridium Difficile Associated Disease</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2014253685</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17 April 2034</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2,909,636</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17 April 2034</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2986316</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Europe</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17 April 2034</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">14/785,527</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17 April 2034</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">201480034857.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17 April 2034</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">713233</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">NZ</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17 April 2034</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Our Development Team
includes Thomas Liquard (CEO), Dr. Dan Peres (MD) (CMO) and Dr. Jerry Kanellos (PhD) (CSO) and has extensive experience in the
field. Bios for our development are set forth in the Management Section of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Government Regulation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">As a pharmaceutical
and biological product company that wishes to conduct clinical trials and ultimately obtain marketing approval in the United States,
we are subject to extensive regulation by the FDA, and other federal, state, and local regulatory agencies. The Federal Food,
Drug, and Cosmetic Act, or the FDC Act, the Public Health Service Act, or PHS Act, and their implementing regulations set forth,
among other things, requirements for the research, testing, development, manufacture, quality control, safety, effectiveness,
approval, labeling, storage, record keeping, reporting, distribution, import, export, advertising and promotion of our products.
A failure to comply explicitly with any requirements during the product development, approval, or post-approval periods, may lead
to administrative or judicial sanctions. These sanctions could include the imposition by the FDA or an IRB, of a suspension on
clinical trials, refusal to approve pending marketing applications or supplements, withdrawal of approval, warning letters, product
recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal
prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Although the discussion
below focuses on regulation in the United States, we anticipate seeking approval for the testing and marketing of our products
in other countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope
as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation
in the European Union are addressed in a centralized way through the EMA, but country-specific regulation remains essential in
many respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Government regulation
may delay or prevent testing or marketing of our products and impose costly procedures upon our activities. The testing and approval
process, and the subsequent compliance with appropriate statutes and regulations, requires substantial time, effort, and financial
resources, and we cannot be certain that the FDA or any other regulatory agency will grant approvals for our products or any future
products on a timely basis, if at all. The FDA&rsquo;s or any other regulatory agency&rsquo;s policies may change and additional
governmental regulations may be enacted that could prevent or delay regulatory approval of our products or any future products
or approval of new indications or label changes. We cannot predict the likelihood, nature or extent of adverse governmental regulation
that might arise from future legislative, judicial, or administrative action, either in the United States or abroad.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Marketing Approval </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">In the United States, for premarket approval
purposes, the FDA regulates our products as biologics under the FDC Act, the PHS Act and related regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The steps required
before a new biologic may be marketed in the United States generally include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nonclinical
                                         pharmacology and toxicology laboratory and animal tests according to good laboratory
                                         practices, or GLPs, and applicable requirements for the humane use of laboratory animals
                                         or other applicable regulations;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                         of an IND application which must become effective before human clinical trials may begin;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
                                         and well-controlled human clinical trials according to GCPs and any additional requirements
                                         for the protection of human research subjects and their health information to establish
                                         the safety and efficacy of the investigational product for each targeted indication;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                         of a biologics license application, or BLA, to the FDA;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&rsquo;s
                                         pre-approval inspection of manufacturing facilities to assess compliance with cGMPs;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&rsquo;s
                                         audit of clinical trial sites that generated data in support of the BLA; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                         approval of a BLA, which must occur before a product can be marketed or sold.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>Product Development Process </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Before testing any
biologic in humans, the product enters the nonclinical, or preclinical, testing stage. Nonclinical tests include laboratory evaluations
of product chemistry, toxicity, and formulation, as well as animal studies to assess the potential safety and activity of the
product. The conduct of nonclinical tests must comply with federal regulations and requirements including GLPs. Because our product
are Generally Regarded as Safe (GRAS), some toxicity and animal studies are not demanded by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The product sponsor
submits the results of the nonclinical testing, together with manufacturing information, analytical data, any available clinical
data or literature, and a proposed clinical protocol, to the FDA in an IND, which is a request for authorization from the FDA
to administer an investigational product to humans. Some nonclinical testing may continue even after the IND application is submitted.
IND authorization is required before interstate shipping and administration of any new product to humans that is not the subject
of an approved BLA. The IND automatically becomes effective 30 days after receipt by the FDA unless the FDA, within the 30-day
time period, raises concerns or questions about the conduct of the clinical trial and places the clinical trial on a clinical
hold. In such case, the IND sponsor must resolve any outstanding concerns with the FDA before the clinical trial may begin. Further,
an IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it
commences at that site. If the site has an IBC, it may also have to review and approve the proposed clinical trial. Clinical trials
involve the administration of the investigational product to patients under the supervision of qualified investigators following
GCPs, requirements meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, investigators,
and monitors. Clinical trials are conducted under protocols that detail, among other things, the objectives of the clinical trial,
dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring safety, including stopping
rules that assure a clinical trial will be stopped if certain adverse events should occur, and the efficacy criteria to be evaluated.
Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the
IND. The informed written consent of each participating subject is required and the form and content of the informed consent must
be approved by each IRB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The clinical investigation
of an investigational product is generally divided into three phases. Although the phases are usually conducted sequentially,
they may overlap or be combined. The three phases of an investigation are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         1 includes the initial introduction of an investigational product into humans. Phase
                                         1 clinical trials may be conducted in patients with the target disease or condition or
                                         on healthy volunteers. These studies are designed to evaluate the safety, metabolism,
                                         pharmacokinetics and pharmacologic actions of the investigational product in humans,
                                         the side effects associated with increasing doses, and if possible, to gain early evidence
                                         on effectiveness. During Phase 1 clinical trials, sufficient information about the investigational
                                         product&rsquo;s pharmacokinetics and pharmacological effects may be obtained to permit
                                         the design of Phase 2 clinical trials.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         2 includes the controlled clinical trials conducted to evaluate the effectiveness of
                                         the investigational product for a particular indication(s) in patients with the disease
                                         or condition under study, to determine dosage tolerance and optimal dosage, and to identify
                                         possible adverse side effects and safety risks associated with the product. Phase 2 clinical
                                         trials are typically well-controlled, closely monitored, and conducted in a limited patient
                                         population, usually involving no more than several hundred participants. Phase&nbsp;2a
                                         trials provide information on the impact of dose ranging on safety, biomarkers and proof
                                         of concept, while Phase&nbsp;2 trials are patient dose-ranging efficacy trials.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         3 clinical trials are controlled clinical trials conducted in an expanded patient population
                                         at geographically dispersed clinical trial sites. They are performed after preliminary
                                         evidence suggesting effectiveness of the investigational product has been obtained, and
                                         are intended to further evaluate dosage, clinical effectiveness and safety, to establish
                                         the overall benefit-risk relationship of the product, and to provide an adequate basis
                                         for product approval. Phase 3 clinical trials usually involve several hundred to several
                                         thousand participants. In most cases, the FDA requires two adequate and well controlled
                                         Phase&nbsp;3 clinical trials to demonstrate the efficacy of the product. FDA may accept
                                         a single Phase 3 trial with other confirmatory evidence in rare instances where the trial
                                         is a large multicenter trial demonstrating internal consistency and a statistically very
                                         persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity
                                         or prevention of a disease with a potentially serious outcome and confirmation of the
                                         result in a second trial would be practically or ethically impossible.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Annual progress reports
detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted
to the FDA and the investigators for serious and unexpected adverse events; any findings from other studies, tests in laboratory
animals or <I>in vitro</I> testing that suggest a significant risk for human subjects; or any clinically important increase in
the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit
an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor
also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after
the sponsor&rsquo;s initial receipt of the information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The decision to terminate
a clinical trial of an investigational biologic may be made by the FDA or other regulatory authority, an IRB, an IBC, or institutional
ethics committee, or by a company for various reasons. The FDA may place a clinical hold and order the temporary, or permanent,
discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not
being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. If the FDA
imposes a clinical hold, trials may not recommence without FDA and IRB authorization and then only under terms authorized by the
FDA and IRB. In some cases, clinical trials are overseen by an independent group of qualified experts organized by the trial sponsor,
or the clinical monitoring board or DSMB. This group provides authorization for whether or not a trial may move forward at designated
check points. These decisions are based on the limited access to data from the ongoing trial. The suspension or termination of
a clinical trial can occur during any phase of clinical trials if it is determined that the participants or patients are being
exposed to an unacceptable health risk. In addition, there are requirements for the registration of ongoing clinical trials of
drugs and biologics on public registries and the disclosure of certain information pertaining to the trials as well as clinical
trial results after completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Assuming successful
completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational product
information is submitted to the FDA in the form of a BLA for a biologic to request marketing approval for the product in specified
indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Biologics License Application
Approval Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">In order to obtain
approval to market a biologic in the United States, a BLA must be submitted to the FDA that provides data from nonclinical studies
and clinical trials and manufacturing information establishing to the FDA&rsquo;s satisfaction the safety, purity, and potency
or efficacy of the investigational product for the proposed indication. The BLA must be accompanied by a substantial user fee
payment unless a waiver or exemption applies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The FDA will initially
review the BLA for completeness before it accepts it for filing. Under the FDA&rsquo;s procedures, the agency has 60 days from
its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&rsquo;s threshold determination
that the application is sufficiently complete to permit substantive review. After the BLA submission is accepted for filing, the
FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, which includes determining
whether it is effective for its intended use, and whether the product is being manufactured in accordance with cGMP, to assure
and preserve the product&rsquo;s identity, safety, strength, quality, potency and purity, and in accordance with biological product
standards. The FDA will inspect the facilities at which the product is manufactured to ensure the manufacturing processes and
facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required
specifications. For a human cellular or tissue product, the FDA also will not approve the product if the manufacturer is not in
compliance with the GTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for,
the manufacture of human cells, tissues, and cellular and tissue based products, which are human cells or tissue intended for
implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure
that cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission, and spread
of communicable disease. Additionally, before approving a BLA, the FDA may inspect one or more clinical sites to assure compliance
with GCP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">If the FDA determines
the application, manufacturing process or manufacturing facilities are not acceptable, it typically will outline the deficiencies
and often will request additional testing or information, or corrective action for a manufacturing facility. This may significantly
delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in accordance
with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy analyses
provided in the BLA. Additionally, notwithstanding the submission of any requested additional information, the FDA ultimately
may decide that the application does not satisfy the regulatory criteria for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The FDA may refer
applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee. The
FDA also may determine a REMS is necessary to assure the safe use of the biologic, in which case the BLA sponsor must submit a
proposed REMS. The REMS may include, but is not limited to, a Medication Guide, a communications plan, and other elements to assure
safe use, such as restrictions on distribution, prescribing, and dispensing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">After the FDA completes
its initial review of a BLA, it will either license, or approve, the product, or issue a complete response letter to communicate
that it will not approve the BLA in its current form and to inform the sponsor of changes that the sponsor must make or additional
clinical, nonclinical or manufacturing data that must be received before the FDA can approve the application, with no implication
regarding the ultimate approvability of the application. If a complete response letter is issued, the sponsor may either resubmit
the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The testing and approval
process for both a drug and biologic requires substantial time, effort and financial resources and this process may take several
years to complete. Data obtained from clinical trials are not always conclusive and may be susceptible to varying interpretations,
which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter
difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us
from marketing our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 85; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Biosimilars</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We believe that any
of our product candidates approved under a BLA should qualify for a 12-year period of exclusivity against biosimilar competition
currently permitted by the Biologics Price Competition and Innovation Act, or BPCIA. Specifically, as part of the Patient Protection
and Affordable Care Act enacted in 2010, as amended by the Health Care and Education Affordability Reconciliation Act, collectively
the Affordable Care Act, the BPCIA established an abbreviated pathway for the approval of biosimilar and interchangeable biological
products. The new abbreviated regulatory pathway provides legal authority for the FDA to review and approve biosimilar biologics
based on their similarity to an existing brand product, referred to as a reference product, including the possible designation
of a biosimilar as interchangeable with a brand product. Under the BPCIA, an application for a biosimilar product cannot be approved
by the FDA until 12 years after the original brand product was approved under a BLA. There is a risk that, as proposed by President
Obama, Congress could amend the BPCIA to significantly shorten this exclusivity period or that the FDA will not consider our product
candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner
than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference
products in a way that is similar to traditional generic substitution for non-biological drug products is not yet clear, and will
depend on a number of marketplace and regulatory factors that are still developing. The BPCIA is complex and is only beginning
to be interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning is subject to uncertainty.
While it is uncertain when any such processes may be fully adopted by the FDA, any such processes that operate to limit the scope
or length of exclusivity afforded by the BPCIA could have a material adverse effect on the future commercial prospects for our
biological products. In addition, the period of exclusivity provided by the BPCIA only operates against third parties seeking
approval via the abbreviated pathway, but would not prevent third parties from pursuing approval via the traditional approval
pathway. In addition, foreign regulatory authorities may also provide for exclusivity periods for approved biological products.
For example, biological products in the European Union may be eligible for at least a ten-year period of exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 12.2pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Orphan Drug Designation
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Under the Orphan
Drug Act, the FDA may grant orphan designation to a drug or biological product candidate intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000
individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug
or biological product available in the United States for this type of disease or condition will be recovered from sales of the
product candidate. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation,
the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation
does not convey any advantage in or shorten the duration of the regulatory review and approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">If a product candidate
that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation,
the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market
the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products
for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication
for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products
for seven years if a competitor obtains approval of the same biological product as defined by the FDA or if our product candidate
is determined to be contained within the competitor&rsquo;s product for the same indication or disease. If a drug or biological
product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may
not be entitled to orphan product exclusivity. Orphan drug status in the European Union has similar, but not identical, benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Expedited Development
and Review Programs </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The FDA has a fast
track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet
certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended
to treat a serious or life-threatening condition and demonstrate the potential to address significant unmet medical needs for
the condition. Fast track designation applies to the combination of the product and the specific indication for which it is being
studied. The sponsor of a new biologic or drug may request the FDA to designate the biologic or drug as a fast track product at
any time during the clinical development of the product. Unique to a fast track product, the FDA may consider for review sections
of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule
for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that
the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Any product submitted
to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite
development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has
the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement
in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional
resources to the evaluation of an application for a new biological or drug product designated for priority review in an effort
to facilitate the review. Additionally, a product may be eligible for accelerated approval. Biological or drug products studied
for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit
over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and
well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely
to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity.
As a condition of approval, the FDA may require that a sponsor of a biological or drug product receiving accelerated approval
perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for
accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of
the product. Lastly, under the provisions of the new Food and Drug Administration Safety and Innovation Act, enacted in 2012,
a sponsor can request designation of a product candidate as a &ldquo;breakthrough therapy.&rdquo; A breakthrough therapy is defined
as a drug or biological that is intended, alone or in combination with one or more other drugs or biological, to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biological may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment
effects observed early in clinical development. Drugs and biologicals designated as breakthrough therapies are also eligible for
accelerated approval and receive the same benefits as drugs and biologicals with Fast Track designation. The FDA must take certain
actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application
for approval of a breakthrough therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Fast Track designation,
and priority review may expedite the product approval process, but do not change the standards for approval. Accelerated approval
and breakthrough therapy designation do change the standards for product approval and thus may expedite the development and/or
approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>FDA Additional Requirements
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The FDA may require,
or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 clinical trials may be
made a condition to be satisfied for continuing drug and biologic approval. The results of Phase 4 clinical trials can confirm
the efficacy of a product candidate and can provide important safety information. In addition, the FDA has express statutory authority
to require sponsors to conduct post-market studies to specifically address safety issues identified by the agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Even if a product
candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and dosages,
or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form of an
onerous REMS, restrictions on distribution, or post-marketing study requirements. Further, even after regulatory approval is obtained,
later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal
of the product from the market. In addition, we cannot predict what adverse governmental regulations may arise from future U.S.
or foreign governmental action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>FDA Post-Approval Requirements
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Any products manufactured
or distributed by us or on our behalf pursuant to FDA approvals are subject to continuing regulation by the FDA, including requirements
for record-keeping, reporting of adverse experiences with the biologic or drug, and submitting biological product deviation reports
to notify the FDA of unanticipated changes in distributed products. Manufacturers are required to register their facilities with
the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies
for compliance with cGMP requirements, which impose certain quality processes, manufacturing controls and documentation requirements
upon us and our third-party manufacturers in order to ensure that the product is safe, has the identity and strength, and meets
the quality, purity and potency characteristics that it purports to have. In November 2013, the Drug Quality and Security Act,
or DQSA, became law and establishes requirements to facilitate the tracing of prescription drug and biological products through
the pharmaceutical supply distribution chain. This law includes a number of new requirements that will be implemented over time
and will require us to devote additional resources to satisfy these requirements, including serializing the product and using
new technology and data storage to electronically trace the product from manufacturer to dispenser. If our products are not covered
by the serialization and tracing requirements of the DQSA, they may be subject to state pedigree and traceability requirements.
We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP and other FDA regulatory
requirements. If our present or future suppliers are not able to comply with these requirements, the FDA may halt our clinical
trials, refuse to approve any BLA, force us to recall a product from distribution, shut down manufacturing operations or withdraw
approval of the applicable BLA. Noncompliance with cGMP or other requirements can result in issuance of warning or untitled letters,
civil and criminal penalties, seizures, and injunctive action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The FDA and other
federal and state agencies closely regulate the labeling, marketing and promotion of drugs and biologics. Government regulators,
including the Department of Justice and the Office of the Inspector General of the Department of Health and Human Services, as
well as state authorities, recently have increased their scrutiny of the promotion and marketing of drugs and biologics. While
doctors are free to prescribe any product approved by the FDA for any use, a company can only make claims relating to safety and
efficacy of a product that are consistent with FDA approval, and the company is allowed to market a product only for the particular
use and treatment approved by the FDA. In addition, any claims we make for our products in advertising or promotion must, among
other things, be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to
comply with these requirements can result in adverse publicity, warning or untitled letters, corrective advertising, injunctions,
potential civil and criminal penalties, criminal prosecution, and agreements with governmental agencies that materially restrict
the manner in which a company promotes or distributes products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Pediatric Research Equity
Act </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Under the Pediatric
Research Equity Act, or PREA, as amended, a BLA or supplement must contain data to assess the safety and efficacy of the product
for the claimed indications in all relevant pediatric subpopulations &nbsp;and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. Manufacturers must submit a pediatric study plan to the IND not later
than 60 days after the end-of-phase 2 meeting with the FDA; if there is no such meeting, before the initiation of any phase 3
studies or a combined phase 2 and phase 3 study; or if no such study will be conducted, no later than 210 days before a marketing
application or supplement is submitted. The intent of PREA is to compel sponsors whose products have pediatric applicability to
study those products in pediatric populations, rather than ignoring pediatric indications for adult indications that could be
more economically desirable. The FDA may grant deferrals for submission of data or full or partial waivers. By its terms, PREA
does not apply to any product for an indication for which orphan designation has been granted, unless the FDA issues regulations
stating otherwise. Because the FDA has not issued any such regulations, submission of a pediatric assessment is not required for
an application to market a product for an orphan-designated indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Patent Term Restoration
and Marketing Exclusivity </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Depending on the
timing, duration and specifics of FDA marketing approval of our product candidates, some of our U.S. patents may be eligible for
limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term
of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However,
patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&rsquo;s approval
date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission
date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable
to an approved biological is eligible for the extension and the application for the extension must be submitted prior to the expiration
of the patent and within sixty days of approval of the biological. The <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USPTO,
in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The Biologics Price
Competition and Innovation Act of 2009, which was included within the Patient Protection and Affordable Care Act, created an abbreviated
approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological
product, and grants a reference biologic twelve years of exclusivity from the time of first licensure. Biosimilarity, which requires
that there be no clinically meaningful differences between the biological product and the reference product in terms of safety,
purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability
requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce
the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference
biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy
relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex,
structure of biological products, as well as the process by which such products are manufactured, pose significant hurdles to
implementation that are still being worked out by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Pediatric exclusivity
is another type of exclusivity in the United States. Pediatric exclusivity, if granted, provides an additional six months of exclusivity
to be attached to any existing exclusivity, e.g., twelve year exclusivity, or patent protection for a drug. This six month exclusivity,
which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a
pediatric trial in accordance with an FDA-issued &ldquo;Written Request&rdquo; for such a trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Government Regulation
Outside the United States </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">In addition to regulations
in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical
trials and any commercial sales and distribution of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Whether or not we
obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior
to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United
States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement
of human clinical trials. In the European Union, for example, a request for a clinical trial authorization, or CTA, must be submitted
to each country&rsquo;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively.
Once the CTA is approved in accordance with a country&rsquo;s requirements, clinical trial development may proceed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The requirements
and process governing the conduct of clinical trials, product approval or licensing, pricing and reimbursement vary from country
to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements
and the ethical principles that have their origin in the Declaration of Helsinki.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">To obtain regulatory
approval of a biological product under European Union regulatory systems, we must submit a marketing authorization application.
The application required in the European Union is similar to a BLA in the United States, with the exception of, among other things,
country-specific document requirements. The European Union also provides opportunities for market exclusivity. For example, in
the European Union, upon receiving marketing authorization, a new biological generally receives eight years of data exclusivity
and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European
Union from referencing the innovator&rsquo;s data to assess a biosimilar application. During the additional two-year period of
market exclusivity, a biosimilar marketing authorization can be submitted, and the innovator&rsquo;s data may be referenced, but
no biosimilar product can be marketed until the expiration of the market exclusivity. The innovator may obtain an additional one
year of market exclusivity if the innovator obtains an additional authorization during the initial eight year period for one or
more new indications that demonstrate significant clinical benefit over existing therapies. This data and market exclusivity regime
in the European Union of a total of 10 or 11 years protects against generic competition, but does not protect against the launch
of a competing product if the competitor, rather than referencing the clinical data of the originator, has conducted its own clinical
trials to support its marketing authorization application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Orphan drugs in the
European Union are eligible for 10-year market exclusivity. This 10-year market exclusivity may be reduced to six years if, at
the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example,
if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization
may be granted to a similar product for the same indication at any time if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         second applicant can establish that its product, although similar, is safer, more effective
                                         or otherwise clinically superior;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         applicant consents to a second orphan medicinal product application; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         applicant cannot supply enough orphan medicinal product.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">If we fail to comply
with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of
regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Pharmaceutical Coverage,
Pricing and Reimbursement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Sales of our products,
when and if approved for marketing, will depend, in part, on the extent to which our products will be covered by third-party payors,
such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations.
These third-party payors are increasingly reducing reimbursements for medical products, biologicals, drugs and services. In addition,
the U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including
price controls, restrictions on coverage and reimbursement and requirements for substitution of interchangeable products. Adoption
of price controls and cost containment measures, and adoption of more restrictive policies in jurisdictions with existing controls
and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our product candidates
or a decision by a third-party payor not to cover our product candidates could reduce physician usage of our products once approved
and have a material adverse effect on our sales, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The containment of
healthcare costs has become a priority of federal, state and foreign governments. Third-party payors are increasingly challenging
the prices charged for drug products and medical services, examining the medical necessity and reviewing the cost effectiveness
of drug products and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider
our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or,
if they do, the level of payment may not be sufficient to allow us to sell our products at a profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">In the United States
and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes
and proposed changes regarding the healthcare system directed at broadening the availability of healthcare and containing or lowering
the cost of healthcare. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care Education
Reconciliation Act, or the ACA, was enacted. The ACA includes measures that have significantly changed, and are expected to continue
to significantly change, the way healthcare is financed by both governmental and private insurers. Other legislative changes have
been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among
other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with
recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required
goals, thereby triggering the legislation&rsquo;s automatic reduction to several government programs. This includes aggregate
reductions of Medicare payments to providers up to 2%&nbsp;per fiscal year, which went into effect in April 2013 and will remain
in effect through 2024 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American
Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals,
imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Other Healthcare Laws
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We also may be subject
to additional healthcare regulation and enforcement by the federal government and by authorities in the states and other countries
in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false
claims, privacy and security and physician sunshine and open payment laws and regulations, many of which may become more applicable
to us if our product candidates are approved and we begin commercialization. If our operations are found to be in violation of
any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation,
administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations,
exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our
ability to operate our business and our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 90; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Facilities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our corporate headquarters
are located at Suite 1, 1233 High Street, Armadale, Victoria, 3143, Australia and consist of approximately 60 square feet of office
space which is provided as part of a services agreement which expires at-will upon six months written notice. We do not have a
lease agreement for our corporate headquarters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our principle office
is located at Suite 10-25 Chapman Street, Blackburn North, Victoria 3130 and consists of approximately 1,500 square feet of leased
office and warehouse space under a lease agreement which expires on December 31, 2018, with an ongoing further three year option
for extension. Our Company has no dedicated research and development facility as the Company&rsquo;s research and development
activities are provided to the company by third party suppliers whom are responsible for their own premises. We believe that our
existing facilities are adequate for our current needs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We have 8 full-time
employees, many of whom hold PhD, DR, CA, MBA or other post-graduate degrees in their respective fields. Of these full-time employees,
4 are engaged in research and development activities and 4 are engaged in finance, legal, human resources, facilities and general
management. Our employees are located in Australia, Israel and the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We are not currently
a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise
in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty,
any such future litigation could have an adverse impact on us because of defense and settlement costs, diversion of management
resources and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_018"></A><B>DIRECTORS and MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directors and Executive Officers </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The following table sets forth information
covering our current directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 6%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Age</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 62%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Dr. Roger Aston</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Non-Executive Chairman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Peter Anastasiou</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">56</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice Chairman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Daniel Pollock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">56</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Non-Executive Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Stephen Anastasiou</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">59</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Non-Executive Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Thomas Liquard</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">45</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Dr. Jerry Kanellos (PhD)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">55</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Operating and Scientific Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Dr. Dan Peres (MD)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Head of Medical</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Phillip Hains </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">57</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Joint-Chief Financial Officer and Company Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Peter Vaughan </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">33</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Joint-Chief Financial Officer and Company Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Professor Ravi Savarirayan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Non-Executive Director (Appointed April 1, 2017)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>Roger Aston
</I></B>has been a member of our board of directors and the board&rsquo;s non-executive Chairman since March 2012. Dr. Aston is
both a scientist and a seasoned biotechnology entrepreneur, with a successful track record in both fields, and brings to the Board
more than 20 years of experience in the pharmaceutical and biotech industries. Dr. Aston has been closely involved in start-up
companies and major pharmaceutical companies. Aspects of his experience include FDA and EU product registration, clinical trials,
global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking
and stock broking sectors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Dr. Aston has had extensive
experience on boards of many biopharmaceutical companies including Directorships/Chairmanships with Clinuvel Limited (ASX:CUV),
HalcyGen Limited (ASX:HGN) and Ascent Pharma Health Limited (ASX:APH). During 2007 and 2008, Dr Aston was a member of the AusIndustry
Biological Committee advising the Industry Research and Development Board. More recently, Dr Aston was Executive Chairman of Mayne
Pharma Group from 2009 to 2011 and CEO of Mayne Pharma Group until 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Dr. Aston has also been
a director of IDT (ASX:IDT) Limited, Cynata Limited (ASX:CYP), Calzada Limited (now Polynovo Limited), Biolife Limited (now Immugene
ASX:IMU, Director and Chairman of Regeneus Limited (ASX:RGS), Director and Chairman of Oncosil Medical Limited (ASX:OSL) and Director
and Chairman of ResApp Limited (ASX:RAP). Roger Aston is also currently the Executive Chairman of Pharmaust Ltd (ASX:PAA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><B>Peter Anastasiou </B>has
been a member of our board of directors and our Executive Vice Chairman since May 2015. Mr. Anastasiou&rsquo;s involvement with
Immuron commenced in May 2013 following his substantial underwriting support of the Company&rsquo;s Renounceable Rights Issue,
which was surpassed by his further funding support of the $9.66M capital raising in February 2014 resulting in an ownership of
approx. 15% of the Company via his associated investment funds. Mr. Anastasiou is an entrepreneur and investor with extensive
experience in business both in Australia and overseas. Mr. Anastasiou was the founding Chairman of the ACSI Group of Companies,
which has owned and managed successful consumer companies such as SABCO, Britex Carpet care, Rug Doctor and Crystal Clear. Mr.
Anastasiou also has a number of philanthropic interests including being a patron of the Identity Theatre for men, a prior board
member and supporter of the Indigenous Eye Health Unit at Melbourne University, a supporter of the John Fawcett Foundation in
Bali, and a founding investor and Director of Melbourne Victory Football Club. Mr. Anastasiou is the brother of Stephen Anastasiou.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>Daniel Pollock
</I></B>has been a member of our board of directors since October 2012. Mr. Pollock is a lawyer admitted in both Scotland and
Australia and holding Practicing Certificates in both Jurisdictions. He is sole practitioner in his own legal firm based in Melbourne,
Australia which operates internationally and specializes in commercial law. Mr Pollock is Chairman and Company Secretary of Amaero
Pty Ltd, a company established to commercialize laser based additive manufacturing emerging from Monash University. He is also
Executive Director and co-owner of Great Accommodation P/L a property management business operating in Victoria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>Stephen Anastasiou
</I></B>has been a member of our board of directors since May 2013. Mr. Anastasiou has over 20 years&rsquo; experience in general
management, marketing and strategic planning within the healthcare industry. His breadth of experience incorporates medical diagnostics,
pharmaceuticals, hospital, dental and OTC products, with companies including the international pharmaceutical company Bristol
- Myers Squibb. While working with KPMG Peat Marwick as a management consultant, Mr. Anastasiou has previously led project teams
in a diverse range of market development and strategic planning projects in both the public and private sector. He is also a director
and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and
funds management. Mr. Anastasiou is the brother of Peter Anastasiou.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B><I>Thomas Liquard
</I></B> has been our Chief Executive Officer since 2015. Mr. Liquard has held various product development and leadership roles
with large pharma and biotech companies. From 2013 to 2014, Mr. Liquard was Chief Operating Officer and later Chief Executive
Officer of Australian Biotech Company Alchemia where he led all major development and corporate development activities. Prior
to joining Alchemia from 2013 to 2014 Mr. Liquard was employed by Pfizer in New York for 7 years where he held various senior
commercial positions in business and portfolio development. Mr Liquard spent three years as a key member of Pfizer's Established
Products U.S. brands P&amp;L Leadership Team where he engineered the groups $700M acquisition of Next Wave Pharmaceuticals, Inc.
(NextWave).&nbsp; Mr. Liquard led the pre and post-acquisition integration efforts of Next Wave into the existing Pfizer business.
The development products acquired with the NextWave acquisition are now approved and generate more than $250M in annual sales
in the U.S. Mr. Liquard holds an MBA from Columbia Business School and a Bachelor of Science Degree from the University of Southern
California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B><I>Dr. Jerry Kanellos
</I>(PhD) </B>has been our Chief Operating and Scientific Officer since July 2015. Dr. Jerry Kanellos has over twenty five years&rsquo;
experience in the pharmaceutical and biotechnology industry, and has held leadership roles in executive management, business development,
project management, intellectual property portfolio management research and development. From 2008 until 2012, Dr. Kanellos was
the Chief Operating Officer of TransBio Limited where he was responsible for the strategic identification, development and maintenance
of commercial partnerships globally, along with development, management and maintenance responsibility for the intellectual property
portfolio, research and development and technology transfer. Prior to this, Dr. Kanellos work for five years as a consultant to
the biotechnology industry and has provided development and commercialization strategies for various bodies including academic
institutes, private and publicly listed companies and government departments both national and international. He has also been
involved in the establishment and management of several startup biotechnology companies. During his ten years tenure in research
and development at CSL Limited, a global specialty biotherapeutics company that develops and delivers innovative biotherapies,
Dr. Kanellos gained considerable experience in the international drug development process, formulation development through to
pharmaceutical scale up and cGMP manufacture successfully leading the Chemistry Manufacturing and Controls (CMC) programs for
the approval, manufacture and launch of several products. Dr. Kanellos holds a PhD in Medicine from the University of Melbourne.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B><I>Dr. Dan Peres
</I>(MD)</B> has served in various clinical and medical managerial roles in pharmaceutical and medical device companies such as
Exalenz Bioscience, CarboFix Orthopedics Ltd, NMB Medical Applications Ltd, ByPass Makafim Ltd, IOPtima Ltd and NovoNordisk Israel.
In addition, Dr. Peres has been responsible for operational, marketing and business development activities throughout his career
in the life sciences industry. Dr. Peres began his career as a physician and medical director in the Israel army. Dr. Peres&rsquo;
expertise lies with medical strategy, research and development, and the management of clinical studies and other laboratory processors.
He has extensive knowledge of the leading International Centers for Liver Disease and established relationships with key Opinion
leaders, including those currently participating in Immuron&rsquo;s NASH and ASH trials. Dr. Peres has been a certified physician
since 2002 when he graduated from the Sackler School of Medicine at Tel-Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B><I>Phillip Hains
</I></B>has been our joint Chief Financial Officer (CFO) and Company Secretary since April 2013. Mr Hains is a Chartered Accountant
and specialist in the public company environment. He has served the needs of a number of public company boards of directors and
related committees. He has over 20 years&rsquo; experience in providing accounting, administration, compliance and general management
services. He holds a Masters of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered
Accountants of Australia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B><I>Peter Vaughan
</I></B>has been our joint Chief Financial Officer (CFO) and Company Secretary since April 2013. Mr Vaughan is a Chartered Accountant
who has worked in the listed company environment for 13 years across a number of industries. He has served on, and provided accounting,
administration, compliance and general management services to a number of private, not-for-profit, and listed public company boards
of directors and related committees. Mr Vaughan is also currently studying a Senior Executive Masters of Business Administration
at Melbourne University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B><I>Professor Ravi
Savarirayan </I></B>was appointed as a Non-Executive Director of the Company on April 1, 2017. He is a consultant clinical geneticist
at the Victorian Clinical Genetics Services since August 1999, as well as Professor and Research Group Leader (Skeletal Biology
and Disease) at the Murdoch Children&rsquo;s Research Institute since September 2000. Mr. Savarirayan is a founding member of
the Skeletal Dysplasia Management Consortium&nbsp; since January 2011 and has been the Chair of the Specialist Advisory Committee
in Clinical Genetics, Royal Australasian College of Physicians since February 2009&nbsp;. He was president of the International
Skeletal Dysplasia Society from July 2009 to June 2011&nbsp;and has been an invited member of several International Working Committees
on Constitutional Diseases of Bone. Mr. Savarirayan&rsquo;s primary research focus is on inherited disorders of the skeleton causing
short stature, arthritis and osteoporosis. He has published over 150 peer-reviewed articles, collaborating with peers from over
30 countries, and has been on the editorial board of Human Mutation since January 2009, European Journal of Human Genetics since
July 2007, American Journal of Medical Genetics since December 2011 and Journal of Medical Genetics since June 2005.&nbsp; Mr.
Savarirayan received his MBBS from the University of Adelaide in 1990 and became a fellow of the Royal Australasian College of
Physicians in December 1997. He was certified as a specialist in clinical genetics from the Human Genetics Society of Australasia
in 1998 and received his Doctor of Medicine from the University of Melbourne in 2004, for his thesis &ldquo;Clinical and Molecular
Studies in the Osteochondrodysplasias.&rdquo;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board of Directors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our board of directors
currently consists of five members. Directors are elected at each annual general meeting of our shareholders and serve until their
successors are elected or appointed, unless their office is earlier vacated. We believe that each of our directors has relevant
industry experience. The membership of our board of directors is directed by the following requirements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         Constitution specifies that there must be a minimum of three directors and a maximum
                                         of 10, and our board of directors may determine the number of directors within those
                                         limits;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                         set forth in our Board Charter, the membership of the board of directors should consist
                                         of a majority of independent directors who satisfy the criteria recommended by the Australian
                                         Securities Exchange (ASX) Corporate Governance Principles and Recommendations of the
                                         Australian Securities and Investments Commission (ASIC);</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         Chairman of our Board should be an independent director who satisfies the criteria for
                                         independence recommended by the ASX Corporate Governance Principles and Recommendations;
                                         and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         board of directors should, collectively, have the appropriate level of personal qualities,
                                         skills, experience, and time commitment to properly fulfill its responsibilities or have
                                         ready access to such skills where they are not available.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our board of directors
has delegated responsibility for the conduct of our businesses to the Chief Executive Officer, but remains responsible for overseeing
the performance of management. Our board of directors has established delegated limits of authority, which define the matters
that are delegated to management and those that require board of directors approval. Under the Corporations Act, at least two
of our directors must be resident Australians. None of our directors have any service contracts with Immuron that provide for
benefits upon termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><B><I>Committees </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">To assist our board
of directors with the effective discharge of its duties, it has established a Remuneration and Nomination Committee and an Audit
and Risk Committee, which committees operate under a specific charter approved by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B><I>Remuneration
and Nomination Committee</I></B>&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The members of our
Remuneration and Nomination Committee are Roger Aston and Daniel Pollock, each of whom our board of directors has determined meets
the criteria for independence under NASDAQ Listing Rule 5605(a)(2). Dr. Aston acts as chairman of the committee. The committee&rsquo;s
role involves:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">identifying,
                                         evaluating and recommending qualified nominees to serve on our board of directors; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">evaluating,
                                         adopting and administering our compensation plans and similar programs advisable for
                                         us, as well as modifying or terminating existing plans and programs; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing
                                         policies with respect to equity compensation arrangements; and </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">overseeing,
                                         reviewing and reporting on various remuneration matters to our board of directors. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><B><I>Audit and Risk Committee</I></B>&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The members of our
Audit and Risk Committee are Daniel Pollock and Roger Aston, each of whom our board of directors has determined meets the criteria
for independence of audit committee members set forth in Rule 10A-3(b)(1) under the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Exchange Act of 1934, as amended, or the Exchange Act, and the applicable rules of the NASDAQ Capital Market. Each member of our
audit committee meets the financial literacy requirements of the listing standards of the NASDAQ Capital Market. Daniel Pollock
acts as the chairman of the audit committee. The principal duties and responsibilities of our audit committee include, among other
things: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
                                         and reporting on various auditing and accounting matters to our board of directors, including
                                         the selection of our independent accountants, the scope of our annual audits, fees to
                                         be paid to the independent accountants, the performance of our independent accountants
                                         and our accounting practices;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
                                         and reporting on various risk management matters to our board of directors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering
                                         and approving or disapproving all related-party transactions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                         our annual and semi-annual financial statements and reports and discussing the statements
                                         and reports with our independent registered public accounting firm and management;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                         and pre-approving the engagement of our independent registered public accounting firm
                                         to perform audit services and any permissible non-audit services;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
                                         the performance of our independent registered public accounting firm and deciding whether
                                         to retain their services; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                         procedures for the receipt, retention and treatment of complaints received by us regarding
                                         financial controls, accounting or auditing matters.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Conduct </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We have established
a Corporate Governance Statement, which includes a code of conduct. Our Corporate Governance Statement, sets out the standards
of behavior that apply to every aspect of our dealings and relationships, both within and outside Immuron. The following standards
of behavior apply to all directors, executive officers and employees of Immuron:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
                                         with all laws that govern us and our operations;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">act
                                         honestly and with integrity and fairness in all dealings with others and each other;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoid
                                         or manage conflicts of interest;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
                                         our assets responsibly and in the best interests of Immuron; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                         responsible and accountable for our actions.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The Code of Conduct
is available on our website at Immuron.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Remuneration </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our remuneration
policy ensures that directors and senior management are appropriately remunerated having regard to their relevant experience,
their performance, the performance of the Company, industry norms and standards and the general pay environment as appropriate.
The Remuneration Policy has been established to enable the Company to attract, motivate and retain suitably qualified directors
and senior Management who will create value for shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our Remuneration
Policy is not directly based on our earnings. Our earnings have remained negative since inception due to the nature of the Company.
Shareholder wealth reflects this speculative and volatile market sector. No dividends have ever been declared by us. We continue
to focus on the research and development of our intellectual property portfolio with the objective of achieving key development
and commercial milestones in order to add further shareholder value</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The Company's performance
over the previous five financial years is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">Financial Year</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">Net Loss</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">Share price at year end</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">AUD$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">AUD$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; text-align: center">2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">7,068,767</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">0.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,691,820</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,495,069</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,539,117</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.16</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,297,520</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.72</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,595,179</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.52</TD><TD STYLE="padding-bottom: 1pt; text-align: left">*</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Share prices have been adjusted to reflect a 40:1 capital
consolidation which was completed in November 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Options: NewSection; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-Executive Director Remuneration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Objective</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Remuneration Policy ensures that Non-Executive
Directors are appropriately remunerated having regard to their relevant experience, individual performance, the performance of
the Company, industry norms/standards and the general pay environment as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Structure</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's Constitution and the ASX
Listing Rules specify that the aggregate remuneration of Non-Executive Directors shall be determined from time to time by a Meeting
of Shareholders. An amount (not exceeding the amount approved at the Shareholders Meeting) is determined by the Board and then
divided between the Non-Executive Directors as agreed. The latest determination was at the Shareholders Meeting held on November
8, 2005 when shareholders approved the aggregate maximum sum to be paid or provided as remuneration to the Directors as a whole
(other than the Managing Director and Executive Directors) for their services as $350,000 per annum. This compensation is cashed
based and does not include stock based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the year ended June 30, 2016, the Non-Executive
Directors were remunerated an aggregate AUD$1,471,938 per annum, including superannuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manner in which the aggregate remuneration
is apportioned amongst Non-Executive Directors is reviewed periodically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board is responsible for reviewing
its own performance. Board, and Board committee performance, is monitored on an informal basis throughout the year with a formal
review conducted during the financial year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No retirement benefits are payable other than statutory superannuation,
if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Director and Executive Officer
Remuneration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Objective</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our policy ensures that Executive Directors
are appropriately remunerated having regard to their relevant experience, individual performance, the performance of the Company,
industry norms/standards and the general pay environment as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Structure</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Non-Executive Directors are responsible
for evaluating the performance of the Chief Executive Officer (CEO) who in turn evaluates the performance of the other Senior
Executives. The evaluation process is intended to assess the Company's business performance, whether long-term strategic objectives
are being achieved and the achievement of individual performance objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The performance of the CEO and Senior
Executives are monitored on an informal basis throughout the year and a formal evaluation is performed annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.65pt; text-align: justify; text-indent: -70.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.65pt; text-align: justify; text-indent: -70.65pt"><U>Fixed
Remuneration</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.65pt; text-align: justify; text-indent: -70.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.7pt">Executives' fixed
remuneration comprises salary and superannuation and is reviewed annually by the CEO, and in turn, the Remuneration Committee.
This review takes into account the Executives' experience, performance in achieving agreed objectives and market factors as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Variable Remuneration - Short Term
Incentive Scheme</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executives may be entitled to receive
a combination of short term incentive (STI) and long term incentive (LTl)&rsquo;s as part of their total remuneration if they
achieve certain performance indicators as set by the Board. These STI /LTI may be paid either by cash, or a combination of cash
and the issue of equity in the Company, at the determination of the Board and Remuneration Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Remuneration Committee would approve
the issue of bonuses following the recommendations of the CEO in the annual review of the performance of the Executives, and the
Company as a whole, against agreed Key Performance Indicators (KPI&rsquo;s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Variable Remuneration - Long Term Incentive
Scheme</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executives may also be provided with longer-term
incentives through the Company's Employee Share and Option Plan (ESOP), that was approved by shareholders at the Annual General
Meeting held on November 13, 2014. The aim of the ESOP is to allow the Executives to participate in, and benefit from, the growth
of the Company as a result of their efforts and to assist in motivating and retaining those key employees over the long term.
Continued service is the condition attached to the vesting of the options. The Board at its discretion determines the total number
of options granted to each Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>Details of Remuneration for fiscal 2016</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>(in AUD$&rsquo;s)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Short&nbsp;term</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Post&nbsp;employment</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Equity</FONT><BR>
    <FONT STYLE="font-size: 8pt">awards</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">%&nbsp;of&nbsp;remuneration</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Salary</FONT><BR> <FONT STYLE="font-size: 8pt">and</FONT><BR>
    <FONT STYLE="font-size: 8pt">Fees</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Cash</FONT><BR> <FONT STYLE="font-size: 8pt">bonus</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Non-</FONT><BR>
    <FONT STYLE="font-size: 8pt">monetary</FONT><BR> <FONT STYLE="font-size: 8pt">benefits</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Superannuation</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Termination</FONT><BR>
    <FONT STYLE="font-size: 8pt">benefits</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Shares/</FONT><BR> <FONT STYLE="font-size: 8pt">Options</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">consisting</FONT><BR>
    <FONT STYLE="font-size: 8pt">of&nbsp;options</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Performance</FONT><BR>
    <FONT STYLE="font-size: 8pt">based</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">Directors:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 28%; text-align: left"><FONT STYLE="font-size: 8pt">Dr. Roger Aston</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">62,500</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">5,938</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">730,125</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">798,563</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">91</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Mr. Daniel Pollock</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">45,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,275</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">292,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">341,325</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">86</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Mr. Stephen Anastasiou</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">40,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">292,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">332,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">88</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Mr. Peter Anastasiou</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">40,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">292,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">332,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">88</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">Key Management Personnel:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Mr. Thomas Liquard</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">287,485</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">287,485</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Dr. Jerry Kanellos</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">149,744</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">14,226</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">163,970</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Dr. Leearne Hinch</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">27,785</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,565</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">29,350</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">652,514</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">26,004</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1,606,275</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">2,284,793</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements with Executive Officers </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The Company has contracts
with all of its senior management and employees, but does not have any employment contracts with any of its directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Thomas Liquard</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 24, 2015,
we entered into an Executive Service Agreement (the &ldquo;Liquard Agreement&rdquo;) with Thomas Liquard, pursuant to which Mr.
Liquard is serving as the Company&rsquo;s Chief Executive Officer. The term of the Liquard Agreement is for three years unless
terminated earlier in accordance with the Liquard Agreement. Pursuant to the Liquard Agreement, the Company will pay Mr. Liquard
AUD$300,000 per annum. The Company also pays up to AUD$15,000 for Mr. Liquard&rsquo;s health insurance. Under the Liquard Agreement,
if the Short-Term Incentive Milestones (as defined below) are achieved within the required time frame, Mr. Liquard will be paid
a AUD$80,000 bonus payable in ordinary shares of the Company at an issue price determined by the seven day volume weighted average
price (&ldquo;VWAP&rdquo;) immediately prior to the issuance. If all of the Long Term Incentive Milestones (as defined below)
are achieved within the required timeframe, Mr. Liquard will be issued 1,000,000 shares over ordinary shares, subject to shareholder
approval.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Short-Term Incentive Milestones are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1) AUD$5 million of Travelan Sales worldwide,
AUD$1 million of which must have been earned from China; and</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2) A successful NASDAQ listing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3) A successful capital raise of $10 million
(or AUD$ equivalent) either in conjunction to, or separate from the NASDAQ listing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Long-Term Incentive Milestones are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1) A Company listed market capitalization
value of $100 million;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2) AUD$10 million of Travelan Sales worldwide;
and</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3) The successful execution of a licensing
agreement the parameters of which are to be agreed between the Board and Mr. Liquard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If a change of control
of the Company occurs within the first twelve months of the effective date of the Liquard Agreement, the Short-Term Incentive
Milestones shall be automatically deemed to have been achieved. If a change of control of the Company occurs twelve months after
the effective date, but prior to the first three year anniversary of the effective date, the Long-Term Incentive Milestones shall
be automatically deemed to have been achieved.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At any time either
the Company or Mr. Liquard can terminate the Liquard Agreement without cause on six months&rsquo; written notice. Subject to the
applicable rules and laws (including the rules of the ASX Limited), the Company may elect to pay six months base salary and superannuation
in lieu of notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also terminate the Liquard
Agreement if (i) within twelve months of the effective date Mr. Liquard has not achieved two of the three Short-Term Incentive
Milestones or (ii) within three years of the effective date Mr. Liquard has not achieved two of the three Long-Term Incentive
Milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Jerry Kanellos</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">On July 23, 2015,
we entered into an Executive Service Agreement (the &ldquo;Kanellos Agreement&quot;) with Dr. Jerry Kanellos, pursuant to which
Dr. Kanellos is serving as the Company&rsquo;s Chief Operating &amp; Scientific Officer. Pursuant to the Kanellos Agreement, the
Company will pay Dr. Kanellos AUD$160,000 per annum. Although the Kanellos Agreement provides that the Board will consider a short
and long term share and/or share option incentive package for Dr. Kanellos after twelve months of continuous employment, subject
to any applicable shareholder approval, no such term share and/or share option incentive package has been established as of the
date hereof. The Company&rsquo;s Board will consider a short and long term share and/or share option incentive package for Dr.
Kanellos after twelve months of continuous employment, subject to any applicable shareholder approval. The Company or Dr. Kanellos
may terminate the Kanellos Agreement without cause on thirty days&rsquo; written notice. Subject to applicable laws and rules,
the Company may elect to pay Dr. Kanellos thirty days&rsquo; base salary in lieu of notice. The Company may also terminate the
Kanellos Agreement for Cause (as defined in the Kanellos Agreement). Although the Kanellos Agreement provides that Dr. Kanellos&rsquo;
remuneration will be reviewed six months from the effective date of the Kanellos Agreement and every six months thereafter, no
changes have been made to Dr. . Kanellos&rsquo; remuneration as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dan Peres</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 29, 2017, we
entered into a subsequent Consultancy Agreement (the &ldquo;Peres Agreement&quot;) with Dan Peres following our agreement with
Mr. Peres dated April 1, 2015, which terminated on April 30, 2017.. Pursuant to the terms of the Peres Agreement, the Company
will provide the Services (defined hereafter). Services shall include: oversight of the clinical trial of IMM-124E-2001 for treatment
of NASH; and active involvement in all other Company activities related to pipeline products in the United States and elsewhere.
The term of the Peres Agreement commenced on March 29, 2017 and will terminate on April 30, 2018. The Company shall pay Dr. Peres
$16,667 per month and Dr. Peres is entitled to receive 1,000,000 options to purchase the Company&rsquo;s ordinary shares at AUD$0.500
per ordinary share, at any time until October 1, 2018. The Peres Agreement may be terminated in writing by either the Company
or Dr. Peres at any time with three months&rsquo; notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employee Share Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Employee Share </U></I><U>&amp; <I>Option Plan (ESOP)</I></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">At the General Meeting
of shareholders held on 13 November 2014 shareholders approved the rules of the ESOP and authorized directors to issue options
at their discretion in accordance with the rules from time to time. Under the rules of the ESOP the Board may offer options to
key management staff and consultants and in special circumstances may provide financial assistance to an entitled option holder
to assist in the exercise of the ESOP options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The aggregate number
of shares that may be issued upon the exercise of the ESOP options, together with all other share purchase plans for eligible
persons, shall not at any time exceed 5% of the total number of the Company's ordinary shares on issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">During the year no
options were issued under the rules of the ESOP to any Directors or Key Management Personnel:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms and conditions of each grant
of options affecting remuneration in the current or future reporting period are as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Options</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vesting
                                         </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conditions</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry
    Date</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUD$</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">4
    Dec 2013</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">1,000,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 19%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Nil</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 19%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">4
    Dec 2016</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">AUD$</FONT></TD><TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">0.456</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">27
    Nov 2015</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">6,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">(i)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">27
    Nov 2019</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">AUD$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">0.500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">To be issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(ii)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1 Oct 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) The options with an issue date of
27 November 2015, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of AUD$0.500. Options
vest based on month of continuous services completed as per the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000,000
                                         Options which will vest on 6<SUP>th</SUP> August 2016 &ndash; subject to completion of
                                         12 months&rsquo; continuous services as a Director of the Company.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000,000
                                         Options which will vest on 6<SUP>th</SUP> August 2017 &ndash; subject to completion of
                                         24 months&rsquo; continuous services as a Director of the Company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The assessed fair
value of options granted to personnel at their grant date is allocated equally over the period from grant date to vesting date,
and the amount for the 2016 financial year is included in the remuneration table as set out above. Fair values at grant date are
determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the
impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend
yield and the risk-free interest rate for the term of the option. The expected price volatility is based on the historic volatility
(based on the remaining life of the options), adjusted for any expected changes to future volatility due to publically available
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">(ii)&nbsp;
Pursuant to an agreement entered between the Company and a consultant on March 29, 2017, the Company granted 1,000,000 options,
which vested immediately upon execution of the agreement<I>; provided, </I>however, these options have not yet been issued. The
options entitle the consultant to purchase one ordinary share of Immuron at an exercise price of AUD$0.500 on or before October
1, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">All options granted
under the ESOP are deemed to be granted for no consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_019"></A><B>PRINCIPAL SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The following table
and accompanying footnotes present certain information regarding the beneficial ownership of our ordinary shares based on 103,641,417
ordinary shares outstanding as of June 7, 2017 by:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                         person known by us to be the beneficial owner of more than 5% of our ordinary shares;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                         of our directors and executive officers individually; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24.5pt"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                         of our directors and executive officers as a group.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Beneficial ownership
is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he,
she or it possesses sole or shared voting or investment power of that security, including options that are exercisable within 60&nbsp;days
of June 7, 2017. Information with respect to beneficial ownership has been furnished to us by each director, executive officer,
or 5% or more shareholder, as the case may be. Ordinary shares subject to options currently exercisable or exercisable within 60
days of June 7, 2017 are deemed to be outstanding for computing the percentage ownership of the person holding these options and
the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage
of any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Ordinary shares subject
to options currently exercisable or exercisable within 60 days of June 7, 2017 are deemed to be outstanding for computing the percentage
ownership of the person holding these options and the percentage ownership of any group of which the holder is a member, but are
not deemed outstanding for computing the percentage of any other person.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Based on information
known to us, as of June 7, 2017, we had 6 shareholders in the United States. These shareholders held an aggregate of 256,011 of
our outstanding ordinary shares, or approximately 0.24% of our outstanding ordinary shares. A large number of our ordinary shares
are held by nominee companies so we cannot be certain of the identity of those beneficial owners.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Unless otherwise
indicated, to our knowledge each shareholder possesses sole voting and investment power over the ordinary shares listed subject
to community property laws, where applicable. None of our shareholders have different voting rights from other shareholders. Unless
otherwise indicated, the address for each of the persons listed in the table below is Immuron Limited, Suite 1, 1233 High Street,
Armadale, Victoria, Australia 3143.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Ordinary Shares</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Owned Prior to</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Offering</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Ordinary Shares</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Owned After the</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Offering<SUP>(1)</SUP></B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Shareholder&nbsp;Name&nbsp;and&nbsp;Address</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 67%"><FONT STYLE="font-size: 10pt"><B><I>5% Shareholders</I></B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9pt">Grandlodge</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9pt">Capital Pty Ltd. (2)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unit 10, 25-37 Chapman Street<BR>
        Blackburn, North VIC 3130</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,663,364</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13.18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,663,364</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.67</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inverarey Pty Ltd and Associates (3)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in">Lvl 4, 349 Collins Street<BR>
        Melbourne, VIC 3000</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,875,567</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.67</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,875,567&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4.59</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authentics Australia Pty. Ltd. (4)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">24 Simla Street,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mitcham, VIC. 3132</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,249,998</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9.89</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,249,998</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.01</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Mr. Chris Retzos</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,620,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.42</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,620,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4.39</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B><I>Officers and Directors</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Dr. Roger Aston</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">607,116</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">607,116&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Mr. Peter Anastasiou(2)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,663,364</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13.18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,663,364&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.67</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Mr. Daniel Pollock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">300,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">300,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Mr. Stephen Anastasiou</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,067,857</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.92</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,067,857&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.18</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Mr. Thomas Liquard</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">134,694</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">134,694&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dr. Jerry Kanellos (PhD)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Dr. Dan Peres (MD)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">79,899</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">79,899&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Mr. Phillip Hains</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">816,804</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">816,804&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Prof. Ravi Savarirayan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Mr. Peter Vaughan</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Officers and directors as a group (10 persons)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">19,669,734</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">18.98</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">19,669,734</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">15.36</FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                         beneficial ownership of less than 1% of the outstanding ordinary shares of Immuron.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0">Based on 128,041,417 ordinary shares outstanding after the offering, including shares underlying ADSs.
Assumes that the underwriters will not exercise their option to purchase additional ADSs and excludes ordinary shares underlying
the Warrants.</P></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
                                         Anastasiou is the Chairman of Grandlodge Capital Pty Ltd. (&ldquo;Grandlodge&rdquo;)
                                         and in such capacity has voting and dispositive power over the securities held by Grandlodge.</FONT></TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ian
                                         Pattison is a director of <FONT STYLE="font-size: 10pt">Inverarey Pty Ltd and Associates
                                         (&ldquo;Inverarey&rdquo;) and in such capacity has voting and dispositive power over
                                         the securities held by Inverarey</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Kenneth
                                         Biddick <FONT STYLE="font-size: 10pt">is a director of Authentics Australia Pty. Ltd.
                                         (&ldquo;Authentics&rdquo;) and in such capacity has voting and dispositive power over
                                         the securities held by Authentics.</FONT></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">To our knowledge,
there have not been any significant changes in the ownership of our ordinary shares by major shareholders over the past three
years (which is based upon substantial shareholder notices filed with the ASX).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_020"></A><B>RELATED
PARTY TRANSACTIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Other than as disclosed
below, from July&nbsp;1, 2013 to December 31, 2016 we did not enter into any transactions or loans with any: (i)&nbsp;enterprises
that directly or indirectly, through one or more intermediaries, control, are controlled by or are under common control with us;
(ii)&nbsp;associates; (iii)&nbsp;individuals owning, directly or indirectly, an interest in our voting power that gives them significant
influence over us, and close members of any such individual&rsquo;s family; (iv)&nbsp;key management personnel and close members
of such individuals&rsquo; families; or (v)&nbsp;enterprises in which a substantial interest in our voting power is owned, directly
or indirectly, by any person described in (iii)&nbsp;or (iv)&nbsp;or over which such person is able to exercise significant influence.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The transactions with related parties are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the fiscal year
    ended<BR> June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: justify">Short-term Loan from Grandlodge Capital Pty
    Ltd:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Grandlodge Capital Pty Ltd (Grandlodge) is an entity part-owned and operated by Immuron Directors
    Peter and Stephen Anastasiou.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">Mr. David Plush is also an owner of Grandlodge, and its associated
                                    entities</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On 1<SUP>st</SUP>
    December 2015 and on 6th June 2016, Immuron executed a short-term funding agreement with Grandlodge for a principle amount
    of AUD$1,000,000 (interest rate of 13%) and AUD$750,000 (interest rate of 15%), respectively, plus interest charges. </FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">The short-term funding is a cash advance against the anticipated refund Immuron will receive
    from the Australian Taxation Office under the Research and Development Income Tax Concession Incentive for the Company's eligible
    R&amp;D expenditure incurred for financial year of 2015 and 2016.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan from 1st December
    2015 has been repaid to Grandlodge on 10<SUP>th</SUP> February 2016. The June 2016, loan from Grandlodge, plus applicable
    fees, will be repaid by the Company upon receipt of the FY2016 R&amp;D Tax Incentive refund which was received in November
    2016. Interest paid was approximately $43,000 in 2016 and loan fees paid to Grandlodge were approximately $20,000 and $15,000
    in 2016, respectively.</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Loans from October and December 2013 were repaid in fiscal 2014. These
    loan agreements were for a period of 6 months or the receipt of the R&amp;D Tax Incentive Refund if sooner, bearing an interest
    rate of 18% per annum. Interest paid was approximately $15,000 in 2014.</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-weight: bold; text-align: left; padding-bottom: 1pt">Total paid by the Company to Grandlodge Pty
    Ltd during the year:</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,043,863</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">435,495</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">At year end the Company owed Grandlodge Pty Ltd:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">772,397</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">The Company fully repaid the loan in the amount of approximately
                                    $772,000 outstanding as of June 30, 2016 to Grandlodge.</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the fiscal year
    ended<BR> June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-weight: bold; text-decoration: underline; text-align: justify">Services rendered by Grandlodge
    Pty Ltd to Immuron Ltd:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Grandlodge, and its associated entities, are marketing, warehousing and distribution logistics
    companies.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Commencing on 1 June 2013, Grandlodge was verbally contracted on terms to provide warehousing,
    distribution and invoicing services for Immuron&rsquo;s products for AUD$70,000 per annum.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">These fees will be payable in new fully paid ordinary shares in Immuron Limited at a set price
    of AUD$0.16 per share representing Immuron Limited&rsquo;s share price at the commencement of the verbal agreement.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">The shares to be issued to Grandlodge, or its associated entities, as compensation in lieu
    of cash payment for the services rendered under this verbal agreement have been subject to the approval of Immuron shareholders
    at Company shareholder meetings held over the past 18 months.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Grandlodge will also be reimbursed in cash for all reasonable costs and expenses incurred
    in accordance with their scope of works under the verbal agreement, unless both parties agree to an alternative method of
    payment.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">The verbal agreement is cancellable by either party upon providing the other party with 30
    days written notice of the termination of the agreement.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Service fees paid to Grandlodge Pty Ltd during the year through the issue
    of equity:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">87,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75,833</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total paid by the Company to Grandlodge Pty Ltd during
    the year:</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">87,500</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">11,667</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">75,833</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">At year end the Company owed Grandlodge Pty Ltd:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the fiscal year
    ended<BR> June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-weight: bold; text-decoration: underline; text-align: justify">Premises Rental services received
    from Wattle Laboratories Pty Ltd to Immuron Ltd:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Wattle Laboratories Pty Ltd (Wattle) is an entity part-owned and operated by Immuron Directors
    Peter and Stephen Anastasiou.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Commencing on 1 January 2016, Immuron executed a Lease Agreement with Wattle whereby Immuron
    will lease part of their Blackburn office facilities for Immuron's operations at a rental rate of AUD$38,940 per annum, payable
    in monthly installments.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">The lease is for a 3 year term with an additional 3 year option period.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">The lease is cancellable by either party upon 6 months written notice of termination of the
    agreement.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Rental fees paid to Wattle Laboratories Pty Ltd during the year through
    the issue of equity:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total paid by the Company to Wattle Laboratories Pty
    Ltd during the year:</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">19,470</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">At year end the Company owed Wattle Laboratories Pty Ltd:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,417</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>


<!-- Field: Page; Sequence: 102; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 9, 2017, the Company executed an R&amp;D Tax
        Incentive Prepayment Loan Facility Agreement with Grandlodge Capital Pty Ltd which is related party of an Immuron Director
        and major shareholder. The Company received a cash advance of $500,000 which is secured against the Company&rsquo;s anticipated
        FY2017 Research &amp; Development R&amp;D Tax Incentive cash refund. The loan has an interest rate of 15% per annum and
        a commitment fee of 4% . Immuron must repay the borrowed amount plus applicable fees and applicable interest upon the
        earlier of:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(a) The date Borrower receives the payment of Offsets
        under the R&amp;D Incentive Program relating to the relevant fiscal year and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(b) Successful completion of NASDAQ IPO capital raising;
        and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) Termination Date (December
        31, 2017).</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>For the six months ended December 31, 2016:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Short-Term Loan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Grandlodge Capital Pty Ltd (Grandlodge)
is an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou, and owns a top 20 shareholding in Immuron
Limited. On 6th June 2016, Immuron executed a short-term funding agreement with Grandlodge for a principal amount of AUD$750,000,
plus interest charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The short-term funding is a cash advance
against the anticipated refund Immuron will receive from the Australian Taxation Office under the Research and Development Income
Tax Concession Incentive for the Company's eligible R&amp;D expenditure incurred for financial year of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Loan has been repaid to Grandlodge on
2nd December 2016. Interest expense for the six months ended December 31, 2016 was AUD $47,158.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Service rendered by Grandlodge Pty
Ltd to Immuron Ltd</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Grandlodge, and its associated entities,
are marketing, warehousing and distribution logistics. Mr David Plush is also an owner of Grandlodge, and its associated entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Commencing on 1st June 2013, Grandlodge
was verbally contracted to provide warehousing, distribution and invoicing services for Immuron&rsquo;s products for AUD$70,000
per annum. These fees will be payable in new fully paid ordinary shares in Immuron Limited at a set price of AUD$0.16 per share
representing Immuron Limited&rsquo;s share price at the commencement of the verbal agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The shares to be issued to Grandlodge,
or its associated entities, as compensation in lieu of cash payment for the services rendered under this verbal agreement have
been subject to the approval of Immuron shareholders at Company shareholder meetings held over the past 18 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Grandlodge will also be reimbursed in
cash for all reasonable costs and expenses incurred in accordance with their scope of works under the verbal agreement, unless
both parties agree to an alternative method of payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The verbal agreement is cancellable by
either party upon providing the other party with 30 days written notice of the termination of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">During the six months period ended December
31, 2016, an amount of AUD$70,000 was charged to the Group&rsquo;s expenses in relation to service rendered by Grandlodge. This
amount remained payable as at the period end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Premises Rental services received from
Wattle Laboratories Pty Ltd to Immuron Ltd:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Wattle Laboratories Pty Ltd (Wattle) is
an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. Commencing on 1st January 2016, Immuron executed
a Lease Agreement with Wattle whereby Immuron will lease part of their Blackburn office facilities for Immuron's operations at
a rental rate of AUD$38,940 per annum, payable in monthly installments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The lease is for a 3 year term with an
additional 3 year option period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The lease is cancellable by either party
upon 6 months written notice of termination of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">During the six months period ended December
31, 2016, an amount of AUD$19,470 (excluding GST) was charged to the Group&rsquo;s expenses in relation to service rendered by
Wattle. This amount was paid during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other related party transactions:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">On August 25<SUP>th</SUP> on behalf of
Immuron, Grandlodge purchased US$1,500,000 at the cost of AUD$1,968,762. On the same day Immuron paid Grandlodge AUD$1,968,762
to settle this transaction. On Sept 12<SUP>th</SUP> Grandlodge returned the USD$1,500,000 purchase to Immuron. Grandlodge received
no financial gains or benefits from this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_021"></A><FONT STYLE="color: Black"><B>DESCRIPTION
OF SHARE CAPITAL </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>General
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
following description of our ordinary shares is only a summary. We encourage you to read our Constitution, which is included as
an exhibit to this registration statement, of which this prospectus forms&nbsp;a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We are a public company
limited by shares registered under the Corporations Act by the Australian Securities and Investments Commission, or ASIC. Our corporate
affairs are principally governed by our Constitution, the Corporations Act and the ASX Listing Rules. Our ordinary shares trade
on the ASX, and our ADSs trade on NASDAQ.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
Australian law applicable to our Constitution is not significantly different than a U.S. company&rsquo;s charter documents except
we do not have a limit on our authorized share capital, the concept of par value is not recognized under Australian law and as
further discussed under &ldquo;&mdash;Our Constitution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Subject
to restrictions on the issue of securities in our Constitution, the Corporations Act and the ASX Listing Rules and any other applicable
law, we may at any time issue shares and grant options or warrants on any terms, with the rights and restrictions and for the
consideration that our board of directors determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
rights and restrictions attaching to ordinary shares are derived through a combination of our Constitution, the common law applicable
to Australia, the ASX Listing Rules, the Corporations Act and other applicable law. A general summary of some of the rights and
restrictions attaching to our ordinary shares are summarized below. Each ordinary shareholder is entitled to receive notice of,
and to be present, vote and speak at, general meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Changes
to Our Share Capital </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">As of December 31,
2016 and June 30, 2016, we had (i) 103,641,417 and&nbsp;78,099,646 ordinary shares outstanding, respectively and (ii)&nbsp;outstanding
options to purchase an aggregate of 34,177,523 and 9,937,629 ordinary shares, respectively at a weighted average exercise price
of AUD$0.543 and AUD$0.529, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">During the last three
and a half years, the following changes have been made to our ordinary share capital:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>During the Six Months ended December, 31 2016, the Company
issued the following securities:</U></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Details</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issue&nbsp;Price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total&nbsp;Value</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; vertical-align: top">7 July 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Right issue<SUP>*</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">18,045,512</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">7 July 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Right issue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,275,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">818,867</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top">29 September 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Right issue to oversubscribes and private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,968,916</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">992,229</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">2 December 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; vertical-align: top">Shares under ESOP &ndash; for 6 months service (vesting
    monthly)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">251,877</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.123</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,855</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">25,541,771</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,841,951</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">*As at June 30, 2016, the Company was committed
to issue 18,045,512 of ordinary shares in relation to the $4,511,378 received in capital raising. These shares were subsequently
issued to respective holders on July 7, 2016. 2,418,129 of these new fully paid ordinary shares were issued to Grandlodge on the
same terms and conditions as all other subscribers.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>During the Full Year ended 30 June 2016, the Company
issued the following securities:</U></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Date</B></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Details</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Issue
                                         Price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Total
                                         Value</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AUD$</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; width: 12%; vertical-align: top">18 Sep 2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify">Exercise of IMCAI Unlisted Options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">218,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.376</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">82,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">30 Sep 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Exercise of IMCAI Unlisted Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.376</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top">19 Oct 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Exercise of IMCAI Unlisted Options by Grandlodge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">556,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.376</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209,056</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">13 Nov 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Exercise of IMCAI Unlisted Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.376</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top">27 Nov 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue of Shares in lieu of cash payment for services as per Resolution 4 of the Annual General
    Meeting (AGM) held on 25 Nov 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">546,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">24 Feb 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue in accordance with executed funding agreement with a New York based Investment fund
    provider announced to the ASX on 17 Feb 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">294,118</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Issue Price</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total Value</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Details</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; width: 12%; vertical-align: top">24 Feb 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify">Issue of fully paid escrow shares as security for any repayment default of the
    Convertible Loan in accordance with executed funding agreement with a New York based Investment fund provider and announced
    to the ASX on 17 Feb 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.400</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">800,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">13 Apr 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue in accordance with executed funding agreement with a New York based Investment fund
    provider announced to the ASX on 17 Feb 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326,797</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top">18 Apr 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">First repayment of Convertible Note Security in accordance with executed funding agreement
    with a New York based investment fund provider announced to the ASX on 17 Feb 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">241,764</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.312</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">16 May 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Exercise of IMCAI Unlisted Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.276</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top">16 May 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Second repayment of Convertible Note Security in accordance with executed funding agreement
    with a New York based investment fund provider announced to the ASX on 17 Feb 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265,694</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.284</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">31 May 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue of Shares in lieu of cash payment for services received</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">30 Jun 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Shares to be Issued from Capital Raising as at 30 June 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">4,511,378</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt; vertical-align: top">Total 2016 Movement</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,135,414</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,233,167</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I><U>During the Full Year ended
30 June 2015, the Company issued the following securities:</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; vertical-align: top"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: Black">Issue&nbsp;Price</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: Black">Total&nbsp;Value</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="color: Black">Date</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">Details</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">No.</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">AUD$</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">AUD$</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; vertical-align: top"><FONT STYLE="color: Black">20 Nov 2014</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="color: Black">Capital Consolidation on a 40:1 basis approved by shareholders
    at the Company's Annual General Meeting held on 13 Nov 2014</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: Black">(2,920,770,804</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt"><FONT STYLE="color: Black">21 Nov 2014</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="color: Black">Issue of shares to supplier in lieu of cash
    payment for services rendered approved by shareholders at the Company's Annual general Meeting held on 13 Nov 2014</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">72,916</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">0.160</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">11,667</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt"><FONT STYLE="color: Black">Total 2015
    Movement</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">(2,920,697,888</FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">11,667</FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I><U>During the Full Year ended
30 June 2014, the Company issued the following securities:</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Issue Price</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total Value</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: top">Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Details</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; vertical-align: top">6 Dec 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify">Issue of shares as per resolution 4 approved by shareholders at the Annual General
    Meeting of the Company held on 29 Nov 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">8,750,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.004</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">35,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">6 Dec 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue of shares as per resolutions 5, 6, &amp; 8 approved by shareholders at the Annual General
    Meeting of the Company held on 29 Nov 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,479,167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top">3 Feb 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Exercise of IMCOA options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,163</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">3 Mar 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue of shares through fully underwritten rights issue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,670,642,320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.005</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,353,212</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top">3 Mar 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue of shares to Grandlodge &amp; related owners as part of fully underwritten rights issue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">261,103,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.005</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,305,516</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">29 May 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue of shares as per resolution 2 approved by shareholders at the General
    Meeting of the Company held on 27 May 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">10,208,333</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">0.004</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">40,833</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; vertical-align: top">Total 2014 Movement</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,960,211,977</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">9,792,599</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Our Constitution </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Our
Constitution is similar in nature to the bylaws of a U.S. corporation. It does not provide for or prescribe any specific objectives
or purposes of Immuron. Our Constitution is subject to the terms of the ASX Listing Rules and the Corporations Act. It may be
amended or repealed and replaced by special resolution of shareholders, which is a resolution passed by at least 75% of the votes
cast by shareholders entitled to vote on the resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Under
Australian law, a company has the legal capacity and powers of an individual both within and outside Australia. The material provisions
of our Constitution are summarized below. This summary is not intended to be complete nor to constitute a definitive statement
of the rights and liabilities of our shareholders. Our Constitution is filed as an exhibit to the registration statement, of which
this prospectus forms&nbsp;a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><FONT STYLE="color: Black"><B><I>Interested Directors
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">A
director may not vote in respect of any contract or arrangement in which the director has, directly or indirectly, any material
interest according to our Constitution. Such director must not be counted in a quorum, must not vote on the matter and must not
be present at the meeting while the matter is being considered. However, that director may execute or otherwise act in respect
of that contract or arrangement notwithstanding any material personal interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Unless
a relevant exception applies, the Corporations Act requires our directors to provide disclosure of certain interests or conflicts
of interests and prohibits directors from voting on matters in which they have a material personal interest and from being present
at the meeting while the matter is being considered. In addition, the Corporations Act and the ASX Listing Rules require shareholder
approval of any provision of related party benefits to our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Borrowing
Powers Exercisable by Directors </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Pursuant
to our Constitution, the management and control of our business affairs are vested in our board of directors. Our board of directors
has the power to raise or borrow money, and charge any of our property or business or any uncalled capital, and may issue debentures
or give any other security for any of our debts, liabilities or obligations or of any other person, in each case, in the manner
and on terms it deems fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Retirement
of Directors </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Pursuant
to our Constitution and the ASX Listing Rules, there must be an election of Directors at each annual general meeting. The directors,
other than the managing director, who are to stand for election at each annual general meeting are: (i) any Director required
to retire after a period of 3 years in office, (ii) any Director appointed by the other Directors in the year preceding the annual
general meeting, (iii) any new directors, or (iv) if no person is standing for election for the aforementioned reasons then the
director longest in office since last being elected. A director, other than the director who is the Chief Executive Officer, must
retire from office at the conclusion of the third annual general meeting after which the director was elected. Retired directors
are eligible for a re-election to the board of directors unless disqualified from acting as a director under the Corporations
Act or our Constitution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Rights
and Restrictions on Classes of Shares </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
rights attaching to our ordinary shares are detailed in our Constitution. Our Constitution provides that our directors may issue
shares with preferred, deferred or other special rights, whether in relation to dividends, voting, return of share capital, or
otherwise as our board of directors may determine. Subject to any approval which is required from our shareholders under the Corporations
Act and the ASX Listing Rules (see &ldquo;&mdash;Exemptions from Certain NASDAQ Corporate Governance Rules&rdquo; and &ldquo;&mdash;Change
of Control&rdquo;), any rights and restrictions attached to a class of shares, we may issue further shares on such terms and conditions
as our board of directors resolve. Currently, our outstanding share capital consists of only one class of ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Dividend
Rights </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Our
board of directors may from time to time determine to pay dividends to shareholders. All dividends unclaimed for one year after
having been declared may be invested or otherwise made use of by our board of directors for our benefit until claimed or otherwise
disposed of in accordance with our Constitution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Voting
Rights </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Under
our Constitution, and subject to any voting exclusions imposed under the ASX Listing Rules (which typically exclude parties from
voting on resolutions in which they have an interest), the rights and restrictions attaching to a class of shares, each shareholder
has one vote on a show of hands at a meeting of the shareholders unless a poll is demanded under the Constitution or the Corporations
Act. On a poll vote, each shareholder shall have one vote for each fully paid share and a fractional vote for each share held
by that shareholder that is not fully paid, such fraction being equivalent to the proportion of the amount that has been paid
to such date on that share. Shareholders may vote in person or by proxy, attorney or representative. Under Australian law, shareholders
of a public company are not permitted to approve corporate matters by written consent. Our Constitution does not provide for cumulative
voting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Note
that ADS holders may not directly vote at a meeting of the shareholders but may instruct the depositary to vote the number of
deposited ordinary shares their ADSs represent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Right
to Share in Our Profits </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Pursuant
to our Constitution, our shareholders are entitled to participate in our profits only by payment of dividends. Our board of directors
may from time to time determine to pay dividends to the shareholders; however, no dividend is payable except in accordance with
the thresholds set out in the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Rights
to Share in the Surplus in the Event of Liquidation </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Our
Constitution provides for the right of shareholders to participate in a surplus in the event of our liquidation, subject to the
rights attaching to a class of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>No
Redemption Provision for Ordinary Shares </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">There
are no redemption provisions in our Constitution in relation to ordinary shares. Under our Constitution, any preference shares
may be issued on the terms that they are, or may at our option be, liable to be redeemed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Variation
or Cancellation of Share Rights </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Subject
to the terms of issue of shares of that class, the rights attached to shares in a class of shares may only be varied or cancelled
by a special resolution of Immuron together with either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">a
                                         special resolution passed at a separate general meeting of members holding shares in
                                         the class; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">the
                                         written consent of members with at least 75% of the shares in the class.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Directors
May Make Calls </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Our
Constitution provides that subject to the terms on which the shares have been issued directors may make calls on a shareholder
for amounts unpaid on shares held by that shareholder, other than monies payable at fixed times under the conditions of allotment.
Shares represented by the ADSs issued in this offering will be fully paid and will not be subject to calls by directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>General Meetings of Shareholders
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;General
meetings of shareholders may be called by our board of directors. Except as permitted under the Corporations Act, shareholders
may not convene a meeting. The Corporations Act requires the directors to call and arrange to hold a general meeting on the request
of shareholders with at least 5% of the votes that may be cast at a general meeting or at least 100 shareholders who are entitled
to vote at the general meeting. Notice of the proposed meeting of our shareholders is required at least 28&nbsp;clear days prior
to such meeting under the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="color: Black"><B>Foreign
Ownership Regulation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">There
are no limitations on the rights to own securities imposed by our Constitution. However, acquisitions and proposed acquisitions
of securities in Australian companies may be subject to review and approval by the Australian Federal Treasurer under the Foreign
Acquisitions and Takeovers Act 1975, or the FATA, which generally applies to acquisitions or proposed acquisitions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">by
                                         a foreign person (as defined in the FATA) or associated foreign persons that would result
                                         in such persons having an interest in 20% or more of the issued shares of, or control
                                         of 20% or more of the voting power in, an Australian company; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">by
                                         non-associated foreign persons that would result in such foreign person having an interest
                                         in 40% or more of the issued shares of, or control of 40% or more of the voting power
                                         in, an Australian company, where the Australian company is valued above the monetary
                                         threshold prescribed by FATA.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">However, no such
review or approval under the FATA is required if the foreign acquirer is a U.S. entity and the value of the target is less than
AUD$1,094 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
Australian Federal Treasurer may prevent a proposed acquisition in the above categories or impose conditions on such acquisition
if the Treasurer is satisfied that the acquisition would be contrary to the national interest. If a foreign person acquires shares
or an interest in shares in an Australian company in contravention of the FATA, the Australian Federal Treasurer may order the
divestiture of such person&rsquo;s shares or interest in shares in that Australian company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Ownership
Threshold </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">There
are no provisions in our Constitution that require a shareholder to disclose ownership above a certain threshold. The Corporations
Act, however, requires a shareholder to notify us and the ASX once it, together with its associates, acquires a 5% interest in
our ordinary shares, at which point the shareholder will be considered to be a &ldquo;substantial&rdquo; shareholder. Further,
once a shareholder owns a 5% interest in us, such shareholder must notify us and the ASX of any increase or decrease of 1% or
more in its holding of our ordinary shares, and must also notify us and the ASX on its ceasing to be a &ldquo;substantial&rdquo;
shareholder. Upon becoming a U.S. public company, our shareholders will also be subject to disclosure requirements under U.S.
securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Issues of
Shares and Change in Capital </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Subject
to our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, we may at any time issue shares
and grant options or warrants on any terms, with preferred, deferred or other special rights and restrictions and for the consideration
and other terms that the directors determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Subject
to the requirements of our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, including relevant
shareholder approvals, we may consolidate or divide our share capital into a larger or smaller number by resolution, reduce our
share capital (provided that the reduction is fair and reasonable to our shareholders as a whole and does not materially prejudice
our ability to pay creditors) or buy back our ordinary shares whether under an equal access buy-back or on a selective basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Change of Control </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;Takeovers
of listed Australian public companies, such as Immuron are regulated by the Corporations Act, which prohibits the acquisition
of a &ldquo;relevant interest&rdquo; in issued voting shares in a listed company if the acquisition will lead to that person&rsquo;s
or someone else&rsquo;s voting power in Immuron increasing from 20% or below to more than 20% or increasing from a starting point
that is above 20% and below 90%, subject to a range of exceptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Generally,
a person will have a relevant interest in securities if the person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">is
                                         the holder of the securities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">has
                                         power to exercise, or control the exercise of, a right to vote attached to the securities;
                                         or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">has
                                         the power to dispose of, or control the exercise of a power to dispose of, the securities,
                                         including any indirect or direct power or control.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="color: Black">If,
at a particular time, a person has a relevant interest in issued securities and the person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">has
                                         entered or enters into an agreement with another person with respect to the securities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">has
                                         given or gives another person an enforceable right, or has been or is given an enforceable
                                         right by another person, in relation to the securities (whether the right is enforceable
                                         presently or in the future and whether or not on the fulfillment of a condition);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">has
                                         granted or grants an option to, or has been or is granted an option by, another person
                                         with respect to the securities; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">the
                                         other person would have a relevant interest in the securities if the agreement were performed,
                                         the right enforced or the option exercised;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">the other person
is taken to already have a relevant interest in the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">There
are a number of exceptions to the above prohibition on acquiring a relevant interest in issued voting shares above 20%. In general
terms, some of the more significant exceptions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">when
                                         the acquisition results from the acceptance of an offer under a formal takeover bid;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">when
                                         the acquisition is conducted on market by or on behalf of the bidder under a takeover
                                         bid, the acquisition occurs during the bid period, the bid is for all the voting shares
                                         in a bid class and the bid is unconditional or only conditioned on prescribed matters
                                         set out in the Corporations Act;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">when
                                         shareholders of Immuron approve the takeover by resolution passed at general meeting;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">an
                                         acquisition by a person if, throughout the six months before the acquisition, that person
                                         or any other person has had voting power in Immuron of at least 19% and, as a result
                                         of the acquisition, none of the relevant persons would have voting power in Immuron more
                                         than three percentage points higher than they had six months before the acquisition;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">when
                                         the acquisition results from the issue of securities under a rights issue;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">when
                                         the acquisition results from the issue of securities under dividend reinvestment schemes;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">when
                                         the acquisition results from the issue of securities under underwriting arrangements;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">when
                                         the acquisition results from the issue of securities through operation of law;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">an
                                         acquisition that arises through the acquisition of a relevant interest in another listed
                                         company which is listed on a prescribed financial market or a financial market approved
                                         by ASIC;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">an
                                         acquisition arising from an auction of forfeited shares conducted on-market; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">an
                                         acquisition arising through a compromise, arrangement, liquidation or buy-back.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Breaches
of the takeovers provisions of the Corporations Act are criminal offenses. ASIC and the Australian Takeover Panel have a wide
range of powers relating to breaches of takeover provisions, including the ability to make orders canceling contracts, freezing
transfers of, and rights attached to, securities, and forcing a party to dispose of securities. There are certain defenses to
breaches of the takeover provisions provided in the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Access to
and Inspection of Documents </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Inspection
of our records is governed by the Corporations Act. Any member of the public has the right to inspect or obtain copies of our
registers on the payment of a prescribed fee. Shareholders are not required to pay a fee for inspection of our registers or minute
books of the meetings of shareholders. Other corporate records, including minutes of directors&rsquo; meetings, financial records
and other documents, are not open for inspection by shareholders. Where a shareholder is acting in good faith and an inspection
is deemed to be made for a proper purpose, a shareholder may apply to the court to make an order for inspection of our books.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Exemptions
from Certain NASDAQ Corporate Governance Rules </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The NASDAQ
listing rules allow for a foreign private issuer, such as Immuron, to follow its home country practices in lieu of certain of
the NASDAQ&rsquo;s corporate governance standards. We rely on exemptions from certain corporate governance standards that are
contrary to the laws, rules, regulations or generally accepted business practices in Australia. These exemptions being sought
are described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 13px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We rely on an exemption from the independence requirements for a majority of our board of directors as prescribed by NASDAQ Listing Rules. The ASX Listing Rules do not require us to have a majority of independent directors although ASX Corporate Governance Principles and Recommendations do recommend a majority of independent directors. During fiscal 2016, we did not, have a majority of directors who were &ldquo;independent&rdquo; as defined in the ASX Corporate Governance Principles and Recommendations, which definition differs from NASDAQ&rsquo;s definition. Accordingly, because Australian law and generally accepted business practices in Australia regarding director independence differ to the independence requirements under NASDAQ Listing Rules, we seek to claim this exemption.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 13px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We rely on an exemption from the requirement that our independent directors meet regularly in executive sessions under NASDAQ Listing Rules. The ASX Listing Rules and the Corporations Act do not require the independent directors of an Australian company to have such executive sessions and, accordingly, we seek to claim this exemption.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 13px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We rely on an exemption from the quorum requirements applicable to meetings of shareholders under NASDAQ Listing Rules. In compliance with Australian law, our Constitution provides that three shareholders present, in person or by proxy, attorney or a representative, shall constitute a quorum for a general meeting. NASDAQ Listing Rules require that an issuer provide for a quorum as specified in its by-laws for any meeting of the holders of ordinary shares, which quorum may not be less than 33% (1/3) of the outstanding shares of an issuer&rsquo;s voting ordinary shares. Accordingly, because applicable Australian law and rules governing quorums at shareholder meetings differ from NASDAQ&rsquo;s quorum requirements, we seek to claim this exemption.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 110; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 13px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We rely on an exemption from the requirement prescribed
    by NASDAQ Listing Rules that issuers obtain shareholder approval prior to the issuance of securities in connection with
    certain acquisitions, private placements of securities, or the establishment or amendment of certain stock option, purchase
    or other compensation plans. Applicable Australian law and the ASX Listing Rules differ from NASDAQ requirements, with the
    ASX Listing Rules providing generally for prior shareholder approval in numerous circumstances, including (i)&nbsp;issuance
    of equity securities exceeding 15% of our issued share capital in any 12-month period (but, in determining the 15% limit,
    securities issued under an exception to the rule or with shareholder approval are not counted), (ii)&nbsp;issuance of equity
    securities to related parties (as defined in the ASX Listing Rules) and (iii)&nbsp;issuances of securities to directors or
    their associates under an employee incentive plan. Due to differences between Australian law and rules and the NASDAQ
    shareholder approval requirements, we seek to claim this exemption.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We rely on an exemption from the requirement that issuers must maintain charters for each of the following committees in compliance with NASDAQ Listing Rules: audit committee, nomination committee and compensation committee. In addition, we rely on an exemption from the requirement that issuers must maintain a code of conduct in compliance with NASDAQ Listing Rules. Applicable Australian law does not require the Company to maintain any charters for their committees nor does such law require the Company maintain a code of conduct.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 111; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_022"></A><FONT STYLE="color: Black"><B>DESCRIPTION
OF AMERICAN DEPOSITARY SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>American
Depositary Shares </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; text-align: justify"><FONT STYLE="color: Black">T<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
Bank of New York Mellon, as depositary, will register and deliver American Depositary Shares, also referred to as ADSs. Each ADS
will represent forty (40) shares (or a right to receive forty (40) shares) deposited with the principal Melbourne, Victoria, Australia
offices of Australia and New Zealand Banking Group Ltd, Hongkong Bank of Australia and National Australia Bank Limited as custodian
for the depositary. Each ADS will also represent any other securities, cash or other property which may be held by the depositary.
The depositary&rsquo;s office at which the ADSs will be administered is located at 101 Barclay Street, New York, New York 10286.
The Bank of New York Mellon&rsquo;s principal executive office is located at 225 Liberty Street, New York, New York 10286.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; text-align: justify"><FONT STYLE="color: Black">You
may hold ADSs either (A) directly (i) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate
evidencing a specific number of ADSs, registered in your name, or (ii) by having ADSs registered in your name in the Direct Registration
System, or (B) indirectly by holding a security entitlement in ADSs through your broker or other financial institution. If you
hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS
holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert
the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out
what those procedures are.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; text-align: justify"><FONT STYLE="color: Black">The
Direct Registration System, also referred to as DRS, is a system administered by The Depository Trust Company, also referred to
DTC, under which the depositary may register the ownership of uncertificated ADSs, which ownership is confirmed by statements
sent by the depositary to the registered holders of uncertificated ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; text-align: justify"><FONT STYLE="color: Black">As
an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Australian law governs
shareholder rights. The depositary will be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you
will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially
holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit
agreement and the ADSs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
following is a summary of the material provisions of the deposit agreement. Because it is a summary, it does not contain all the
information that may be important to you. For more complete information, you should read the entire deposit agreement and the
form of ADR which summarizes certain terms of your ADSs. A copy of the deposit agreement is filed as an exhibit to the registration
statement of which this prospectus forms&nbsp;a part. You may also obtain a copy of the deposit agreement at the SEC&rsquo;s Public
Reference Room which is located at 100&nbsp;F Street, NE, Washington, DC 20549. You may obtain information on the operation of
the Public Reference Room by calling the SEC at 1-800-732-0330. You may also find the registration statement and the deposit agreement
on the SEC&rsquo;s website at http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Dividends
and Other Distributions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: left"><FONT STYLE="color: Black"><I>How
will you receive dividends and other distributions on the shares?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary has agreed to pay to ADS holders the cash dividends or other distributions it or the custodian receives on shares or
other deposited securities, after deducting its fees and expenses. You will receive these distributions in proportion to the number
of shares your ADSs represent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Cash.
                                         </I></B> The depositary will convert any cash dividend or other cash distribution we
                                         pay on the shares into U.S. dollars, if it can do so on a reasonable basis and can transfer
                                         the U.S. dollars to the United States. If that is not possible or if any government approval
                                         is needed and cannot be obtained, the deposit agreement allows the depositary to distribute
                                         the foreign currency only to those ADS holders to whom it is possible to do so. It will
                                         hold the foreign currency it cannot convert for the account of the ADS holders who have
                                         not been paid. It will not invest the foreign currency and it will not be liable for
                                         any interest. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Before making a distribution,
any withholding taxes, or other governmental charges that must be paid will be deducted. It will distribute only whole U.S. dollars
and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary
cannot convert the foreign currency, you may lose some or all of the value of the distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B><I>Shares.
                                         </I></B>The depositary may distribute additional ADSs representing any shares we distribute
                                         as a dividend or free distribution. The depositary will only distribute whole ADSs. It
                                         will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing
                                         those shares) and distribute the net proceeds in the same way as it does with cash. If
                                         the depositary does not distribute additional ADSs, the outstanding ADSs will also represent
                                         the new shares. The depositary may sell a portion of the distributed shares sufficient
                                         to pay its fees and expenses in connection with that distribution (or ADSs representing
                                         those shares).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B><I>Rights
                                         to purchase additional shares. </I></B> If we offer holders of our securities any rights
                                         to subscribe for additional shares or any other rights, the depositary may make these
                                         rights available to ADS holders. If the depositary decides it is not legal and practical
                                         to make the rights available but that it is practical to sell the rights, the depositary
                                         will use reasonable efforts to sell the rights and distribute the proceeds in the same
                                         way as it does with cash. The depositary will allow rights that are not distributed or
                                         sold to lapse. In that case, you will receive no value for them. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify"><FONT STYLE="color: Black">If
the depositary makes rights available to ADS holders, it will exercise the rights and purchase the shares on your behalf. The
depositary will then deposit the shares and deliver ADSs to the persons entitled to them. It will only exercise rights if you
pay it the exercise price and any other charges the rights require you to pay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify"><FONT STYLE="color: Black">U.S.
securities laws may restrict transfers and cancellation of the ADSs represented by shares purchased upon exercise of rights. For
example, you may not be able to trade these ADSs freely in the United States. In this case, the depositary may deliver restricted
depositary shares that have the same terms as the ADSs described in this section except for changes needed to put the necessary
restrictions in place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B><I>Other
                                         Distributions.</I></B> The depositary will send to ADS holders anything else we distribute
                                         on deposited securities by any means it thinks is legal, fair and practical. If it cannot
                                         make the distribution in that way, the depositary has a choice. It may decide to sell
                                         what we distributed and distribute the net proceeds, in the same way as it does with
                                         cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent
                                         the newly distributed property. However, the depositary is not required to distribute
                                         any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence
                                         from us that it is legal to make that distribution. The depositary may sell a portion
                                         of the distributed securities or property sufficient to pay its fees and expenses in
                                         connection with that distribution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders.
We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation
to&nbsp;take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that
you may not receive the distributions we make on our shares or any value for them if it is illegal or impractical for us to make
them available to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Deposit,
Withdrawal and Cancellation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>How
are ADSs issued?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian.
Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary
will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person
or persons that made the deposit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 113; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>How
can ADS holders withdraw the deposited securities?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">You
may surrender your ADSs at the depositary&rsquo;s office. Upon payment of its fees and expenses and of any taxes or charges, such
as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares&nbsp;and any other deposited securities
underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request,
risk and expense, the depositary will deliver the deposited securities at its office, if feasible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>How
do ADS holders interchange between certificated ADSs and uncertificated ADSs? </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">You
may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel
that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated
ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting
the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing
those ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Voting Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>How
do you vote? </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">ADS
holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. Otherwise, you won&rsquo;t
be able to exercise your right to vote unless you withdraw the shares. However, you may not know about the meeting enough in advance
to withdraw the shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary will notify ADS holders of shareholders&rsquo; meetings and arrange to deliver our voting materials to them if we ask
it to. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to
vote. For instructions to be valid, they much reach the depositary by a date set by the depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary will try, as far as practical, subject to the laws of Australia and of our articles of association or similar documents,
to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. The depositary will
only vote or attempt to vote as instructed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-size: 10pt">We
cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your
shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the
manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote and there may be
nothing you can do if your shares are not voted as you requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">In
order to give you a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to Deposited
Securities, if we request the Depositary to act, we agree to give the Depositary notice of any such meeting and details concerning
the matters to be voted upon at least 30 days in advance of the meeting date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Fees and
Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Persons
    depositing or withdrawing shares or ADS holders must pay</I>:</B></FONT></td>
    <TD STYLE="width: 4%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 52%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>For</I>:</B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$5.00 (or less) per 100 ADSs
    (or portion of 100 ADSs)</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="color: Black">Issuance
        of ADSs, including issuances resulting from a distribution of shares or rights or other property</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="color: Black">Cancellation
        of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</FONT></P></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$0.05 (or less) per ADS </FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt; color: Black">Any cash distribution to ADS holders</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A fee equivalent to the fee
    that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs
    </FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt; color: Black">Distribution of securities distributed
    to holders of deposited securities which are distributed by the depositary to ADS holders</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$0.05 (or less) per ADS per
    calendar year </FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt; color: Black">Depositary services</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Registration or transfer fees</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt; color: Black">Transfer and registration of
    shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares </FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Expenses of the depositary</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="color: Black">Cable,
        telex and facsimile transmissions (when expressly provided in the deposit agreement)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="color: Black">converting
        foreign currency to U.S. dollars</FONT></P></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Taxes and other governmental
    charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as&nbsp;&nbsp;stock transfer
    taxes, stamp duty or withholding taxes</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="color: Black">As
        necessary</FONT></P></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any charges incurred by the
    depositary or its agents for servicing the deposited securities</FONT></td>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt; color: Black">As necessary</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs
for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to
investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees.
The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing
investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its
fees by deduction from any cash distribution payable to ADS holders that are obligated to pay those fees. The depositary may generally
refuse to provide fee-attracting services until its fees for those services are paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">From
time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment
and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from
the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers,
foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share
fees, spreads or commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account
and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation,
transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between
the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its
affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the
exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could
be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject
to the depositary&rsquo;s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency
conversions is available upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Payment
of Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">You
will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented
by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities
represented by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities
represented by your American Depositary Shares to pay any taxes owed and you will remain liable for any deficiency. If the depositary
sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any
proceeds, or send to ADS holders any property, remaining after it has paid the taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Reclassifications,
Recapitalizations and Mergers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>If we:</I></B></FONT></td>
    <TD STYLE="width: 50%; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Then:</I></B></FONT></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD STYLE="padding-left: 5pt"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT><FONT STYLE="color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change
        the nominal or par value of our shares</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT><FONT STYLE="color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reclassify,
        split up or consolidate any of the deposited securities</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT><FONT STYLE="color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distribute
        securities on the shares that are not distributed to you</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT><FONT STYLE="color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recapitalize,
        reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action</FONT></P></td>
    <TD STYLE="padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><FONT STYLE="color: Black">The
                                  cash, shares or other securities received by the depositary will become deposited securities.
                                  Each ADS will automatically represent its equal share of the new deposited securities.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><FONT STYLE="color: Black">The depositary may
        distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange
        for new ADRs identifying the new deposited securities.</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Amendment
and Termination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>How
may the deposit agreement be amended?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">We
may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment
adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration
fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become
effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment
becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs
and the deposit agreement as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="color: Black"><B><I>How
may the deposit agreement be terminated?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary will terminate the deposit agreement at our direction by mailing notice of termination to the ADS holders then outstanding
at least 30 days prior to the date fixed in such notice for such termination. The depositary may also terminate the deposit agreement
by mailing notice of termination to us and the ADS holders if 60 days have passed since the depositary told us it wants to resign
but a successor depositary has not been appointed and accepted its appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">After
termination, the depositary and its agents will do the following under the deposit agreement but nothing else:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">collect
                                         distributions on the deposited securities,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">sell
                                         rights and other property, and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">deliver
                                         shares and other deposited securities upon cancellation of ADSs. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Four
months after termination, the depositary may sell any remaining deposited securities by public or private sale. After that, the
depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement for
the pro rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and has no liability
for interest. The depositary&rsquo;s only obligations will be to account for the money and other cash. After termination our only
obligations will be to indemnify the depositary and to pay fees and expenses of the depositary that we agreed to pay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Limitations
on Obligations and Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="color: Black"><B><I>Limits
on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the
liability of the depositary. We and the depositary:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">are
                                         only obligated to take the actions specifically set forth in the deposit agreement without
                                         negligence or bad faith;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">are
                                         not liable if we are or it is prevented or delayed by law or circumstances beyond our
                                         or its control from performing our or its obligations under the deposit agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">are
                                         not liable if we or it exercises discretion permitted under the deposit agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">are
                                         not liable for the inability of any holder of ADSs to benefit from any distribution on
                                         deposited securities that is not made available to holders of ADSs under the terms of
                                         the deposit agreement, or for any special, consequential or punitive damages for any
                                         breach of the terms of the deposit agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">have
                                         no obligation to become involved in a lawsuit or other proceeding related to the ADSs
                                         or the deposit agreement on your behalf or on behalf of any other person; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">are
                                         not liable for the acts or omissions of any securities depository, clearing agency or
                                         settlement system; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">may
                                         rely upon any documents we believe or it believes in good faith to be genuine and to
                                         have been signed or presented by the proper person. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">In
the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Requirements
for Depositary Actions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Before
the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary
may require:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">payment
                                         of stock transfer or other taxes or other governmental charges and transfer or registration
                                         fees charged by third parties for the transfer of any shares or other deposited securities;
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">satisfactory
                                         proof of the identity and genuineness of any signature or other information it deems
                                         necessary; and </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">compliance
                                         with regulations it may establish, from time to time, consistent with the deposit agreement,
                                         including presentation of transfer documents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer
books are closed or at any time if the depositary or we think it advisable to do so.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Your Right
to Receive the Shares Underlying your ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">ADS
holders have the right to cancel their ADSs and withdraw the underlying shares at any time except:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">when
                                         temporary delays arise because: (i) the depositary has closed its transfer books or we
                                         have closed our transfer books; (ii) the transfer of shares is blocked to permit voting
                                         at a shareholders' meeting; or (iii) we are paying a dividend on our shares; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">when
                                         you owe money to pay fees, taxes and similar charges; or </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">when
                                         it is necessary to prohibit withdrawals in order to comply with any laws or governmental
                                         regulations that apply to ADSs or to the withdrawal of shares or other deposited securities.
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">This
right of withdrawal may not be limited by any other provision of the deposit agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Pre-release
of ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
deposit agreement permits the depositary to deliver ADSs before deposit of the underlying shares. This is called a pre-release
of the ADSs. The depositary may also deliver shares upon cancellation of pre-released ADSs (even if the ADSs are canceled before
the pre-release transaction has been closed out). A pre-release is closed out as soon as the underlying shares are delivered to
the depositary. The depositary may receive ADSs instead of shares to close out a pre-release. The depositary may pre-release ADSs
only under the following conditions: (1) before or at the time of the pre-release, the person to whom the pre-release is being
made represents to the depositary in writing that it or its customer owns the shares or ADSs to be deposited; (2) the pre-release
is fully collateralized with cash or other collateral that the depositary considers appropriate; and (3) the depositary must be
able to close out the pre-release on not more than five business days' notice. In addition, the depositary will limit the number
of ADSs that may be outstanding at any time as a result of pre-release, although the depositary may disregard the limit from time
to time if it thinks it is appropriate to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; color: blue"><FONT STYLE="text-underline-style: double; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Direct Registration
System</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the deposit agreement, all parties to the deposit agreement acknowledge that the DRS and Profile Modification System, or Profile,
will apply to uncertificated ADSs upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC under which the
depositary may register the ownership of uncertificated ADSs, which ownership will be confirmed by statements sent by the depositary
to the registered holders of uncertificated ADSs. Profile is a required feature of DRS that allows a DTC participant, claiming
to act on behalf of a registered holder of ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee
and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization
from the ADS holder to register that transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">In
connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement
understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS
holder in requesting registration of transfer and delivery described in the paragraph above has the actual authority to act on
behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties
agree that the depositary&rsquo;s reliance on and compliance with instructions received by the depositary through the DRS/Profile
System and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; color: blue"><FONT STYLE="text-underline-style: double; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Shareholder
communications; inspection of register of holders of ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited
securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications
if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders
about a matter unrelated to our business or the ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Disclosure
of Interests </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">We
may from time to time request ADS holders to provide information as to the capacity in they own or owned ADSs and regarding the
identity of any other persons then or previously interested in such ADSs and the nature of such interest. Each ADS holder agrees
to provide any information of that kind that is requested by us or the depositary. To the extent that provisions of or governing
the deposited securities or the rules or regulations of any governmental authority or securities exchange or automated quotation
system may require the disclosure of beneficial or other ownership of deposited securities, other shares and other securities
to us or other persons and may provide for blocking transfer and voting or other rights to enforce such disclosure or limit such
ownership, the depositary has agreed to use its reasonable efforts to comply with our written instructions in respect of any such
enforcement or limitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="d_0032"></A><B>DESCRIPTION OF THE
WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following summary
of certain terms of the Warrants is not complete and is subject to, and qualified in its entirety by the provisions of the ADS
Warrant Agent Agreement and Form of Global Warrant to Purchase ADSs, which are filed as exhibits to the registration statement
of which this prospectus is a part. Prospective investors should carefully review the terms set forth in the ADS Warrant Agent
Agreement and Form of Global Warrant to Purchase ADSs. Warrants issued in connection with this offering will be administered by
The Bank of New York Mellon as Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&bull; <B>&nbsp;&nbsp;&nbsp;Global
Certificates, Book-entry Interests</B>. The Warrants will be represented by one or more global certificates in registered form.
The global certificate will be deposited with the Warrant Agent as custodian for DTC and registered in the name of Cede &amp;
Co., as nominee of DTC. Ownership of interests in the global warrant certificate will be limited to persons that have accounts
with DTC or persons that have accounts with DTC participants. Book-entry interests in the Warrants will be shown on, and transfers
of such interests will be effected only through records maintained by DTC and its participants. So long as the Warrants are held
in global form, DTC will be considered the sole holder of the Warrants. Beneficial owners must rely on the procedures of the participants
through which they own book-entry interests to exercise their Warrants or transfer their Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&bull; <B>&nbsp;&nbsp;&nbsp;Exercisability</B>.
The Warrants are exercisable immediately upon issuance and at any time up to the date that is five years from the date of issuance.
The Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of ADSs purchased upon such exercise. The Company will pay the ADS issuance
fee of US$ 0.05 per ADS and any other applicable charges and taxes in connection with any such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&bull; <B>&nbsp;&nbsp;&nbsp;Maximum
Percentage</B>. A holder of a Warrant shall not have the right to exercise such Warrant, to the extent that after giving effect
to such exercise, such person (together with such person&rsquo;s affiliates and certain other persons), would beneficially own
in excess of 4.99% (the &ldquo;Maximum Percentage&rdquo;) of the ordinary shares outstanding immediately after giving effect to
such exercise. Subject to certain exceptions, &ldquo;beneficial ownership&rdquo; for purposes of determining the Maximum Percentage
is calculated in accordance with Section 13(d) of the Exchange Act and the regulations of the SEC thereunder. Upon request by
a Warrant holder, we will provide current information regarding the number of our outstanding ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&bull; <B>&nbsp;&nbsp;&nbsp;Exercise
Price</B>. The initial exercise price per ADS purchasable upon exercise of the Warrants is $10.00. The Warrants may not be exercised
on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo; basis except in certain limited circumstances.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&bull; <B>&nbsp;&nbsp;&nbsp;Restrictive
Legend Events</B>. We will notify the Warrant Agent and each holder if we are unable to deliver ADSs via DTC transfer or otherwise
(without restrictive legend), because (a) the SEC has issued a stop order with respect to the registration statement relating
to the ADSs, (b) the SEC otherwise has suspended or withdrawn the effectiveness of such registration statement, either temporarily
or permanently, (c) we have suspended or withdrawn the effectiveness of the registration statement, either temporarily or permanently,
or (d) otherwise (each a &ldquo;Restrictive Legend Event&rdquo;). If a Restrictive Legend Event occurs after a Warrant holder
has exercised a Warrant in accordance with its terms but prior to the delivery of the ADSs, or if we do not cause the depositary
to timely deliver ADSs to a Warrant holder upon exercise of the Warrants, we will be obligated to pay a cash buy-in amount to
the holder of the Warrants who did not receive ADSs upon such holder&rsquo;s exercise of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&bull; <B>&nbsp;&nbsp;Anti-Dilution
Provisions</B>. The exercise price per Warrant and the numbers of Warrants shall be subject to adjustment from time to time in
accordance with the ASX Listing Rules upon the occurrence of certain stock dividends and distributions, stock splits, stock subdivisions
and combinations, reclassifications, rights issues, or similar events affecting our ADSs or ordinary shares, or upon the occurrence
of a change in ADS ratio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&bull; <B>&nbsp;&nbsp;Transferability</B>.
Subject to applicable laws, the Warrants may be transferred at the option of the holders upon surrender of the Warrants to us
together with the appropriate instruments of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&bull; <B>&nbsp;&nbsp;Warrant
Agent and Exchange Listing</B>. The Warrants will be issued in registered form under an ADS Warrant Agent Agreement between The
Bank of New York Mellon, as warrant agent and us and listed on The NASDAQ Capital Market under the symbol &ldquo;IMRNW&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&bull; <B>&nbsp;&nbsp;Rights
as a Shareholder</B>. Except as otherwise provided in the ADS Warrant Agent Agreement or by virtue of such holder&rsquo;s ownership
of ADSs or ordinary shares, the holder of Warrants does not have rights or privileges of a holder of ADSs or ordinary shares,
including any voting rights, until the holder exercises the Warrant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_023"></A><FONT STYLE="color: Black"><B>SHARES
ELIGIBLE FOR FUTURE SALE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Upon completion of
this offering, there will be outstanding 24,400,000 ordinary shares, including shares underlying the ADSs, and 610,000&nbsp;ADSs,
representing approximately 19.06% of our outstanding ordinary shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Future
sales of substantial amounts of our ordinary shares or ADSs in the public market in the United States or in Australia, including
ordinary shares issued upon exercise of outstanding options, or the possibility of such sales, could negatively affect the market
price in the United States of the ADSs and our ability to raise equity capital in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">All
of the ADSs sold in the offering will be freely transferable in the United States by persons other than our &ldquo;affiliates,&rdquo;
as that term is defined in Rule&nbsp;144 under the Securities Act. As defined in Rule&nbsp;144, an &ldquo;affiliate&rdquo; of
an issuer is a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under
common control with, the issuer. ADSs purchased by one of our affiliates may not be resold, except pursuant to an effective registration
statement or an exemption from registration, including Rule&nbsp;144 under the Securities Act (as described below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Lock-up Agreements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We and our executive
officers and directors have generally agreed not to sell or transfer any ordinary shares, ADSs or other capital stock of Immuron
or securities convertible into or exchangeable or exercisable for ordinary shares, ADSs or other capital stock of Immuron for
(i) 3 months after the date of this prospectus in the case of our directors and officers and (ii) 180 days after the date of this
prospectus in the case of the Company without first obtaining the written consent of Joseph Gunner &amp; Co., LLC. Specifically,
we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">offer
                                         to sell, sell, pledge, contract to sell, purchase any option to sell, grant any option
                                         for the purchase of, lend, or otherwise dispose of directly or indirectly, including
                                         the filing or participation in a filing with the SEC of a registration statement under
                                         the Securities Act to register, any of our ordinary shares or ADSs or any securities
                                         convertible into, or exercisable or exchangeable for our ordinary shares, ADSs, options
                                         or warrants or other rights to acquire ordinary shares or ADSs; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">enter
                                         into any swap or other agreement, arrangement, hedge or transaction that transfers, in
                                         whole or in part, directly or indirectly, the economic benefits or risks of ownership
                                         of any ordinary shares, ADSs or other capital stock or any securities convertible into
                                         or exercisable or exchangeable for ordinary shares, ADSs or other capital stock.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">For
more detail on the lock-up agreements, see &ldquo;Underwriting.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Rule&nbsp;144
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">In
general, under Rule&nbsp;144 of the Securities Act and beginning 90&nbsp;days after the date of this prospectus, a person who
is not deemed to have been our affiliate at any time during the three months preceding a sale and who has beneficially owned &ldquo;restricted
securities&rdquo; within the meaning of Rule&nbsp;144 for more than six months would be entitled to sell an unlimited number of
shares, subject only to the availability of current public information about us. A non-affiliate who has beneficially owned &ldquo;restricted
securities&rdquo; for at least one year from the later of the date these shares were acquired from us or from our affiliate would
be entitled to freely sell those shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">A
person who is deemed to be an affiliate of ours and who has beneficially owned &ldquo;restricted securities&rdquo; for at least
six months would be entitled to sell, within any three-month period, a number of shares that is not more than the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">1.0%
                                         of the number of our ordinary shares then outstanding; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">the
                                         average weekly reported trading volume of our ordinary shares on NASDAQ during the four
                                         calendar weeks preceding the date on which a notice of the sale on Form&nbsp;144 is filed
                                         with the SEC by such person.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Sales
under Rule&nbsp;144 of the Securities Act by persons who are deemed to be our affiliates are also subject to manner-of-sale provisions,
notice requirements and the availability of current public information about us as specified in Rule&nbsp;144. In addition, in
each case, these shares would remain subject to lock-up arrangements and would only become eligible for sale when the lock-up
period expires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Regulation&nbsp;S
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Regulation&nbsp;S
provides generally that sales made in offshore transactions are not subject to the registration or prospectus delivery requirements
of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Rule&nbsp;701
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">In
general, under Rule&nbsp;701 of the Securities Act, each of our employees, consultants or advisors who purchases our ordinary
shares from us in connection with a compensatory stock plan or other written agreement executed prior to the completion of this
offering is eligible to resell such ordinary shares in reliance on Rule&nbsp;144, but without compliance with some of the restrictions,
including the holding period, contained in Rule&nbsp;144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_024"></A><FONT STYLE="color: Black"><B>TAXATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black"><I>The
following is a summary of material U.S. federal and Australian income tax considerations to U.S. holders, as defined below, of
the acquisition, ownership and disposition of ordinary shares and ADSs. This discussion is based on the laws in force as of the
date of this registration statement, and is subject to changes in the relevant income tax law, including changes that could have
retroactive effect. The following summary does not take into account or discuss the tax laws of any country or other taxing jurisdiction
other than the United States and Australia. Holders are advised to consult their tax advisors concerning the overall tax consequences
of the acquisition, ownership and disposition of ordinary shares and ADSs in their particular circumstances. This discussion is
not intended, and should not be construed, as legal or professional tax advice. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I>&nbsp;&nbsp;</I></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><I>This summary does
not address the effects of U.S. federal estate and gift tax laws, the alternative minimum tax, or any state and local tax considerations
within the United States, and is not a comprehensive description of all U.S. federal or Australian income tax considerations that
may be relevant to a decision to acquire or dispose of ordinary shares or ADSs. Furthermore, this summary does not address U.S.
federal or Australian income tax considerations relevant to holders subject to taxing jurisdictions other than, or in addition
to, the United States and Australia, and does not address all possible categories of holders, some of which may be subject to
special tax rules. </I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>U.S. Federal
Income Tax Considerations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The following summary
describes the material U.S. federal income tax consequences to U.S. holders (as defined below) of the acquisition, ownership and
disposition of our ordinary shares and ADSs as of the date hereof. Subject to the qualifications, assumptions and limitations
set forth herein, this discussion of the material U.S. federal income tax consequences to U.S. holders of our ordinary shares
and ADSs represents the opinion of, our U.S. counsel. Except where noted, this summary deals only with ordinary shares or ADSs
acquired in the initial offering and held as capital assets within the meaning of Section&nbsp;1221 of the Internal Revenue Code
of 1986, as amended (the &ldquo;Code&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">This
section does not discuss the tax consequences to any particular holder, nor any tax considerations that may apply to holders subject
to special tax rules, such as:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">insurance
                                         companies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">financial
                                         institutions;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">individual
                                         retirement and other tax-deferred accounts;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">regulated
                                         investment companies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">real
                                         estate investment trusts;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">individuals
                                         who are former U.S. citizens or former long-term U.S. residents;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">brokers
                                         or dealers in securities or currencies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">traders
                                         that elect to use a mark-to-market method of accounting;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">investors
                                         in pass-through entities for U.S. federal income tax purposes;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">tax-exempt
                                         entities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in">&nbsp;</TD>
    <TD STYLE="width: 0.14in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    that hold ordinary shares or ADSs as a position in a straddle or as part of a hedging, constructive sale, conversion or other
    integrated transaction for U.S. federal income tax purposes;</FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">persons
                                         that have a functional currency other than the U.S. dollar;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">persons
                                         that own (directly, indirectly or constructively) 10% or more of our equity; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">persons
                                         that are not U.S. holders (as defined below).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">In
this section, a &ldquo;U.S. holder&rdquo; means a beneficial owner of ordinary shares or ADSs that is, for U.S. federal income
tax purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">an
                                         individual who is a citizen or resident of the United States;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">a
                                         corporation created or organized in or under the laws of the United States or any state
                                         thereof or the District of Columbia;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">an
                                         estate the income of which is subject to U.S. federal income taxation regardless of its
                                         source; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">a
                                         trust (i)&nbsp;the administration of which is subject to the primary supervision of a
                                         court in the United States and for which one or more U.S. persons have the authority
                                         to control all substantial decisions or (ii)&nbsp;that has an election in effect under
                                         applicable income tax regulations to be treated as a U.S. person.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">As used in this section,
a &ldquo;non-U.S. holder&rdquo; is a beneficial owner of ordinary shares or ADSs that is not a U.S. holder. An entity or arrangement
treated as a partnership or other pass-through entity for U.S. federal income tax purposes is considered a non-U.S. holder for
purposes of the tax discussion in this section .&nbsp;If an entity or arrangement treated as a partnership for U.S. federal income
tax purposes acquires, owns or disposes of ordinary shares or ADSs, the U.S. federal income tax treatment of a partner generally
will depend on the status of the partner and the activities of the partnership. Partners of partnerships that acquire, own or
dispose of ordinary shares or ADSs should consult their tax advisors.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
discussion below is based upon the provisions of the Code, and the U.S. Treasury regulations, rulings and judicial decisions thereunder
as of the date hereof, and such authorities may be replaced, revoked or modified, possibly with retroactive effect, so as to result
in U.S. federal income tax consequences different from those discussed below. In addition, this summary is based, in part, upon
representations made by the depositary to us and assumes that the deposit agreement, and all other related agreements, will be
performed in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black"><B><I>You
are urged to consult your own tax advisor with respect to the U.S. federal, as well as state, local and non-U.S., tax consequences
to you of acquiring, owning and disposing of ordinary shares or ADSs in light of your particular circumstances, including the
possible effects of changes in U.S. federal and other tax laws. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>ADSs
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">If you hold ADSs, you
generally will be treated, for U.S. federal income tax purposes, as the owner of the underlying ordinary shares that are represented
by such ADSs. Accordingly, deposits or withdrawals of ordinary shares for ADSs will not be treated as transactions subject to
U.S. federal income tax.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Distributions
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Subject
to the passive foreign investment company (&ldquo;PFIC&rdquo;) rules discussed below, U.S. holders generally will include as dividend
income the U.S. dollar value of the gross amount of any distributions of cash or property (without deduction for any withholding
tax), other than certain pro rata distributions of ordinary shares, with respect to ordinary shares to the extent the distributions
are made from our current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. A U.S. holder
will include the dividend income on the day actually or constructively received by the holder, in the case of ordinary shares,
or by the depositary, in the case of ADSs. To the extent, if any, that the amount of any distribution by us exceeds our current
and accumulated earnings and profits, as so determined, the excess will be treated first as a tax-free return of the U.S. holder&rsquo;s
tax basis in the ordinary shares or ADSs and thereafter as capital gain. Notwithstanding the foregoing, we do not intend to maintain
calculations of earnings and profits, as determined for U.S. federal income tax purposes. Consequently, any distributions generally
will be reported as dividend income for U.S. information reporting purposes. See &ldquo;Backup Withholding Tax and Information
Reporting Requirements&rdquo; below. Dividends paid by us will not be eligible for the dividends-received deduction generally
allowed to U.S. corporate shareholders.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Subject to certain exceptions
for short-term and hedged positions, the U.S. dollar amount of dividends received by an individual, trust or estate with respect
to the ordinary shares or ADSs will be subject to taxation at a maximum rate of 20% if the dividends are &ldquo;qualified dividends.&rdquo;
Dividends will be treated as qualified dividends if (a)&nbsp;certain holding period requirements are satisfied, (b)&nbsp; we are
eligible for benefits under the Convention between the Government of the United States of America and the Government of Australia
for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income, as amended (the &ldquo;Treaty&rdquo;)
or our ordinary shares or ADSs are readily tradable on a U.S. securities market, and (c)&nbsp;we were not, in the taxable year
prior to the year in which the dividend was paid, and are not, in the taxable year in which the dividend is paid, a PFIC. The
Treaty has been approved for the purposes of the qualified dividend rules and we have applied to list the ADSs on NASDAQ. We do
not believe we were a PFIC for our taxable year ended June 30, 2016, and do not expect to be a PFIC for our taxable year ended
June 30, 2017. However, our status as a PFIC in the current taxable year ending June 30, 2017 and future taxable years will depend
in part upon our use of the funds from the offering, as well as our income and assets (which for this purpose depends in part
on the market value of our shares) in those years. See the discussion below under &ldquo;&mdash;Passive Foreign Investment Company&rdquo;.
Dividends included by U.S. Holders in the amount of their net investment income when calculating limitations on the deductibility
of interest income are not treated as qualified dividends. You should consult your tax advisor regarding the availability of the
reduced tax rate on any dividends paid with respect to our ordinary shares or ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Dividends received by
an individual, trust or estate will be counted as investment income that is subject to the 3.8% surtax on net investment income.
You should consult your tax advisor to determine whether, based on all your investment income, you are subject to this tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>


<!-- Field: Page; Sequence: 122; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Includible
distributions paid in Australian dollars, including any Australian withholding taxes, will be included in the gross income of
a U.S. holder in a U.S. dollar amount calculated by reference to the spot exchange rate in effect on the date of actual or constructive
receipt, regardless of whether the Australian dollars are converted into U.S. dollars at that time. If Australian dollars are
converted into U.S. dollars on the date of actual or constructive receipt, the tax basis of the U.S. holder in those Australian
dollars will be equal to their U.S. dollar value on that date and, as a result, a U.S. holder generally should not be required
to recognize any foreign exchange gain or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">If
Australian dollars so received are not converted into U.S. dollars on the date of receipt, the U.S. holder will have a basis in
the Australian dollars equal to their U.S. dollar value on the date of receipt. Any gain or loss on a subsequent conversion or
other disposition of the Australian dollars generally will be treated as ordinary income or loss to such U.S. holder and generally
will be income or loss from sources within the United States for foreign tax credit limitation purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Dividends
received by a U.S. holder with respect to ordinary shares or ADSs will be treated as foreign source income, which may be relevant
in calculating the holder&rsquo;s foreign tax credit limitation. The limitation on foreign taxes eligible for credit is calculated
separately with respect to specific classes of income. For these purposes, dividends generally will be categorized as &ldquo;passive&rdquo;
or &ldquo;general&rdquo; income depending on a U.S. holder&rsquo;s circumstance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Subject
to certain complex limitations, a U.S. holder generally will be entitled, at its option, to claim either a credit against its
U.S. federal income tax liability or a deduction in computing its U.S. federal taxable income in respect of any Australian taxes
withheld. If a U.S. holder elects to claim a deduction, rather than a foreign tax credit, for Australian taxes withheld for a
particular taxable year, the election will apply to all foreign taxes paid or accrued by or on behalf of the U.S. holder in the
particular taxable year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">You
may not be able to claim a foreign tax credit (and instead may claim a deduction) for non-U.S. taxes imposed on dividends paid
on the ordinary shares or ADSs if you (i)&nbsp;have held the ordinary shares or ADSs for less than a specified minimum period
during which you are not protected from risk of loss with respect to such shares, or (ii)&nbsp;are obligated to make payments
related to the dividends (for example, pursuant to a short sale).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
availability of the foreign tax credit and the application of the limitations on its availability are fact specific and are subject
to complex rules. You are urged to consult your own tax advisor as to the consequences of Australian withholding taxes and the
availability of a foreign tax credit or deduction. See &ldquo;Australian Tax Considerations&mdash;<I>Taxation of Dividends</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Sale,
Exchange or other Disposition of Ordinary Shares or ADSs </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Subject to the PFIC
rules discussed below, a U.S. holder generally will, for U.S. federal income tax purposes, recognize capital gain or loss on a
sale, exchange or other disposition of ordinary shares or ADSs equal to the difference between the amount realized on the disposition
and the U.S. holder&rsquo;s tax basis (in U.S. dollars) in the ordinary shares or ADSs. This recognized gain or loss will generally
be long-term capital gain or loss if the U.S. holder has held the ordinary shares or ADSs for more than one year. Generally, for
U.S. holders who are individuals (as well as certain trusts and estates), long-term capital gains are subject to U.S. federal
income tax at preferential rates. For foreign tax credit limitation purposes, gain or loss recognized upon a disposition generally
will be treated as from sources within the United States. However, in limited circumstances, the Treaty can re-source U.S. source
income as Australian source income. The deductibility of capital losses is subject to limitations for U.S. federal income tax
purposes.<FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">You
should consult your own tax advisor regarding the availability of a foreign tax credit or deduction in respect of any Australian
tax imposed on a sale or other disposition of ordinary shares or ADSs. See &ldquo;Australian Tax Considerations&mdash;<I>Tax on
Sales or other Dispositions of Shares</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercise, Sale, and Expiration of the
Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder&rsquo;s
tax basis in the Warrants will be equal to the fair market value of the Warrants on the date of acquisition (and the holder&rsquo;s
basis in his ordinary shares will be reduced by the amount of the investment allocated to the Warrants). If a U.S. Holder subsequently
sells the Warrants, such holder will recognize capital gain or loss in an amount equal to the amount by which the consideration
received in the sale exceeds, or is less than, such holder's tax basis in the Warrants. The capital gain or loss will be long-term
if the U.S. holder's holding period in the Warrants is more than one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder who
subsequently exercises the Warrants will have no income, gain or loss upon such exercise. Such holder's tax basis in the ordinary
shares acquired on the exercise of the Warrants will equal the sum of the exercise price paid for the ordinary shares and the
U.S. holder's tax basis in the Warrants. The holder's holding period for the ordinary shares acquired in the exercise of the Warrants
will begin on the date the Warrants are exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 12.2pt">If a U.S. holder
allows the acquired Warrants to expire unexercised, the expiration of the Warrants will be treated as a sale or exchange of a
capital asset on the expiration date and the holder will realize a capital loss equal to the holder&rsquo;s basis in the Warrants.
Because the term of the Warrants is more than one year, the U.S. holder's resulting capital loss will be a long-term capital loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Passive
Foreign Investment Company </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">The Code provides special,
generally adverse, rules regarding certain distributions received by U.S. holders with respect to, and sales, exchanges and other
dispositions, including pledges, of, shares of stock of a PFIC. A foreign corporation will be a PFIC for any taxable year if at
least 75% of its gross income for the taxable year is passive income or at least 50% of its gross assets during the taxable year,
based on a quarterly average and generally determined by value, produce or are held for the production of passive income. Passive
income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from commodities
and securities transactions and gains from the disposition of assets that produce or are held for the production of passive income.
In determining whether a foreign corporation is a PFIC, a pro-rata portion of the income and assets of each corporation in which
it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Based on our business
results for the last fiscal year and the composition of our assets, we believe that we were not a PFIC for U.S. federal income
tax purposes for the taxable year ended June&nbsp;30, 2016. Similarly, based on our business projections and the anticipated composition
of our assets for our current taxable year ending June 30, 2017, we expect that we will not be a PFIC for such taxable year. However,
the determination of PFIC status is a factual determination that must be made annually at the close of each taxable year and therefore,
there can be no certainty as to our PFIC status for a taxable year until the close of that taxable year. Our PFIC status could
change depending upon, among other things, a decrease in the trading price of our ordinary shares or ADSs and how quickly we make
use of the proceeds from the offering, as well as changes in the composition and relative values of our assets and the composition
of our income. Moreover, the rules governing whether certain assets are active or passive are complex and in some cases their
application can be uncertain. If we were a PFIC in any year during a U.S. holder&rsquo;s holding period for the ordinary shares
or ADSs, we generally would continue to be treated as a PFIC for each subsequent year during which the U.S. holder owned the ordinary
shares or ADSs.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">If we are a PFIC
for any taxable year during which a U.S. holder holds ordinary shares or ADSs, any &ldquo;excess distribution&rdquo; that the
holder receives and any gain recognized from a sale or other disposition (including a pledge) of such ordinary shares or ADSs
will be subject to special tax rules, unless the holder makes a mark-to-market election or qualified electing fund election, as
discussed below. Any distribution in a taxable year that is greater than 125% of the average annual distribution received by a
U.S. holder during the shorter of the three preceding taxable years or such holder&rsquo;s holding period for the ordinary shares
or ADSs will be treated as an excess distribution. Under these special tax rules:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">the
                                         excess distribution or gain will be allocated ratably over the U.S. holder&rsquo;s holding
                                         period for the ordinary shares or ADSs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">the
                                         amount allocated to the current taxable year, and any taxable year prior to the first
                                         taxable year in which we were a PFIC in the U.S. holder&rsquo;s holding period, will
                                         be treated as ordinary income arising in the current taxable year; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         amount allocated to each other year will be subject to income tax at the highest rate
                                         in effect for that year and applicable to the U.S. holder and the interest charge generally
                                         applicable to underpayments of tax will be imposed on the resulting tax attributable
                                         to each such year.</FONT></TD>
</TR></TABLE>




<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">If we are a PFIC, the
tax liability for amounts allocated to years prior to the year of disposition or excess distribution cannot be offset by any net
operating loss, and gains (but not losses) recognized on the transfer of the ordinary shares or ADSs cannot be treated as capital
gains, even if the ordinary shares or ADSs are held as capital assets. In addition, non-corporate U.S. holders will not be eligible
for reduced rates of taxation on any dividends that we pay if we are a PFIC for either the taxable year in which the dividend
is paid or the preceding year. Furthermore, unless otherwise provided by the U.S. Treasury Department, each U.S. holder of a PFIC
is required to file an annual report (currently Form 8621) describing the holder&rsquo;s interest in the PFIC, making an election
on how to report PFIC income, and providing other information about the holder&rsquo;s share of the PFIC&rsquo;s income.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">If we are a PFIC for
any taxable year during which any of our non-U.S. subsidiaries is also a PFIC, a U.S. holder of ordinary shares or ADSs during
such year would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the
application of these rules to such subsidiary. You should consult your tax advisor regarding the tax consequences if the PFIC
rules apply to any of our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">In
                                         certain circumstances, in lieu of being subject to the special tax rules discussed above,
                                         you may make an election to include gain on the stock of a PFIC as ordinary income under
                                         a mark-to-market method, provided that such stock is regularly traded on a qualified
                                         exchange. Under current law, the mark-to-market election may be available to U.S. holders
                                         of ADSs if the ADSs are listed on NASDAQ, which constitutes a qualified exchange, although
                                         there can be no assurance that the ADSs will be &ldquo;regularly traded&rdquo; for purposes
                                         of the mark-to-market election. It should also be noted that it is intended that only
                                         the ADSs and not the ordinary shares will be listed on NASDAQ. While we would expect
                                         the Australian Stock Exchange, on which the ordinary shares are listed, to be considered
                                         a qualified exchange, no assurance can be given as to whether the Australian Stock Exchange
                                         is a qualified exchange, or that the ordinary shares would be traded in sufficient frequency
                                         to be considered regularly traded for these purposes. Additionally, because a mark-to-market
                                         election cannot be made for equity interests in any lower-tier PFIC that we may own,
                                         a U.S. holder that makes a mark-to-mark election with respect to us may continue to be
                                         subject to the PFIC rules with respect to any indirect investments held by us that are
                                         treated as an equity interest in a PFIC for U.S. federal income tax purposes. If you
                                         make an effective mark-to-market election, you will include in each year that we are
                                         a PFIC as ordinary income the excess of the fair market value of your ordinary shares
                                         or ADSs at the end of your taxable year over your adjusted tax basis in the ordinary
                                         shares or ADSs. You will be entitled to deduct as an ordinary loss in each such year
                                         the excess of your adjusted tax basis in the ordinary shares or ADSs over their fair
                                         market value at the end of the year, but only to the extent of the net amount previously
                                         included in income as a result of the mark-to-market election. If you make an effective
                                         mark-to-market election, any gain you recognize upon the sale or other disposition of
                                         your ordinary shares or ADSs in a year that we are a PFIC will be treated as ordinary
                                         income and any loss will be treated as ordinary loss, but only to the extent of the net
                                         amount previously included in income as a result of the mark-to-market election. Any
                                         gain or loss you recognize upon the sale or other disposition of your ordinary shares
                                         or ADSs in a year when we are not a PFIC will be a capital gain or loss. See &ldquo;<I>&mdash;Sale,
                                         Exchange or other Disposition of Ordinary Shares or ADSs&rdquo;</I> above for the treatment
                                         of capital gains and losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Your
adjusted tax basis in the ordinary shares or ADSs will be increased by the amount of any income inclusion and decreased by the
amount of any deductions under the mark-to-market rules. If you make a mark-to-market election, it will be effective for the taxable
year for which the election is made and all subsequent taxable years unless the ordinary shares or ADSs are no longer regularly
traded on a qualified exchange or the IRS consents to the revocation of the election. You are urged to consult your tax advisors
about the availability of the mark-to-market election, and whether making the election would be advisable in your particular circumstances.
In the case of a valid mark-to-market election, any distributions we make would generally be subject to the rules discussed above
under &ldquo;&mdash;<I>Taxation of Dividends</I>,&rdquo; except the reduced rates of taxation on any dividends received from us
would not apply if we are a PFIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Alternatively,
you can sometimes avoid the PFIC rules described above by electing to treat us as a &ldquo;qualified electing fund&rdquo; under
Section&nbsp;1295 of the Code. However, this option will not be available to you because we do not intend to comply with the requirements
necessary to permit you to make this election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">U.S.
holders are urged to contact their own tax advisors regarding the determination of whether we are a PFIC and the tax consequences
of such status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Backup
Withholding Tax and Information Reporting Requirements </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Payments
of dividends with respect to the ordinary shares or ADSs and proceeds from the sale, exchange or other disposition of the ordinary
shares or ADSs, by a U.S. paying agent or other U.S. intermediary, or made into the United States, will be reported to the IRS
and to the U.S. holder as may be required under applicable Treasury regulations. Backup withholding may apply to these payments
if the U.S. holder fails to provide an accurate taxpayer identification number or certification of exempt status or fails to comply
with applicable certification requirements. Certain U.S. holders (including, among others, corporations) are not subject to backup
withholding and information reporting. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding
rules from a payment to a U.S. holder will be refunded (or credited against such U.S. holder&rsquo;s U.S. federal income tax liability,
if any), provided the required information is timely furnished to the IRS. Prospective investors should consult their own tax
advisors as to their qualification for exemption from backup withholding and the procedure for establishing an exemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Certain individual U.S.
holders (and under Treasury regulations, certain entities) may be required to report to the IRS (on Form 8938) information with
respect to their investment in the ordinary shares or ADSs not held through an account with a U.S. financial institution. U.S.
holders who fail to report required information could become subject to substantial penalties. U.S. holders are encouraged to
consult with their own tax advisors regarding foreign financial asset reporting requirements with respect to their investment
in the ordinary shares or ADSs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">U.S.
holders who acquire any of the ordinary shares or ADSs for cash may be required to file an IRS Form 926 (Return by a U.S. Transferor
of Property to a Foreign Corporation) with the IRS and to supply certain additional information to the IRS if (i)&nbsp;immediately
after the transfer, the U.S. holder owns directly or indirectly (or by attribution) at least 10% of our total voting power or
value or (ii)&nbsp;the amount of cash transferred to us in exchange for the ordinary shares or ADSs when aggregated with all related
transfers under applicable regulations, exceeds U.S.$100,000. Substantial penalties may be imposed on a U.S. holder that fails
to comply with this reporting requirement. Each U.S. holder is urged to consult with its own tax advisor regarding this reporting
obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
discussion above is not intended to constitute a complete analysis of all tax considerations applicable to an investment in ordinary
shares or ADSs. You should consult with your own tax advisor concerning the tax consequences to you in your particular situation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Australian
Tax Considerations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">In this section, we discuss
the material Australian income tax, stamp duty and goods and services tax considerations related to the acquisition, ownership
and disposal by the absolute beneficial owners of the ordinary shares or ADSs. This discussion represents the opinion of, Australian
counsel to Immuron.&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">It
is based upon existing Australian tax law as of the date of this registration statement, which is subject to change, possibly
retrospectively. This discussion does not address all aspects of Australian tax law which may be &nbsp;important to particular
investors in light of their individual investment circumstances, such as shares held by investors subject to special tax rules
(for example, financial institutions, insurance companies or tax exempt organizations). In addition, this summary does not discuss
any foreign or state tax considerations, other than stamp duty and goods and services tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Prospective
investors are urged to consult their tax advisors regarding the Australian and foreign income and other tax considerations of
the acquisition, ownership and disposition of the shares. As used in this summary a &ldquo;Non-Australian Shareholder&rdquo; is
a holder that is not an Australian tax resident and is not carrying on business in Australia through a permanent establishment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Nature
of ADSs for Australian Taxation Purposes </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Ordinary
shares represented by ADSs held by a U.S. holder will be treated for Australian taxation purposes as held under a &ldquo;bare
trust&rdquo; for such holder. Consequently, the underlying ordinary shares will be regarded as owned by the ADS holder for Australian
income tax and capital gains tax purposes. Dividends paid on the underlying ordinary shares will also be treated as dividends
paid to the ADS holder, as the person beneficially entitled to those dividends. Therefore, in the following analysis we discuss
the tax consequences to Non-Australian Shareholders of ordinary shares for Australian taxation purposes. We note that the holder
of an ADS will be treated for Australian tax purposes as the owner of the underlying ordinary shares that are represented by such
ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Taxation
of Dividends </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Australia
operates a dividend imputation system under which dividends may be declared to be &ldquo;franked&rdquo; to the extent of tax paid
on company profits. Fully franked dividends are not subject to dividend withholding tax. An exemption for dividend withholding
tax can also apply to unfranked dividends that are declared to be conduit foreign income, or CFI, and paid to Non-Australian Shareholders.
Dividend withholding tax will be imposed at 30%, unless a shareholder is a resident of a country with which Australia has a double
taxation agreement and qualifies for the benefits of the treaty. Under the provisions of the current Treaty, the Australian tax
withheld on unfranked dividends that are not declared to be CFI paid by us to a resident of the United States which is beneficially
entitled to that dividend is limited to 15% where that resident is a qualified person for the purposes of the Treaty.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">If
a Non-Australian Shareholder is a company and owns a 10% or more interest, the Australian tax withheld on dividends paid by us
to which a resident of the United States is beneficially entitled is limited to 5%. In limited circumstances the rate of withholding
can be reduced to zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Tax
on Sales or other Dispositions of Shares&mdash;Capital gains tax </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Non-Australian
Shareholders will not be subject to Australian capital gains tax on the gain made on a sale or other disposal of ordinary shares,
unless they, together with associates, hold 10% or more of our issued capital, at the time of disposal or for 12&nbsp;months of
the last 2&nbsp;years prior to disposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Non-Australian Shareholders
who own a 10% or more interest would be subject to Australian capital gains tax if more than 50% of our direct or indirect assets,
determined by reference to market value, consists of Australian land, leasehold interests or Australian mining, quarrying or prospecting
rights. The Treaty is unlikely to limit Australia&rsquo;s right to tax any gain in these circumstances. Net capital gains are
calculated after reduction for capital losses, which may only be offset against capital gains.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Tax
on Sales or other Dispositions of Shares&mdash;Shareholders Holding Shares on Revenue Account </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Some
Non-Australian Shareholders may hold shares on revenue rather than on capital account for example, share traders. These shareholders
may have the gains made on the sale or other disposal of the shares included in their assessable income under the ordinary income
taxing provisions of the income tax law, if the gains are sourced in Australia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Non-Australian Shareholders
assessable under these ordinary income provisions in respect of gains made on shares held on revenue account would be assessed
for such gains at the Australian tax rates for non-Australian residents, which start at a marginal rate of 32.5%. This rate does
not include the Temporary Budget Repair Levy of 2% that applies in certain circumstances. Some relief from Australian income tax
may be available to Non-Australian Shareholders under the Treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">To
the extent an amount would be included in a Non-Australian Shareholder&rsquo;s assessable income under both the capital gains
tax provisions and the ordinary income provisions, the capital gain amount would generally be reduced, so that the shareholder
would not be subject to double tax on any part of the income gain or capital gain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Dual
Residency </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">If a shareholder
is a resident of both Australia and the United States under those countries&rsquo; domestic taxation laws, that shareholder may
be subject to tax as an Australian resident. If, however, the shareholder is determined to be a U.S. resident for the purposes
of the Treaty, the Australian tax would be subject to limitation by the Treaty. Shareholders should obtain specialist taxation
advice in these circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Stamp
Duty </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">No
stamp duty is payable by Australian residents or non-Australian residents on the issue and trading of shares that are quoted on
the ASX or NASDAQ at all relevant times and the shares do not represent 90% or more of all of our issued shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Australian
Death Duty </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Australia
does not have estate or death duties. As a general rule, no capital gains tax liability is realized upon the inheritance of a
deceased person&rsquo;s shares. The disposal of inherited shares by beneficiaries may, however, give rise to a capital gains tax
liability if the gain falls within the scope of Australia&rsquo;s jurisdiction to tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-align: justify"><FONT STYLE="color: Black"><B><I>Goods
and Services Tax </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
issue or transfer of shares to a non-Australian resident investor will not incur Australian goods and services tax.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_025"></A><FONT STYLE="color: Black"><B>UNDERWRITING
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We and the underwriters
named below have entered into an underwriting agreement, dated June 8, 2017, with respect to the ADSs being offered. Subject to
certain conditions, each underwriter has severally agreed to purchase the number of ADSs &nbsp;and Warrants indicated in the following
table. Joseph Gunner &amp; Co., LLC and Rodman &amp; Rendshaw, a unit of H.C. Wainwright &amp; Co., LLC are the representatives
of the underwriters.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Underwriters</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number&nbsp;of</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>ADSs</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number
    of Warrants</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 73%; text-align: justify"><FONT STYLE="font-size: 10pt">Joseph Gunner &amp; Co., LLC</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><P STYLE="margin: 0; text-align: right">305,000</P>


</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right">305,000</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Rodman &amp; Rendshaw, a unit of H.C. Wainwright
    &amp; Co., LLC</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">305,000</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">305,000</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">610,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">610,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">All
of the ADSs and Warrants to be purchased by the underwriters will be purchased from us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The underwriting
agreement provides that the obligations of the underwriters to pay for and accept delivery of the ADSs and Warrants offered by
us in this prospectus are subject to various conditions and representations and warranties, including the approval of certain
legal matters by their counsel and other conditions specified in the underwriting agreement. The ordinary shares in the form of
ADSs and Warrants are offered by the underwriters, subject to prior sale, when, as and if issued to and accepted by them. The
underwriters reserve the right to withdraw, cancel or modify the offer to the public and to reject orders in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The underwriting
agreement provides that the underwriters are obligated to take and pay for all of the ordinary shares in the form of ADSs and
Warrants offered by this prospectus if any such ADSs and Warrants are taken, other than those ADSs and Warrants covered by the
over-allotment option described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments
of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We have granted an
option to the underwriters to purchase up to 15% of the total number of ordinary shares in the form of ADSs and/or Warrants at
the initial public offering price per ADS and per Warrant, less the underwriting discount, set forth on the cover page of this
prospectus. This option is exercisable during the 45-day period after the date of this prospectus. The underwriters may exercise
this option only to cover over-allotments made in connection with this offering. If the underwriters exercise this option in whole
or in part, then the underwriters will be severally committed, subject to the conditions described in the underwriting agreement,
to purchase the additional ADSs and/or Warrants in proportion to their respective commitments set forth in the prior table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Discounts
and Commissions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The representatives
have advised us that the underwriters propose to offer the ordinary shares in the form of ADSs and Warrants to the public at the
initial public offering price per share set forth on the cover page of this prospectus. The underwriters may offer shares to securities
dealers at that price less a concession of not more than $0.45 per
ADS. After the initial offering to the public, the public offering price and other selling terms may be changed by the representative.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 128; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
following table summarizes the underwriting discounts and commissions and proceeds, before expenses, to us assuming both no exercise
and full exercise by the underwriters of their over-allotment option:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Per ADS</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Per Warrant&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Without</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Option</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>With</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Option</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">9.99</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">0.01</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">6,100,000</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">7,015,000</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions (7%)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">0.6993</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0.0007</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">427,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">491,050</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Non-accountable expense allowance (1%)(1)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">0.0999</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0.0001</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">61,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">70,150</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">9.1908</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0.0092</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">5,612,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">6,453,800</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The non-accountable expense allowance of 1%
    is not payable with respect to the ADS and per Warrant sold upon exercise of the underwriters&rsquo; over-allotment option.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;<FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">We
have paid an expense deposit of $25,000 to the representative, which will be applied against the out-of-pocket accountable expenses
that will be paid by us to the underwriters in connection with this offering, and will be reimbursed to us to the extent not incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">In
addition, we have also agreed to pay the following expenses of the underwriters relating to the offering: (a) all fees, expenses
and disbursements relating to background checks of our officers and directors in an amount not to exceed $15,000 in the aggregate;
(b) all filing fees and communication expenses associated with the review of this offering by FINRA; (c) all fees, expenses and
disbursements relating to the registration, qualification or exemption of securities offered under the securities laws of foreign
jurisdictions designated by the underwriter, including the reasonable fees and expenses of the underwriter&rsquo;s blue sky counsel
up to $5,000; (d) $29,500 for the underwriters&rsquo; use of Ipreo&rsquo;s book-building, prospectus tracking and compliance software
for this offering; (e) the underwriter&rsquo;s legal fees incurred in connection with this offering in an amount up to $50,000;
(f) $20,000 of the representative&rsquo;s actual accountable road show expenses for the offering; and (g) the costs associated
with bound volumes of the public offering materials as well as commemorative mementos and Lucite tombstones in an amount not to
exceed $2,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We estimate the expenses
of this offering payable by us, not including underwriting discounts and commissions, will be approximately $812,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Representative
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Upon the closing of
this offering, we have agreed to issue to the representative warrants, or the Representative&rsquo;s Warrants, to purchase a number
of ADSs equal to 5% of the ADSs sold in this public offering. The Representatives&rsquo; Warrants will be exercisable at a per
share exercise price equal to $12.50. The Representatives&rsquo; Warrants are exercisable at any time and from time to time, in
whole or in part, during the four year period commencing one year from the effective date of the registration statement related
to this offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The Representatives&rsquo;
Warrants and the ordinary shares underlying the Representatives&rsquo; Warrants have been deemed compensation by the Financial
Industry Regulatory Authority, or FINRA, and are therefore subject to a 180-day lock-up pursuant to Rule&nbsp;5110(g)(1) of FINRA.
The representative, or permitted assignees under such rule, may not sell, transfer, assign, pledge, or hypothecate the Representatives&rsquo;
Warrants or the securities underlying the Representatives&rsquo; Warrants, nor will the representative engage in any hedging, short
sale, derivative, put, or call transaction that would result in the effective economic disposition of the Representatives&rsquo;
Warrants or the underlying ordinary shares for a period of 180&nbsp;days from the effective date of the registration statement.
Additionally, the Representatives&rsquo; Warrants may not be sold transferred, assigned, pledged or hypothecated for a 180-day
period following the effective date of the registration statement except to any underwriter and selected dealer participating in
the offering and their bona fide officers or partners. The Representatives&rsquo; Warrants will provide for adjustment in the number
and price of the Representatives&rsquo; Warrants and the ordinary shares underlying such Representatives&rsquo; Warrants in the
event of recapitalization, merger, stock split or other structural transaction, or a future financing undertaken by us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Right of
First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Until twelve (12)
months from the effective date of this registration statement, the representatives shall have an irrevocable right of first refusal
to act as exclusive investment bankers, exclusive book-runners and/or exclusive placement agents, at the representatives sole discretion,
for each and every future public or private equity or debt offerings, including any equity linked financing, for the Company, or
any successor to or any subsidiary of the Company, on terms customary to the representatives. The representatives shall have the
exclusive right to determine whether or not any other broker-dealer shall have the right to participate in any such offering and
the economic terms of any such participation. The representatives will not have more than one opportunity to waive or terminate
the right of first refusal in consideration of any payment or fee.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We and each of our
directors and officers have agreed for a period of (i) three months after the date of this prospectus in the case of our directors
and officers and (ii) 180&nbsp;days after the date of this prospectus in the case of the Company, without the prior written consent
of the representative, not to directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">issue
                                         (in the case of us), offer, pledge, sell, contract to sell, sell any option or contract
                                         to purchase, purchase any option or contract to sell, grant any option, right or warrant
                                         to purchase, lend or otherwise transfer or dispose of any ordinary shares, ordinary shares
                                         in the form of ADSs or other capital stock or any securities convertible into or exercisable
                                         or exchangeable for our ordinary shares, ordinary shares in the form of ADSs or other
                                         capital stock;&nbsp;or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">in
                                         the case of us, file or cause the filing of any registration statement under the Securities
                                         Act with respect to any ordinary shares, ordinary shares in the form of ADSs or other
                                         capital stock or any securities convertible into or exercisable or exchangeable for our
                                         ordinary shares, ordinary shares in the form of ADSs or other capital stock; or&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">complete
                                         any offering of debt securities of the Company, other than entering into a line of credit
                                         with a traditional bank; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">enter
                                         into any swap or other agreement, arrangement, hedge or transaction that transfers to
                                         another, in whole or in part, directly or indirectly, any of the economic consequences
                                         of ownership of our ordinary shares, ordinary shares in the form of ADSs or other capital
                                         stock or any securities convertible into or exercisable or exchangeable for our ordinary
                                         shares, ordinary shares in the form of ADSs or other capital stock, whether any transaction
                                         described in any of the foregoing bullet points is to be settled by delivery of our ordinary
                                         shares, ordinary shares in the form of ADSs or other capital stock, other securities,
                                         in cash or otherwise, or publicly announce an intention to do any of the foregoing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Indemnification
of Underwriters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
underwriting agreement provides that we will indemnify the underwriters against certain liabilities that may be incurred in connection
with this offering, including liabilities under the Securities Act, or to contribute payments that the underwriters may be required
to make in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Listing</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">The ADSs and Warrants
are listed on the NASDAQ Capital Market under the symbols &ldquo;IMRN&rdquo; and &ldquo;IMRNW&rdquo;, respectively. In order to
meet the requirements for listing on that exchange, the underwriters have undertaken to sell a minimum number of ADSs and Warrants
to a minimum number of beneficial owners as required by that exchange.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">Prior to this
offering, there has been no active public market for the ADSs. The initial public offering price will be determined through
negotiations between us and the representatives. In determining the initial public offering price, we and the representatives
expect to consider a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the information set forth in
    this prospectus and otherwise available to the underwriters;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our prospects for future earnings;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our prospects and the history
    and prospects of the industry in which we compete;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">an assessment of our management;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the present state of our development;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the general condition of the
    securities markets at the time of this offering;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the recent market prices of,
    and demand for, our Ordinary Shares on the ASX and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the recent market prices of,
    and demand for, publicly traded common shares of generally comparable companies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">We and the underwriters
cannot assure you that an active trading market for the ADSs will develop or that ADSs will trade in the public market at or above
the initial public offering price after this offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">In connection with
this offering, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of our ordinary
shares, including ordinary shares in the form of ADSs. Specifically, the underwriters may over-allot in connection with this offering
by selling more ADSs than they are obligated to purchase under the underwriting agreement, creating a short position in our ADSs.
The short position may be either a covered short position or a naked short position. In a covered short position, the number of
ADSs over-allotted by the underwriter is not greater than the number of ADSs that it may purchase in the over-allotment option.
In a naked short position, the number of ADSs involved is greater than the number of ADSs in the over-allotment option. To close
out a short position or to stabilize the price of our ordinary shares, the underwriters may bid for, and purchase, ordinary shares,
including ordinary shares in the form of ADSs, in the open market. The underwriters may also elect to reduce any short position
by exercising all or part of the over-allotment option. In determining the source of ordinary shares, including ordinary shares
in the form of ADSs, to close out the short position, the underwriters will consider, among other things, the price of ordinary
shares available for purchase in the open market as compared to the price at which it may purchase ADSs through the over-allotment
option. If the underwriters sell more shares than could be covered by the over-allotment option, a naked short position, the position
can only be closed out by buying ordinary shares, including ordinary shares in the form of ADSs, in the open market. A naked short
position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of
the ADSs in the open market after pricing that could adversely affect investors who purchase in the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
underwriters may also impose a penalty bid. This occurs when a particular underwriter or dealer repays selling concessions allowed
to it for distributing our ordinary shares in the form of ADSs in this offering because the underwriter repurchases that stock
in stabilizing or short covering transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Finally, the underwriters
may bid for, and purchase, our ordinary shares, including ordinary shares in the form of ADSs, in market making transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
foregoing transaction may stabilize or maintain the market price of our ADSs at a price that is higher than the price that might
otherwise exist in the absence of these activities. The underwriters are not required to engage in these activities, and may discontinue
any of these activities at any time without notice. These transactions may be effected on NASDAQ or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_026"></A><FONT STYLE="color: Black"><B>EXPENSES
RELATING TO THIS OFFERING </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Set
forth below is an itemization of the estimated expenses, excluding underwriting discounts, that are expected to be incurred in
connection with our offer and sale of the ADSs. Expenses for the offering will be borne by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,979.30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">NASDAQ listing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financial Industry Regulatory Authority&nbsp;Inc. filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,249.22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">220,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">278,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Roadshow expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other fees and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,771.48</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">812,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_027"></A><FONT STYLE="color: Black"><B>LEGAL
MATTERS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The validity of the
ordinary shares represented by the ADSs &nbsp;and the Warrants to be issued in this offering will be passed upon for us by Francis
Abourizk Lightowlers, our Australian counsel. Certain matters as to U.S. federal law and New York state law will be passed upon
for us by Sichenzia Ross Ference Kesner LLP, our U.S. counsel. Loeb &amp; Loeb LLP is U.S. counsel to the underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 131; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_028"></A><FONT STYLE="color: Black"><B>EXPERTS
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">The audited consolidated
financial statements as of June 30, 2016 and 2015 and for the years ended June 30, 2016, 2015 and 2014 included in this prospectus
and elsewhere in the registration statement, have been so included in reliance upon the report of Marcum LLP, independent registered
public accounting firm, upon the authority of said firm as experts in accounting and auditing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_029"></A><FONT STYLE="color: Black"><B>ENFORCEABILITY
OF CIVIL LIABILITIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">We
are a public limited company incorporated under the laws of Australia. Certain of our directors are non-residents of the United
States and substantially all of their assets are located outside the United States. As a result, it may not be possible for you
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">effect
                                         service of process within the United States upon our non-U.S. resident directors or on
                                         us;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">enforce
                                         in U.S. courts judgments obtained against our non-U.S. resident directors or us in the
                                         United States courts in any action, including actions under the civil liability provisions
                                         of U.S. securities laws;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">enforce
                                         in U.S. courts judgments obtained against our non-U.S. resident directors or us in courts
                                         of jurisdictions outside the United States in any action, including actions under the
                                         civil liability provisions of U.S. securities laws; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.14in"><FONT STYLE="color: Black">&bull;</FONT></TD><TD><FONT STYLE="color: Black">bring
                                         an original action in an Australian court to enforce liabilities against our non-U.S.
                                         resident directors or us based solely upon U.S. securities laws.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">You
may also have difficulties enforcing in courts outside the United States judgments that are obtained in U.S. courts against any
of our non-U.S. resident directors or us, including actions under the civil liability provisions of the U.S. securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">With
that noted, there are no treaties between Australia and the United States that would affect the recognition or enforcement of
foreign judgments in Australia. We also note that investors may be able to bring an original action in an Australian court against
us to enforce liabilities based in part upon U.S.&nbsp;federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">The
disclosure in this section is not based on the opinion of counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">We have appointed Delaney
Corporate Services Ltd. at 99 Washington Avenue, Suite 805A, Albany, New York 12210, as our agent to receive service of process
with respect to any action brought against us in the U.S. District Court for the Southern District of New York under the federal
securities laws of the United States or any action brought against us in the Supreme Court of the State of New York in the County
of New York under the securities laws of the State of New York.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_030"></A><FONT STYLE="color: Black"><B>WHERE
YOU CAN FIND ADDITIONAL INFORMATION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">We
have filed with the SEC a registration statement on Form&nbsp;F-1, including relevant exhibits and schedules, under the Securities
Act with respect to the ordinary shares to be sold in this offering. This prospectus, which constitutes a part of the registration
statement, summarizes material provisions of contracts and other documents that we refer to in this prospectus. Since this prospectus
does not contain all of the information contained in the registration statement, you should read the registration statement and
its exhibits and schedules for further information with respect to us and our ordinary shares represented by ADSs. Statements
contained in this prospectus regarding the contents of any agreement, contract or other document referred to are not necessarily
complete and reference is made in each instance to the copy of the contract or document filed as an exhibit to the registration
statement. All information we file with the SEC is available through the SEC&rsquo;s Electronic Data Gathering, Analysis and Retrieval
system, which may be accessed through the SEC&rsquo;s website at www.sec.gov. Information filed with the SEC may also be inspected
and copied at the public reference room maintained by the SEC at 100&nbsp;F Street, N.E., Washington, D.C. 20549. You can request
copies of these documents upon payment of a duplicating fee, by writing to the SEC. Please visit the SEC&rsquo;s website at www.sec.gov
for further information on the SEC&rsquo;s public reference room.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">Immediately
upon completion of this offering, we will become subject to periodic reporting and other informational requirements of the Exchange
Act as applicable to foreign private issuers. Our annual reports on Form&nbsp;20-F for the year ending June&nbsp;30, 2017 and
subsequent years will be due within four months following the fiscal year end. We are not required to disclose certain other information
that is required from U.S. domestic issuers. As a foreign private issuer, we are exempt under the Exchange Act from, among other
things, the rules prescribing the furnishing and content of proxy statements, and our executive officers, directors and principal
shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange
Act and Regulation&nbsp;FD (Fair Disclosure), which was adopted to ensure that select groups of investors are not privy to specific
information about an issuer before other investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="color: Black">We
are, however, still subject to the anti-fraud and anti-manipulation rules of the SEC, such as Rule&nbsp;10b-5. Since many of the
disclosure obligations required of us as a foreign private issuer are different than those required by companies filing as a domestic
issuer, our shareholders, potential shareholders and the investing public in general should not expect to receive information
about us in the same amount and at the same time as information is received from, or provided by, companies filing as a domestic
issuer. We are liable for violations of the rules and regulations of the SEC, which do apply to us as a foreign private issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_031"></A><FONT STYLE="color: Black"><B>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Financial Statements for June 30, 2016, 2015 and 2014 and the years then ended</FONT></TD>
    <TD STYLE="width: 10%; line-height: 115%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%; padding-left: 0.125in"><A HREF="#fin_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="line-height: 115%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%; padding-left: 0.125in"><A HREF="#fin_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Profit or Loss and Other Comprehensive Income for the Years Ended June 30, 2016, 2015 and 2014</FONT></A><P STYLE="margin: 0pt 0"></P>


</TD>
    <TD STYLE="line-height: 115%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%; padding-left: 0.125in"><A HREF="#fin_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Financial Position as of June 30, 2016 and 2015</FONT></A></TD>
    <TD STYLE="line-height: 115%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%; padding-left: 0.125in"><A HREF="#fin_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Changes in Equity for the Year Ended June 30, 2016, 2015 and 2014</FONT></A></TD>
    <TD STYLE="line-height: 115%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%; padding-left: 0.125in"><A HREF="#fin_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Cash Flows for the Year Ended June 30, 2016, 2015 and 2014</FONT></A></TD>
    <TD STYLE="line-height: 115%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%; padding-left: 0.125in"><A HREF="#fin_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="line-height: 115%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt">Consolidated Financial Statements for December 31, 2016 and the Six Months
    Ended December 31, 2016 and 2015 (unaudited)</FONT></TD>
    <TD STYLE="width: 10%; text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><A HREF="#fin2_01"><FONT STYLE="font-size: 10pt">Consolidated Statement of Profit or Loss and
    Other Comprehensive Income for the Six Months Ended December 31, 2016 and 2015 (unaudited)</FONT></A></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-50</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><A HREF="#fin2_02"><FONT STYLE="font-size: 10pt">Consolidated Statement of Financial Position
    as of December 31, 2016 (unaudited) &nbsp;and June 30, 2016</FONT></A></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-51</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><A HREF="#fin2_03"><FONT STYLE="font-size: 10pt">Consolidated Statement of Changes in Equity
    for the Six Months Ended December 31, 2016 and 2015 (unaudited)</FONT></A></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-52</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><A HREF="#fin2_04"><FONT STYLE="font-size: 10pt">Consolidated Statement of Cash Flows for the
    Six Months Ended December 31, 2016 and 2015 (unaudited)</FONT></A></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-53</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><A HREF="#fin2_05"><FONT STYLE="font-size: 10pt">Notes to Consolidated Financial Statements
    (unaudited)</FONT></A></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-54</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 134; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="fin_001"></A><U>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Audit Committee of the</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Board of Directors and Shareholders</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">of Immuron Limited</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated
statements of financial position of Immuron Limited (the &ldquo;Company&rdquo;) as of June 30, 2016 and 2015, and the related
consolidated statements of profit or loss and other comprehensive income, changes in equity and cash flows for the years ended
June 30, 2016, 2015 and 2014. These financial statements are the responsibility of the Company&rsquo;s management. Our responsibility
is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance
with the standards of the Public Company Accounting Oversight Board (United States).&nbsp; Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.&nbsp;
<FONT STYLE="font-weight: normal; font-style: normal">The Company is not required to have, nor were we engaged to perform, an
audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting
as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such
opinion.</FONT>&nbsp; An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating
the overall financial statement presentation.&nbsp; We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In our opinion, the financial statements referred
to above present fairly, in all material respects, the consolidated financial position of Immuron Limited as of June 30, 2016
and 2015, and the consolidated results of its operations and its cash flows for the years ended June 30, 2016, 2015 and 2014 in
conformity with International Financial Reporting Standards, as issued by the International Accounting Standards Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described in Notes 2, 17, 18 and 20, the
consolidated financial statements as of June 30, 2016 and for the years ended June 30, 2016, 2015 and 2014 have been restated
to give effect for errors in the classification of customer discounts and allowances as a reduction to revenue, measurement and
recognition of share-based payments, the accounting for equity issued in connection with convertible debt and certain amounts
reflected in the statements of cash flows. Further, as described in Note 6 in the consolidated financial statements, the loss
per share for each year has been restated. In addition, as described in Note 1t(ii), the Company has made certain revisions to
the footnotes to the consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Philadelphia, Pennsylvania<BR>
December 20, 2016</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%"><A NAME="fin_002"></A><FONT STYLE="font-size: 12pt; color: Black"><B>Consolidated Statement of Profit
    or Loss and Other Comprehensive Income </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: Black"><B>For the year ended 30 June</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: Black">2016</FONT><BR> <FONT STYLE="color: Black">(Restated)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: Black">2015</FONT><BR> <FONT STYLE="color: Black">(Restated)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: Black">2014</FONT><BR> <FONT STYLE="color: Black">(Restated)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">Notes</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">AUD$</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">AUD$</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">AUD$</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline"><FONT STYLE="color: Black">Revenue</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="color: Black">Operating
    Revenue</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: Black">2</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">1,001,077</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">1,002,380</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">981,051</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">Total Operating Revenue</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="color: Black">1,001,077</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="color: Black">1,002,380</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="color: Black">981,051</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">Cost of Goods Sold</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(301,435</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(316,128</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(277,928</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">Gross Profit</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="color: Black">699,642</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="color: Black">686,252</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="color: Black">703,123</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left"><FONT STYLE="color: Black">Direct Selling Costs</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: Black">Sales and Marketing Costs</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(133,781</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(76,794</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(79,796</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="color: Black">Freight Costs</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(134,967</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(116,379</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(114,278</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">Total Gross Profit less Direct Selling Costs</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="color: Black">430,894</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="color: Black">493,079</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="color: Black">509,049</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">Other Income</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">2</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">1,539,015</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">1,591,021</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">804,477</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline"><FONT STYLE="color: Black">Expenses</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="color: Black">Amortisation</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(680,587</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: Black">Consulting, Employee and Director</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">3</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(2,840,037</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(728,140</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(555,487</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: Black">Corporate Administration</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">3</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(1,320,570</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(557,422</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(492,465</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="color: Black">Depreciation</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(3,892</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(3,719</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(3,989</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: Black">Finance Costs</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(341,600</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(463,685</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="color: Black">Impairment of Inventory</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(4,176</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(35,340</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(50,204</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: Black">Marketing and Promotion</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(487,591</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(304,687</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(235,176</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: Black">Research and Development</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(3,623,961</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(3,018,294</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">(1,289,675</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="color: Black">Travel and Entertainment</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(416,849</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(128,318</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(37,327</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">Loss Before Income Tax</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="color: Black">(7,068,767</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="color: Black">(2,691,820</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="color: Black">(2,495,069</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">Income Tax Expense</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: Black">4</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">Loss for the Period</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="color: Black">(7,068,767</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="color: Black">(2,691,820</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="color: Black">(2,495,069</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">Other Comprehensive Income (Loss)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">8,846</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">(12,581</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: Black">Total Comprehensive Loss
    for the Period</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="color: Black">(7,059,921</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="color: Black">(2,704,401</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="color: Black">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="color: Black">(2,495,069</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: Black">Basic/Diluted Loss per Share (cents per share)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">6</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">9.248</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">3.592</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">5.947</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The accompanying
notes form part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%"><A NAME="fin_003"></A><FONT STYLE="font-size: 12pt; color: Black"><B>Consolidated Statement of Financial
    Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: Black"><B>As of 30 June </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="color: Black; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="color: Black">&nbsp;</TD>
    <TD NOWRAP STYLE="color: Black; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center">2016<BR> (Restated)</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center">2015</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="color: Black; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Notes</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-decoration: underline">ASSETS</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Current Assets</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; color: Black; text-align: left; text-indent: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 12%; color: Black; text-align: center">7</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: Black; text-align: right">2,290,639</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: Black; text-align: right">3,116,074</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; text-indent: 10pt">Trade and other receivables</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center">8</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">4,387,772</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">1,691,629</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-indent: 10pt">Inventories</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center">9</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">2,056,067</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">1,146,267</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; padding-bottom: 1pt; text-indent: 10pt">Other</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 1pt">10</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">74,943</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">44,928</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Assets</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">8,809,421</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">5,998,898</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Non-Current
    Assets</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Property, plant and equipment</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 1pt">12</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">18,063</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">19,514</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Non-Current Assets</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">18,063</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">19,514</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL ASSETS</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">8,827,484</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">6,018,412</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-decoration: underline">LIABILITIES</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Current liabilities</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left; text-indent: 10pt">Trade and other payables</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center">14</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">1,986,407</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">1,207,810</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-indent: 10pt">Borrowings</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center">22</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">772,397</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other financial liabilities</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 1pt">15</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">1,128,117</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Liabilities</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">3,886,921</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">1,207,810</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">3,886,921</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">1,207,810</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET ASSETS</TD><TD STYLE="color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">4,940,563</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">4,810,602</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-decoration: underline">EQUITY</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left; text-indent: 10pt">Issued capital</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center">17</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">45,633,354</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">40,335,347</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-indent: 10pt">Reserves</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center">18</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">2,128,566</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">548,065</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Accumulated losses</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(42,821,357</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(36,072,810</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL EQUITY</TD><TD STYLE="color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="color: Black; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">4,940,563</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">4,810,602</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The accompanying
notes form part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%"><A NAME="fin_004"></A><FONT STYLE="font-size: 12pt; color: Black"><B>Consolidated Statement of Changes
    in Equity </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: Black"><B>For the year ended 30 June </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="color: Black; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center">Issued&nbsp;&nbsp;capital</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center">Reserves</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center">Accumulated<BR> Losses</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black; text-align: center">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; color: Black">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; color: Black">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; color: Black">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Balance as at 30 June 2013
    (see Note 1(d))</TD><TD STYLE="width: 1%; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">31,357,697</TD><TD STYLE="width: 1%; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">1,208,271</TD><TD STYLE="width: 1%; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(31,756,833</TD><TD STYLE="width: 1%; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">809,135</TD><TD STYLE="width: 1%; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left">Total comprehensive loss for the period</TD><TD STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; text-align: right">-</TD><TD STYLE="color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; text-align: right">-</TD><TD STYLE="color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; text-align: right">(2,495,069</TD><TD STYLE="color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; text-align: right">(2,495,069</TD><TD STYLE="color: Black; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-style: italic; text-decoration: underline; text-align: left">Transactions with owners in their
    capacity as owners</TD><TD STYLE="color: Black; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-indent: 10pt">Shares issued, net of costs</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">8,967,598</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">8,967,598</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left; text-indent: 10pt">Options issued</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">211,721</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">211,721</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; text-indent: 10pt">Employee and consultant share options</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">7,191</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">7,191</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; padding-bottom: 1pt; text-indent: 10pt">Lapse or exercise of share options</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(760,591</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">760,591</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">Balance as at 30 June 2014</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">40,325,295</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">666,592</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(33,491,311</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">7,500,576</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Loss after income tax expense for the year</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(2,691,820</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(2,691,820</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1pt">Other comprehensive loss for the period</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(12,581</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(12,581</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Total comprehensive loss for the period</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(12,581</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(2,691,820</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(2,704,401</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-style: italic; text-decoration: underline; text-align: left">Transactions with owners in their
    capacity as owners</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left; text-indent: 10pt">Employee and consultant share options</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">4,375</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">4,375</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-indent: 10pt">Lapse or exercise of share options</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(110,321</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">110,321</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; padding-bottom: 1pt; text-indent: 10pt">Shares issued, net of costs</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">10,052</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">10,052</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">Balance as at 30 June 2015</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">40,335,347</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">548,065</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(36,072,810</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">4,810,602</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Loss after income tax expense for the year (restated)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(7,068,767</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(7,068,767</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1pt">Other comprehensive income for the period</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">8,846</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">8,846</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Total comprehensive loss for the period
    (restated)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">8,846</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(7,068,767</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(7,059,921</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-style: italic; text-decoration: underline; text-align: left">Transactions with owners in their
    capacity as owners</TD><TD STYLE="color: Black; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="color: Black; font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left; text-indent: 10pt">Options issued/expensed (restated)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">1,891,875</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">1,891,875</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-indent: 10pt">Lapse or exercise of share options</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(320,220</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">320,220</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-indent: 10pt">Shares issued, net of costs</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">1,586,629</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">1,586,629</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; text-indent: 10pt">Share to be issued</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">4,511,378</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">4,511,378</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; padding-bottom: 1pt; text-indent: 10pt">Treasury shares (restated)</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(800,000</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(800,000</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">Balance as at 30 June 2016 (Restated)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">45,633,354</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">2,128,566</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(42,821,357</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">4,940,563</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The accompanying
notes form part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%"><A NAME="fin_005"></A><FONT STYLE="font-size: 12pt; color: Black"><B>Consolidated Statement of Cash
    Flows</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: Black"><B>For the year ended 30 June</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="color: Black; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="color: Black">&nbsp;</TD>
    <TD NOWRAP STYLE="color: Black; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center">2016<BR> (Restated)</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center">2015</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center">2014<BR> (Restated)</TD><TD NOWRAP STYLE="color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black; text-align: center">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Note</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Cash flows Related
    to Operating Activities</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; color: Black; text-align: left">Receipts from customers</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 12%; color: Black">&nbsp;</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: Black; text-align: right">1,114,596</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: Black; text-align: right">1,402,958</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: Black; text-align: right">541,788</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Payments to suppliers and employees</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(7,710,997</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(5,286,772</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(3,787,497</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Interest received</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">12,165</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">112,440</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">88,345</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Interest and other costs of finance paid</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(43,863</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">27,991</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(159,864</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1pt">Other - R&amp;D Tax Concession Refund</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">1,469,763</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">722,450</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">666,651</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Used In Operating Activities</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; font-weight: bold; text-align: center; padding-bottom: 1pt">20</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(5,158,336</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(3,020,933</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(2,650,577</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Cash Flows Related
    to Investing Activities</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1pt">Payment for purchases of plant and equipment</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(2,441</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(3,168</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(15,901</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Used In Investing Activities</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(2,441</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(3,168</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(15,901</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Cash Flows Related
    to Financing Activities</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Proceeds from issues of securities</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">2,482,861</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">9,665,724</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Capital raising costs</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(20,299</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(1,614</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(819,168</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Proceeds from borrowings</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">2,950,000</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">420,000</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; padding-bottom: 1pt">Repayment of borrowings</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(1,077,220</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(1,905,001</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows From/(Used In) Financing
    Activities</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">4,335,342</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">(1,614</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">7,361,555</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">&nbsp;</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Net increase/(decrease) in cash and cash equivalents</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(825,435</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(3,025,715</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">4,695,077</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at the beginning of the year</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">3,116,074</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">6,141,789</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">1,446,712</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents at the End
    of the Year</TD><TD STYLE="color: Black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">2,290,639</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">3,116,074</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; color: Black; font-weight: bold; text-align: right">6,141,789</TD><TD STYLE="padding-bottom: 2.5pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The accompanying
notes form part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid"><A NAME="fin_006"></A><FONT STYLE="font-size: 12pt"><B>Notes to the
    Consolidated Financial Statements</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-weight: normal; color: Black">Note
1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="color: Black">Summary of Significant Accounting Policies</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Corporate Information</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The consolidated
financial report of Immuron Limited (&lsquo;the Company&rsquo;, &lsquo;Group&rsquo;) for the year ended 30 June 2016, 2015 and
2014 was authorised for issue in accordance with a resolution of the Directors on December 20, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Immuron Limited
is a listed public company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian
Securities Exchange (ASX).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The principal
activity of the Company is a product development driven biopharmaceutical Company focused on the research and development of polyclonal
antibodies for the treatment and prevention of major diseases.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Basis of Preparation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The financial
report is a general-purpose financial report, which has been prepared in accordance with the requirements of International Financial
Reporting Standards (IFRS), required for a for-profit entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The financial
report has been prepared on an accruals basis and is based primarily on historical costs. The financial report is presented in
Australian dollars, which is the Company&rsquo;s functional and presentation currency. All values are rounded to the nearest dollar
unless otherwise stated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Management
is required to make judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily
apparent from other sources. The estimates and associated assumptions are based on historical experience and various other factors
that are believed to be reasonable under the circumstance, the results of which form the basis of making the judgements. Actual
results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions
to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period,
or in the period of the revision and future periods if the revision affects both current and future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Judgements
made by management in the application of IFRS that have significant effects on the financial statements and estimates with a significant
risk of material adjustments in the next year are disclosed, where applicable, in the relevant notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Accounting
policies are selected and applied in a manner which ensures that the resulting financial information satisfies the concepts of
relevance and reliability, thereby ensuring that the substance of the underlying transactions or other events is reported.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Statement of Compliance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">This financial
report complies with International Financial Reporting Standards (&quot;IFRS&quot;) as issued by the International Accounting
Standards Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">New, revised or amending
Accounting Standards and Interpretations adopted</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The Company
has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting
Standards Board ('IASB') that are mandatory for the current reporting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">There were
no significant new standards adopted during the reporting periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Accounting
Standards and Interpretations that have recently been issued or amended but are not yet effective and have not been adopted by
the Group for the annual reporting period ending 30 June 2016 are outlined in the table below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center; width: 66%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Standard</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Mandatory&nbsp;date&nbsp;for&nbsp;annual</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>reporting&nbsp;periods&nbsp;</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>beginning&nbsp;on&nbsp;or&nbsp;after</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Reporting&nbsp;period&nbsp;standard</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>adopted&nbsp;by&nbsp;the&nbsp;company</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Clarification of Acceptable Methods
    of Depreciation and Amortisation (Amendments to IAS 16 and IAS 38)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 January
    2016</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 July
    2016</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IFRS 15 Revenue from Contracts
    with Customers</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 January
    2018</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 July
    2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Annual improvements 2012 &ndash;
    2014 cycle</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 January
    2016</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 July
    2016</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Disclosure Initiative (Amendments
    to IAS 1)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 January
    2016</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 July
    2016</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IFRS 16 - Leases</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 January
    2019</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 July
    2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IFRS 2 Share-based payments -
    Amendments</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 January
    2018</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 July
    2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IAS 12 Income tax &ndash; Amendments
    on recognition of deferred tax assets for unrealized losses</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 January
    2017</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 July
    2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IAS 7 Statement of cash flows
    &ndash; Amendments on additional disclosures</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 January
    2017</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1 July
    2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Management has determined that the
standards that have been adopted in fiscal year 2017 have not had a material impact on the Group. Management is currently assessing
the impact of the standards to be adopted in fiscal year 2018 and forward on the Group. The Company has adopted IFRS 9 (2014)
prior to its effective date. This adoption did not have a material impact on its financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><U>Accounting Policies</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The following
is a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting
policies have been consistently applied, unless otherwise stated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(a)</B></FONT></TD><TD><FONT STYLE="color: Black">Basis
                                         of Consolidation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">The
consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its
subsidiaries) referred to as &lsquo;the Group&rsquo; in the financial statements. Control is achieved where the consolidated entity
is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns
through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is
transferred to the consolidated entity. They are de-consolidated from the date that control ceases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">A
list of controlled entities is contained in Note 11 to the financial statements. All controlled entities have a 30 June financial
year-end.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">All
intra-group transactions, balances, income and expenses are eliminated in full on consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Accounting
policies of subsidiaries have been changed where necessary to ensure consistency with those policies applied by the parent entity.
Subsidiaries are accounted for at cost in the parent entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">The
results of subsidiaries acquired or disposed of during the year are included in profit or loss from the effective date of acquisition
or up to the effective date of disposal, as appropriate.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(b)</B></FONT></TD><TD><FONT STYLE="color: Black">Segment
                                         Reporting</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">The
Company determines and presents operating segments using the &lsquo;management approach&rsquo; where the information presented
is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM are responsible
for the allocation of resources to operating segments and assessing their performance and provide the strategic direction and
management oversight of the day to day activities of the entity in terms of monitoring results, providing approval for research
and development expenditure decisions and challenging and approving strategic planning for the business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(c)</B></FONT></TD><TD><FONT STYLE="color: Black">Foreign
                                         Currency Translation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="color: Black"><I><U>Functional and
Presentation Currency</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Items
included in the financial statements are measured using the currency of the primary economic environment in which the entity operates
(&ldquo;the functional currency&rdquo;). The financial statements are presented in Australian dollars, which is the Company&rsquo;s
functional and presentation currency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="color: Black"><I><U>Transactions and
Balances</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Transactions
in foreign currencies are translated into the functional currency using the rates of exchange ruling at the date of each transaction.
At reporting date, amounts outstanding in foreign currencies are translated into the functional currency using the rate of exchange
ruling at the end of the financial year. Refer to Note 3 for the foreign currency gains and losses recognized during the periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Foreign
exchange gains and losses that relate to borrowings are presented in the statement of profit or loss and other comprehensive income,
within finance costs. All other foreign exchange gains and losses are presented in the statement of profit or loss and other comprehensive
income on a net basis within Corporate Administration Costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Immuron
Inc., a subsidiary of the Group, has USD as its functional currency. Accordingly, this entity&rsquo;s balance sheet and income
statement balances have been translated to the Group&rsquo;s presentation currency (which is AUD$) at the reporting date. A gain
arising from this translation of AUD$8,846 (2015: loss of AUD$12,581) are recognized as Other Comprehensive Income for the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(d)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Revenue
                                         Recognition</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Revenue
is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade
allowances, rebates and amounts collected on behalf of third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">The
Company recognises revenue when the amount of the revenue can be reliably measured, it is probable that the future economic benefits
will flow to the entity and specific criteria have been met for each of the activities as described below. The amount of the revenue
is not considered to be reliably measured until all contingencies relating to the sale have been resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">The
following specific revenue criteria must be met before revenue is recognized:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(iv)</FONT></TD>
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Sale
    of Goods and services&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ndash;</FONT></TD>
    <TD STYLE="width: 58%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Significant
    risks and rewards of ownership of goods has passed to the buyer and an invoice for the goods or services is issued;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(v)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Interest</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Interest
    income is recognized using the effective interest rate method;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(vi)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">R
    &amp; D Tax Refund</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Income
    is recognized in the year the research and development &nbsp;expenses were incurred.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">A difference of AUD$644,149
in the Accumulated losses balance at 30 June 2013 between this statement and the original statement lodged with ASX relates to
the previous recognition of FY13 R&amp;D refund in FY14, which does not significantly affect the overall financial position and
results presented in the original statement. For the fiscal year 2014, 2015 and 2016, the Company has reassessed and made changes
to the amount of R&amp;D Tax Refund recognised as Other Income for the period as compared to the previous statements lodged with
the ASX. Effectively, these changes resulted&nbsp; in an increase of AUD$49,481 and AUD$756,131 in Other income, resulting in
a related decrease in the net loss, for the period on the Consolidated Statement of Profit or Loss and Other Comprehensive Income
for the fiscal year 2014 and 2015. These changes also resulted in a decrease in Other income of AUD$1,469,763, and a related increase
in Net Loss, for the period on the Consolidated Statement of Profit or Loss and Other Comprehensive Income for fiscal year 2016.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">These adjustments were the
result of additional information being made available to the Company subsequent to the previous lodgements with ASX which changed
the timing of recognition, but not the actual amount of the R&amp;D refund; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company has worked with
experienced advisors to improve its internal process on advanced findings of the R&amp;D activities, which includes determining
and evaluating the eligibility of R&amp;D related expenditure to support its submission of the R&amp;D Tax Refund claim.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt">&nbsp;<FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(e)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Government
                                         Grants</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify"><FONT STYLE="color: Black">Grants
from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received and
the Company will comply with all attached conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify"><FONT STYLE="color: Black">Government
grants relating to costs to be incurred are deferred or accrued such that they are recognized in the statement of profit or loss
and other comprehensive income over the period necessary to match them with the costs that they are intended to compensate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(f)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Income
                                         Tax</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify"><FONT STYLE="color: Black">The
income tax expense or revenue for the period is the tax payable or tax rebate receivable on the current period&rsquo;s taxable
income adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax base of
assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Deferred
income tax is provided in full, using the liability method on temporary differences arising between the tax bases of assets and
liabilities and their carrying amounts in the financial statements. However, the deferred income tax is not accounted for if it
arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of
the transaction affects neither the accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and
laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred
income tax is realized or the deferred income tax liability is settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Deferred
tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable
amounts will be available to utilize those temporary differences and losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred
tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and
when the deferred balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the
entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle
the liability simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Current
and deferred tax balances attributable to amounts recognized directly in equity are also recognized directly in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(g)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Impairment
                                         of Assets</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Assets
are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss is recognized for the amount by which the asset&rsquo;s carrying amount exceeds its recoverable amount. The
recoverable amount is the higher of an asset&rsquo;s fair value less costs to sell and value in use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(h)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Cash
                                         and Cash Equivalents</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">For
presentation purposes, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other
short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts
of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(i)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Trade
                                         Receivables</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Trade
receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate
method, less provision for impairment. Trade receivables are due for settlement no more than 30 days from the date of recognition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Collectability
of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off. A provision for
impairment of trade receivables is established when there is objective evidence that the Company will not be able to collect all
amounts due according to the original terms of receivables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Significant
financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganisation and default
or delinquency in payment (more than 30 days overdue) are considered indicators that the trade receivable is impaired. The amount
of the provision is the difference between the asset&rsquo;s carrying amount and the present value of estimated future cash flows,
discounted at the original effective interest rate. Cash flows relating to short term receivables are not discounted if the effect
of discounting is immaterial. The amount of the provision is recognized in the statement of profit or loss and other comprehensive
income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(j)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Inventories</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Raw
materials, work in progress and finished goods are stated at the lower of cost and net realisable value. Where appropriate, cost
comprises direct materials, direct labor and an appropriate proportion of variable and fixed overheads expenditure, the latter
being allocated on the basis of normal operating capacity. The Company classifies inventory as a current asset as all amounts
are held for the purpose of trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Costs
are assigned to individual items of inventory on basis of weighted average costs. Net realisable value is the estimated selling
price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the
sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(k)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Property,
                                         Plant &amp; Equipment</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Plant
and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable
to the acquisition of the items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Repairs
and maintenance are charged to the statement of profit or loss and other comprehensive income during the financial period in which
they are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Depreciation
on assets is calculated using the straight line method to allocate their cost, net of their residual values, over their estimated
useful lives, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -17.85pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.6in">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">-</FONT></TD>
    <TD NOWRAP STYLE="width: 20%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Plant
    &amp; Equipment</FONT></TD>
    <TD NOWRAP STYLE="width: 75%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(3
    - 15 years)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">-</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Computer
    Equipment</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(2
    - 4 years)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">-</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Furniture
    &amp; Fittings</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(3
    - 15 years)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -17.85pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">The
assets&rsquo; residual values and useful lives are reviewed, and adjusted if appropriate, annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">An
asset&rsquo;s carrying amount is written down immediately to its recoverable amount if the asset&rsquo;s carrying amount is greater
than its estimated recoverable amount (Note 1(g)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Gains
and losses on disposals are determined by comparing proceeds with carrying amount. These are included in the statement of profit
or loss and other comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(l)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Intangible
                                         Assets</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(i)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Research
                                         &amp; Development</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">Expenditure
on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is
recognized in the statement of profit or loss and other comprehensive income as an expense when it is incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify"><FONT STYLE="color: Black">Expenditure
on development activities, being the application of research findings or other knowledge to a plan or design for the production
of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is
probable that the product or service is technically and commercially feasible, will generate probable economic benefits and adequate
resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized
in the statement of profit or loss and other comprehensive income as an expense as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(m)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Trade
                                         and Other Payables</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">These
amounts represent liabilities for goods and services provided to the entity prior to the end of the financial year and which are
unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade payables are recognized initially
at fair value and subsequently measured at amortized cost using the effective interest rate method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(n)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Employee
                                         Benefits</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(i)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Short-term
                                         obligations</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">Liabilities
for wages and salaries, annual leave and long service leave that are expected to be settled wholly within 12 months after the
end of the period in which the employees render the related service are recognized in respect of employees&rsquo; services up
to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(ii)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Other
                                         long-term employee benefits obligations</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">The
liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end
of the period in which the employees render the related service are recognized in the provision for employee benefits and measured
as the present value of expected future payments to be made in respect of services provided by employees up to the end of the
reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience
of employee departures and periods of service. &nbsp;Expected future payments are discounted using market yields at the end of
the reporting period of government bonds with terms and currencies that match, as closely as possible, the estimated future cash
outflows. The obligations are presented as current liabilities in the Statement of financial position if the entity does not have
an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual
settlement is expected to occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -21.3pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I>&nbsp;&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(iii)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Retirement
                                         benefit obligations</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">Contributions
to the defined contribution superannuation funds are recognized as an expense as they become payable. Prepaid contributions are
recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(iv)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Share-based
                                         payments</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">Share-based
compensation benefits may be provided through the issue of fully paid ordinary shares under the Immuron Employee Share and Option
Plan. Options are also granted to employees and consultants in accordance with the terms of their respective employment and consultancy
agreements. Any options granted are made in accordance with the terms of the Company&rsquo;s Employee Share and Option Plan (ESOP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: justify"><FONT STYLE="color: Black">The
fair value of options granted under employment and consultancy agreements are recognized as an employee benefit expense with a
corresponding increase in equity. The fair value is measured at grant date and recognized over the period during which the employees
become unconditionally entitled to the options.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.1pt"></TD><TD STYLE="width: 21.6pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The fair
                                         value at grant date is determined using a Black-Scholes option pricing model that takes
                                         into account the exercise price, the term of the option, the vesting and performance
                                         criteria, the impact of dilution, the non-tradeable nature of the option, the share price
                                         at grant date and expected price volatility of the underlying share, the expected dividend
                                         yield and the risk-free interest rate for the term of the option.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.45pt"></TD><TD STYLE="width: 21.25pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                         fair value of the options granted excludes the impact of any non-market vesting conditions
                                         (for example, profitability and sales growth targets). Non-market vesting conditions
                                         are included in assumptions about the number of options that are expected to become exercisable.
                                         At each reporting date, the entity revises its estimate of the number of options that
                                         are expected to become exercisable. The employee benefit expense recognized each period
                                         takes into account the most recent estimate. The impact of the revision to original estimates,
                                         if any, is recognized in the statement of profit or loss and other comprehensive in come
                                         with a corresponding adjustment to equity.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.25pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Upon
                                         the exercise of options, the balance of the share-based payments reserve relating to
                                         those options is transferred to contributed equity.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(v)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Termination
                                         benefits</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: justify"><FONT STYLE="color: Black">Termination
benefits are payable when employment is terminated before the normal retirement date, or when an employee accepts voluntary redundancy
in exchange for these benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify"><FONT STYLE="color: Black">The
Company recognises termination benefits when it is demonstrably committed to either terminating the employment of current employees
according to a detailed formal plan without possibility of withdrawal or providing termination benefits as a result of an offer
made to encourage voluntary redundancy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify"><FONT STYLE="color: Black">Benefits
falling due more than 12 months after reporting date are discounted to present value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(o)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Interest
                                         Bearing Loans and Borrowings</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Generally,
loans and borrowings are initially recognized at cost, being the fair value of the consideration received net of issue costs associated
with the borrowing. After initial recognition, interest bearing loans and borrowings are subsequently measured at amortized cost
using the effective interest method. Amortized cost is calculated by taking into account any issue costs and any discount or premium
on settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">The
component of the convertible notes that were issued in connection with the February 2016 financing arrangement, that exhibits
characteristics of a liability is recognised as a liability in the statement of financial position. On the date of issuance and
each subsequent reporting period, the Company records the entire hybrid instrument as measured at fair value through profit and
loss as the embedded derivative does significantly modify the cash flows under the contract.The associated transaction costs have
also been expensed as incurred and are recorded as Finance and Termination costs in the Statement of Profit or Loss and Other
Comprehensive Income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="color: Black">Fair
Value of Convertible Notes</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">The
convertible notes were measured and disclosed as a level 3 instrument, using a three level hierarchy, based on the lowest level
of input that is significant to the entire fair value measurement, as defined below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 46.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Level
                                         1: Quoted price (unadjusted) in active markets for identical assets or liabilities that
                                         the entity can access at the measurement date</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 46.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Level
                                         2: Inputs other than quoted prices included within Level 1 that are observable for the
                                         asset and liability, either directly or indirectly</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 46.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Level
                                         3: Unobservable inputs for the asset or liability </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">No
transfers between the levels of the fair value hierarchy occurred during the current year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(p)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Contributed
                                         Equity</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Ordinary
shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity
as a deduction from the proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(q)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Earnings
                                         per Share</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(i)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Basic
                                         earnings per share</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">Basic
earnings per share is calculated by dividing the profit or loss attributable to equity holders of the Company, excluding any costs
of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the full
year, adjusted for bonus elements in ordinary shares issued during the full year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(ii)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Diluted
                                         earnings per share</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">Diluted
earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income
tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number
of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(r)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Goods
                                         and Services Tax (GST)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Revenues,
expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation
authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Receivables
and payables are stated inclusive of the amount of GST recoverable or payable. The net amount of GST recoverable from, or payable
to, the taxation authorities is included with other receivable or payables in the statement of financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Cash
flows are presented on a gross basis. The GST components of cash flow arising from investing or financing activities which are
recoverable for, or payable to, the taxation authorities are presented as operating cash flow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(s)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Leases</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Leases
in which a significant portion of the risk and reward of ownership are not transferred to the Company as lessee are classified
as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the
statement of profit or loss and other comprehensive income on a straight-line basis over the period of the lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="color: Black"><B>(t)</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Previously
                                         issued Financial Statements</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt; text-align: justify"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black"><I>(i)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Reclassification:</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black">The Company has reclassified
certain items in the statement of profit or loss and other comprehensive income for the years ended 30 June 2015 and 2014 to conform
with the current year presentation and reclassified certain items in the statement of change in equity for the year ended 30 June
2016, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black"><B><U>Statement of profit
or loss and other comprehensive income:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="color: Black">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="color: Black">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Previously<BR>
    Issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Reclassification</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Revised</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Previously<BR>
    Issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Reclassification</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Revised</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; color: Black; text-align: left">Cost of Goods Sold</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; color: Black; text-align: right">(316,128</TD><TD STYLE="width: 1%; color: Black; text-align: left">)</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; color: Black; text-align: right">-</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; color: Black; text-align: right">(316,128</TD><TD STYLE="width: 1%; color: Black; text-align: left">)</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; color: Black; text-align: right">(332,686</TD><TD STYLE="width: 1%; color: Black; text-align: left">)</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; color: Black; text-align: right">54,758</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; color: Black; text-align: right">(277,928</TD><TD STYLE="width: 1%; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Sales and Marketing Costs</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(360,073</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">*283,279</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(76,794</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(401,811</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">**322,015</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(79,796</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Freight Costs</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(116,379</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(116,379</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(38,445</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(75,833</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(114,278</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black">Amortisation</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(680,567</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(20</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(680,587</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Consulting, Employee and Director</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(728,140</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(728,140</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(555,487</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(555,487</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Corporate Administration</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(557,422</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(557,422</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(367,514</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(124,951</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(492,465</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black">Depreciation</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(3,719</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(3,719</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(4,010</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">21</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(3,989</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Finance Costs</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(588,636</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">124,951</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(463,685</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black">Impairment of Inventory</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(35,340</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(35,340</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(50,204</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(50,204</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Marketing and Promotion</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(142,735</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(161,952</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(304,687</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(52,085</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(183,091</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(235,176</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; text-align: left">Research and Development</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(3,018,294</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(3,018,294</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(1,285,121</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(4,554</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(1,289,675</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">Travel and Entertainment</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(128,318</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">-</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(128,318</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(37,326</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(1</TD><TD STYLE="color: Black; text-align: left">)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">(37,327</TD><TD STYLE="color: Black; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.1pt; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.3pt"></TD><TD STYLE="width: 14.7pt"><FONT STYLE="color: Black">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Amount
                                         includes AUD121,327 that has been reflected as a restatement to decrease both Operating
                                         revenue and Sales and Marketing Costs.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.3pt"></TD><TD STYLE="width: 14.7pt"><FONT STYLE="color: Black">**</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Amount
                                         includes AUD63,091 that has been reflected as a restatement to decrease both Operating
                                         revenue and Sales and Marketing Costs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.1pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black"><B><U>Statement of change
in equity: </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Previously&nbsp;Issued</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Reclassification</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Revised</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; color: Black">Shares issued, net of costs</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: Black; text-align: right">1,658,504</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: Black; text-align: right">(71,875</TD><TD STYLE="width: 1%; color: Black; text-align: left">)</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: Black; text-align: right">1,586,629</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left; padding-bottom: 1pt">Options exercised</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(71,875</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">71,875</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black">The reclassifications
had no impact on the net loss for each period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black"><I>(ii)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Restatement:</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black">As described in Notes
2, 6, 17, 18 and 20, the Company has restated its previously issued 2016, 2015 and 2014 financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 64.4pt">In addition to these restatements, the Company has made
revisions to Notes 1, 3, 4, 7, 8, 9, 13, 15, 16, 19, 21, 22, 23 and 24.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><U>Critical Accounting Estimates
and Judgments </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">Management
evaluates estimates and judgments incorporated into the financial statements based on historical knowledge and best available
current information. Estimates assume a reasonable expectation of future events are based on current trends and economic data,
obtained both externally and within the group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(i)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Share-based
                                         Payments</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">The
value attributed to share options and remunerations shares issued is an estimate calculated using an appropriate mathematical
formula based on an option pricing model. The choice of models and the resultant option value require assumptions to be made in
relation to the likelihood and timing of the conversion of the options to shares and the value of volatility of the price of the
underlying shares. Refer to note 21 for more details.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(ii)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Impairment
                                         of Inventories</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">The
provision for impairment of inventories assessment requires a degree of estimation and judgment. The level of the provision is
assessed by taking into account the recent sales experience, the ageing of inventories and in particular the shelf life of inventories
that affects obsolescence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="color: Black"><I>(iii)</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><I>Fair
                                         value measurement hierarchy</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">The
preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported
amounts in the financial statements. Management continually evaluates its judgments, estimates in relation to assets, liabilities,
contingent liabilities, revenue and expenses. Management bases its judgments, estimates, and assumptions on historical experience
and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances.
The resulting accounting judgments and estimates will seldom equal the related actual results. The judgments, estimates and assumptions
that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next
financial year are discussed within the relevant sections where applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">The
fair value of convertible note classified as level 3 is determined by the use of valuation model. These include discounted cash
flow analysis and the use of observable inputs that required significant adjustments based on unobservable inputs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">As
at 30 June 2016, management has assessed the terms of the convertible notes and determined that in their view the fair value of
the debt component is equal to the proceeds such that there is no residual amount to be allocated to an equity component. In making
this determination, management is of the view that the value of the consideration received, net of costs, provided reliable evidence
of the fair value of the debt component of the convertible note. Fair value has been determined by the income approach based on
a discounted cash flow analysis, with the most significant inputs being the discount rate that reflects the investors credit risk.
A slight increase or decrease in the discount rate used would not be material to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black"><B><I><U>Reconciliation
of level 3 fair value measurements:</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 49.65pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="color: Black">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; text-align: right">Convertible&nbsp;notes/debentures</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="color: Black">&nbsp;</TD><TD NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: Black; font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="color: Black; font-weight: bold; border-bottom: Black 1pt solid">Balance at 30 June 2015</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: Black; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; color: Black">-&nbsp;&nbsp;Issue</TD><TD STYLE="width: 1%; color: Black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: Black; text-align: right">1,200,000</TD><TD STYLE="width: 1%; color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; text-align: left">-&nbsp;&nbsp;Change in fair value (*)</TD><TD STYLE="color: Black">&nbsp;</TD>
    <TD STYLE="color: Black; text-align: left">&nbsp;</TD><TD STYLE="color: Black; text-align: right">156,000</TD><TD STYLE="color: Black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="color: Black; padding-bottom: 1pt">-&nbsp;&nbsp;Repayments</TD><TD STYLE="color: Black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; text-align: right">(227,883</TD><TD STYLE="padding-bottom: 1pt; color: Black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Balance at 30 June 2016 (Note 15)</TD><TD STYLE="color: Black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: right">1,128,117</TD><TD STYLE="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><FONT STYLE="color: Black">(*)
These amounts are recorded in the Finance Costs on the Statement of Profit or Loss and Other Comprehensive Income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in; font-size: 10pt"><FONT STYLE="font-weight: normal">Note
    2.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in; font-size: 10pt">Revenue and other income <I>(Restated)</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left; padding-left: 9pt">Revenue from Operating Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; padding-bottom: 1pt; padding-left: 0.25in">Sale of goods</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">1,001,077</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">1,002,380</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">981,051</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total Revenue from Operating Activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,001,077</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,002,380</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">981,051</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left; padding-left: 9pt">Other Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,440</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,345</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">R&amp;D tax concession refund</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,512,840</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,478,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">713,632</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other Income from Non-Operating Activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,539,015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,591,021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">804,477</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Revenue and Other Income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,540,092</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,593,401</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,785,528</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company revised all customer allowances
and discounts, previously recognised as Selling and Marketing Costs as reduction to Operating revenue. These revisions resulted
in decreases in both Operating revenue and Selling and Marketing Costs of AUD$154,446, AUD$121,327 and AUD$63,091 for the fiscal
year ended 30 June 2016, 2015 and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    3.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Expenses</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="15" STYLE="font-weight: bold; text-decoration: underline">Expenses</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 5%; font-weight: bold; text-align: left; vertical-align: top">a)</TD><TD STYLE="width: 1%; font-weight: bold; text-decoration: none">&nbsp;</TD>
    <TD STYLE="width: 55%; font-weight: bold; text-decoration: underline; text-align: left">Consulting, Employee and Director
    Expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 8.45pt">Consulting expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,955</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 8.45pt">Wages and salaries expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">956,737</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">543,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,263</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 8.45pt">Superannuation and other employee related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,122</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,351</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 8.45pt">Director expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">197,713</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,713</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,659</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.45pt">Share- based payments (restated)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,606,275</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,375</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">219,214</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Consulting, Employee and Director Expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,840,037</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">728,140</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">555,487</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: top">b)</TD><TD STYLE="font-weight: bold; text-decoration: none">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Corporate Administrative Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 10pt">Audit and accounting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,825</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,708</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-indent: 10pt">Insurances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,609</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,852</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 10pt">Foreign exchange (gain) / losses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">217,904</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,254</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 10pt">Corporate administration costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">939,232</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">324,841</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326,870</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Provisions for doubtful debts</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,230</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Corporate Administrative Costs</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,320,570</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">557,422</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">492,465</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    4.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Income Tax Benefit</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 5%; font-weight: bold; text-align: left; vertical-align: top">(a)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 55%; font-weight: bold; text-align: left">The prima facie tax on loss from ordinary activities before the
    loss is reconciled to the income tax as follows:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">Loss before income tax</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(7,068,767</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,691,820</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,495,069</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Income tax benefit calculated at 30% (2015, 2014:30%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,120,630</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(807,546</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(748,521</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Impairment and amortization expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,168</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,116</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,373</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity-based payments expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">530,842</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,674</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,972</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Other expenses not deductible</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">264,848</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,699</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">116,076</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Non-deductible amounts associated with R&amp;D rebates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">606,177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">538,913</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">261,665</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Temporary differences not recognized</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(44,895</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(199,495</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deferred tax assets relating to tax losses not recognized</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">689,603</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">199,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">314,930</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Income tax expense</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">The
Company has estimated total tax losses of AUD$27,955,616, representing a Deferred Tax Asset of AUD$8,386,685 (at 30%) that has
not been recognized in the Financial Statements, refer to Note 1(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    5.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Key Management Personnel Compensation</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 5 details the nature and amount of
remuneration for each Director of Immuron Limited, and for the Key Management Personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Directors of Immuron Limited during
the year ended 30 June 2016 were:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Roger Aston</FONT></TD>
    <TD STYLE="width: 65%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Non-Executive Chairman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Peter Anastasiou</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice Chairman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Daniel Pollock</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Stephen Anastasiou</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Key Management Personnel of Immuron
Limited during the year were:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
    Leearne Hinch <SUP>1</SUP></FONT></TD>
    <TD STYLE="width: 65%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (CEO)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Thomas Liquard
    <SUP>1</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer (CEO)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jerry Kanellos
    (PhD)<SUP>1</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating
    &amp; Scientific Officer (COSO)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">1</TD><TD STYLE="text-align: justify">Denotes a person(s)
                                         who was appointed or resigned during or after the year.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate compensation made to Directors and Other Key
Management Personnel of the Company is set out below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Key Management Personnel Compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-left: 9pt">Short-term employee benefits</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">652,514</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">358,908</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">308,413</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Post-employment benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,004</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,908</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Share-based payments</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,606,275</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">184,602</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Key Management Personnel Compensation</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,284,793</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">373,816</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">501,260</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    6.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Loss per Share (Restated)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="text-align: left; vertical-align: top">Basic/Diluted loss per share (cents)</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">9.248</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">3.592</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">5.947</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 5%; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 55%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 10%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 10%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 10%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Net loss used in the calculation of basic and diluted loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,068,767</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,691,820</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,495,069</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Weighted average number of ordinary shares outstanding during the period used in the calculation
    of basic and diluted loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,435,993</TD><TD STYLE="text-align: left">*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,935,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,955,199</TD><TD STYLE="text-align: left">**</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-indent: -14.2pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-indent: -14.2pt"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">This amount includes
                                         182,169 of weighted average shares for ordinary shares in relation to the $4,511,378
                                         received in capital raising that was not issued as of 30 June 2016.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-indent: -14.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: justify">The 2014 weighted
                                         average number of ordinary shares outstanding during the period used in the calculation
                                         of basic and diluted loss per share was recalculated to account for the post-consolidation
                                         impact.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The company is currently in a loss making position any thus
the impact of any potential shares is concluded as anti-dilutive which includes the company&rsquo;s stock options and convertible
notes payable. Treasury shares are excluded from the calculation of weighted average number of ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the previously issued financial statements, the basic and
diluted loss per share was 5.705 cents, 4.603 cents, 3.398 cents and the weighted average number of ordinary shares outstanding
was 76,944,879, 74,907,491, 74,891,316 for the years ended 30 June 2016, 2015 and 2014, respectively.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    7.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Cash and Cash Equivalents</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Cash at Bank:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Cash at bank</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">2,290,639</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">3,116,074</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Cash and Cash Equivalents</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,290,639</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,116,074</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">The
interest rates on cash at bank at 30 June 2016 ranged from 0.95% to 0.03% (2015: from 2.55% to 0.30%)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    8.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Trade and Other Receivables</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Trade receivables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">154,217</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">216,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    income <SUP>1</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,621,416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,475,422</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
    receivables <SUP>2</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,612,139</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Trade and Other Receivables</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,387,772</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,691,629</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">All trade receivables
                                         are non-interest bearing.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">1</TD><TD STYLE="text-align: justify">Primarily comprises
                                         of receivables from the Australian Tax Office in relation to R&amp;D tax concession for
                                         the year.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">2</TD><TD STYLE="text-align: justify">Represents uncleared
                                         funds from the Capital Raising as at 30 June 2016. Funds received 7 July 2016 upon the
                                         issuance of shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    9.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Inventories</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,259,445</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">932,895</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Work in Progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,960</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Finished goods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">269,156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,863</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid inventory</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">405,953</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">96,549</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Inventory</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,056,067</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,146,267</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    10.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Other Assets</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; padding-bottom: 1pt; padding-left: 9pt">Prepayments</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">74,943</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">44,928</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Other Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">74,943</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">44,928</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    11.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Controlled Entities</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Country of</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">Percentage of Ownership</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Incorporation</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">30 Jun 2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">30 Jun 2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Parent Entity:</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-left: 9pt">Immuron Limited</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">&nbsp;Australia</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Subsidiaries of Immuron Limited:</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Immuron Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;USA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anadis
    EPS Pty Ltd <SUP>1</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;Australia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 14.15pt"><SUP>1</SUP></TD><TD>Shares in subsidiary company &ndash; Anadis ESP
                                         Pty Ltd</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -14.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">This company is a wholly owned
subsidiary of Immuron Limited and was formed for the sole purpose to act as trustee for the Immuron Limited Executive Officer
Share Plan Trust. All costs associated with the operations of this company are borne by Immuron Limited. Consolidated accounts
have not been prepared as the net assets and trading activity of Anadis ESP Pty Ltd are not material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    12.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Plant and Equipment</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Plant &amp; Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">At cost</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">304,215</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">304,215</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(290,705</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(289,568</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Plant &amp; Equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">13,510</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">14,647</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Computer Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">At cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,186</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,886</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(24,132</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Computer Equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,741</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,054</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Furniture &amp; Fittings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">At cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(33,365</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(32,364</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Furniture &amp; Fittings</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">812</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,813</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Plant and Equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,063</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">19,514</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Plant &amp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Computer</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Furniture &amp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Equipment</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Equipment</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Fittings</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold; padding-bottom: 1pt">Carrying Amount as at 30 June 2014</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">15,783</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,282</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">20,065</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,168</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,168</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Depreciation expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,136</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(114</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,469</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,719</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Carrying Amount as at 30 June 2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">14,647</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,054</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,813</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">19,514</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,441</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Depreciation expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,137</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,754</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,892</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Carrying Amount as at 30 June 2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">13,510</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,741</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">812</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,063</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    13.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Intangible Assets</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Intellectual Property</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">At cost</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,460,587</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,460,587</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,460,587</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,460,587</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Intellectual Property</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The intellectual property was acquired
from Hadasit Medical Research Services and Development Limited in 2009. At the end of fiscal year 2012, the estimated useful life
of the intellectual property was <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewed, and it was
determined to have a remaining finite useful life of two years and was fully amortized by the end of the 2014 fiscal year.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    14.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Trade and Other Payables</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Trade payables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,517,255</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">918,493</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">253,607</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other payables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52,062</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,710</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,986,407</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,207,810</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    15.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Other Financial Liabilities</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Other Financial Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Convertible Note</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">1,128,117</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,128,117</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 17 February 2016, the Company secured
AUD$1,700,000 in funding with a New York-based Investment Fund. The facility is being used to fund the immediate start of the
clinical phase for IMM-529 in Clostridium <I>difficile</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The investment is structured in 3 tranches
with a mix of equity financing and convertible securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
    #1</FONT></TD>
    <TD STYLE="width: 89%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- AUD$100,000
    private placement of securities plus a AUD$600,000 repayable Convertible Note with AUD$78,000 finance charge; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
    #2</FONT></TD>
    <TD STYLE="width: 89%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- 45
    days after issuance of the tranche 1, the company can call a second Tranche as per Tranche 1 terms.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tranche #3</P></TD>
    <TD STYLE="width: 89%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- by
    mutual consent, AUD$339,000 Face Value repayable Convertible Note issued on same terms as Tranche 1 and 2. Tranche #3 has
    not been issued as of the issuance date of the consolidated financial statements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Convertible Notes are repayable monthly
over an 18 month period with each repayment to be settled at Immuron&rsquo;s discretion monthly by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">the issuance
                                         of new shares at a 10% discount to a 5 Day Volume Weighted Average Price (VWAP) over
                                         the 20 trading days immediately prior to a repayment due date; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">cash repayment
                                         plus a 2.5% premium to the repayment amount.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron repaid AUD$150,666 in shares as
disclosed under Note 18, together with a cash amount of AUD$77,217 prior to 30 June 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the Capital Raising that was closed
on 7 July 2016, Immuron has executed its commitment to shareholders and will repay all future obligations pertaining to the Convertible
Note in cash, rather than via the issuance of new securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 15th May 2014 Immuron Limited fully
repaid the convertible debenture debt of CAD$1,500,000 to Paladin Labs Inc utilising funds raised from the renounceable pro-rata
rights issue announced on 22nd January 2014. The balance as of June 30, 2013 was $1,150,319 and the payment made on 22 January
2014 was in the amount of $1,504,443. This payment resulted in a charge to earnings of approximately $335,000 and the Company
incurred approximately $129,000 of interest expense during the year ended 30 June 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    16.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Commitments and Contingencies</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Note</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left">Lease commitments not recognized in the financial statements:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">-&nbsp;&nbsp;&nbsp;not later than 12 months</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: center">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">38,940</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">-&nbsp;&nbsp;&nbsp;between 1 and 5 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,410</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">97,350</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1</TD><TD STYLE="text-align: justify">The property lease is a non-cancellable
                                         lease with a 3 year term, with rent payable monthly in advance. The minimum lease payments
                                         shall be increased by CPI per annum. An option exists to renew the lease at the end of
                                         the 3 year term for an additional term of 3 years. The current 3 year lease period expires
                                         in December 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The
Group has recognised AUD$25,501, AUD$41,624 and AUD$35,274 of rental expenses in its Statement of Profit or Loss and Other Comprehensive
Income for the year 2016, 2015 and 2014, respectively, a</FONT>s Corporate Administration Expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Pursuant to the Executive Service
Agreement between Immuron and its CEO, the Company commits to pay a bonus of AUD$80,000 in ordinary shares and to issue 1,000,000
ordinary shares of the Company to the CEO if certain Short and Long Term Incentive Milestones are met, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    17.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Contributed Equity</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>30
                                         June 2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Restated)</B></P></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline">Fully Paid Ordinary Shares (No par value)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%; text-align: left; padding-left: 9pt">Balance at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">74,964,232</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">40,335,347</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2,995,662,120</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">40,325,295</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,035,450,143</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">31,357,697</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Capital consolidation (40:1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,920,770,804</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Shares issued during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,135,414</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,721,789</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,916</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,960,211,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,792,599</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Shares to be issued (*)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,511,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,833</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Treasury shares (**)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(800,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Transactions costs (cash-based)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(135,160</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,615</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(819,168</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Contributed Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">80,099,646</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">45,633,354</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">74,964,232</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">40,335,347</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,995,662,120</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">40,325,295</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(*) As at 30 June 2016, the Company was committed to issue
18,045,512 of ordinary shares in relation to the $4,511,378 received in capital raising (see note 24).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(**) An adjustment was made in relation to the treasury shares
which resulted in a decrease of AUD$800,000 in Non-current assets and Equity as compared to the previous statement lodged with
ASX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>During the Full Year ended 30 June 2016, the Company
issued the following securities:</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; vertical-align: top"></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Issue Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total Value</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; vertical-align: top"><B>Date</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid"><B>Details</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>No.</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>AUD$</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>AUD$</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; padding-bottom: 1pt; vertical-align: top">18 Sep 2015</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify; padding-bottom: 1pt">Exercise of IMCAI Unlisted Options</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">218,750</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">0.376</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">82,250</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">30 Sep 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Exercise of IMCAI Unlisted Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">93,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.376</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">35,250</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">19 Oct 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Exercise of IMCAI Unlisted Options by Grandlodge</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">556,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.376</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">209,056</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">13 Nov 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Exercise of IMCAI Unlisted Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">41,666</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.376</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">15,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">27 Nov 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue of Shares in lieu of cash payment for services as per Resolution
    4 of the Annual General Meeting (AGM) held on 25 Nov 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">546,875</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.160</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">87,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">24 Feb 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue in accordance with executed funding agreement with a New York based
    Investment fund provider announced to the ASX on 17 Feb 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">294,118</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.340</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Issue Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total Value</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: top">Date</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Details</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; padding-bottom: 1pt; vertical-align: top">24 Feb 2016</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify; padding-bottom: 1pt">Issue of fully paid escrow shares as security for any repayment
    default of the Convertible Loan in accordance with executed funding agreement with a New York based Investment fund provider
    and announced to the ASX on 17 Feb 2016</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">2,000,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">0.400</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">800,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">13 Apr 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue in accordance with executed funding agreement with a New York based
    Investment fund provider announced to the ASX on 17 Feb 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">326,797</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.306</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">18 Apr 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">First repayment of Convertible Note Security in accordance with executed
    funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">241,764</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.312</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">75,333</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">16 May 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Exercise of IMCAI Unlisted Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">150,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.276</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">41,400</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">16 May 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Second repayment of Convertible Note Security in accordance with executed
    funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">265,694</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.284</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">75,333</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">31 May 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue of Shares in lieu of cash payment for services received</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">400,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.250</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">30 Jun 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Shares to be Issued from Capital Raising as at 30 June 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,511,378</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; vertical-align: top">Total 2016 Movement</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,135,414</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,233,167</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>During the Full Year ended 30 June 2015, the Company
issued the following securities:</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Issue Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total Value</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: top">Date</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Details</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; padding-bottom: 1pt; vertical-align: top">20 Nov 2014</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify; padding-bottom: 1pt">Capital Consolidation on a 40:1 basis approved by shareholders
    at the Company's Annual General Meeting held on 13 Nov 2014</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">(2,920,770,804</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">21 Nov 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue of shares to supplier in lieu of cash payment for services rendered
    approved by shareholders at the Company's Annual General Meeting held on 13 Nov 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72,916</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.160</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total 2015 Movement</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,920,697,888</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">11,667</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>During the Full Year ended 30 June 2014, the Company
issued the following securities:</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Issue Price</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total Value</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: top">Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Details</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; vertical-align: top">6 Dec 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify">Issue of shares as per resolution 4 approved by shareholders at the Annual General
    Meeting of the Company held on 29 Nov 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">8,750,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.004</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">35,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">6 Dec 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue of shares as per resolutions 5, 6, &amp; 8 approved by shareholders at the Annual General
    Meeting of the Company held on 29 Nov 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,479,167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top">3 Feb 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Exercise of IMCOA options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,163</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top">3 Mar 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue of shares through fully underwritten rights issue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,670,642,320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.005</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,353,212</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: top">3 Mar 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Issue of shares to Grandlodge &amp; related owners as part of fully underwritten rights issue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">261,103,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.005</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,305,516</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">29 May 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue of shares as per resolution 2 approved by shareholders at the General
    Meeting of the Company held on 27 May 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">10,208,333</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">0.004</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">40,833</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; vertical-align: top">Total 2014 Movement</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,960,211,977</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">9,792,599</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of all share based payments
of stock is per the terms of an underlying agreement or based on the fair value of the stock on the date of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary shares participate in dividends
and the proceeds on winding up of the Company in proportion to the number of shares held. At shareholder meetings each ordinary
share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands. The ordinary
shares have no par value.</P>


<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    18.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Reserves</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nature and Purpose of the Reserve</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reserve recognises option reserves
which are the expense recognised in respect of share based payments, and foreign currency translation reserve (&ldquo;FCTR&rdquo;)
arising from translation of foreign subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>30
                                         June 2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Restated)</B></P></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Options
                                         over Fully Paid Ordinary Shares</U></I></B></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%; text-align: justify">Opening balance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">7,188,676</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">560,646</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">365,542,766</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">666,592</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">289,860,577</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,208,271</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Capital consolidation (40:1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(356,404,893</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options issued during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,425,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">285,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-<P STYLE="margin: 0"></P>


</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,963,494</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,721</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0">Granted options to be issued*</P>

<P STYLE="margin: 0pt 0"></P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options exercised during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,060,166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71,875</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,075</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expense of vested options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,606,275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Lapse of unexercised options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,616,413</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(248,345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,949,197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(110,321</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,252,230</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(760,591</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Closing&nbsp;&nbsp;Balance</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">9,937,629</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,132,301</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,188,676</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">560,646</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">365,542,766</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">666,592</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Foreign currency translation
    reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%; text-align: left; padding-left: 9pt">Opening balance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(12,581</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Movement during the year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,846</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Closing balance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,735</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(12,581</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Reserves</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">9,937,629</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,128,566</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,188,676</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">548,065</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">365,542,766</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">666,592</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An adjustment of AUD$1,209,338 was made
to the Total reserves balance at 30 June 2016 as compared to the previous statement lodged with ASX, as a result of a change in
volatility assessment. Effectively, this resulted in an increase in Consulting, Employee and Director expense and the Loss for
the period on the Statement of Profit or Loss and Other Comprehensive income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">* On 9 December 2016, the Company issued 1
million options exercisable at $0.50 per option expiring on April 1, 2017 to an employee under the Company's Employee Share and
Options Plan (ESOP) following the successful completion of related milestone pertaining to a minimum recruitment of 100 patients
into the Company&rsquo;s NASH Phase 2 clinical trial</P>





<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>During the Full Year ended 30 June
2016, the Company issued the following options:</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Issue Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total Value</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: top">Date</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; padding-bottom: 1pt; vertical-align: top">27 Nov 2015</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify; padding-bottom: 1pt">Issue of Unlisted Options in lieu of cash payment for additional
    services as per Resolution 5A - 5D of the AGM held on 25 Nov 2015</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">6,000,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">1,606,275</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">18 Feb 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue in accordance with executed funding agreement with a New York based
    Investment fund provider announced to the ASX on 17 Feb 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.186</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">185,600</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">31 May 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue of Unlisted Options in lieu of cash payment for services received</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">425,532</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; vertical-align: top">Total 2016 Movement</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,425,532</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,891,875</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>During the Full Year ended 30 June 2015, the Company
issued the following options:</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Issue Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total Value</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; vertical-align: top">20 Nov 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify">Capital Consolidation on a 40:1 basis approved by shareholders at the Company's
    Annual General Meeting held on 13 Nov 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(356,404,893</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">1 April 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Granted
                                         unlisted options to be issued to employees under ESOP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="margin: 0">1,000,000</P>


</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total 2015 Movement</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(355,404,893</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>During the Full Year ended 30 June 2014, the Company
issued the following options:</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Issue Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total Value</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: top">Date</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center; padding-bottom: 1pt; vertical-align: top">4 Jul 2013</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify; padding-bottom: 1pt">Issue of unlisted options to employees under ESOP</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">31,746,031</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">0.0022</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">70,159</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">4 Dec 2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue of options as per resolutions 5, 6, 7, &amp; 8 approved by shareholders
    at the Annual General Meeting of the Company held on 29 Nov 2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">50,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.0025</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">127,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">3 Mar 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue of options in lieu of cash payment for consulting services rendered</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">615,222</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.0019</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1,173</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: top">29 May 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Issue if unlisted options to employees under ESOP</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,602,241</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.0024</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,389</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total 2014 Movement</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">87,963,494</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">211,721</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    19.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Segments Reporting</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Primary Reporting Format - Business
Segments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The entity has identified its operating
segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and
determining the allocation of resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The executive management team considers
the business from both a product and a geographic perspective and has identified three reportable segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Segments </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Research and Development (R&amp;D)</U></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&ndash;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income
                                         and expenses directly attributable to the Company&rsquo;s research and development projects
                                         performed in Australia and Israel.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>HyperImmune Products</U></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&ndash;</TD><TD STYLE="text-align: justify">Income and expenses
                                         directly attributable to Travelan activities which occur in Australia, New Zealand, Canada
                                         and the United States. In 2016, the Company earned 90% and 10% of its revenues from customers
                                         located in Australia and Canada, respectively. In 2015, the Company earned 75%, 2% and
                                         23% of its revenues from customers located in Australia, United States and Canada, respectively.
                                         In 2014, the Company earned 80%, 16% and 4% of its revenues from customers from customers
                                         located in Australia, United States and Canada, respectively.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Corporate </U></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&ndash;</TD><TD STYLE="text-align: justify">Other items
                                         of income and expenses not directly attributable to R&amp;D or HyperImmune Products segment
                                         are disclosed as corporate costs. Corporate activities primarily occur within Australia.
                                         This segment includes interest expenses from financing activities and depreciation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Research &amp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">HyperImmune</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Development</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Products</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>Corporate</B></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 10pt">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Revenue &amp; Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Revenue from external customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,001,077</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,001,077</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">R&amp;D tax concession refund</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,512,840</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,512,840</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,165</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,810</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,010</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Revenues &amp; Other income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,512,840</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,011,277</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">15,975</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,540,092</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Depreciation &amp; amortization expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,892</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(156,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(156,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Share-based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,079,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,079,375</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,623,961</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(570,183</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,175,448</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,369,592</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,623,961</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(570,183</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(5,414,715</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(9,608,859</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income Tax Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss)/Profit for the Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,111,121</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">441,094</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(5,398,740</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,068,767</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Segment assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,512,840</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,318,860</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,995,784</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,827,484</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,512,840</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,318,860</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,995,784</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">8,827,484</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Segment liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(769,434</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(538,806</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,578,681</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,886,921</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(769,434</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(538,806</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,578,681</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,886,921</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 263.25pt">&nbsp;</P>


<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Research &amp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">HyperImmune</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Development</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Products</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>Corporate</B></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 10pt">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Revenue &amp; Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Revenue from external customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,002,380</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,002,380</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">R&amp;D tax concession refund</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,478,581</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,478,581</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">112,440</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">112,440</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Revenues &amp; Other income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,478,581</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,002,380</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">112,440</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,593,401</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Depreciation &amp; amortization expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,719</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,719</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Share-based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,042</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,042</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,018,294</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(509,301</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,737,865</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,265,460</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,018,294</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(509,301</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,757,626</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(5,285,221</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income Tax Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss)/Profit for the Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,539,713</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">493,079</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,645,186</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,691,820</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Segment assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,478,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,359,315</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,180,516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,018,412</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,478,581</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,359,315</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,180,516</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,018,412</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Segment liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(502,178</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(494,647</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(210,985</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,207,810</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(502,178</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(494,647</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(210,985</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,207,810</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Research &amp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">HyperImmune</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Development</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Products</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>Corporate</B></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Revenue &amp; Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Revenue from external customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">981,051</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">981,051</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">R&amp;D tax concession refund</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">713,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">713,632</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,345</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Revenues &amp; Other income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">713,632</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">981,051</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">90,845</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,785,528</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Depreciation &amp; amortization expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(684,576</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(684,576</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(463,685</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(463,685</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Share-based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(351,619</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(351,619</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,289,675</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(472,002</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,019,040</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,780,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,289,675</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(472,002</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,518,920</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,280,597</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income Tax Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss)/Profit for the Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(576,043</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">509,049</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,428,075</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,495,069</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Information on major customers:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended 30 June 2016, 2015
and 2014, the Company had the following major customers (and their respective contribution to the Group&rsquo;s total revenue):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; text-align: center">Customer A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">16</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">17</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">28</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Customer B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Customer C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Customer D</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Less than 10% of revenue for the respective
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No other single customers contributed
10% or more to the Group&rsquo;s revenue for all periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    20.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Cash Flow Information</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>(a)</B></TD><TD STYLE="text-align: justify"><B>Reconciliation
                                         of cash flow from operations with loss after income tax</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-weight: bold; text-align: left">Net Loss for the Year</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-weight: bold; text-align: right">(7,068,767</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-weight: bold; text-align: right">(2,691,820</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-weight: bold; text-align: right">(2,495,069</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline">Non-Cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Add depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,892</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,989</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Add amortisation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">680,587</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Add change in fair value and interest accrued on borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">334,681</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Add back equity issued for non-cash consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">187,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,708</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Add back share based payments expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,891,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,912</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Changes in Working Capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Add (increases) in current trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(84,004</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(460,204</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(551,835</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Add (increases) / decreases in other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,015</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329,130</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(314,260</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Add (increases) in inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(909,800</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(580,310</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(274,263</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Add increases / (decreases) in current trade and other
    payables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">672,582</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">362,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(386,027</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(5,158,336</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,020,933</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,650,577</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>(b)</B></TD><TD STYLE="text-align: justify"><B>Non-cash
                                         financing and investing activities</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">See Note 8 for details on the
uncleared funds of AUD$2,612,139 from capital raising as at 30 June 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">An amount of AUD$114,861 of
capital raising costs were recognised as expenses but remained unpaid during the period as at 30 June 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">See Note 21 for details regarding
issues of options to employees and for details surrounding the issue of shares to suppliers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Changes were made to the Consolidated Statement of
Cash Flows for the year 2016 as compared to the previous statement lodged with ASX, details as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Previously
    issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Restatement</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Receipts from customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,242,884</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(128,288</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,114,596</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payments to suppliers and employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,639,088</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71,909</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,710,997</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Interest and other costs of finance paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(43,863</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(43,863</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Used In Operating Activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,914,276</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(244,060</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(5,158,336</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issues of securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,282,861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,482,861</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Repayment of borrowings</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,121,080</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,860</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,077,220</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Provided By Financing Activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,091,482</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">243,860</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,335,342</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net increase/(decrease) in cash and cash equivalents</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(825,235</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(200</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(825,435</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Effects of exchange rate changes on cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Changes were made to the Consolidated Statement of
Cash Flows for the year 2014 as compared to the previous statement lodged with ASX, details as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Previously
    issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Restatement</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Proceeds from borrowings</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">420,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">420,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Repayment of borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,485,001</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(420,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,905,001</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    21.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Share-based Payments</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executives and consultants may be provided
with longer-term incentives through the Company&rsquo;s Employee Share and Option Plan (ESOP), to allow the executives and consultants
to participate in, and benefit from, the growth of the Company as a result of their efforts and to assist in motivating and retaining
these key employees over the long term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>(a)</B></TD><TD STYLE="text-align: justify"><B>Options
                                         Issued under the ESOP</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates the number
and weighted average exercise price of and movement in share options issued under the scheme during the year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted <BR> Avg</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted <BR> Avg</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted <BR> Avg</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise <BR> Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise <BR> Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise <BR> Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: left">Outstanding at the beginning of the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,856,150</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.440</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">36,246,031</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">14,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.051</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Capital consolidation (40:1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,339,881</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options granted during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,746,031</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.008</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0">Granted options to be issued*&nbsp;</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(150,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.276</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Lapse of unexercised options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(643,650</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.276</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1.556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,500,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.052</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Options Outstanding at End of the Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,062,500</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.562</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,856,150</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.440</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">36,246,031</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Options Exercisable at the End of the Year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">856,150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.369</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,996,031</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.011</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* On 9 December 2016, the Company issued 1 million options exercisable
at $0.50 per option expiring on April 1, 2017 to an employee under the Company's Employee Share and Options Plan (ESOP) following
the successful completion of related milestone pertaining to a minimum recruitment of 100 patients into the Company&rsquo;s NASH
Phase 2 clinical trial.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options outstanding at 30 June 2016 have a weighted average
remaining contractual life of 0.79 years and exercise prices ranging from $0.500 to $1.556.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>(b)</B></TD><TD STYLE="text-align: justify"><B>Options
                                         Issued to Directors</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted <BR>
    Avg</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted <BR>
    Avg</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted <BR>
    Avg</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise<BR>
    Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise<BR>
    Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise <BR>
    Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: left">Outstanding at the beginning of the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.456</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">40,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Capital consolidation (40:1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,000,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options granted during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0114</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Lapse of unexercised options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Options Outstanding at End of the Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,000,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.494</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,000,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.456</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">40,000,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.0114</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Options Exercisable at the End of the Year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.456</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.456</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.0114</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 407.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options outstanding at 30 June 2016
have a weighted average remaining contractual life of 2.94 years and exercise prices ranging from $0.456 to 0.500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>(c)</B></TD><TD STYLE="text-align: justify"><B>Options
                                         Issued to third parties</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted <BR> Avg</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted <BR> Avg</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted <BR> Avg</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise <BR> Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise <BR> Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise <BR> Price</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: justify">Outstanding at the beginning of the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">4,332,526</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.400</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">289,296,735</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.022</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">275,860,577</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.024</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Capital consolidation (40:1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(282,065,012</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Options granted during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,425,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.549</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,217,463</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.012</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(910,166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.376</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,075</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.040</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Lapse of unexercised options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,972,763</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.376</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,899,197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,752,230</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.120</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Options Outstanding at End of the Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,875,129</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.561</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,332,526</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.400</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">289,296,735</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Options Exercisable at the End of the Year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,875,129</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.561</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,332,526</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.400</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">289,296,735</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.022</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options outstanding at 30 June 2016
have a weighted average remaining contractual life of 2.85 years and exercise prices ranging from $0.300 to $1.944.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>(d)</B></TD><TD STYLE="text-align: justify"><B>Vesting
                                         Terms of Options</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes information about
options held by employees, Directors and third parties as at 30 June 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issue Date</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vesting
                                         </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Conditions</B></P></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiry Date</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price<BR>
    AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; text-align: center">29 Jun 2012</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">14,493</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: center">Nil</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: center">30 Nov 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">AUD$</TD><TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.944</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">29 Jun 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,668</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17 Jan 2022</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">1.876</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">15 Nov 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25% per annum</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1 Nov 2017</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">1.556</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">4 Dec 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4 Dec 2016</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.456</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">4-Dec-13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4 Dec 2016</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.456</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">3-Mar-14</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">28 Feb 2019</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">1.892</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">29-May-14</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">28 May 2019</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">27 Nov 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">See below</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27 Nov 2019</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">18 Feb 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24 Feb 2019</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.570</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">31 May 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">425,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27 Nov 2019</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">9 Dec 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Performance based</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1 Apr 2017</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>November 2012 Options </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options with an issue date of 15 November
2012, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of AUD$1.556*. There are no performance
conditions attached to the options as the options vest accordingly to the following anniversary dates:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">25%
                                         of the total quantum of these options issued vested immediately upon issue</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">25%
                                         of the total quantum of these options issued vest on 1 July 2013</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">25%
                                         of the total quantum of these options issued vest on 1 July 2014</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">25%
                                         of the total quantum of these options issued vest on 1 July 2015</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>July 2013 Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options with an issue date of 4 July
2013, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of $0.30*. There are no performance
conditions attached to the options. The options were deemed to have been fully vested on their date on issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>December 2013 Options </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options with an issue date of 4<SUP>th
</SUP>December 2013, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of AUD$0.456*.
There are no performance conditions attached to the options. The options were deemed to have been fully vested on their date on
issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>November 2015 Options </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options with an issue date of 27 November
2015, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of AUD$0.500. Options vest based
on month of continuous services completed as per the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000,000
                                         Options which will vest on 6<SUP>th</SUP> August 2016 &ndash; subject to completion of
                                         12 months&rsquo; continuous services as a Director of the Company</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000,000
                                         Options which will vest on 6<SUP>th</SUP> August 2017 &ndash; subject to completion of
                                         24 months&rsquo; continuous services as a Director of the Company</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>February 2016 Options </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options with an issue date of 18 February
2016, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of AUD$0.570. There are no performance
conditions attached to the options. The options were deemed to have been fully vested on their date on issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>May 2016 Options </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options with an issue date of 31 May
2016, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of AUD$0.500. There are no performance
conditions attached to the options. The options were deemed to have been fully vested on their date on issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">The above value has
                                         been adjusted for 40:1 share consolidation which was completed on 20 Nov 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>December 2016 Options </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to an agreement entered between the
Company and a consultant on 1 April 2015, the Company granted 1,000,000 options, which became vested and issued on 9 December
2016, and entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of AUD$0.500. These options
were vested and issued following the successful completion of related milestone pertaining to a minimum recruitment of 100 patients
into the Company&rsquo;s NASH Phase 2 clinical trial.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>(e)</B></TD><TD STYLE="text-align: justify"><B>Deemed
                                         Valuation of Options</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The fair value of the options
granted under the Company&rsquo;s Executive Share and Option Plan (ESOP) is estimated as at the grant date using Black-Scholes
model taking into account the terms and conditions upon which the options were granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>November 2012
Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The following table lists the inputs to the model
used to determine the weighted average value of the options expensed during the year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                         per above</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">70</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.25</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life of option (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
                                         years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Option exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0.04</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average share price at grant date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.017</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Value per option</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.280</TD><TD STYLE="text-align: left">*</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">The above value
                                         has been adjusted for 40:1 share consolidation which was completed on 20 Nov 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -14.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.55pt">At 30
June 2016 the Australian Securities Exchange (ASX) market share price for Immuron was AUD$0.25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>July 2013 Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table lists the inputs to the model used to determine the weighted average value of the</FONT> options expensed during
the year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">62</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.79</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life of option (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
                                         years </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Option exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0075</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average share price at grant date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0060</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Value per option</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.088</TD><TD STYLE="text-align: left">*</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* The above value has been adjusted for 40:1 share consolidation
which was completed on 20 Nov 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">At 30 June 2016 the Australian Securities
Exchange (ASX) market share price for Immuron was AUD$0.25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><I><U>December 2013 Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The following table lists the inputs to the model
used to determine the weighted average value of the options expensed during the year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">62</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.03</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life of option (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
                                         years </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Option exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.0114</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average share price at grant date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.0080</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Value per option</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.1016</TD><TD STYLE="text-align: left">*</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">The above values
                                         have been adjusted for 40:1 share consolidation which was completed on 20 Nov 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.55pt">At 30
June 2016 the Australian Securities Exchange (ASX) market share price for Immuron was AUD$0.25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The expected life of the option
is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects
the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><I><U>November 2015
Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The following table lists the inputs to the model
used to determine the weighted average value of the options expensed during the year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                         per above</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.11</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life of option (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
                                         years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Option exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.5000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average share price at grant date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Value per option</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.3186</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At 30 June 2016 the Australian
Securities Exchange (ASX) market share price for Immuron was AUD$0.25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The expected life of the option
is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects
the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><I><U>February 2016
Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The following table lists the inputs to the model
used to determine the weighted average value of the options expensed during the year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">97</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.73</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life of option (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
                                         years </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Option exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0.5700</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average share price at grant date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Value per option</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.1856</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At 30 June 2016 the Australian
Securities Exchange (ASX) market share price for Immuron was AUD$0.25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The expected life of the option
is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects
the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><I><U>May 2016 Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The following table lists the inputs to the model
used to determine the weighted average value of the options expensed during the year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">84</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.11</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life of option (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
                                         years </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Option exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0.5000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average share price at grant date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.41</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Value per option</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AUD$</TD><TD STYLE="text-align: right">0.235</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At 30 June 2016 the Australian
Securities Exchange (ASX) market share price for Immuron was AUD$0.25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The expected life of the option
is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects
the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 174; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    22.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Related Party Transactions</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transactions with related parties
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-weight: bold; text-decoration: underline; text-align: justify">Short-term Loan from Grandlodge
    Capital Pty Ltd:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Grandlodge Capital Pty Ltd (Grandlodge) is an entity part-owned and operated by Immuron Directors
    Peter and Stephen Anastasiou.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Mr David Plush is also an owner of Grandlodge, and its associated entities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On 1<SUP>st</SUP>
    December 2015 and on 6th June 2016, Immuron executed a short-term funding agreement with Grandlodge for a principle amount
    of AUD$1,000,000 (interest rate of 13%) and AUD$750,000 (interest rate of 15%) respectively, plus interest charges.</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">The short-term funding is a cash advance against the anticipated refund Immuron will receive
    from the Australian Taxation Office under the Research and Development Income Tax Concession Incentive for the Company's eligible
    R&amp;D expenditure incurred for financial year of 2015 and 2016.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan from 1st December
    2015 has been repaid to Grandlodge on 10<SUP>th</SUP> February 2016. The June 2016, loan from Grandlodge, plus applicable
    fees, will be repaid by the Company upon receipt of the FY2016 R&amp;D Tax Incentive refund which was received in November
    2016. Interest paid was approximately $43,000 in 2016 and loan fees paid to Grandlodge were approximately $20,000 and $15,000
    in 2016, respectively.</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Loans from October and December 2013 were repaid in fiscal 2014. These
    loan agreements were for a period of 6 months or the receipt of the R&amp;D Tax Incentive Refund if sooner, bearing an interest
    rate of 18% per annum. Interest paid was approximately $15,000 in 2014.</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total paid by the Company to Grandlodge Pty Ltd during
    the year:</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,043,863</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">435,495</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">At year end the Company owed Grandlodge Pty Ltd:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">772,397</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 175; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-weight: bold; text-decoration: underline; text-align: justify">Services rendered by Grandlodge
    Pty Ltd to Immuron Ltd:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Grandlodge, and its associated entities, are marketing, warehousing and distribution logistics
    companies.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Commencing on 1 June 2013, Grandlodge was verbally contracted on terms to provide warehousing,
    distribution and invoicing services for Immuron&rsquo;s products for AUD$70,000 per annum.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">These fees will be payable in new fully paid ordinary shares in Immuron Limited at a set price
    of AUD$0.16 per share representing Immuron Limited&rsquo;s share price at the commencement of the verbal agreement.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">The shares to be issued to Grandlodge, or its associated entities, as compensation in lieu
    of cash payment for the services rendered under this verbal agreement have been subject to the approval of Immuron shareholders
    at Company shareholder meetings held over the past 18 months.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Grandlodge will also be reimbursed in cash for all reasonable costs and expenses incurred
    in accordance with their scope of works under the verbal agreement, unless both parties agree to an alternative method of
    payment.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">The verbal agreement is cancellable by either party upon providing the other party with 30
    days written notice of the termination of the agreement.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Service fees paid to Grandlodge Pty Ltd during the year through the issue
    of equity:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">87,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75,833</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total paid by the Company to Grandlodge Pty Ltd during
    the year:</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">87,500</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">11,667</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">75,833</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">At year end the Company owed Grandlodge Pty Ltd:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 176; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-weight: bold; text-decoration: underline; text-align: justify">Premises Rental services received
    from Wattle Laboratories Pty Ltd to Immuron Ltd:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Wattle Laboratories Pty Ltd (Wattle) is an entity part-owned and operated by Immuron Directors
    Peter and Stephen Anastasiou.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Commencing on 1 January 2016, Immuron executed a Lease Agreement with Wattle whereby Immuron
    will lease part of their Blackburn office facilities for Immuron's operations at a rental rate of AUD$38,940 per annum, payable
    in monthly installments.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">The lease is for a 3 year term with an additional 3 year option period.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">The lease is cancellable by either party upon 6 months written notice of termination of the
    agreement.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Rental fees paid to Wattle Laboratories Pty Ltd during the year through
    the issue of equity:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total paid by the Company to Wattle Laboratories Pty
    Ltd during the year:</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">19,470</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">At year end the Company owed Wattle Laboratories Pty Ltd:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,417</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    23.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Financial Risk Management Objectives and Policies</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>(a)</B></TD><TD>Financial Instruments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company's financial instruments
consist of cash and cash equivalents, trade and other receivables and trade and other payables:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,290,639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">3,116,074</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,387,772</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,691,629</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,986,407</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,207,810</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Borrowings (See Note 22)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(772,397</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,128,117</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The fair values of cash and
cash equivalents, trade and other receivables and trade and other payables approximate their carrying amounts largely due to being
liquid assets and payables will be settled within 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>(b)</B></TD><TD>Risk Management Policy</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Board is responsible for
overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the
Company's implementation of that system on a regular basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Board and Senior Management
identify the general areas of risk and their impact on the activities of the Company, with Management performing a regular review
of:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Wingdings">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         major risks that occur within the business;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Wingdings">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         degree of risk involved;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Wingdings">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         current approach to managing the risk; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Wingdings">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         appropriate, determine:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">any inadequacies of the current
                                         approach; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">possible new approaches that more
                                         efficiently and effectively address the risk.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Management report risks identified
to the Board through the monthly Operations Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company seeks to ensure
that its exposure to undue risk which is likely to impact its financial performance, continued growth and survival is minimised
in a cost effective manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>(c)</B></TD><TD>Significant Accounting Policies</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Details of significant accounting
policies and methods adopted, including the criteria for recognition, the basis for measurement and the basis on which income
and expenses are recognised, in respect of each class of financial asset, financial liability and equity instrument are disclosed
in Note 1 to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The carrying amounts of cash
and cash equivalents, trade and other receivables, trade and other payables and financial liabilities represents their fair values
determined in accordance with the accounting policies disclosed in Note 1. Interest income on cash and cash equivalents is disclosed
in Note 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>(d)</B></TD><TD>Capital Risk Management</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company's objectives when
managing capital are to safeguard the Company's ability to continue as a going concern and to maintain an optimal capital structure
so as to maximise shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">In order to maintain or achieve
an optimal capital structure, the Company may issue new shares or reduce its capital, subject to the provisions of the Company's
constitution. The capital structure of the Company consists of equity attributed to equity holders of the Company, comprising
contributed equity, reserves and accumulated losses disclosed in Notes 17 and 18.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">By monitoring undiscounted
cash flow forecasts and actual cash flows provided to the Board by the Company's Management the Board monitors the need to raise
additional equity from the equity markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><I><U>Financial Risk Management</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The main risks the Company
is exposed to through its operations are interest rate risk, foreign exchange risk, credit risk and liquidity risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><I><U>Interest Rate
Risk</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company is exposed to
interest rate risks via the cash and cash equivalents and borrowings that it holds. Interest rate risk is the risk that a financial
instruments value will fluctuate as a result of changes in market interest rates. The objective of managing interest rate risk
is to minimise the Company's exposure to fluctuations in interest rate that might impact its interest revenue and cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Interest rate risk is considered
when placing funds on term deposits. The Company considers the reduced interest rate received by retaining cash and cash equivalents
in the Company's operating account compared to placing funds into a term deposit. This consideration also takes into account the
costs associated with breaking a term deposit should early access to cash and cash equivalents be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">There has been no change to
the Company's exposure to interest rate risk or the manner in which it manages and measures its risk in the year ended 30 June
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><I><U>Foreign Currency
Risk</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company is exposed to
foreign currency risk via the trade and other receivables and trade and other payables that it holds. Foreign currency risk is
the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company aims to
take a conservative position in relation to foreign currency risk hedging when budgeting for overseas expenditure however, the
Company does not have a policy to hedge overseas payments or receivables as they are highly variable in amount and timing, due
to the reliance on activities carried out by overseas entities and their billing cycle.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">The following financial assets and liabilities
are subject to foreign currency risk:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Cash and cash equivalents (AUD/USD)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">40,702</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">6,840</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Trade and other receivable (AUD/USD)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Trade and other payables (AUD/USD)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">564,104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">193,443</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Trade and other payables (AUD/CHF)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,069</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Trade and other payables (AUD/NZD)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">452,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">394,064</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Trade and other payables (AUD/ISL)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,260</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,613</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Foreign currency risk is measured
by regular review of cash forecasts, monitoring the dollar amount and currencies that payment are anticipated to be paid in. The
Company also considers the market fluctuations in relevant currencies to determine the level of exposure. If the level of exposure
is considered by Management to be too high, then Management has authority to take steps to reduce the risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Steps to reduce risk may include
the acquisition of foreign currency ahead of the anticipated due date of an invoice, or may include negotiations with suppliers
to make payment in our functional currency, or may include holding receipted foreign currency funds in a foreign currency denominated
bank account to make future payments denominated in that same currency. Should Management determine that the Company consider
taking out a hedge to reduce the foreign currency risk, they would need to seek Board approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company conducts some
activities outside of Australia which exposes it to transactional currency movements, where the Company is required to pay in
a currency other than its functional currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">There has been no change in
the manner the Company manages and measures its risk in the year ended 30 June 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company is exposed to
fluctuations in the United States and New Zealand dollars. Analysis is conducted on a currency by currency basis using sensitivity
variables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company has conducted
a sensitivity analysis of the Company's exposure to foreign currency risk. The analysis shows that if the Company's exposure to
foreign currency risk was to fluctuate as disclosed below and all other variables had remained constant, then the foreign currency
sensitivity impact on the Company's loss after tax and equity would be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">30 June 2015</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold"></TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Higher)
                                         /</B></FONT></P> <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lower</B></FONT></P></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Higher)
                                         /</B></FONT></P> <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lower</B></FONT></P></TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid"><B>Trade and Other Payables</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">AUD / USD: 2016 +8.00%&nbsp;&nbsp;(2015: +8.00%)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">45,128</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">15,475</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">AUD / USD: 2016 -8.00%&nbsp;&nbsp;(2015:-8.00%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,128</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,475</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">AUD / CHF: 2016 +11.00%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,108</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">AUD / CHF: 2016 -11.00%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,108</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">AUD / NZD: 2016 +11.00%&nbsp;&nbsp;(2015: +11.00%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,347</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">AUD / NZD: 2016 -11.00%&nbsp;&nbsp;(2015: -11.00%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,786</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,347</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">AUD / ISL: 2016 +11.00%&nbsp;&nbsp;(2015: +11.00%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,089</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,057</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">AUD / ISL: 2016 -11.00%&nbsp;&nbsp;(2015: -11.00%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,089</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,057</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><I><U>Credit Risk</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company is exposed to
credit risk via its cash and cash equivalents and trade and other receivables. Credit risk is the risk that a counter-party will
default on its contractual obligations resulting in a financial loss to the Company. To reduce risk exposure for the Company's
cash and cash equivalents, it places them with high credit quality financial institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company&rsquo;s major
ongoing customers are the large pharmaceutical companies for the distribution of Travelan and other Hyperimmune products, and
Government bodies for the receipt of GST refunds and Research and Development Tax Concession amounts due to the Company from the
Australian Tax Office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company has a policy that
limits the credit exposure to customers and regularly monitors its credit exposure. The Board believes that the Company does not
have significant credit risk at this time in respect of its trade and other receivables. Regarding customers with over 30-day
debt balance, management has maintained on-going communication with relevant counter parties in regard of repayment schedule,
and concluded that there have been no changes to the initial assessment of credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">The Company has analyzed its trade and other receivables
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">0 - 30 days</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">31 - 60 days</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">61 - 90 days</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">90 days +</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: left">2016 Trade and other receivables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2,822,116</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">45,687</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">7,129</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2,874,932</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2016 R&amp;D tax concession refund</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a
                                         </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,512,840</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2015 Trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,622</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,202</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,325</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,899</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,048</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2015 R&amp;D tax concession refund</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a
                                         </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,478,581</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">R&amp;D tax concession refund in each period is
recovered upon finalization of the Australian Tax Office&rsquo;s review of the Company&rsquo;s annual R&amp;D tax concession claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><I><U>Liquidity Risk</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company is exposed to
liquidity risk via its trade and other payables and its recurring and projected losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Liquidity risk is the risk
that the Company will encounter difficulty in raising funds to meet the commitments associated with its financial instruments.
Responsibility for liquidity risk rests with the Board who manage liquidity risk by monitoring undiscounted cash flow forecasts
and actual cash flows provided to them by the Company's Management at Board meetings to ensure that the Company continues to be
able to meet its debts as and when they fall due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Contracts are not entered
into unless the Board believes that there is sufficient cash flow to fund the additional activity. The Board considers when reviewing
its undiscounted cash flow forecasts whether the Company needs to raise additional funding from the equity markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">The Company has analysed its trade and other payables
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">0 - 30&nbsp;days</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">31 - 60 days</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">61 - 90 days</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">90 days +</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: left">2016 Trade and other payables and notes payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,008,089</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">659,494</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">299,239</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">19,585</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,986,407</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2016 Borrowings (see Note 22 for repayment terms)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">772,397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2016 Convertible notes (note 15 for repayment terms)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128,117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2015 Trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">923,181</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">172,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,207,810</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">As at 30 June 2016, the Company
maintained a cash and cash equivalents balance of AUD$2,290,639. Additionally, the Company also recognised a total of AUD$4,387,772
in receivables, including a AUD$1,512,840 related to R&amp;D Tax Concession, which was received in November 2016. On this basis,
even though the company has been in loss making position historically, management is satisfied that the Group is a going concern
and are of the opinion that no asset is likely to be realized for an amount lower than the amount at which it is recorded in the
Consolidated Statement of Financial Position at 30 June 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    24.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Events after the Reporting Date</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">7 July 2016:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify">The Company issued
                                         21,320,978 new fully paid ordinary shares in the Company to subscribers and shortfall
                                         participants of the Rights Issue Capital Raising. 2,418,129 of these new fully paid ordinary
                                         shares were issued to Grandlodge on the same terms and conditions as all other subscribers.
                                         The Rights Issue capital Raising raised a total of AUD$5,330,245. An amount of AUD$4,511,378
                                         was recorded as Share to be issued as at 30 June 2016.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -70.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify">The Company is
                                         also committed to issue 21,320,978 free-attaching 1:1 new Unlisted Options exercisable
                                         at AUD$0.55 expiring 3 years from the date of issue to subscribers and shortfall participants
                                         of the Rights Issue. This issuance of these options is subject to shareholder approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -70.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">25 August 2016:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0">On
                                         August 25<SUP>th</SUP> on behalf of Immuron, Grandlodge purchased US$1,500,000 at the
                                         cost of AUD$1,968,762. On the same day Immuron paid Grandlodge AUD$1,968,762 to settle
                                         this transaction. On Sept 12<SUP>th</SUP> Grandlodge returned the USD$1,500,000 purchase
                                         to Immuron. Grandlodge received no financial gains or benefits from this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -70.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -70.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">4 October 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify">The Company issued
                                         3,968,816 of new fully paid ordinary shares and 3,968,816 Unlisted Options exercisable
                                         at AUD$0.55 expiring 3 years from the date of issue to Shortfall Participants of the
                                         Rights Issue as described in the Offer Booklet announced to the ASX on 31 May 2016 and
                                         to the over-subscribers of the Rights Issue, which raised a total of AUD$992,229.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -70.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -70.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">30 November 2016:&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Company issued 251,877</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">fully
                                         paid ordinary shares to three employees under the Company's Employee Share and Options
                                         Plan (ESOP) which were issued in lieu of cash payment for future salary services rendered
                                         over the period October through March 2016.</FONT></TD></TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">6 December 2016:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">The
                                         Company fully repaid the loan in the amount of approximately $772,000 outstanding as
                                         of June 30, 2016 to Grandlodge.</P>


</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -70.9pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">9 December 2016:&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Company issued 1 million options exercisable at $0.50 per option expiring on 1 April
                                         2017 to an employee under the Company's Employee Share and Options Plan (ESOP) </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Company issued 200,000 </FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">options
                                         exercisable at $0.50 per option expiring on 27 November 2019 to an employee under the
                                         Company's Employee Share and Options Plan (ESOP)</FONT></TD></TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">Other than the events listed
above, there have not been any other matters or circumstances that have arisen since the end of the financial year, which significantly
affected, or may significantly affect, the operations of Immuron Limited, the results of those operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.3in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Note
    25.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in">Company Details</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><U>The registered office of the Company
is:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Suite 1, 1233 High Street, Armadale, Victoria,
Australia 3143.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><U>The principal place of business of the
Company is:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Suite 1, 1233 High Street, Armadale, Victoria,
Australia 3143</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 182; Options: NewSection; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 12pt"><A NAME="fin2_01"></A><B>Consolidated Statement of Profit or Loss and Other Comprehensive
    Income </B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>For the six months ended December 31,</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">2016<BR> (Unaudited)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">2015<BR> (Unaudited)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Notes</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>(Restated)</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Revenue</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Operating Revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">703,099</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">497,220</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Total Operating Revenue</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">703,099</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">497,220</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cost of Goods Sold</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(223,394</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(153,640</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Gross Profit</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">479,705</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">343,580</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Direct Selling Costs</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Sales and Marketing Costs</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(93,520</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52,659</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Freight Costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(62,590</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(61,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Total Gross Profit less Direct Selling Costs</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">323,595</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">229,622</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">816,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">763,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Expenses</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Consulting, Employee and Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(907,390</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,113,214</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Corporate Administration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(790,103</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(708,625</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,975</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,944</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance Costs</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,183</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Impairment of Inventory</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(135,170</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Marketing and Promotion</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(471,735</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,724</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and Development</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,117,867</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,839,990</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Travel and Entertainment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(112,453</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(195,605</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss Before Income Tax</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,409,349</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,068,086</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income Tax Expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss for the Period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,409,349</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,068,086</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other Comprehensive Loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41,425</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Comprehensive Loss for the Period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,450,774</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,072,867</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Basic/Diluted Loss per Share (cents per share)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.065</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes form part of these
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 183; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 12pt"><A NAME="fin2_02"></A><B>Consolidated Statement of Financial Position</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December
                                         31, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>June
                                         30, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2016</B></P></TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Notes</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">ASSETS</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Current Assets</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,103,683</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,290,639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,387,772</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt">Inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,751,871</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,056,067</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 10pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">81,933</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">74,943</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,837,834</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">8,809,421</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Non-Current Assets</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Property, plant and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,967</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,063</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Non-Current Assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">17,967</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,063</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,855,801</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">8,827,484</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline">LIABILITIES</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,624,621</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,986,407</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt">Borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">772,397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other financial liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">678,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,128,117</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,302,621</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,886,921</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,302,621</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,886,921</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,553,180</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,940,563</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">EQUITY</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Issued capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,485,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,633,354</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt">Reserves</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,243,061</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,128,566</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Accumulated losses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(46,175,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(42,821,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,553,180</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,940,563</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes form part of these
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 184; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 12pt"><A NAME="fin2_03"></A><B>Consolidated Statement of Changes in Equity </B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>For the six months ended December 31, 2016 and
    2015 (unaudited) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Issued&nbsp;capital</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Reserves</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated<BR> Losses</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; padding-bottom: 1pt">Balance as at June 30, 2015 (Restated)</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">40,335,347</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">548,065</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(36,072,810</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,810,602</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss after income tax expense for the period (Restated)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,068,086</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,068,086</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other comprehensive loss for the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total comprehensive loss for the period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,781</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,068,086</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,072,867</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-decoration: underline; text-align: left">Transactions with owners in their capacity as
    owners</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Employee and consultant share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">537,309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">537,309</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt">Lapse or exercise of share options (Restated)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,615</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Shares issued, net of costs (Restated)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">422,264</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">422,264</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Balance as at December 31, 2015 (Restated)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">40,816,226</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,021,978</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(39,140,896</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,697,308</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Balance as at June 30, 2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">45,633,354</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,128,566</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(42,821,357</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,940,563</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss after income tax expense for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,409,349</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,409,349</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other comprehensive income for the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41,425</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41,425</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total comprehensive loss for the period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(41,425</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,409,349</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,450,774</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-decoration: underline; text-align: left">Transactions with owners in their capacity as
    owners</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Employee and consultant share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282,920</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282,920</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt">Lapse or exercise of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(127,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt">Shares issued, net of costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,780,471</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,780,471</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Balance as at December 31, 2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">47,485,700</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,243,061</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(46,175,581</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,553,180</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes form part of these
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 185; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 12pt"><A NAME="fin2_04"></A><B>Consolidated Statement of Cash Flows</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>For the six months ended December 31,</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2016</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Unaudited)</B></P></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2015</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Unaudited)</B></P></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Note</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(Restated)</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(Restated)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Cash flows Related to Operating
    Activities</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left">Receipts from customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">773,476</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">553,406</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Payments to suppliers and employees</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,572,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,014,796</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest received</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest and other costs of finance paid</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(54,555</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other - R&amp;D Tax Concession Refund</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,590,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Used In Operating Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,256,539</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,454,247</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Cash Flows Related to Investing
    Activities</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Payment for purchases of plant and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,879</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,441</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Used In Investing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,879</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,441</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Cash Flows Related to Financing
    Activities</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issues of securities</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,423,234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">342,223</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Capital raising costs</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(149,919</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,458</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from borrowings</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Repayment of borrowings</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">9</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,202,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Provided By Financing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,071,315</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,334,765</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net increase/(decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">812,897</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,121,923</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash and cash equivalents at the beginning of the year</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,290,639</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,116,074</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Effects of exchange rate changes on cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents at the End of the Year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,103,683</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">994,151</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">The accompanying
notes form part of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 186; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 12pt"><A NAME="fin2_05"></A><B>Notes to the Consolidated
    Financial Statements (unaudited) </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Basis of preparation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Basis of Preparation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The general purpose financial report for
the interim six months reporting periods ended December, 31 2016 and 2015 have been prepared in accordance with International
Accounting Standard (IAS) 134 Interim Financial Reporting, under the International Financial Reporting Standards, as issued by
the International Accounting Standards Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This half year financial report does not
include all notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction
with the annual report for the years ended June 30, 2016, 2015 and 2014 included in the Form F-1 and any public announcements
made by Immuron Limited and its controlled entities (the &ldquo;Group&rdquo;), during the interim reporting periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The half year financial report reflects
all adjustments which are, in the opinion of management, necessary to a fair statement of the results for the interim periods
presented. All adjustments are of a normal recurring nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Accounting Policies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All accounting policies adopted are consistent
with the most recent Annual Financial Report for the years ended June 30, 2016, 2015 and 2014. The consolidated entity has adopted
all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards
Board ('IASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations
did not have any significant impact on the financial performance or position of the consolidated entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Fair value measurement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to the nature of the Group&rsquo;s operating profile, the
Directors and management do not consider that the fair values of the Group&rsquo;s financial assets and liabilities are materially
different from their carrying amounts at December, 31 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Going Concern</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended December, 31
2016 the Company experienced a net cash outflow of AUD$2,256,539 (2015: AUD$3,454,247) from operating activities. Net loss for
the period was AUD$3,409,349 which included AUD$2,117,867 of expenditures associated with research, development and commercialisation
programs predominantly surrounding the Non- Alcoholic Steatohepatitis (NASH) Clinical Trial (2015: AUD$3,068,086 and AUD$1,839,990,
respectively). These factors raise substantial doubt on the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whilst the Company is projecting further
net losses and a net cash outflow from operations for the remainder of the 2017 financial year, management is in the process of
enhancing its internal cost control procedures to further reduce operating costs. Additionally, the Company also plans to raise
additional capital from domestic or oversea market. The following historical successes achieved in the past 6 months further support
the Company&rsquo;s position in future capital raising and cost reduction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">successfully
                                         completion of an oversubscribed AUD$6.32M Right Issue Capital Raising (before costs);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">completion
                                         of patient recruitment in the Company&rsquo;s (NASH) IMM-124E Phase 2 clinical trial.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the above discussion,
there exists a degree of uncertainty in the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 187; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Having considered all the above, the Directors
have prepared the financial statements on a going concern basis. &nbsp;As such, the financial statements do not include any adjustments
as to the recoverability and classification of recorded asset amounts or to the amounts and classification of liabilities that
might be necessary should the entity not continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Restatements:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has restated certain items
in the previously issued financial statements as at and for the six months ended December 31, 2015, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consolidated statement
of profit or loss and other comprehensive income:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">Previously<BR> Issued</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Adjustments</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Other income*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,476,906</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(713,343</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">763,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sales and Marketing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(242,150</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189,491</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52,659</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Marketing and Promotion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,233</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(189,491</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,724</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consolidated statement
of changes in equity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">Previously<BR> Issued</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Adjustments</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Balance at June 30, 2015 / Accumulated losses*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(37,542,572</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,469,762</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(36,072,810</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Lapse or exercise of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,615</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Shares issued, net of costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">480,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">422,264</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consolidated statement
of cash flows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">Previously<BR> Issued</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Adjustments</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Receipts from customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">613,528</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(60,122</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">553,406</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payments to suppliers and employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,074,918</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,122</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,014,796</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* These adjustments were the result of the timing of the recognition
of the R&amp;D refund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restatements were also made to the Consolidated Statement of
Cash Flows for the six months ended December 31, 2016 as compared to the previous statement lodged with ASX, details as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Previously
    issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Adjustments</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">Revised</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Receipts from customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">664,900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">108,576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">773,476</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payments to suppliers and employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,423,797</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(148,497</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,572,294</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Cash Flows Used In Operating Activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,216,618</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(39,921</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,256,539</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Capital raising costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(120,285</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,634</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(149,919</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Repayment of borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,271,555</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,555</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,202,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Cash Flows Provided By Financing Activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,031,394</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">39,921</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,071,315</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">As described in Note
8, the Company has restated its previously issued financial statements for the six months ended December 31, 2016. In addition
to these restatements, the Company has made revisions to Notes 3, 6, 7 and 9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 188; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
2.&nbsp;<B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has not declared any dividends
in the period ended December 31, 2016. (2015: AUD$Nil)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
3.&nbsp;<B>Segment Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The entity has identified its operating
segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and
determining the allocation of resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The executive management team considers
the business from both a product and a geographic perspective and has identified three reportable segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Segments </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development (R&amp;D)
&ndash;</B> Income and expenses directly attributable to the company&rsquo;s research and development projects performed in Australia
and Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>HyperImmune Products &ndash;</B> Income
and expenses directly attributable to primarily Travelan activities which occur in Australia, New Zealand, Canada and United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate &ndash;</B> Other items of
income and expenses not directly attributable to R&amp;D or HyperImmune Products segment are disclosed as corporate costs. Corporate
activities primarily occur within Australia. This segment includes interest expenses from financing activities and depreciation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Research &amp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">HyperImmune</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Development</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Products</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Corporate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 0.125in">December 31, 2016</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Revenue &amp; Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; padding-left: 9pt">Revenue from external customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">703,099</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">703,099</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">R&amp;D tax concession refund</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">779,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">779,826</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,791</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,007</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,308</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,315</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Revenues &amp; Other income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">804,833</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">708,407</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,791</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,520,031</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Depreciation &amp; amortization expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,975</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,975</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,183</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,183</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Share-based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(80,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(233,467</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(313,775</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,197,867</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(514,674</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,887,906</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,600,447</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,278,175</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(514,674</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,136,531</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,929,380</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income Tax Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss)/Profit for the Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,473,342</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">193,733</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,129,740</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,409,349</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Segment assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">702,623</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,949,595</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,203,583</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,855,801</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">702,623</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,949,595</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,203,583</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,855,801</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Segment liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(708,474</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(131,630</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,462,517</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,302,621</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(708,474</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(131,630</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,462,517</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,302,621</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 189; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Research &amp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">HyperImmune</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Development</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Products</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Corporate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 0.125in">December 31, 2015</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Revenue &amp; Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; padding-left: 9pt">Revenue from external customers</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">497,220</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">497,220</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">R&amp;D tax concession refund</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">756,420</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">756,420</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,143</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,143</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Revenues &amp; Other income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">756,420</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">497,220</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,143</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,260,783</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Segment Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Depreciation &amp; amortization expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,944</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,944</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Share-based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(87,500</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(537,309</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(624,809</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,909,734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(180,098</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,612,284</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,702,116</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Segment Expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,909,734</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(267,598</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,151,537</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,328,869</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income Tax Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss)/Profit for the Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,153,314</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">229,622</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,144,394</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,068,086</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Information on major customers:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended December 31,
2016 and 2015, the Group had the following major customers (and their respective contribution to the Group&rsquo;s total revenue):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; text-align: center">Customer A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">33</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">49</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Customer B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Customer C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Customer D</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Customer E</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Less than 10% of revenue for the respective
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No other single customers contributed
10% or more to the Group&rsquo;s revenue for all periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 190; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
4.&nbsp;<B>Inventories</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">December 31, 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">June 30, 2016</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,118,912</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,259,445</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Work in Progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,513</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Finished goods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">269,156</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid inventory</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">294,883</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">405,953</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Inventory</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,751,871</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,056,067</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As certain raw materials held by the Company
at December 31, 2016 may approach their expiration date for clinical use in the future, management has alternative options to
utilize these inventories as for R&amp;D purpose, or sale as non-clinical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
5. <B>Contingent Liabilities and Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There has been no change in contingent
liabilities and assets since the last annual reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
6. <B>Contributed Equity </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">December 31, 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">(Restated) December 31, 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline">Fully Paid Ordinary Shares (No par value)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; padding-left: 9pt">Balance at beginning of the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">80,099,646</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">45,633,354</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">74,964,232</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">40,335,347</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Shares issued during the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,541,771</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,841,951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,457,041</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">429,723</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Transfer from reserve from exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Transactions costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(61,480</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,459</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Contributed Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">105,641,417</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">47,485,700</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">76,421,273</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">40,816,226</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended December,
31 2016 the Company issued the following Ordinary Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date</B></P></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Details</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issue</B><BR>
                                         <B>Price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total</B><BR>
                                         <B>Value</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center">7 July 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">Right issue<SUP>*</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">18,045,512</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">7 July 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Right issue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,275,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">818,867</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">29 September 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Right issue to oversubscribes and private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,968,916</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">992,229</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">2 December 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Shares under ESOP &ndash; for 6 months service (vesting monthly)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">251,877</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.123</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,855</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">25,541,771</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,841,951</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*As at June 30, 2016, the Company was
committed to issue 18,045,512 of ordinary shares in relation to the $4,511,378 received in capital raising. These shares were
subsequently issued to respective holders on July 7, 2016. 2,418,129 of these new fully paid ordinary shares were issued to Grandlodge
on the same terms and conditions as all other subscribers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 191; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
7. <B>Reserves</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">December 31, 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">December 31, 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Options over Fully Paid Ordinary
    Shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: justify">Opening balance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">9,937,629</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,132,301</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7,188,676</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">560,646</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options issued during the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,489,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,620</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">537,309</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options exercised during the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(910,166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,615</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expense of vested options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Lapse of unexercised options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,250,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(127,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Closing&nbsp;&nbsp;Balance</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">34,177,523</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,288,221</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">12,278,510</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,039,340</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">December 31, 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">December 31, 2015</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Foreign currency translation
    reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Opening balance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(3,735</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(12,581</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Movement during the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41,425</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Closing balance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(45,160</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(17,362</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Reserves</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">34,177,523</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,243,061</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">12,278,510</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,021,978</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the six months ended December, 31 2016 the Company issued
the following Options:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date</B></P></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Details</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issue
                                         Price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total
                                         Value</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUD$</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: center">7 July 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">Right issue<SUP>*</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">18,045,512</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">7 July 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Right issue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,275,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">29 September 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Right issue to oversubscribes and private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,968,916</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">9 December 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Unlisted options in lieu of services</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">200,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.143</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28,620</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">25,489,894</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">28,620</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*As at June 30, 2016, the Company was
committed to issue 18,045,512 of options in relation to the $4,511,378 received in capital raising. These options were subsequently
issued to respective holders on July 7, 2016. 2,418,129 of these options were issued to Grandlodge on the same terms and conditions
as all other subscribers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the options granted
during the period is estimated as at the grant date using Black-Scholes model taking into account the terms and conditions upon
which the options were granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>December 2016 Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table lists the inputs to the model used to determine
the weighted average value of the options expensed during the year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Vesting date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Dividend yield</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 82%"><FONT STYLE="font-size: 10pt">Expected volatility</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Risk-free interest rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.61</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Expected life of option (years)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.17 years </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Option exercise price</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;0.5000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Weighted average share price at grant date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.275</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Value per option</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">AUD$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.1431</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 192; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2016 the Australian Securities
Exchange (ASX) market share price for Immuron was AUD$0.27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected life of the option is based
on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the
assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
8. <B>Loss per share (Restated)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December
                                         31, </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2016</B></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December
                                         31, </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2015</B></P></TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>AUD$</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>AUD$</B></FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD NOWRAP COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Basic/Diluted loss per share (cents) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">3.300</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">4.065</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 67%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 11%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Net loss used in the calculation of basic and diluted loss
    per share</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">3,409,349</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">3,068,086</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Weighted average number of ordinary shares outstanding during
    the period used in the calculation of basic and diluted loss per share</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">103,328,491</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">75,470,006</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the previously issued financial statements,
(i) the basic and diluted loss per share was 3.318 cents and 3.120 cents, for the six months ended December 31 2016 and 2015,
respectively; (ii) the weighted average number of ordinary shares outstanding was 102,756,793 for the six months ended December
31 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
9. <B>Related party transactions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Short-Term Loan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grandlodge Capital Pty Ltd (Grandlodge)
is an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou, and owns a top 20 shareholding in Immuron
Limited. On 6<SUP>th</SUP> June 2016, Immuron executed a short-term funding agreement with Grandlodge for a principal amount of
AUD$750,000, plus interest charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
The short-term funding is a cash advance against the anticipated refund Immuron will receive from the Australian Taxation Office
under the Research and Development Income Tax Concession Incentive for the Company's eligible R&amp;D expenditure incurred for
financial year of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loan has been repaid to Grandlodge on
2<SUP>nd</SUP> December 2016. Interest expense for the six months ended December 31, 2016 was AUD $47,158.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Service rendered by Grandlodge Pty
Ltd to Immuron Ltd</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grandlodge, and its associated entities,
are marketing, warehousing and distribution logistics. Mr David Plush is also an owner of Grandlodge, and its associated entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commencing on 1<SUP>st</SUP> June 2013,
Grandlodge was verbally contracted to provide warehousing, distribution and invoicing services for Immuron&rsquo;s products for
AUD$70,000 per annum. These fees will be payable in new fully paid ordinary shares in Immuron Limited at a set price of AUD$0.16
per share representing Immuron Limited&rsquo;s share price at the commencement of the verbal agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares to be issued to Grandlodge,
or its associated entities, as compensation in lieu of cash payment for the services rendered under this verbal agreement have
been subject to the approval of Immuron shareholders at Company shareholder meetings held over the past 18 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grandlodge will also be reimbursed in
cash for all reasonable costs and expenses incurred in accordance with their scope of works under the verbal agreement, unless
both parties agree to an alternative method of payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 193; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The verbal agreement is cancellable by
either party upon providing the other party with 30 days written notice of the termination of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months period ended December
31, 2016, an amount of AUD$70,000 was charged to the Group&rsquo;s expenses in relation to service rendered by Grandlodge. This
amount remained payable as at the period end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Premises Rental services received from
Wattle Laboratories Pty Ltd to Immuron Ltd:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wattle Laboratories Pty Ltd (Wattle) is
an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. Commencing on 1<SUP>st</SUP> January 2016,
Immuron executed a Lease Agreement with Wattle whereby Immuron will lease part of their Blackburn office facilities for Immuron's
operations at a rental rate of AUD$38,940 per annum, payable in monthly installments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
The lease is for a 3 year term with an additional 3 year option period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
The lease is cancellable by either party upon 6 months written notice of termination of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months period ended December
31, 2016, an amount of AUD$19,470 (excluding GST) was charged to the Group&rsquo;s expenses in relation to service rendered by
Wattle. This amount was paid during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other related party transactions:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25<SUP>th</SUP> on behalf of
Immuron, Grandlodge purchased US$1,500,000 at the cost of AUD$1,968,762. On the same day Immuron paid Grandlodge AUD$1,968,762
to settle this transaction. On Sept 12<SUP>th</SUP> Grandlodge returned the USD$1,500,000 purchase to Immuron. Grandlodge received
no financial gains or benefits from this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
10. <B>Fair value measurement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of convertible note classified
as level 3 is determined by the use of valuation model, which includes discounted cash flow analysis and the use of observable
inputs that required significant adjustments based on unobservable inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at December 31, 2016, management has
assessed the terms of the convertible notes and determined that in their view the fair value of the debt component is equal to
the proceeds such that there is no residual amount to be allocated to an equity component. In making this determination, management
is of the view that the value of the consideration received, net of costs, provided reliable evidence of the fair value of the
debt component of the convertible note. Fair value has been determined by the income approach based on a discounted cash flow
analysis, with the most significant inputs being the discount rate that reflects the investors credit risk. A slight increase
or decrease in the discount rate used would not be material to the financial statements. The fair value of the convertible note
approximated its carrying value as at December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Reconciliation of level 3 fair value
measurements:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 49pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; font-style: italic; text-align: right">Convertible&nbsp;notes/debentures</TD><TD NOWRAP STYLE="font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: right; border-bottom: Black 1pt solid">AUD$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Balance at 30 June 2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">1,128,117</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 77%; text-align: left">-&nbsp;&nbsp;Finance Costs (*)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">1,883</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">-&nbsp;&nbsp;Repayments</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(452,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Balance at 31 December 2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">678,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">(*) These amounts are recorded
in the Finance Costs on the Statement of Profit or Loss and Other Comprehensive Income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 194; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.25in">Note
11. <B>Events Occurring after the Reporting Date</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">29 March 2017:&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Company re-engaged consultant Dr. Dan Peres
    on the same terms and conditions of his previous contract which expired on 1 April 2017. Under this re-engagement agreement,
    Dr. Peres was granted 1 million fully vested options exercisable at $0.50 per option expiring on 1 October 2018 under the
    Company's Employee Share and Options Plan (ESOP).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">9 May 2017:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company executed an R&amp;D Tax Incentive Prepayment
        Loan Facility Agreement with Grandlodge Capital Pty Ltd which is related party of an Immuron Director and major shareholder.
        The Company received a cash advance of $500,000 which is secured against the Company&rsquo;s anticipated FY2017 Research
        &amp; Development R&amp;D Tax Incentive cash refund. The loan has an interest rate of 15% per annum and a commitment fee
        of 4% . Immuron must repay the borrowed amount plus applicable fees and applicable interest upon the earlier of:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(a) The date Borrower receives the payment of Offsets
        under the R&amp;D Incentive Program relating to the relevant fiscal year and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(b) Successful completion of NASDAQ IPO capital raising;
        and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) Termination Date (December
        31, 2017).</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">Other than the events listed above, there have not been any other matters or circumstances that have
arisen since the end of the financial year, which significantly affected, or may significantly affect, the operations of Immuron
Limited, the results of those operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 195; Value: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: center"><FONT STYLE="font-size: 16pt"><B>610,000
American Depositary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>Each ADS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>Representing
40 Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>Warrants
to Purchase up to 610,000 American Depositary Shares</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="logo_424b4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 18pt"><B>Joseph
Gunnar &amp; Co.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 18pt"><B>Rodman
&amp; Renshaw,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>a unit of H.C.
Wainwright &amp; Co.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 11pt"><B>WallachBeth
Capital, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">June 9, 2017&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 196; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_424b4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ ' "F P$1  (1 0,1 ?_$ +<   ,!  (# 0
M      @)"@<$!@$"!0,!  ,! 0$! 0$           8'" 4$ P(!"1    4"
M P<"! 0# PT      0(#! 4&!Q$2"  A$Q05%@D7&#$B&0I!,B,E45(D0C,U
M87&A8D,T1$4VIB<I&A$  0(#!@,& P8"!PD      1$"$@,$ "$Q!08'01,6
M46$B%!4(<8$RD:&Q0E(78B/!<C-3-#4F\-'AHK)#<S88_]H # ,!  (1 Q$
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M*Z0F(,RXBN> GFI@<-LXB8H9BB(Y<=IVW:VTJ-LM<NTS/+G4S@R9+)1>7,O
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ME/G!G,WVE*T\HSY:%"E\IO'#&U*]^PS6,O,7$H9K4W#+B8P%+B:D9< Q,(@
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1E_\ Z1ZUN7J-2OZ>'_"W_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pg8img1_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg8img1_424b4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!F ** P$1  (1 0,1 ?_$ /\  0 !! ,! 0
M       ( P8'"0$"!00* 0$  P$  P$!             0(#! 4("0<&$
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M1<_'D]"8JJCH=FSTX(&6* F[H"[";IU4%IM,M3N?_@RS\]\A;48JFKWQXP/
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MT]-G_CC3_P#24/\ \Z761UD<^([5T;CK01*@J<#3N9#%$A#'*8@YVR=TG Q
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M"N57\QSBL-F;$BW>A94.4\]NY;M3J_R;V?ENJPK/ERKN]' S'E+_ +<>(/\
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MGXMN+]\7%_'>/%Y6Z5>H.RV:#2<QK%ROYU8H1@LQ33,**1^_$55"HE5WTAW
M=O4WG5JE'L<GCNW+W2LN_P [$_!<O8,HCRC\-41$0\+S&0@([@(8@XT  @/D
M$ [KLW#6:[@.\#A9^-+YI;[_ #L/QG[!QZ47AK?-=XS_ )(>-'_LM/N [P.%
MGXTOFC[_ #L/QG[ ]*+PUOFN\9_R0\:/_9:?<!W@<+/QI?-'W^=A^,_8'I1>
M&M\UWC/^2'C1_P"RT^X#O X6?C2^:/O\[#\9^P/2B\-;YKO&?\D/&C_V6GW
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ML]X6W_BS\9?YM\^: VSZ : : : : : : : : A]Q,_9[E_\ ]\&^_P V^(]
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M989D!#G BSA+K.783 110H"(AUF\N@+PT T T T T!JCYI_UBO@T?QZ<Q_\
M,/S7H#:YH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"(63?Z9_%/^)SEK_E'C?H
M"7N@&@&@&@&@&@&@-2_^EHT!!_P;^76->,_@E<*9&\1-_FC5#BM(Y1?QM%JI
M+-+OZXIR%D,;%:0C+WQ8A)3PV2VLQ*TZB'.V[PY1$Q>@<[LG&-4Z8H&W>[\X
M</T6V1]4<'M-H<RG&V^<JF\A281I/P!,745@PDR(JRYY&/!*SW>.=.%Z\T,G
MW<DE'N3&60!,O>3>DXPBXX-LVA!2C7\*G$/SGPU-H<3UHP+C(*<Q57Z.,V;>
MNMQ?5@8FIR-HFU,JM329%:6$ [CA@GA !V9&PG*S]T(B<O3.&6N&QF<%FLY_
MP\QF&W9LAZ9E7%.)96#NZTQF!6UM*U98^L@M0XZ2J=4F;DXB+)9G#I C"9DX
M.MOU6;5!-TJKYN)E 12$ISX+89Q;<:O:89=<W*) 1>=7M[HN8<=R?'RM5FXV
M:JVNK5A]9[G7KZK8V>/%,=-:1<;9&V"7O$M4WS%C%+.F,P5X5--RT;@JF8TE
MCW8[E[59^\8NH56H>2+'(Y4Q52,RLI- ,:0L34Z1D-:01K;JTI6O)->L3R1
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M3,6\O\XQ43)V"DCD>ESU0R%BO!:-KK%HIR%KHDD[*K(5>)?LG;.88N&CN/(
MBJ@JL@H!?L7P+<5VHV&/K&<[9"Y$LF(+'CZ0RNU@6\=:#7"[9FL&<[S?VR]9
MFZW+0C6T7&SNT5(N*D(Y5K'BF1L_1<(HN4Z.-74E.A>_&SAYZ/SRNRKO)LO?
M)6(K>7X.1<2#&< 91SF',@9EEI#WVMMVO]V7+"RHF9-1E)F6?*MC=;EXLJ G
M-:"R5\)2:<VO 33 NP%\@;!V@4-@W'R[![ ;ZJXUDI<"Z>%"#_*^NEM^7.(E
M3.[,P):+CR KIWQ40<&8EF^*69HTSPB'>(BN=L#GK G>)]6VW4'EU<@PN_\
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MG0$<[EW:%A40C6SV9DD&J2BPD*HX6(F41.8I1 E#^61\)SYR'A1ZR.*?NGT
M_+(^$Y\Y#PH]9'%/W3Z ?ED?"<^<AX4>LCBG[I] /RR/A.?.0\*/61Q3]T^@
M'Y9'PG/G(>%'K(XI^Z?0#\LCX3GSD/"CUD<4_=/H!^61\)SYR'A1ZR.*?NGT
M _+(^$Y\Y#PH]9'%/W3Z ?ED?"<^<AX4>LCBG[I] 8CXD<H>&MZX7Q=/L'(S
M#+RK9 )G=B]58Y-KB/G]3ON7LHMD9%C((2!C-6TI$2Q5&SH-M@5*<NX[:F%Z
M]I]=#J&GPE;:>_;%U7L[3EU%K3RLO0ZEK+<35.*E_P"3%R?&[PE4D$ +R"A
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MSEMHGY3[]:%RR<E'(GCF_J*)D533I-J.HDJ4QTU"%@GYCIJ$(8ASD.4-A !
M1#R"&@*U 5(I2:@!"%2 M3K1NY33.FFD52%9F*0@'$3=!0[  1$0 .W0%X:
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M1_W/]MIGTOTN'G0Y.L^BR^*QW9OT(_[G^VTSZ7Z7#SH<G6?19?%8[LWZ$?\
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M ;7- - - - - - - - - - - - - - - - 1"R;_ $S^*?\ $YRU_P H\;]
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MP'QI(A8\=8U"AS4DU2C%9FJ\1<Q5R:58OW13^8.G,;AMJ_205=;&52.8"E$
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M^WV>_'9OJ?\ K_V&XZFOYZ]P??EVU_TW[O\ E.?RG_,S]^M _DOC?_PQJ/\
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MVX (@ : JT4JHTRIF5<&54-5ZZ)S=ZHN G]YV?6<JZI$E%P4/N;J,4#&WW$
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MI DDQEI*.Q_<,2.6ECA)B0A;%79[%-_F;%<\=66L2K!1C(Q,F^<NVSQ!0#"
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M+;CX#W*N7=3*\\UM*#CB^!ZFM2I962>]''5^!%'SE8:5:NZ;]VHKYPK[Q/\
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M(23^(3G2P;ZT)4RQOX@LRLT5E@BW M?.!1 "@%64F_$+CZUMDI=4L91 STO
MR59?"M*V=W"+0TQ48>@S*3:INYU2IQC^P4FOL8F1>H,B/G[%HDDX64 A=@/?
MK'&O#E.JI*5 4./;UP7U!DEV;V7L<VX<O\5EKX8Z?/9F=EY&>?O*D%7CR-#K
M.3B5-FF4W4!0#0':!XW8@K,+DBMPE+;MJWE[W^#(5<6F[*_KTLE:%)A6P,X^
M!D9AW%U6+EE["^679PQ(YJHX=**B3K-U: ^97C!@U>]RN3%\7U16^3B6)DIF
MT&:K%DI7XAY:<G,-*/Q3<E;/%L;2UE>KQ:BJ1UD3')U'/W20I@>7:.)N#+I<
M?AY9L?,Y*R*V.*N,D8ECN,; V.U00UT\+,V^G14^RIEP7B5:C&JMBRL:^30<
M-$U2% Y1,8#)43AW&\*O6W4=4XQLXJ-MN5[KBQ!>&/$V_(06+X;6!L*CH^\A
M9/A;(^<"?J(/G9^DI>S8#)N@(,\0?Z&B/_&')#^>;+&IM?YVS^<OQ'/K?\I>
M_92^2S\I4'^P<+_Q-$_Y.;:^G.E_R6G_ &%OY*/G5U'^(ZC]M/Y3/4UL<0T
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M* CVF$A^D.W8?)H"O0=PI52[4S%&KUPQ#)J&4 2C#,@WZQ(F4X")1$# 4O4
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MR[$<F*8V1N/0$.=N4ABH@8,L"!57 F$I.K8H&*/6)0V$0.I<]YH.0#%X>Y6
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M3KYR?,P<P?6-\.K\;S0#TZ^<GS,','UC?#J_&\T ].OG)\S!S!]8WPZOQO-
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M@N@@<5%#%[T>Z.Z3$O:8Z9]T"@2X*@@)0V3+L)2;#V^0O28FPB.X  E ?S=
M!;("("*8")0V =QW .SL =]]A -A#V0\N@.1;HF 0,F @/8("(^R A[?M".@
M. ;( .X)@ [=.^X[B&P%V'M[>P/9T \V0 -@2( >Z'8 V >K[+?;R]6_;[>@
M+*R2U;_%W?QZ4TQ&EVH16.8Q 3$8)[NH*A4USI@3I >HI#"'2 @ B !H#ZJ$
MB0:54!/W:A_@K6^M4AC'*L?WE9 94#&31,?KV#W1B@8P &X!V!H"ZO-6^XCW
M1=S  #Y=AV,)PW#?;<#&'MT!SYLA[G=(H] =)!'<1*&QB[%$1W -CC]/0#S9
M ?\ T1>S;V_8  #V?8 .SVM  ;-P\B1 \GD#8.P=P#8.S8!T!U*S;%$HE2 !
M((B00,?<HB  /3[KL#L#8/(&V@-57,\A$O$2\&=-,I2D#.?,8 +L @4"\#LU
M '3ON)1V#RAVC^>.@-KNP>T'T@T V#V@^D&@&P>T'T@T V#V@^D&@&P>T'T@
MT V#V@^D&@&P>T'T@T V#V@^D&@&P>T'T@T V#V@^D&@&P>T'T@T V#V@^D&
M@&P>T'T@T V#V@^D&@&P>T'T@T V#V@^D&@(A9. /3/XJ!L&WQ.<M?\ *''
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M133W'M A0';0%X: : : : : U1\T_P"L5\&C^/3F/_F'YKT!M<T T T T T
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MZ)S;<,7<P9>]\=83,^-8=>:>9[XP4W+2\&PA,I,<H2V*KU<8RMTBG46:R8C
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M\-TB'4.XDO@A>@A2 (F H 7<P[F'8-MS#L&XZ U->*KVSWA;!_\ ]9N,P_\
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M*DT\@'!02U2M$$Y2F*1020K(O>$[Q!NKTG -]C%*(>R4H[AH"[] - - - -
M:G>;C=!WXAO@WM7*2:[=SF[F8W<(+)IK(K(K<#,VIJI*HJE.DJDH0P@8I@$I
M@'80$- ;/4JA6D&#&*0@H5"+BUP<QL:E$1R<=&N0!< <QK K8&;!SNY4^V)$
M*;W9NWW1A$"M&5B"A6B+"(B(J*9MA5,U:1<7'Q[5H+@-G(MFS1NBBCYSY%-@
MW4#L'<- <&J\&9N^:>]D>#255<K2S,&+0&4J=\0J;\TFS*B5O('>D( *F7*H
M=0 V,(AV: KLX&,CRMDV+-FS18-?,HYNT9-FK>.9[);M62*"::;9L(H$]P0
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M !Y #8"FM 13E%TV<LFKAJ_*J5\U7:MUFST%@(53SQ%1,R;OO2)@"G>@?O
M -N    >0VH-/9H,VK2M5]HUCI'WWC6K6 A&[:-EMP$):/12CRILI/L#[>F!
M5-^T! = ?4UIU:9OWDLW@H-&6D2+)R,JA"12$E()N!3%9)Z^2:%<NDU02*!P
M4,;KZ"]6^W:![C9HBT*":!2IIE*4A$DRE(DF0H !2)D*  1,@[])0["@.P;
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M1V#J[-^SZ ?F!H0ZTPV@ ,'D*4-_+L !OV ']@ #\[5O1,_TO@.X!L !L ;
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MX-'\>G,?_,/S7H#:YH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"(63?Z9_%/\
MB<Y:_P"4>-^@)>Z : : : : : : U+_Z6C0$.? =FN7+/PB>"S;'6/>-\S2B
M8DD/@[)W;,F4*S:GK(;[;S**S,'!X&MD1&NBN3F+W:$B[() *;K]UL &W+X1
M<[_O4\1O6"S+[/DW_P#LR=F^GC!S\(N>'WJ>(WK YEW^EZ,F@./A'SOWV^*K
MB+O[7I!9EW'\[T9=] /A'SN[/^JKB*._:&W(+,H[_F?_ &9>W0'/PBYW_>IX
MC>L#F7\[_P#9D]G0&K_Q,)GF$YG/#8^%>.>-,>HW\43CFO6 K^:LIRI'UJ)C
M[.(1T?/&DL 0AHN!7;"N*SIL#QRDH5,"MCE.8Q -G_PBYW_>HXC^L!F;\630
M#X1<[_O4<1_6!S-^+)H!\(N=_P!ZCB/ZP.9OQ9- /A%SO^]1Q']8',WXLF@'
MPBYW_>HXC^L#F;\630#X1<[_ +U'$?U@<S?BR: ?"+G?]ZCB/ZP.9OQ9- /A
M%SO^]1Q']8',WXLF@'PCYW_>IXC^L!F;\630$5^,DYS31F^5/O+C3BTZ45Y6
M7A29+(YSRZS(UF!Q]BP'#6/.VXYOA>,$VP(F*LH"*ACG, I@!0$P$J/A%SO^
M]1Q']8',WXLF@'PBYW_>HXC^L#F;\630#X1<[_O4<1_6!S-^+)H"+6;)OFJK
MGOADI)8UXJMY)')^5Q@6K7.>8'#5^Z/QURF1^G).U>.34T<W;Q1EE2'(FN=1
M<I$^DI3&4(!*7X1<[_O4<1_6!S-^+)H!\(N=_P!ZCB/ZP.9OQ9- /A%SO^]1
MQ']8',WXLF@'PBYW_>HXC^L#F;\630#X1<[_ +U'$?U@<S?BR: ?"+G?]ZCB
M/ZP.9OQ9- /A%SO^]1Q']8',WXLF@'PBYW_>HXC^L#F;\630 +%SP'L^*CB/
MZP.9@^KZ,G9H"*_"^W\N6W'6GMH/!N$):/;6W,YE7[GD)9XQ>1<FSIDM!Z$8
MP^(UZHV;%? HHB9PJ14[/;K*FXZD-)YI34X.C-(JVDX7*T9*E&Z<TT4B=7'K
M!:@F*'VM/DG:N\253-NY%PHM@,$Q(Z+_ (N*76(&_N@$[=5N*Y<EF<DO$C",
M+=GT+2;A6NW>\6=CWCFJ4YFX<><$G/MW97Q.25K][^]*8Y3..@^ DGXM#@F!
MBE[L%=E";AN"@$IR[E??^PQF_FOSE)QD#F3L._'G!P$Z>DS-3DK8P=NA6$@%
M!JL3 BC-,6I2F%4%S)E.)TP(8?=;1%7(RK&XG-;O"3Z$_P!'.+R2P>-<"DG=
M^9K?J5#CU@98%RE.1!OR3LZ+E%)N D6*Z\XP("(KF%NIT 0QBD*X;@8VY%P2
MM&U<YO.O.IGEI/D64E$^@M[YJ; 0, X!,/="<KDO(^V^:J[B"R8)IFP"5X'4
M@D9(1,0H X63$?M15#ETJGBMAME</0>U8>8C=RCMO*5Y3<<!;\,8=@&K?D1Q
MU<,%(S/UFF7,S9&N9*FI6J\BP'#<*S2:34LB0KMTZ5.DS9*]\#==9+N@ DN:
M]\T"^Z'CU@DY#&Z@23Y*6<%TDT@W4(H*N "('5<] ]T)3=)0.43B E,&@*!K
MYS43.DW/@/CZ*W2)5'9>2%O)'G,01W<)E/@ 7Y6ZY6JO=E,GW@"ND!@V36$H
M'<;]S0,!E$^/."B%2W$S9;DG8Q>.0,F<2&0,C@8[1(B2K<P*"HH B"R0E >E
M7I $OG-(H@93CU@MR0"=0IL^1]G(J)B%'J3ZW>!$4!47,V,*0@;H KM#KV,1
MP"0'9.]<TQ+TCQ^P&8Y! QW)>2%M(U6*7W:A&R9\ BZ#O2I&32.J5/J.JF8Y
M2%[SI ZJ7CF><![WCU@@4.DY%D$^2=H%V/:)RKH*#@1)#NBIM3E$#&3/WKA'
M;W!%C$ CI3[;RJ0Y-9ND$,$8E<61_BK J4C FS_,,(UE$LYO,9(N3C9U/"13
MV-S*NP?E5(Y:D58))MD@6.FH=- "1/PZYK)[I&P!@%91$@=:Z/(^W>;O5$5#
MD4\Q(? !'*:;X$P\W,L1/I%0O? GTGZ0.PWWFB I[<>L%F A/MI3<C[,4[@X
MF,7K0/\ $+T(($[D>H5 [P3.$2E((%7,D!4^'O,TO:/'O!#G<PF[MIR5L_?)
M)D$2G24!UQ_;IF< 9L?M*82;.$.W<JP$ IEOG-(!!,_'[ AQ(3[8Z2Y(6HK5
MPHAUJ."M"*8$!T4SE- Q$BK%)W9U4Q4,!05%,#L%[YHJE.=+C[@4G084^Y5Y
M)6DSA0>U0K@.ZP$H@DV.FD8@=1A5!0Y!$G0!Q*!;-VNO,IS3;<U><><(^:O*
MS/(KBSY#SLBX:-5(5^DY!9B_P0V:O70G2$Z*("HBL19(BADQ[T2 5JE=N8S>
ML5MLVX_8((@U@H9 CAWR+LK S]%I%( 'FS!IQ^6+'JO$2E.BDIT$1#<A^G8#
M& ]\]]YHAN)>/."NP#D!+TD;*9590=SI+MS&P.DB9N1-$X'*<R:@F4((!T@<
M2@<_#WF< D(/'W P&6$.E4>2EG\W9E4$R!?/!^(+SA0R*Y>]/W*9]T3 4NZ@
M"4 .PWCFJ43!Z/F!!Z1*?K])*UE(<B.QG#=,!X_B<'#L@]+83 ! . BJ*9=A
M$"G\/^9_2*GH]8*+TB)!:J\D;*1V<>OJ*N)B8&69I-3(B!1V444!3<1+TB Z
M X#(',W8X^C[@8PGZO-R^DG:""F(!L";@38 V5%(4A44.AUE!)4G2!E"J$ #
M69S!M'*Y_P \_",5=8BP7$6AKFKEK\$BJ9TN,M5YU\'"7+Z$U[\2#'""4Q ,
M2PQG+AD=)D^45<))HK%0!3O2@;,?A%SO^]1Q']8',WXLF@'PBYW_ 'J.(_K
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M.@&@&@(?Y_,4O(O@SN([CE7,NP 4QA$0XR9=,( !0$1'8![ [1]C0$MA=IE
M#&(H!1Z>D0)U@83% P '0)MA_-VT!635(J7J)OMOMVAL/MAN ]H"(#Y![0\@
M]N@.QS=(!V;B([ 4! !$=A'8-Q#?8 $?S- "' Y0, "&_L& 2C^> ["'Y^PZ
M [: : : : : UAXS5<-_#2R@[:++-W36C<QG#9PW64;N$%DL@9M.@LBNB)54
M5D%@*<ARB!B&*!@'<->2Z):MZGM'I87<$[UN/D=Q)^=5/#]<O7-)V?U%RQC*
M-J=/BL_-TA)RHH(F"<L8]21!$?A+82[CT@'4(!*F]T;;<P[]IA$?9U]#7V1[
M)6X6XWM/;G<Y<,5"/Y*\!Z%OM1VEG<N.S<<+?-GA5_E,J#)3&Y3)S]E34(HF
MH10MFL95$CIF!1-5)0LJ4Z:B2I"F*)1 P& ! P;;#*[(=CKZEIGI8*%Q4;R1
MP7F)7:OM#II+5:BXYNVZQ57M_P#!^AGP\N;2>7(EIA_+EB2'+T&3IJTG()IM
M#9)K$<R2."A'7? W?WN%)WX2"14T57C0B;PA5!!R9/T][VN[C3=C^L/4]"M2
METFY1N5*N$FW5-TKE:::JW1U7!'M3W5]XR[6Z#U;K#C#J4,()X9J+"GA7L^<
MVOI*E6 1+Y V\HE$0$0WV$"F-L.VOR$_8BKH"(O,@PIT3&1N[5.4_)[BND8R
M*@)F*!L[4OW2A1=-N_2(80W3 JQC"(;)F'M "76@&@&@&@&@*2_]R/Y0[ '<
MI0,8-A =P*/88?H#V>WH"(N/DC$Y?\D13%,H*X@XSG5! BI.Z,61SJDFFX 4
M6I7"RH!UD.!G70E[GO4S *0 2^ =P ?; !^F'Y^@.= - - - 61DQ/OL<9 2
M]Q]MI%K3^VD.HG[N!?E^V)IHN5#D[>T"IJ"(>0IA[! KT O32:B "04QJM;%
M+NTSID GO*R* %(<B723W.X!T)B #L)0'0%X: : : : : U1\T_ZQ7P:/X].
M8_\ F'YKT!M<T T T T T T T T T T T T T T T T!$+)O],_BG_$YRU_R
MCQOT!+W0#0#0#0#0#0#0&I?_ $M&@,$> =BK&UV\'#P_IJW4R L$H7!*D-[X
M2C)-PX")B,W3UWCF'>&$!\U8VZ 92)"^0KMJF?RE#591C-4ELJ#;<7C7Q_!*
M:12Q'04D;,^RS)SZ;> 8H)S<EGE9%UF5_(@BF0'KW)JK=,TRJ?J.^Z"]X(@
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MJB^ BJBH&?>1'.G)^$K8%*IKK'M7FKIG7-5:K4UE^877HST:%7\&NHH++-Y
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M'MV[! >W;?;\W;0'4%4Q$0!0@B4!$P <HB4 '81$-^P 'RZ X!9(0W!5,0V
M=P.40V'I$!WWVV$#A],/;T !9$0 P*IB41V P'*("/;V .^V_9H#GO$]M^LF
MW9V]1=NW80]GV0,'T] .]2WV[Q/?8!VZR[["(  [;[["([:  JD(](*)B;?;
MI Y1'?;?;;???;0 %$Q'8%""/8.P&+O[K?I[-_9V[-  . @40.40'R" E$!V
M'8=A#R[#K*?,<ED?H;]A. ZRAL!CE 1WV 3% 1V[1V#?MV#6KBWBJT'B *)F
M IBJ$,!MND0,40-OMMTB [#OU!]/2C6T@YZR;"/678/*/4&P>7RCOV>30'0%
MT3  E62$!\@@H00'R^38>WR#]+0'8%4Q,!04()A#<"@<HF$/)N  .^VX: B)
MD\P%YG<5!,(% ,.<MAW$0 .R0XX"/:/M &^@)=&61(4QCJID*3L.8QRE*40
M!V,(B %[! >WV] <]XF  /6381  'J+L(F,!2@ []HF,.P>V.@'>)B!1 Y!
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M"/8 !VB/8&LKSOJU)Z5-ZFCRKC+<7AR<Z]9PT]?2_-W^P9ZXPUS,]ESE1FF
MG$A&9'CI!.3)8VF_O75*^1PBTL<M<5!*=HK5/,53H+LW!5"R*YTVJ:9W!RE)
M^?=\&N[+Z;L7_P#>*%WJ<E16ZY9N6W!T;JGC6F&UX']SW5].[1W^U2N='E*U
MTU2]_1N.79CBMV[?L/V"- 4!JV!94BZP-T05631%NFLJ"9045(W,HJ9 BA]Q
M @F,)0';<?+KT%S*?IQ5(O&FVE=U3WKMQE"$8S>::23>RKWNF-*^,B5S,.U^
M N+4W)RIF'E'Q4,T$ZHI];OX^*5W2*9"JI"X55*4P EL?K+O[D=MP%R7H?\
ME_Y#N.@&@&@&@&@*#G^XJ;EZPV#<NV^X=0;]GD\GM[![8@';H")%#44+S Y$
MIKIK 0N&^-_O6=< Z%&OPASL#I1$Z1$C.2GD#&!0RAEA[P!+U% .Z "7I1W
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M<^JZJ3C;D\(5;45[57OP1[Q]CNR^B[)])ATW3Q3E';*BJ\%Y:+<2O* %*!0
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M H@ @!BFZRFV\G44X;@/E >WRZ "0AOLB@/YOT2B4?\ <F$- <B0HF XA[H
M$ '<>P!VWV#?8!';R^70 "E#?8-NH=S>7<P])2[B/E$>DH!^=H#@J9"B(E+L
M([=1NWJ-TATEZC?9&V#R;Z ZB@B).Z%,O=[B(I[>X$1."@B8OD,)C]H[^41'
M?RCH#N)2CY0W[!+[/D';</S!VT!P*9#>4OL& ?* "!_L@$ 'M VWLZ =V0?]
MC_L@-OV[]0% H&W\O4!0VWT!STEVVZ0V'<!#;L'J'<V__P!X?+[>@ $*!>G;
MW.VW2/: @(;" @.^X#H#H**8G*H8O48OV(F,8P%]T)MR@81*4VX^4 WVV#R
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M[611/L$X (E\NWL@!+G0#0#0#0#0%%< %(_44#AV;E$G6 AU!_L *<3"'E[
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M5P=,S=,0,H!0U$'GV$Y6>Z63;*))+H"=PDL0BB9T2@?K(H&Z8E+U <W6&VP
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M0'8R")RB'3[@VQA IA*41WZNO8H@ F$W;O[?;H#H5H@7?8@^Z+TCU&.8!+N
M@42F,)1    #L["AMY- ?0  4  /(   ;B(]@=@=H[B.@.= :R,9?U9>5O\
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MG\V564J\UD>0S=1T$;IQ-KCF?LT?B&GP>"&,^59 6%>(87+(/>YS)$5<%A[
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M46AXR4\W[\A>3W%?O! Z)#(D^/:E@*_VXA^L$A,'N2"0X[]A@VT+$NM - -
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MWD';;<.WL'_S[C[(Z$-M[3O]J >H!+OV]O4';OMN(]O:/9[.@.W63]$7Z8:
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M-0YU%5.D!V$3&-OV>Z$=] 79YPANH JD 4B]:@"8 Z"]O:;?R!V?G: Z"[;
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MM#'^(]P"[+W?28"F#J*4NQMP$Q@+C#C=DT#IF],_DJ($2.D)!8<?1*KUJ)*
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M,?H7/*,+#6/'E;+8F3B5N==L+@[:!L5=9MUCJR4%,J(J>;.B[(K"00*8=A$
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ME'!TTND"G%0F5Z',AE_G)^9U)4LKJ3[2X(\CG9Y^6MM@Q_9[1'X2Y/<9L>S
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M2I#UE.;XM,^#T[F*0 +N/2 [ /9U;!Y  L]EP0Y4MWELL\KEBK/Y#D6P3-R
MJ%,6F,6%K<HIGVLY<1"L91I_F5ZO"=?HCVR4M!X[][7JD0NS*44RE4*('W3O
M _*$#\7WQ?P,6=UC".YT8[Q!+)YPR/!2.&Z/G%RC(8'DXM8YWIIU*I%C"LW3
M-;O5HPBR MCKE:$V E!EO%O(IM,XAOU9-!9L=8WR[&71MCE](Q6+W<)7C82R
M)CF7;M;\[96(+C(J66VH/!4?MFBAFW>E(<IMNH#$3W@_-3+3.MZR6QL>5YNW
M9$R;;\8X-;9988]J%*:9&>T)XYL%6O\ 5:'#7BNY38+T]-TS?N99\WCGZ!5F
M)F:BHJI@3)XM5?,M.PM5H#/-A<6?(3!:>24DI*;CK38V]5&PRJM%A;A<(BN5
M"+NMS@J>JS:2LPWBV*<B]246[LQCF54 D-H!H!H!H#4/4J'E-7-F2,WXII];
MR5)8DY;\E*Y+8\L%J2I#IY&96Q%Q];_"RIV9W#S<6RLE:>U,C8R+A)+SB+EG
MP$<$.!45P/#/P5S<-0-,2;6CV*_0^*\L2](HBN1\CLL44W-6<,V9 R!<XZ)K
M\(\J<;+HP>-[ZO7(^>?)D47,4W4W:M5UTSR;PN*,4GQ]C_R9RX9<9\S8>>X\
MELGJ5U,E:Q?G"D!$Q4T>0^#C.\\@FV1\>U:):),PC&D'5Z&BFP[AHL#*/,W3
M:-"&:I)&+!%R<9)4VFR @"4A2CY0*4!_-  #0Q( \UJ0KDR\\9,<(2JL OD"
M5Y+TA&>1*JHM"*VOB'FR!3E4D45VRBJL>=^"Q0*H0PBGL!BB.X 8FON$>0V8
ML!X]Q7E'CQCM6JXPEZ+$W;"E4Y RL'5^0%/K]!MU0=13"R0M-K;JI4FO6Q[!
M6./AY$1"1"+,T=$1 A#+2:0N43I[[<>1B[A9R"A*TE5;Q<HU_'V19-CD$[?(
M-[?N)VL&XG67$$?7I^97.VLUR:U2Z24>BBXD'2KMTA')R(F(Y I"F7U%R-R>
M:*HJ?C9CQIPYY/Q& *=1(6OL&$U3D>.1*3CI]FQ]=,85RP8QH%WJEV?7AO;H
M1=:V8]FI^9;R:;&-,PF4'9&+]FX:O8U$A8,#=2Q271:()NC$.X*D0%SIF4,F
M978!4%,5?=]V)]^D!VV#8- ?5H!H!H!H!H#61C+^K+RM_P P.9O_ $\S9KR/
M1OXIIOK%OY:.#KO\,U?["?R6?FI;?XLW_P"!)_8U],/[*S]7M?(1\X8_K+WU
MB[\ME;4%P.P=HB!0]D3"!2A^:8=@ !U66GMZJ+TMUTMW%E?B8]9GH_\ %VU6
MY:])>-8DRN&_#VP\J;>Y6?.'5?Q+4'[9*]69DX!K,NGY4TWJ-,JIR&!RSGG;
M<R:BK\-B13<2JEZUCHD'\<[W>]#2]G.C?[9Z>HW=2XTQQ22^$]N_!+X3PV59
M^O=V/=U?[2=07:+79K=EXU6#==W\NX_5A&M$V$<P8HBL9%FR:M$C.5UW3@4V
MZ!$4Q7<N5%G+A82$#K44.8YS;B81$1'7I*[G.;O-4<\:<*XGN/8M+3V86(NL
M8145OV*FWR$3^9Q$%,?XR(JD910>4/%8S8X(+JE:N"YXI INCG015!$B8"8!
M.<4REZOLP';>#4EX'8 !] - <Z : : : IK!U)G ! !$.P1ZM@-_L?L1 V^_
MDV[=] 1,H9SGY=\ARG7!P".'N-I8],BP.2MD#36=CNV_VERX\V(N\'O026!N
MH8!!4I#)G!4P$MB_8E\OD#R[@/D]D![0'0'.@&@&@&@++R0HJECR^JH*E163
MIEH416.HFB1)4D&^,FJ9999NDD5,X (F,H0I0#<3%#M "M0CJ'I51[XQ3K?!
M:NF64(H59,ZIX=F8YB+IJ+)K%,;M Q3G 0'L$0V$0+NT T T T T!I3\4.H2
M^0>5GAC4&OF:DGKQ9/$&J$(9^X4:L2R]E\./D##1IGKI)%PJV:%>O2"HH5,Y
MB$W$"B(;"!G='AYDDN=:%FU6205L%$NV%F,&Z/D[('O? X;AL(#2LQU2(IB2
MR=.(K:;TBB\,F9H/OB5))=94BJ"1"@6_E3BIF6SY#Y3V6)K325LN3XB!;8\S
M";.ETJ4F.)HTV+7%CXMJ52(9G1HC.VN*S9$PLD?UF:!/BY* .!5* %A8NX,9
M<JS0R#.NU3'U**]H@4/$WQF6*^DQ#3*IR?P]E8U#C;5.1KY608)5JA2DBW01
M,#!D_D2L&Y2MR L'-<LRG?5Q/!)>PV"P7_!WE!:#<BQNE0Q?)US(.3\%W-KC
MFN92N6/X;("6+,[6^]VV2/:(I*?LU?GK?C.0BXI&1<JED'2C,K%T*$:BW[KK
MU$U.U&.]2\"PILKXP>C4>".?8JY8?E9.!CR? R<H$MBBR!R+R1**<-J- YHM
M-\O.(:_%NFR:F96UQQ4\C:B9V\,"+Q%'S5V 1S1OWDVY)+'@#Z<V<$N0S[!,
M%4,5,J;)Y9MN1\J9&R?D*[9+OL_8HJ^2DHH;#UTK5BL<HX]ZV=&A6C-L ,FG
MG<*1BT)$(I@14=4!E-;B#GZ*R)R(DL6RC;%A,NW_ "E>D,BLLN7I\K,O\B<6
M0QQ67\O2C$7:1$MC[,+4) ?-MT!0,W<M0 [9-NF!:6-> UK=UM.AVJAHXLP)
M8\V0ESMG'2,Y&95O,<%::X9R!7;T[?6Y!_#OYH,EY:L$7,/(9-9%BX/'>?NP
M.]<.$QE%HTI0S)D/C9R8M/&CC5CFO9(<US*=5K==Q-F^R1^3KA%++XTNE$+C
MK+]MJ]G:QSN6L&5J@T[N7J[]ZFW7&2;"<7+5585R"6UNV&#KAPSY696P7?ZQ
MF.8B+Q:[KC"QM)2D$S/?HVGR=]J63L;N,4$:2S-@S-#&E\9XU[Y_(I-D_-IJ
M:=$,FNF91PI!0S16^&=AA^2+#DA'0S.N65[ENI/)7JR?>9E1I@9KQ/:XTGL?
M.8=5X:I3#X,MPD4Y444:*JOBL$WYW(K)(D)M:NJU9E;>QI^RTUYCI5V-*>"G
ME.MDX_Y[M&5+G5AJ%,B,53W,/%?*=MF)>_"\L\9$8Q@,3K?!&KX^3JQW+"Y6
M:Q8[5BW+Q:018$@9!R<QEU#>:*\FDCDMT>^4GYVV8QDN:WM65+V#UVW#NS1?
M ^S\=HATJGE?(538O<@VA]DN\S;^?RK).( UPN!LCV!S+6]%^\2ARBU<I"D9
MJ**0($0 A.GHDT]G$SDZW7390A_9/#FS?#+NJ[&*.<LL(NXY$L&)\RWKD)D"
M R=CK(]SGXN:C.4%_+6F$:&2LAUVIR:M3\V*/>JP]8:()]TC*OP"A)9],Q=F
MC+/(GEY 2U<O99R6M5X0IDS+2UGB<?150C>1..;? MLKDG:G!,Y>]V*CU,YZ
M,>+5L3*'JZ)VZ;EN+DY2 9M:\(.2D[:.0+:^7.;>1N1KHH1.RUO)#RBMK_BJ
M?Y/U+)[F$LKNGJLLC(6:C87CG=4BC^<MF[9@X>L43^:NR&1 DQF7$]3E\Y<;
M\) S-'428XN\QL9(Q[=95S[UU!_$\=*FDP9G>&57-YA$J 1(53J''H 3&$1[
M , X6X6\DHC).%,D976QBI*W&2"[<S1@['*3/O\ WO \@X3XHNJB+VI1*EG%
MK%/&YI1X],Q6C#0;%%N1PF!AT!:M:X'9]0+F9H<RM/FLDP!*]E;(T1R+RD:<
MY,V9[FVA6$<J.FD89D;$<I7,-5F5A4"1PHO@3F"QJ"R;!HDIH#X<U^';D.=I
M4SCFIX^J=PQ^$GR>1QC2'&<[]C2$QK.9(K5!K^$LLR3F!CGTA9GF/H.NS,4J
MQ4%PN@WFE#)&7[U80 RME;BWS,FLQ6.=Q[E-"(Q@YF8!M7XA3*MYC7*=8SA!
M05'Y0+24(A%.&+>1Q-&T9C/8Y3;..DLE+/42FC@%19>4:1:H6-F'@[GC(\WC
MQS88B,RBK5WSA6E3UEY!9&KQ,(/&/*FP94=V-.*8L'H9(=77##Z(@2MW13$9
MC ),%-F+E50AE94W$@>-O'+/&/>4>9\F90L;J;K]@E<L+5>?B)F(1BKC6;YD
MIA<*'$76![H]E=SF'ZDB6!A3+'*QCFH/2MMR/  L%39'H#4O_I:- 61_J\H;
M^"[X?V_WG93^<6ZZ;"&E)49N>Z0T6#JMY*PP0V#1JJHQOKO.=0DHJBV :D#0
M&ICQ5?V>\+;_ ,6?C+_-OGS0&V?0#0#0#0#0#0#0#0#0$/N)G[/<O_\ O@WW
M^;?$>@)@Z : : B!GW^D7P:_C5S)_FRY<T!+[8/IZFI512=4<[;:@L- - -
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M^H/UM .LOM_4'ZV@'67V_J#];0#J+[?U!T!#WB<<"6#EX0VX"?E_D X>Y/L
M$QSB(O:(E .WJW 0W#Z.^@)A=9?;^H/UM .LOM_4'ZV@'67V_J#];0$0,^F#
MTB>#@AN/3E/,IA I1$=B\9LM@.WD#?<P;!N&^@)? H00 0'<! !#\P>T- <]
M9?;^H/UM .LOM_4'ZV@'67V_J#];0#K+[?U!^MH!UE]OZ@_6T ZR^W]0?K:
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M<0+MZR^W]0?K: =9?;^H/UM .LOM_4'ZV@'67V_J#];0#K+[?U!^MH#5-S1
M#>(EX-9P$?<9SYCCMTFV$/01S601ZNP V$?H[_3V VL]9?;^H/UM .LOM_4'
MZV@'67V_J#];0#K+[?U!^MH!UE]OZ@_6T ZR^W]0?K: =9?;^H/UM .LOM_4
M'ZV@'67V_J#];0#K+[?U!^MH!UE]OZ@_6T ZR^W]0?K: =9?;^H/UM .LOM_
M4'ZV@'67V_J#];0#K+[?U!^MH"(63S@',[BF;81+\3W+0!$ [ WD.. [B([!
MV  CMON( .V^V@)>]9?;_P#/]4.S0#K+[?U!^MH!UE]OZ@_6T ZR^W]0?K:
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M5P?9$S*VJ;)T9B[LJG.7EE[Q-WI)DM=4:+2A<_"R(Y2L!@8G()^HCO[4( H
MET)HSVYCB/QXKT7)3D_:\[P<+#L7,G+S$QS9Y<QD5%1K)(SAY(24B]SV@S8L
MFB!1.JJJ<I$R )C" !OH0>:IQ?XPI.:TS5R!F9)Y<^_^![53G/RP(YM?FL8,
MVY^#2!N0 *SOF\,'GA_-05Z&OVT=D_=:;<"5&4O>IL\^X\<^*>/&S%Y>LCYF
MJ#63,]+'.+%SBY;1*3XT:P7E'Y6AWF?$@<"SC6RBZG3OT)$$P]@;ZB34<).F
M-"5"4JT3=-I>7H88.W$/?CD1N4-S!Z9O,+<H=O:;_KW[ [-6H]NXBCI7<<!P
MRP:)0.$QR($H@ ]7IF<PMMAZ?_Z[?[8/IZ@K5''H9X+Z1-[]<A@* =0B/,WF
M"  78@]0[YW#8-E"CO\ [8/;T)K4[>AA@X0 ???D3L/D'TR^8?;^9_U[=OET
M!XJ/%/C8X]Z_-[MFYQ[]N'S2%[CG!RT6]]W<61VK)M8L$\_&]\',<FP7,NFC
MUF1*B<3@ $-L!]+KB/QX9/XV*>6S.[24F5'2,/'.N;/+EN_EEF+0[]ZE&-%<
M]D</U&;%(RRI4BG%-$HG-L4!'0'WAPRP8(F )GD.(E$0, <S>80B42B!3 ;;
M.X](@8=NW0'8O##!QP Q)CD08H@)BB7F9S"$#% =A$HAG;M !]K0'F17$KCK
M.QK29@[;G:9B'Z9UF,K$\VN7,E&O4DCBDHHT?,\]K-7)"*E$HB0Q@ P"'E =
M >F3AA@Y0!%.8Y$' !$!$O,SF$/: [>QG;0'?T+,(_MKR*]<OF'\NV@(KY$X
MBX=:<NN,L,E)9\,RE<2<I73HRW+CEFN_(M&/^/A6WF4JMFT\G'(J$?J ND@L
MFDY]P*I3BDD) )4>A9A']M>17KE\P_EVT ]"S"/[:\BO7+YA_+MH!Z%F$?VU
MY%>N7S#^7;0#T+,(_MKR*]<OF'\NV@'H681_;7D5ZY?,/Y=M /0LPC^VO(KU
MR^8?R[: >A9A']M>17KE\P_EVT!JW]%'$'ZJS9_6E_!_^E-RD_Q7]7_]LO\
MRA_^9_LA_P"NT!EK_5Y/ZE[P_OXG93^<6ZZ W/: : : : : U,>*K^SWA;?^
M+/QE_FWSYH#;/H!H!H!H!H!H!H!H!H"'W$S]GN7_ /WP;[_-OB/0$P= - -
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MJV<D(Z7!@95Z!U@2$&IC ;O"D.0>],!+HH;%*'M% .SL#L#V [-M <Z : :
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MGTM -@'V \N_D]GV_P W0 2@/E !_- /:V_L: =("&VP;!ML&P;=GD[/)V:
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MV_,T!$/)O],_BG_$YRU_RCQOT!+S8/:#Z0>SO]?0 2E'M$I1'L\H![':'TM
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M2LPY/Z59:J,JKPIN6!QR[@^Q]R]:OW'<_0SS4PQW4?@-H.-N??A(XEIE;H%
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2S_Y5_P#)3_YC_B/_ *[0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pg64img1_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg64img1_424b4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!F ** P$1  (1 0,1 ?_$ /\  0 !! ,! 0
M       ( P8'"0$"!00* 0$  P$  P$!             0(#! 4("0<&$
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M1<_'D]"8JJCH=FSTX(&6* F[H"[";IU4%IM,M3N?_@RS\]\A;48JFKWQXP/
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MT]-G_CC3_P#24/\ \Z761UD<^([5T;CK01*@J<#3N9#%$A#'*8@YVR=TG Q
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M"N57\QSBL-F;$BW>A94.4\]NY;M3J_R;V?ENJPK/ERKN]' S'E+_ +<>(/\
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MGXMN+]\7%_'>/%Y6Z5>H.RV:#2<QK%ROYU8H1@LQ33,**1^_$55"HE5WTAW
M=O4WG5JE'L<GCNW+W2LN_P [$_!<O8,HCRC\-41$0\+S&0@([@(8@XT  @/D
M$ [KLW#6:[@.\#A9^-+YI;[_ #L/QG[!QZ47AK?-=XS_ )(>-'_LM/N [P.%
MGXTOFC[_ #L/QG[ ]*+PUOFN\9_R0\:/_9:?<!W@<+/QI?-'W^=A^,_8'I1>
M&M\UWC/^2'C1_P"RT^X#O X6?C2^:/O\[#\9^P/2B\-;YKO&?\D/&C_V6GW
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ML]X6W_BS\9?YM\^: VSZ : : : : : : : : A]Q,_9[E_\ ]\&^_P V^(]
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M989D!#G BSA+K.783 110H"(AUF\N@+PT T T T T!JCYI_UBO@T?QZ<Q_\
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MCW8[E[59^\8NH56H>2+'(Y4Q52,RLI- ,:0L34Z1D-:01K;JTI6O)->L3R1
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M3,6\O\XQ43)V"DCD>ESU0R%BO!:-KK%HIR%KHDD[*K(5>)?LG;.88N&CN/(
MBJ@JL@H!?L7P+<5VHV&/K&<[9"Y$LF(+'CZ0RNU@6\=:#7"[9FL&<[S?VR]9
MFZW+0C6T7&SNT5(N*D(Y5K'BF1L_1<(HN4Z.-74E.A>_&SAYZ/SRNRKO)LO?
M)6(K>7X.1<2#&< 91SF',@9EEI#WVMMVO]V7+"RHF9-1E)F6?*MC=;EXLJ G
M-:"R5\)2:<VO 33 NP%\@;!V@4-@W'R[![ ;ZJXUDI<"Z>%"#_*^NEM^7.(E
M3.[,P):+CR KIWQ40<&8EF^*69HTSPB'>(BN=L#GK G>)]6VW4'EU<@PN_\
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MG0$<[EW:%A40C6SV9DD&J2BPD*HX6(F41.8I1 E#^61\)SYR'A1ZR.*?NGT
M_+(^$Y\Y#PH]9'%/W3Z ?ED?"<^<AX4>LCBG[I] /RR/A.?.0\*/61Q3]T^@
M'Y9'PG/G(>%'K(XI^Z?0#\LCX3GSD/"CUD<4_=/H!^61\)SYR'A1ZR.*?NGT
M _+(^$Y\Y#PH]9'%/W3Z ?ED?"<^<AX4>LCBG[I] 8CXD<H>&MZX7Q=/L'(S
M#+RK9 )G=B]58Y-KB/G]3ON7LHMD9%C((2!C-6TI$2Q5&SH-M@5*<NX[:F%Z
M]I]=#J&GPE;:>_;%U7L[3EU%K3RLO0ZEK+<35.*E_P"3%R?&[PE4D$ +R"A
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MSEMHGY3[]:%RR<E'(GCF_J*)D533I-J.HDJ4QTU"%@GYCIJ$(8ASD.4-A !
M1#R"&@*U 5(I2:@!"%2 M3K1NY33.FFD52%9F*0@'$3=!0[  1$0 .W0%X:
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M1_W/]MIGTOTN'G0Y.L^BR^*QW9OT(_[G^VTSZ7Z7#SH<G6?19?%8[LWZ$?\
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M ;7- - - - - - - - - - - - - - - - 1"R;_ $S^*?\ $YRU_P H\;]
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MP'QI(A8\=8U"AS4DU2C%9FJ\1<Q5R:58OW13^8.G,;AMJ_205=;&52.8"E$
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M^WV>_'9OJ?\ K_V&XZFOYZ]P??EVU_TW[O\ E.?RG_,S]^M _DOC?_PQJ/\
MK]V'XZGXZ]P??GVT_P!-^[_E'Y3_ )F?OUH'\E\;_P#AC3_K]V'XZGXZ]P??
MGVU_TW[O^4LJ]\_^5.1HN)B+/<*6JS@[I1K]'>98XBVJR5@Q[:(VX5XRBAI)
M<%&@340@98@ 4RB91(!R@8='_P ?>PDE2?K+C^?[.S=N+1[]>W$'6#TZ;5,+
M>[S[R]/RGW,W]^U!'R[;XOC-_LMR[[3 ;[%[!\F_E[-3_P!?^PW^I^.O<*_?
MEVU_TW[O^4Y_*?\ ,S]^M _DOC?_ ,,:C_K]V'XZGXZ]P??EVU_TW[O^4?E/
M^9G[]:!_)A&__AC3_K_V'XZGXZ]P??EVT_TW[O\ E'Y3[F9^_:@>7[U\;]+]
MF-3_ -?^PW'4_'7N#[\NVO\ IOW?\IP/B?<S?W[4 /+_ /BOC?9 0#_]<>P.
MP_1VU'_7_L/QU/QU[@^_+MK_ *;]W_*/RGW,S]^U \GWKXWR^W^S&G_7[L-_
MJ:?GKW!]^7;7_3?N_P"4LJ-\0'EA$WFUY$9W>GC9KI7ZC6YP[C'4<O'C'TEQ
M:W,"#!B,L7S%1%:Y/!5Z#]*VR8F#<IA._P"OO81NM-15_P _^0E]^O;=Q4:Z
M?*MV3#V]YF?'OBI\F(2XPDAD9S5;W2".^[L=;A:>RK4XXCE@Z5G4'+I2:Q$I
M2-+NLDFN46Z_0*:@D W>D\7UO_C_ -GWTB[J^B:F_P"NQBW&$DI)M;$WFK1O
M!M*JVH\OT#OSZW<ZA;TW5K5IV)2Q:EE=.*]#S)NA^@K&.4*7EZCP60<?3Z%C
MJ]C;BNQ?H'4252526.W?1D@U4*1Q&3$2\(=LZ:K%(NV7()%"@(;CZIZ[IFKZ
M5JYZ'6VI6;\'C%U\C\3W-536QGM!TWJ.EZMHX:W23C.U+>O!M7@:WI^T9' #
M"(AUF[0'8?+VCL&^WT-<6-? =S5$5.D=C>Z'W0CV_H0]H/:[-"#J!#!N'68=
M_;[=OS/:T!9^1B*CCR]E16%)8:9:"I+"NHW[I48-\!%1<(I++(=!MAZRD.8F
MVX (@ : JT4JHTRIF5<&54-5ZZ)S=ZHN G]YV?6<JZI$E%P4/N;J,4#&WW$
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MI DDQEI*.Q_<,2.6ECA)B0A;%79[%-_F;%<\=66L2K!1C(Q,F^<NVSQ!0#"
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M+;CX#W*N7=3*\\UM*#CB^!ZFM2I962>]''5^!%'SE8:5:NZ;]VHKYPK[Q/\
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M(23^(3G2P;ZT)4RQOX@LRLT5E@BW M?.!1 "@%64F_$+CZUMDI=4L91 STO
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M_92^2S\I4'^P<+_Q-$_Y.;:^G.E_R6G_ &%OY*/G5U'^(ZC]M/Y3/4UL<0T
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M* CVF$A^D.W8?)H"O0=PI52[4S%&KUPQ#)J&4 2C#,@WZQ(F4X")1$# 4O4
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MR[$<F*8V1N/0$.=N4ABH@8,L"!57 F$I.K8H&*/6)0V$0.I<]YH.0#%X>Y6
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M3KYR?,P<P?6-\.K\;S0#TZ^<GS,','UC?#J_&\T ].OG)\S!S!]8WPZOQO-
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M@N@@<5%#%[T>Z.Z3$O:8Z9]T"@2X*@@)0V3+L)2;#V^0O28FPB.X  E ?S=
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M@&P>T'T@T V#V@^D&@&P>T'T@T V#V@^D&@(A9. /3/XJ!L&WQ.<M?\ *''
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M133W'M A0';0%X: : : : : U1\T_P"L5\&C^/3F/_F'YKT!M<T T T T T
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MZ)S;<,7<P9>]\=83,^-8=>:>9[XP4W+2\&PA,I,<H2V*KU<8RMTBG46:R8C
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M\-TB'4.XDO@A>@A2 (F H 7<P[F'8-MS#L&XZ U->*KVSWA;!_\ ]9N,P_\
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M*DT\@'!02U2M$$Y2F*1020K(O>$[Q!NKTG -]C%*(>R4H[AH"[] - - - -
M:G>;C=!WXAO@WM7*2:[=SF[F8W<(+)IK(K(K<#,VIJI*HJE.DJDH0P@8I@$I
M@'80$- ;/4JA6D&#&*0@H5"+BUP<QL:E$1R<=&N0!< <QK K8&;!SNY4^V)$
M*;W9NWW1A$"M&5B"A6B+"(B(J*9MA5,U:1<7'Q[5H+@-G(MFS1NBBCYSY%-@
MW4#L'<- <&J\&9N^:>]D>#255<K2S,&+0&4J=\0J;\TFS*B5O('>D( *F7*H
M=0 V,(AV: KLX&,CRMDV+-FS18-?,HYNT9-FK>.9[);M62*"::;9L(H$]P0
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M !Y #8"FM 13E%TV<LFKAJ_*J5\U7:MUFST%@(53SQ%1,R;OO2)@"G>@?O
M -N    >0VH-/9H,VK2M5]HUCI'WWC6K6 A&[:-EMP$):/12CRILI/L#[>F!
M5-^T! = ?4UIU:9OWDLW@H-&6D2+)R,JA"12$E()N!3%9)Z^2:%<NDU02*!P
M4,;KZ"]6^W:![C9HBT*":!2IIE*4A$DRE(DF0H !2)D*  1,@[])0["@.P;
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M1V#J[-^SZ ?F!H0ZTPV@ ,'D*4-_+L !OV ']@ #\[5O1,_TO@.X!L !L ;
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MX-'\>G,?_,/S7H#:YH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"(63?Z9_%/\
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M2PQG+AD=)D^45<))HK%0!3O2@;,?A%SO^]1Q']8',WXLF@'PBYW_ 'J.(_K
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M.@&@&@(?Y_,4O(O@SN([CE7,NP 4QA$0XR9=,( !0$1'8![ [1]C0$MA=IE
M#&(H!1Z>D0)U@83% P '0)MA_-VT!635(J7J)OMOMVAL/MAN ]H"(#Y![0\@
M]N@.QS=(!V;B([ 4! !$=A'8-Q#?8 $?S- "' Y0, "&_L& 2C^> ["'Y^PZ
M [: : : : : UAXS5<-_#2R@[:++-W36C<QG#9PW64;N$%DL@9M.@LBNB)54
M5D%@*<ARB!B&*!@'<->2Z):MZGM'I87<$[UN/D=Q)^=5/#]<O7-)V?U%RQC*
M-J=/BL_-TA)RHH(F"<L8]21!$?A+82[CT@'4(!*F]T;;<P[]IA$?9U]#7V1[
M)6X6XWM/;G<Y<,5"/Y*\!Z%OM1VEG<N.S<<+?-GA5_E,J#)3&Y3)S]E34(HF
MH10MFL95$CIF!1-5)0LJ4Z:B2I"F*)1 P& ! P;;#*[(=CKZEIGI8*%Q4;R1
MP7F)7:OM#II+5:BXYNVZQ57M_P#!^AGP\N;2>7(EIA_+EB2'+T&3IJTG()IM
M#9)K$<R2."A'7? W?WN%)WX2"14T57C0B;PA5!!R9/T][VN[C3=C^L/4]"M2
METFY1N5*N$FW5-TKE:::JW1U7!'M3W5]XR[6Z#U;K#C#J4,()X9J+"GA7L^<
MVOI*E6 1+Y V\HE$0$0WV$"F-L.VOR$_8BKH"(O,@PIT3&1N[5.4_)[BND8R
M*@)F*!L[4OW2A1=-N_2(80W3 JQC"(;)F'M "76@&@&@&@&@*2_]R/Y0[ '<
MI0,8-A =P*/88?H#V>WH"(N/DC$Y?\D13%,H*X@XSG5! BI.Z,61SJDFFX 4
M6I7"RH!UD.!G70E[GO4S *0 2^ =P ?; !^F'Y^@.= - - - 61DQ/OL<9 2
M]Q]MI%K3^VD.HG[N!?E^V)IHN5#D[>T"IJ"(>0IA[! KT O32:B "04QJM;%
M+NTSID GO*R* %(<B723W.X!T)B #L)0'0%X: : : : : U1\T_ZQ7P:/X].
M8_\ F'YKT!M<T T T T T T T T T T T T T T T T!$+)O],_BG_$YRU_R
MCQOT!+W0#0#0#0#0#0#0&I?_ $M&@,$> =BK&UV\'#P_IJW4R L$H7!*D-[X
M2C)-PX")B,W3UWCF'>&$!\U8VZ 92)"^0KMJF?RE#591C-4ELJ#;<7C7Q_!*
M:12Q'04D;,^RS)SZ;> 8H)S<EGE9%UF5_(@BF0'KW)JK=,TRJ?J.^Z"]X(@
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MJB^ BJBH&?>1'.G)^$K8%*IKK'M7FKIG7-5:K4UE^877HST:%7\&NHH++-Y
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M'MV[! >W;?;\W;0'4%4Q$0!0@B4!$P <HB4 '81$-^P 'RZ X!9(0W!5,0V
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MD\P%YG<5!,(% ,.<MAW$0 .R0XX"/:/M &^@)=&61(4QCJID*3L.8QRE*40
M!V,(B %[! >WV] <]XF  /6381  'J+L(F,!2@ []HF,.P>V.@'>)B!1 Y!
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M"/8 !VB/8&LKSOJU)Z5-ZFCRKC+<7AR<Z]9PT]?2_-W^P9ZXPUS,]ESE1FF
MG$A&9'CI!.3)8VF_O75*^1PBTL<M<5!*=HK5/,53H+LW!5"R*YTVJ:9W!RE)
M^?=\&N[+Z;L7_P#>*%WJ<E16ZY9N6W!T;JGC6F&UX']SW5].[1W^U2N='E*U
MTU2]_1N.79CBMV[?L/V"- 4!JV!94BZP-T05631%NFLJ"9045(W,HJ9 BA]Q
M @F,)0';<?+KT%S*?IQ5(O&FVE=U3WKMQE"$8S>::23>RKWNF-*^,B5S,.U^
M N+4W)RIF'E'Q4,T$ZHI];OX^*5W2*9"JI"X55*4P EL?K+O[D=MP%R7H?\
ME_Y#N.@&@&@&@&@*#G^XJ;EZPV#<NV^X=0;]GD\GM[![8@';H")%#44+S Y$
MIKIK 0N&^-_O6=< Z%&OPASL#I1$Z1$C.2GD#&!0RAEA[P!+U% .Z "7I1W
M!WWW !W#V>SR^QY= <Z : : : LW(PJEQ]>Q03,LL%-LXHHD2*N=54(1\*:9
M$#D4(L8Y]@ @E,!A'80'R: [T)50].JJ:Q#IKI5>M@NF<A$A36-#M!43%$@%
M!(Y#;@)=@Z1[-M 7?H!H!H!H!H#2#XKCJP,>2GAN/:FO,-K4TD?$5=5IS7O/
M/A WL#?PV>0RL,O!>]X#(>_"4B1,S;N/MW? 7H]UMH#.[3+/)]EFW';?SV.^
M)2.M^%<33]1=8CLTE<[2?*&"E+S8<E2N6'-G(E")TFY,4VYRI10MC&572?*F
M7.B*('C94Y'9WK.1.4R$'<X&,6Q1"P<?CO"#[!5CM4F6C/D<7.;'RP?W6*L#
M-W=(*H-;I.F6K$>D@#I.O W(H1T*QS 1XKMRSADY\64L]KFLM-89'$M-K.::
MSCBQXHKN9ZW \U,#*O+\%(9NY6/AW0L'$NR>KLSD9/642L\1129'$A0/&N/*
M#.^5T,Z1[2?M-/K&,\Z\:I^HY!L& COU,<(^D1::OD>-GJ-C6[2,I9*W6J+4
M64V\8S3MI+(H/UGS_NXMPBU;@7U4N6/+*:NF'8N3O%:[A29HL16JLVXVVIBZ
MYOTBVYJLU"M&6X*5=6@5,$MZ1BN!0MIFA!<H-?.CNWG7&KM4R@5<V<IN5^(\
M$0.3',DXD\B9/R5E60Q_0:IQZC6]?AZAC607B*CBJVR%RR 6R24ID-",(]46
M8)'G9@SUR2)19HM"* !?3S.'(^MY:SPP:F+FB;I>5LNRF,\<DQ[>ZBZJ-70X
M?!DO%]</+P%M+#9"@+[?B+QK5S(M54SOQ<^;@F]\W(U \S&6<N663*VWI-,S
ME3+RI:<U1%+K_*XW%6?K\)&UFP87R'E"UQ3+%+^^QT6_D\7V^O1,&C*.W969
M2R)6CY%S)-UCJ@9FR#R2Y'P'&?C5E6G8ZC9/)>;:S6Z;+UQ[1+BLVJV;LJ44
M$<6S-FA8J13F*IBV'RJH"-D,\6ZF,8Y+UNFXE.N $;[WR<Y-Y P_?\J4YE*8
M4D4L-6NRUFR*8KR78YFG(XRS3BRD7]M-8_DK.PA9=Q,O6%L=,UACTI48!!!=
ML=1N)C+ 9FH5AS]7^4\Y8FE[963!V4,\T:@2E71P_-M1D2R7"^L79/,->R"Z
MN3Y*N5=*YTHC-"-)''9$-*+).'3ER*)DYMTA!Q:JP?5<<GVEOE7(F#B6C(!<
MJSW,_CO<\?U5NE=2>?<;6[W!=ER,^AIQ-FI6VF-TX>HVQ*51%TFV,X1=,U2@
MN\(DK-N7+CE:KM]G9YB:E+B'DI>JY#Y7Q%@F[3F*#IX2F3WF;H^4SC)D<,E;
M1?G7Q-6#$N1UW]7H66*#&LQ23:T?ICYN-*V6591R@-4%+3GGV;""/>)<I<\H
MAM9*7-0=XQ?=N360,79'H5ZS%'M\]Q6*H_*[Z>BLP5FL5.JW1HTIL+B.-CZV
MI 0,RZ9MFSB2=+.FZ@ X2/F#)&2LH\\TI_)DQ2,@T>M5*%3Y('JM5/Q=FK)+
M"CQ9GX24A&P6 ^16'OU(<A8R2<QRZB30$VZ"!58= '0**Z DYACD!E/(G*3(
M.$9NHLJ]#XHJ33(]CG@K5A:-INJ9B;0#SC_#PLJ_D3QAK)'%B[HQM'0"AO.J
M^T430;).P*4#S>6U4L5ZSKAZFT^>E*O;[/QAYO0E4L<)+.X&7@K*]0X\E@)9
MA-QZJ#Z,593!4#"HF8!Z.H![!T!#S$.5.0&7LLX^F)5?.<#1N:MIJ&1H6NRL
M1<:Y%8$K?#Z0*RRY25&C^(C5L=16=WL3#F,P?K(K3AY*240%=!,^X'K5?E3S
M$E@S$YC+!3K#8O@^5V&/WG'.ZM6'$G(3O-%%Q7"XWMLTSN47+9E&5I\C-V!8
MR0L'(K0RKI)8D6NBD0#%F:[MR1QYB3+6,BY4<5>0M5BYCNIG);WC[;[W(9LN
MU=J5!A*EB>B52L3[9;'(96^%$Q-,W<:NZ40/$]#(PE(YW DME+EKR:QGF"<Q
ME 8D0LM>K\S6ZHSLIL>7]\62E>0$%#1/%U\REFD@6,D&U>R7$V1GD)5,R:4=
M'%9KG%@4W6N-(P4E6M#!^=<OY^E8VC8]:V93%L/,65::^#*.',KY%LW("6C>
M:<Y4+!6:W;'=N?S&,FE)H%=BK =0%730S2?*J1%.':]R45E%1I1U)><:>0F=
MLE<ILT8XN\1%5JH421RK''J4F%<CYV&:57)+.NXDL]1;QL@^MTU"Y-QZY4F9
M=S-D1; LJP]ZP30%<AQ4V4Z U+_Z6C0&%O\ 5\YS'L/X/7!\\G+TZ,LT;QP&
MPVL[U_#,YZ.H;7)^5#0T[83+*IR+.H-'K25%L[<]+)-5)V)#@8JVP&\%D^C9
M%DRD8YTV>1SYLV>1SQFL5=D\9NTDUFCIDLB8R#ELY15*8ATQ,0Y3 ("(#H"R
MLHTW&MYI,S"96B(.5I""*<S+!/'%FRB@KH^_3>=3E"+-',$[@3-?.DGJ"R"S
M04^\(H00WT>"J]A-&>M2H"E5"J0,!0XV'AJ>T8-R0#&"(D6)%FZ(#I)=H9 3
MINSR/?BN=<3'4=**&5.8YS&,,)IJJV$%U@5,P[]/NB[[#L8HEZ^T=M]A*8P>
M7V=2"IH#4QXJO[/>%O\ 1\6;C* ^SV!CC/@AY?(.^@-LADR'WZB@;<-AW[>S
MR[=OL;]OYN@,99*PKBO,*4"EDRD0EO+67[B0@S2:2Q5F*CY(J$HT!PT6;+N(
M::03(F_CU3*,9 B9"N$50(0  R0V:-639!DS;HLV;9!-LV:M4RMFS9NB0$T4
M&R"($30123 "E*0  H  !Y T!6 A2^0-O8[!'R!V 'E\@>P'L: ZF12,!@,0
MI@/MU /:!@ -@ P>00VT!VZ"[]6P]6PAU;CN #T[@ [[@ ](;@'E$-  (0H%
M I2@!!$2@   %$>H!$/:$>H?IZ  0@ 4 *'N=Q ?*("/:8>H>W<PCVCY1]G0
M'(  ;[>R.X^4>W\_0$/N)H;SW+X1\H<P;[ML(A_^+?$?9V;=G9H"7^VWD+[.
M^_T1\H_1'MU-$4<I)T2P % =^HOL[]O;N/DW$![.P-'0F+D]JH=@    #R!Y
M-06("\SHZT2V0N+472E10MTE.<DH^K+$61;+)69[Q%S8V@%473DQ6K8Z<HJD
M/>*B"9=MS" : CAD+BER<O"%LEI"?RL\GK1$2N+E8!IR#L4#0T<2V3A YK-D
M1:TN%N4546=BDN5K-DY/*@T&:34ZW"#DL>90! \-#C?SF@<HMV%3NEQA*A6L
M*1=>Q'<%[(>[L8&61XVN::^H.4I:V\CT7SA)7/29+&I*-L;6Q^Y,WC?_ (ND
M@@9!L!>-3XYY0C[)QNN4)CGE%6%Z5CGDU4[#&9.Y8J9)EJ[?LEQ%&E8.VW-1
M[GJ]1%[I4]:8.43:-TG$LK&+*,E31C- H>9 658^/_-M[;H:RQJ^9TLK16/:
M=#UW)+'D3&16#Z_4@XXM(7)>-[%A]M=T8NR9:L/(.-5DFMB6J$@@0'#%T28:
MI,SL= >M8>.'*ZD8]LE;Q^XS1?56^5,09(ID/<,Y.+XG:9Q3%!FF5HS)UJNF
M=L?7RN8R2RKM*IHUV:54C9E%J]CH9\S359* ;C&@*@V0[XA4UN[**J93BH4B
M@AN<I5#%(8Y ,([")2B(>4H>0 /HT T T!K'QD(?DS,KAOV_ #F8/YPWS-H!
M]77D>C8=7TMM^_Y]O#^FCQ_7))])U5Q>\Y$\?Z+/S5-O\6;_ / D_L:^F$7G
MLV90Q7(MKRJ*J?.3).%V\I)I\^X_(YNA6U*A)R4$O2DZ)<6:PLW;D92@FXP5
M7X%Q+OH-%MF3[I6L?42+-,7&UR1(RNQXN&S-)=X1%=\[<NG:XE291<.Q:*.G
M:Y@.9)!,1 AC"0I_#]INOV.Q?3KW5NHRC;NV+;G"+>,Y+WL4E7&3HEX6>8[.
M=F]3VMZC:Z7IH2GIKUQ0N26R$7[Z3\"56Z'ZJ.(O%NM\6\9DJ3)5O-VZ9<)R
MMYN/O<@S7G)4J!6Z$>S/TF?)UN!2(*,<@NJH9,AC*"/6J?7S_P"VO:OJ/;'K
M<^JZJ3C;D\(5;45[57OP1[Q]CNR^B[)])ATW3Q3E';*BJ\%Y:+<2O* %*!0
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M H@ @!BFZRFV\G44X;@/E >WRZ "0AOLB@/YOT2B4?\ <F$- <B0HF XA[H
M$ '<>P!VWV#?8!';R^70 "E#?8-NH=S>7<P])2[B/E$>DH!^=H#@J9"B(E+L
M([=1NWJ-TATEZC?9&V#R;Z ZB@B).Z%,O=[B(I[>X$1."@B8OD,)C]H[^41'
M?RCH#N)2CY0W[!+[/D';</S!VT!P*9#>4OL& ?* "!_L@$ 'M VWLZ =V0?]
MC_L@-OV[]0% H&W\O4!0VWT!STEVVZ0V'<!#;L'J'<V__P!X?+[>@ $*!>G;
MW.VW2/: @(;" @.^X#H#H**8G*H8O48OV(F,8P%]T)MR@81*4VX^4 WVV#R
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M[611/L$X (E\NWL@!+G0#0#0#0#0%%< %(_44#AV;E$G6 AU!_L *<3"'E[
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M5P=,S=,0,H!0U$'GV$Y6>Z63;*))+H"=PDL0BB9T2@?K(H&Z8E+U <W6&VP
M';OJ[BTZ,G*SQ'5XJ+"'6L3ZQ0K.O-G1F+F><2T<2%;/BS 5XS)>5\Z%@F\+
M/"#(R0J=X5T/=" *>YU%&R&J%PE=I'5*D4#]1@W 1+T@.W5N'2804 2]/: A
MV?F:4PJ0?5J :E_]+1H#4GX8/&*S\AO"%X-Q T!&[8]N'#"&QG9VSEU HHOD
M!YT52[V:).A*OV1Q,2@UN2>$4$!("B!0)U+&(0V-]-PHORE[8)]RW$SE%?)6
M9N>5J TLEXK_ !FY>\0:.]^$M8F??S&9J-4ZMC"W/W;YXB:-F^3%I9.YJ7:+
M[ R319(O^[%KJVHKDCEXHZ822A1TV?A[1<5+XAYYALE\<8R9I+53%?"O,$)#
M<:GRD_"RWFV*;EBO([VRW*5AQ7"2B7&+2V""QG&M$A!VI&1KM9#=L\$^NZ[*
M,JM;68V7ET^5[:>X2?R'3\IGSOPMN]LPBCD_(5"N5Y-D;-V(:I2Z[4J71[=C
MK)E%91! R5E@<I(QQ9NTQCY^RCRRJ9R(K."[J$3;FY$91V$33<><X98JO*)[
M#<6XC#<SG29J%6O&&\CRM&QGCFZ8$QY#9)8UBCL+?@Y3-1[+;KA9)Q-_;'4G
M"Q;9]"R8P22X((>=#)8OW&.$<SU/+W$VUY(Q!>$UZIQ#X_XELGQ6-..60J!5
M<ATB6N))Z,OEHRG$Q>6(J*KK289.DWM(09F66,J05'14$@,![/BD%.6;\+GO
M  IC>+3QE-MT])BA\6V?  INWI'I -@V  [/(&@):2G-GBS%5^Y6]YF6 ;U6
MC3JU=N%G"'MSB AI5N\F&#A%:::0)F"Z+.0@GB3EP@JHU;J-A*H<H_9 717N
M4_'ZRVRJ42MY&92=ON<&VL=:KJ4-;"R3F%DE9QK'R+]-U!H$@49-U67P(#('
M;"N#53H Q=A #RJ?R)XNW8,FWVFY$HTH6@P?G.4;W&E<-6#*I5EQ9U"OW]L%
MBT9V*G0+I"6.BZ:N'L<@8RRA3!W@F.!EFO2>-8V<>U"LNJI'3K]BADZ7@8(D
M>T=O&=TF'K).^2234I"N#6J:8NB$?+B99\LBJ(&.)#=(&2NX;AN&X )Q/_L]
MA$1$"&VV'R@<P=OE P^V.@+>1EXE2RKUQ)<XRZ42WG%614'P)!$O'CADV?@]
M[KWK6,JZ8F*!"J"X)T )@ O2.@/>[IFF<B1E"E.<@]VD9<2F%-N)#CW:?6 ]
M"/47?8/<AMO[&@.2$9K%,D0R2Q$E!143*H"A"*) 03(J$ QBE,7L$Q! .WM$
M-] =VC-JQ;HLV3=%HT;I)(-FK9,B#9LW;HD000;() 5)N@BBD4I"$ I2@'8&
M@-,Q*%.RN9KQDWXEY#D)C_&?,7DFTMF,(4M)DYUG8K[AC D73<EP]8R/8JI2
M[ K54HV4BEP5>D>M&MB570 Y2KE$"A7^._*>J8YBE(J!R97F]%P_E.TXWX^8
MVS.WQW2X3(&6,Y9"G8C'5A6HMEK9[%*8@PM:FK%DW1F6M=*];"FP<(JD9O4,
MY+TMY94H9LX;8KY$5^P8WM.<H.Q-'<+A_.E%.\L]B2G[!&1DQR)C;3BNN2+M
MWD7*=C>.4,8QZ(%5>STR[1(B1)T]5< .KV=]?!^/W3.[M5/PV>X;.2AV)[;B
M !Y1#M\GE';LW$=9R3YBX&BV,AKR1>M8W/'"N2?J'281^1LWO7RJ:;E=1-HU
MXO9?7<*)H,TUG:YB(IF$"I$.H80V*43"&M2I*1W8*_&U5:XNI K6MLH)2RNI
M1T+Q-%G!-V 23F1<)+I^>)-VK!/O3E,0%"@780 P;: \O'MQ@<BU&OW6""<1
MB;5'$F84MEKMBI4XXC%!2[IXO5+8PB;'$)*=X0Z9'39(_0H0^VRA3& KNF]-
MKDA,2Z24''6.>C5)*:?))-0LL_$4TO<F=.3()GF9UM52S!4DP$%@:><D3*!1
M4*4P"EQ-):5JL%I\+"1%>1B"GK#*)ATH5HRAY $')DX^,,U:+QK9T91,ZR(I
MIF[TWVPO>: N\_FZ1 .JJ5,@'(F!U%>@H'44!%),IC& "F.J<"E -A$VP>7;
M0'8R")RB'3[@VQA IA*41WZNO8H@ F$W;O[?;H#H5H@7?8@^Z+TCU&.8!+N
M@42F,)1    #L["AMY- ?0  4  /(   ;B(]@=@=H[B.@.= :R,9?U9>5O\
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MG\V564J\UD>0S=1T$;IQ-KCF?LT?B&GP>"&,^59 6%>(87+(/>YS)$5<%A[
M6UFSBAR&+CF^8PJD/R7GZ9,S'*P]598LSQ!UJW62[6RM8\KN#;GG&VVW(,#(
M7_',A",K,E+,Y-Q)^<R+Q->1C7)NY<H1IZ)UV+-[!IAY3-F5*SXAZ&8[ VQ@
MZGS8F2FH*&KCDECH"2"T%R!KL!4+A-E9RSE&8CR<,YFGK61BF"1UY=O/G;M?
M/U@.@WUE3,Z;!Z.TQ=F7 7*R]_ J(FX7/\_&Q\NO)5B.QCEFA4>BL)R/Y>6"
MW2<UR(KX6VKMLDQ4S@#X/GB419S9B+M'P"@RE%B.%$:)E9TW$F.-51Y7L>4F
M8Y_-CRT(4D)'*R%>%-('^.[I79C)#24PJ]AWCW-5G""F,>8Q$\6JWCJ55A>+
MNG9Y!9\JBW74.E*(H;*-4)-2_P#I:- 63_J\G]2]X?W\3LI_.+== ;GM - -
M - - :F/%5_9[PMO_%GXR_S;Y\T!Z6-.,.;J_P <>2&!9F)BXB9R#%Y)84ZV
M+\D<I93K,VXN5MO$I'+M:#;JLU881C48FPMP<1\!YPU54*)>@PI <P&1[O@/
M)<URDNN1&\4+G'.3L-TW&$C98WD/D6DOJ6O%1V6XN>E9+!$97W>-LMK^;WUJ
MXC7,L[3<-#I&%/NQ('4!DSC?3\R0&*HC"V=J#B>,K&/<;US$L3*T"\S5L:Y'
MAH*%&I.IEU49;'].1H45+UQ@@J>,\[EQ;K.#H N8C<%5@(,VK@OR(F<!VND.
MW6&K]D2<N%9I:"EI<IR$*GQPP_0KGCO"96KR[8OO$4PR,B[L(3L\"T(_0(ZD
M9(C!PFZ\V>D N!WPFS6N3)"\G'8[M&5;?QWHV-JUR/>Y/N;:^U4U<QECZJ7/
M!3:*&FN7+;&62+I4925>S[:02>E&Q+KJ,%7")-P+V<\+;%/U:O4!&B8VP]A1
M."P/ S''VE9)N,G1H: Q]GFY9 R17X]>.J]0:24-=*5.MVJJ0M&23PY#L%P*
MT*"AI-%L,5T#@3G2GYKQ)8'5FAWN(<>2422KURL6Z,BY3$E6HV7,PVBKU*M?
M"O$=MM3^EVG'%R@XF:BHJP5TCI!@JP7,X:IMA(96>TF?PZPMD+"S7*D5;V->
MC:[8<ERUFH3-E9FMZMZ<)*H YD5[[?&="QNM:GSJ:55+'GD&4A*M(Y%)L[DW
MHHHF+!4FOH"'W$S]GN7_ /WP;[_-OB/0$P= - - 0'YEP<W9\B<6:U6G@QMB
ML4_R0@H&2!XM'ECIJ6XC9L8Q3X[]LFJY8@U?KIG[Y,IE$A#J*41#0$=;UX>U
MGO![#:YPU.F\B6=M(4*3M$[;[S)N'&&)CA,ZPC/8^,=1$$6\1-9U186)RR21
M[AT#4))43/@*0H%N>@+G5AD_SVLWQO4Z*QQ'$5/&,O4K6QC9["T['\;Y##BU
M2*@^Q?*9"L^-AR$\4M@,V-NA6J\DX2<K,C.&2:AP+OI'"65KL[QUM4%QVP1B
M68Q51N1E&DHRD9=N,W\"9S+T=2G3#*-*E5\>0/PFE9FR5E][Z-';5@X3]\_.
MO.W"Q#IG L"S<!\Y3UOA[2(X_7R3%T&FU^&Y..<L9$;Y.I=?@N/#'&-RP#6J
M\WK8IJX^ON48U>R.YA252.J:85=KQRK]@S4$#VIG@/DBGX^GZ7A:+HS5N?+N
M(LJU&(EKL_)26-WAL-N*9E*Z9&J5SHF16&06]PN3L\D=@3S*1=2"B,PC)L)5
MLFX,!N4:]7FR'48AC=T3J,D4Q4Q-TAN*93B8X$W\FXB.WE$1[= 5] - - :R
M,9?U9>5O^8',W_IYFS7D>C?Q33?6+?RT<'7?X9J_V$_DL_-2V_Q9O_P)/[&O
MIA_96?J]KY"/G#']9>^L7?ELK=GLZF$Y*7+7P\"TJ*+EO6PRGAG#%_SW?HO'
M.-XPKZ;?_P"%OY%P"@0E5@TC($=V>RND2*&9Q+-5<I"D !7=JB"*!%%1$I?X
M[MEVVZ=V"Z?=NN26NE;?+2VN=/12_&]BWG]9V/[%=1[7ZZU9<6]%*Y%3X9*^
ME7P4/U=<>,$4KCMCF,Q]2HYL@FW20=V*9*W%*1MEH.V32E;'+JJN7;DZ[PZ1
M2(HG55*S:IIMTS=VF4H>@?:3KNM[2]:N=1ZA+-?N3S/@ENBO!'9X75[SWB[/
M=!TG9GI$.GZ)9;<(^=TVOQ^U3QF>2]I2B/M!_8UXII)T6P\W!MP3>UI$1N9/
M46AXR4\W[\A>3W%?O! Z)#(D^/:E@*_VXA^L$A,'N2"0X[]A@VT+$NM - -
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MWD';;<.WL'_S[C[(Z$-M[3O]J >H!+OV]O4';OMN(]O:/9[.@.W63]$7Z8:
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M-0YU%5.D!V$3&-OV>Z$=] 79YPANH JD 4B]:@"8 Z"]O:;?R!V?G: Z"[;
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MM#'^(]P"[+W?28"F#J*4NQMP$Q@+C#C=DT#IF],_DJ($2.D)!8<?1*KUJ)*
MJKU8,$PK)BET@)1*'0<P" B)1*!T]&O)P$6('-+DQ]N,<W6+'CV)T!40*@8K
M80P4!4TR;"<@& XE4'?<0V+H"H;C?D\4R)^F?R2 "*-U!/[V\>Q54! QC=RJ
M8<&"0R+@3;*@!0$Q0  $- <>C=DX%.\+S/Y)%#NQ3!((WCX*(B94RQEC%/@T
MZ@K"80#<# '2&VW:(Z ZEXW90 JY1YH\DS"NH=03#'<?=TNM%%+H0$N#@,FF
M7N>L W$ .<X_[(  #6+S"P#<D.>/A$UV8Y3<AIXTWF7EBR8V!5?$4/9*RK%\
M)<P29Y&#?U_$T8U&0E4&QV3LSINY24:+J 0B:H@KH#9AZ)]B_#"Y@?PWQ=\C
MN@'HGV+\,+F!_#?%WR.Z >B?8OPPN8'\-\7?([H!Z)]B_#"Y@?PWQ=\CN@'H
MGV+\,+F!_#?%WR.Z >B?8OPPN8'\-\7?([H!Z)]B_#"Y@?PWQ=\CN@'HGV+\
M,+F!_#?%WR.Z >B?8OPPN8'\-\7?([H!Z)]B_#"Y@?PWQ=\CN@'HGV+\,+F!
M_#?%WR.Z >B?8OPPN8'\-\7?([H!Z)]B_#"Y@?PWQ=\CN@'HGV+\,+F!_#?%
MWR.Z >B?8OPPN8'\-\7?([H!Z)]B_#"Y@?PWQ=\CN@(N9"XS3S7EMQHB#<KN
M6#D\EBCE \3E%KMC8)*.&+D./Y3-F2B>)"-P:R!7^ZY3IG,)D4A*8H 8#@2C
M]$^P_AA<P/X;XN^1W0#T3[%^&%S _AOB[Y'= /1/L7X87,#^&^+OD=T ]$^Q
M?AA<P/X;XN^1W0#T3[%^&%S _AOB[Y'= /1/L7X87,#^&^+OD=T ]$^Q?AA<
MP/X;XN^1W0&L+T<Y;\)OE)_6?_!S_EOC_P#QO]\W_99^SG_\/_ZK0&7_ /5Y
M/ZE[P_OXG93^<6ZZ W/: : : : : U,>*K^SWA;?^+/QE_FWSYH#;/H!H!H!
MH!H!H!H!H!H"'W$S]GN7_P#WP;[_ #;XCT!,'0#0#0$0,^_TB^#7\:N9/\V7
M+F@)?Z : : : : : : : : UAXV()_#*RN&V_P#] \RA[=O*6_9M'R?0 =>1
M[/QCI^OZ6Y%YK*OVO_\ 1/\ '0\+VAM7)]!U-O9=5F;_ *K/S7MCG\W0$1,(
MBD01'J'<>SRC[8Z^F$)25JWEBHIVH.E%OBGNXGSNE<E<NW97$YS5V:JWPDU3
M;N*W48=NT>SM#M\@ZUMZAVY9;D(W+4\);,%Q(=F%V+DI.U=AC&C>+X85]DVO
M>'/S6'&$I7N/>2S"?',W.D:4*S@H)#4"?GGAS$AIX5G()#29R17$&[@ *$4Z
M5Z#%%JH!F_JWWT=UGK-V[VKZ%:3LVH.[>BG&-%!5<XIM-M+:DGF2X[?9#N?[
MQXZ96NS?6KC5R]<5NTVG+TI.B54FDF^+2B\>-?T2$53.)BD-U"0=C; /8.Y@
MVWVVW 2B AY0$->KSBUM/9NJW%34$D1^8QUPHV,2)%*8BG)[BN5;J.( ")L\
M4H#F$A$53J !NG<!,B40\J@;"4P$N- - - - - 47 "9%0H>R40\H!Y?;$?(
M'M^SMY.W0$1L?@4G+WD< .3+'<8BXUJ. -LGYNJG)YR213 A%'9E ,V2%7</
M-#$$XE[I0/\ "# 2^*.X /M@ _4T!SH!H!H!H"R,F 0V.,@%4-T)FI-J*<X[
M;$(,$_ YAW6;![DH[_W1/_[Q?* %7'PA\"ZH0I^\(G6:Z0A@#8IBEA612G+]
MM6*!5 +U;%,8H;_9&'<= 7EH!H!H!H!H#5'S3_K%?!H_CTYC_P"8?FO0&US0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0$0LF_TS^*?\3G+7_*/&_0$O= - - -
M - - - :E_\ 2T: COX%>:\38A\$[@M+90R70\=Q5>X]RMOGY*[6>*K;"%JW
MQNV>NA8Y1Y*NFK=C">_\HU9BY4,5,'+A-/?J. "!N5M&<L44><3J]UR/1*C9
ME:)<,HI0%CM$5$2J^-,>DC#7O(*3%ZY2=#3:>,RT"1D0(9JS%RGWIR]1=P*8
M9VQ(9MB=T&3<?E0SVHDA@Y;X50YT\N+.ZJ]O+$N.Q!Z4UN[ZE1ZLO_@0+ ,>
MF9;?H*)M >U+92HD%>*OC29N50B<A7I*8<T>DR-BC&MLM[&O,3R<\_KU?5<E
ME)1K#QZ1EG)TDC$03*(F-V"  6%7>46 K=7LEVJM9IQ=*US#*+IWEF>0ML2$
M3CB/8,7<D\D[J\5>(HUR,3C8URZ!RY,1 S9NH<#"!#B4#ZGG)7!T?8Z#2WN6
M,?H7/*,+#6/'E;+8F3B5N==L+@[:!L5=9MUCJR4%,J(J>;.B[(K"00*8=A$
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ME'!TTND"G%0F5Z',AE_G)^9U)4LKJ3[2X(\CG9Y^6MM@Q_9[1'X2Y/<9L>S
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M2I#UE.;XM,^#T[F*0 +N/2 [ /9U;!Y  L]EP0Y4MWELL\KEBK/Y#D6P3-R
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M^;?$>@)@Z : : B!GW^D7P:_C5S)_FRY<T!+[8/IZFI512=4<[;:@L- - -
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M^H/UM .LOM_4'ZV@'67V_J#];0#J+[?U!T!#WB<<"6#EX0VX"?E_D X>Y/L
M$QSB(O:(E .WJW 0W#Z.^@)A=9?;^H/UM .LOM_4'ZV@'67V_J#];0$0,^F#
MTB>#@AN/3E/,IA I1$=B\9LM@.WD#?<P;!N&^@)? H00 0'<! !#\P>T- <]
M9?;^H/UM .LOM_4'ZV@'67V_J#];0#K+[?U!^MH!UE]OZ@_6T ZR^W]0?K:
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M<0+MZR^W]0?K: =9?;^H/UM .LOM_4'ZV@'67V_J#];0#K+[?U!^MH#5-S1
M#>(EX-9P$?<9SYCCMTFV$/01S601ZNP V$?H[_3V VL]9?;^H/UM .LOM_4'
MZV@'67V_J#];0#K+[?U!^MH!UE]OZ@_6T ZR^W]0?K: =9?;^H/UM .LOM_4
M'ZV@'67V_J#];0#K+[?U!^MH!UE]OZ@_6T ZR^W]0?K: =9?;^H/UM .LOM_
M4'ZV@'67V_J#];0#K+[?U!^MH"(63S@',[BF;81+\3W+0!$ [ WD.. [B([!
MV  CMON( .V^V@)>]9?;_P#/]4.S0#K+[?U!^MH!UE]OZ@_6T ZR^W]0?K:
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M5P?9$S*VJ;)T9B[LJG.7EE[Q-WI)DM=4:+2A<_"R(Y2L!@8G()^HCO[4( H
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MR^8?R[: >A9A']M>17KE\P_EVT!JW]%'$'ZJS9_6E_!_^E-RD_Q7]7_]LO\
MRA_^9_LA_P"NT!EK_5Y/ZE[P_OXG93^<6ZZ W/: : : : : U,>*K^SWA;?^
M+/QE_FWSYH#;/H!H!H!H!H!H!H!H!H"'W$S]GN7_ /WP;[_-OB/0$P= - -
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MJV<D(Z7!@95Z!U@2$&IC ;O"D.0>],!+HH;%*'M% .SL#L#V [-M <Z : :
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MGTM -@'V \N_D]GV_P W0 2@/E !_- /:V_L: =("&VP;!ML&P;=GD[/)V:
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MV_,T!$/)O],_BG_$YRU_RCQOT!+S8/:#Z0>SO]?0 2E'M$I1'L\H![':'TM
M-@]H/:\@>3VM -@]H/I>V(B/TQ'0#8/+L&_M[?F?6#Z6@ %* [@  .VVX  #
MMOOM^9OH#G0&I?\ TM&@(#>!/XA7 S$?A)<&\=94YM<2<;7VK8GD6-GI%]Y%
M8BJ%OKK]2^W%V1E.UR?N#"7B'9FKA)0$UT2*&(<#=( (#H#;9^51\,CYQ/@U
MZU^"ONYT _*H^&1\XGP:]:_!7W<Z ?E4?#(^<3X->M?@K[N= /RJ/AD?.)\&
MO6OP5]W.@'Y5'PR/G$^#7K7X*^[G0&L?Q*/$3\/Z]S?APJ4OG%Q"MR='\3GC
MO?+BI6>2&(9TE3I4-0<VLY>X612*M[HD'6(IU)MDG#]UW31!1PD510HJ$ 0-
MG'Y5'PR/G$^#7K7X+#ZGPZ[- /RJ/AD?.)\&O6OP5]W.@'Y5'PR/G$^#7K7X
M*^[G0#\JCX9'SB?!KUK\%?=SH!^51\,CYQ/@UZU^"ONYT _*H^&1\XGP:]:_
M!7W<Z ?E4?#(^<3X->M?@K[N= /RJ/AD?.)\&O6OP5]W.@'Y5'PQ_G$^#7K7
MX*^[G0$5>,OB7^'17YSE(K-<]^&$0WL/*B]6"%6E.3^%F!)>$<T/%S%G,Q9G
M5Q0*^BG+J/<))KI"HBHH@<"G$2F  )5?E4?#(^<3X->M?@K[N= /RJ/AD?.)
M\&O6OP5]W.@'Y5'PR/G$^#7K7X*^[G0$6LV^)=X=$OGCAS,1//CA=)156R1E
ME_8I-ER@PL[CX%I(<>,H0L<ZFG3>Z'1C6KZ7D$6R1UC)E4<*D3*(G, : E('
MBI>&0( (^(EP: 1 -P'EA@KL'V0[+T(=F@.?RJ/AD?.)\&O6OP5]W.@'Y5'P
MR/G$^#7K7X*^[G0#\JCX9'SB?!KUK\%?=SH!^51\,CYQ/@UZU^"ONYT _*H^
M&1\XGP:]:_!7W<Z ?E4?#(^<3X->M?@K[N= /RJ/AD?.)\&O6OP5]W.@ >*C
MX9'SB?!KUL,%?^>] &@(1<<^?7AO3G#MWB.\^(!P[IZET)R'JLPDZY.82B[#
M'1E\RIE!%"0:,9BVF!)9Q!S2;QH*J:B:A%4S['3.4QM]'?EI]3#71]_;DI+Q
MQ=4<NJM+5:>6BE[VY%I^)X$2TL<>#FFFFG^6)X\^X(4H"?D]P_(8=B@&YBBX
M+L)A[?(&V^OV&SW\=L[-J-JWR<D5183?_L?DFJ[C^S%^_*]><N9)U>"*I<=^
M#D!R"/C#<>E"@<O6FGR?X@]9TS#T*$*9-R)TS*)&,7J .HO5N&ME_P @.W,8
M2LPY/Z59:J,JKPIN6!QR[@^Q]R]:OW'<_0SS4PQW4?@-H.-N??A(XEIE;H%
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2S_Y5_P#)3_YC_B/_ *[0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>pg67img1_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg67img1_424b4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!*0(P P$1  (1 0,1 ?_$ .@   $$ @,! 0
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M:G6LQ/6:"/\ @KH_CJY=5KF75;9;XZ!AJQ:*ZY6KUFJT>874<>,(V B+PWG
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MLG6%>K(?]7$/PIB":9<%\;_NPCCN/K%.81$;-\$;O1#' *]..N$36@&M:@-
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MS&2LK!DW=+A#KJ2AF,4V=H>5,Q%5# X72,8_0WH8?36BVLVSO#6@U/)3+%[
MXL=0U'[4\4(6+.>5XQFZQY7*P1%G%S5H*FZ\\4DD!60+)@,(R<&[WI2@4X&/
MWB'VCOMUUU%QL?0V][Y,?3[5GN]AJVZ0L<[317A<JN063<$R.)LI0P#/DN$"
MD4U16<>WAR^Z:$-Y4W!0$0, &W >NPAKA-MC@GCEM'M!./JXC&N'V+Y_M6Q?
M,-FB UO<T4/','!=L#::!R6DL<\KYS(TC6X?$R(*/:,O$@A$QKY4IV,Z1^LH
M'<]>'42W(H(=O;L.HK'"R+[6,N)QSR7N\6$\%@+3JR EWPDX8*Z;%\Q$S]08
M2\"\;OXEZ999DY;&(9(Z!C[IA]FY2F H]0]0'7R'>=0W!SWYC/VA=KVW"ZWV
MYL;_ (E(VJ]7R6B+%]\T =A<)@/0 W'MW$QA( !OMN/< _X-$4-V?,=0K&1J
M?C:1<RZEBOP2SB!7CXYTZ@$$8*.5E703DRD QT/Y6Z)P3%8VZ_C$ ]-$50'%
MS+MG:\POD0:4RXUV<C;+S5QE58.&<DD+@]E$%<)U)[97=?(SDDF$!!T:+;JR
M*RW<=)PN!D3^-0Z0'(CZC,X91C<#9JR[/IQ<N6EO[6EC-2,KOXH]M@Z^LA#*
MV4T"WF9I8J$K.D<F8MQ<(N?$F +%*(@.B*/9CF1;8>3Q=2HR+@+/:[5;W]=O
MCNY'1Q0XB4DK2SJ,5!1-37DI^2>VR9G'H@3L759(-&KA517R"B0Y%MZ+S$F(
MC+!\5YN@"TIH=]7ZW%W%_%+PZ$W?[@^B&<)0VL&F_EEHP6#V6:M2OE53(2GY
M!FL0$Q.L1,BL3:J$5*)RCW"/;]VX"(@)0'M$2_:(IF$2B(?4-$09_(G9[)2>
M&>=[949J3KMCAJW"+1,W$.CLY*.66N=:;KJLG*6RJ2RC98Y-P]2F$/KHB-)$
MH%)^[VCW&$0VVZB(C^W?U]?UT1=NB*N&E<J+W9)"Y6F5CJTSJ4?ESD[B6,K
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M6)863>-HUB?RY$70)_D91L\?-4%'OE'=,Z#9JGL ;=^P;:[>[W5K-J+74-6
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M4?Z>NB+GHB@*@?Y\>0O].(O^BCW1%/AMQ*(!MN(#MOZ;_MVT18ITCG*).PH
M EZ=XE*8=MC''L'J  /0! >O71%T$:'\A14 HD3'[0 1VWW$QE"AN7QJ"H/=
MT#;;IHBY*-3',':0@%*IY@$QO54 $H;ID(!.PY3&WWZ@([AHBBK.C8&^"\V[
M%( GQ+D;]W?]PE,ER$*._3["AMTVWT1,;A+_ .IGQ*__  SX)_\ 1?5]$4O9
M-;%>8ZR(V47%HFZI5L;F<"(;-TU:[)(F<A^@)@?O_JU[;_\ B#7FW[T9@^IR
MJ%^5AE!WF[$>29*BX=RZID.&3AE'L>W4/VQD,\*J*BYVRCM9,&[ILWW,;Q (
M]VWZZ^K?U2:R<V)C<"1]ZZ8[3#>1.GFQ:QI=3_**JTZQ?&MR9R! 8*O^:\I-
MHW'LO(1%KN*END6CU&>%*.82C1-LBV3.WCF0B E%500'?IKJ7O?<'J4.52N7
M@WJSN&]*  3DD \<,$\<_P#.?%N&;]B#%&/*3&VZXM';"MO+;%*IR57CHIP\
M,151R1F5PY>+-(X#"*0F#Q@.^WTUG9]S&W8=M!]!=7CS6<FQ;O.TW9?6STFO
M+RI_#-6.UW!*,ED&+RHUS/&3=5MR#=\[J2+)0R;UJZ9^1PVA553D-%I(F()1
MW$!+MOKMX-P;=V9&"X2$OMKUUN :ZE\Y"FD1H%5B6]@6;MJ%-PM[:LG"C^0;
MFAXZ3!=W%.I5<ZPE*C&FW*H8WC(H':&N6N6NZI("G6'5-W*7@AM$^*<R@Y>%
M:-JV]=#+(MEK$A,Q[@RKIZU?*@\+%J.?\D<42".P ([EU-MH8-%9*9>U29 *
M$A1)D>J2%FMD@]@C33YPX;,5(=U6E3(R4;+@9N1TE,)JG!!%D)DQ%41#80$1
MU9_[1L/Z7Q#.JVV(<'.<[X*+;\H,B9/XU<'KUDJ/4_FB2A48N'8PAC$]I&.Y
MZ1.E(O54VJAS$;L3"!MOW0#K]=<!W"YA!T_$MFQ;5#?[F\24#B?^"$3AKA^+
MEL:0W(C(D8SOV0[;'N)^PR5E00DFA&2 '<-H&-3=)&:,89 I4Q'[>_IOZAJA
MC&DAU!1==+?S[!;OVVT_,*&G#%%,ZYG1,3BO#F2&F-VDY<,ZS3F%>"P?-C1E
M=CJO,#$-6-?9N4@025.3M$?%U^TWZ:[&VLH'VW5B(+P,EQXM).F^6\/K><CF
MB+G\W46#KMX.U(<X) @WL+1-L[4>/EFR17*K)LW13$HE;F, B(!]P:K''4XN
M&55XVV8W X."9>7H[)$0_P :6RKS3]G59?'C9[%N8LZ[<3LVRJ,@_(^( =[>
M6+[D"B!@[CD+VZLK6-LC=+LEC--'$WU.#<4\KI!VR@X?@;S26\[)/<@)3-K-
M%-6;DRSBSQ3$5(GQMP#RKNSH@45"'VW !'6R6WMVNI5M:>"\CTAPD--'-2=A
MK).4K-1G5B?49T5K<$$T;2[JC*/92T!;7$<T1(\= Y*0S9HDY:G(H<!#[A'4
M/11YCCSSH.7-0-WF=/.UC,8RP#P4<9AR79V$ 62E*M%+7"+GXV,93#RV%%TT
MJ+@QF\BM8 *F**3)RX,0I2"(AW   .XZUSR/LOUGBCFX^]2>WMIJ\LF&D$UX
M(0<7\?X/(^<V6?\ )5M_F8U<KAV3"*D:2A'UM*PH.GJ,>$Z+?L<R4!&@]*5,
M7'V&(0!W'7/6+3+<NG JUSB:KK-QW1S8NC&26LP]R-/ATRCY/F!BUU!)R]GB
M8J7=+.YF!DRNZ?$3!&,TV>K(M&)Q9LH@QC 5)$P;IB8HZV]Q2M_IDS ['1E[
ME102R3O! J*XE-/GK:I:R<E\YX]AXAM!S#6SQJ,3;7J:*_NB*4^"7>)D:N2@
MFNEX%CD#[M@$.GIKZ/\ 2R5T7;C>GQK6F'-5UVRESCD'?CA_!5N.\,S3>_P%
MIKUU<0435$8]W;:]'NV[9K:V3A9%H[$[1,@)%("AMS%[M]NNW373/NY9WF.0
MFE>.-5(^:+(Z_DY^)1@N,*EKB#RP13N.ET066%88]9(JK.(F3![1N5<!*5T0
MQ"E*;M#IL.M$QH-)S49\_4&GBHNS7'P]B9UNJ6QV64CIET6JF"J,E5I2OMW2
M3KV3:6A4S).4TU#*_P"4[A _KK!EZ;6(QC,FOX*5:1QO82\T-4P:"'_ER[P)
M&XTN3&GXVK,5(2%ZG4%"0TLCN"1XYFY5+Y&:A$0Z)]P^OKJ@OKJ20.(!)Q4L
M1P,.K4,$^<&U-GA^U9*R'1Z6A&DDU7ZLG8'SE9V9=T7=!BV(=4JJ (MFRQC>
M,>WN$VM<?<-PVW%J:T\UC>=*6$ '"OX*5K4U6_EV,L9FK^PHR\/*PB<A%.53
M(0;Y\L@9FDN">Q"=[7N[NNQ1Z==1F2ATE9#0E1]M9T90*X$FB'RBY;CZ O9I
M?.UF?5F):2D;7JP^LLTD6-C8](I2QC)%BJIWE.9Q_$[M^NM.Z7;9#H81CR5O
M=;.RZ];\^2GZM9QR)D:1D;A+@JC2H9VO1HIT\40F5;-#+G8N4WS8J!#^U9IK
M+@5,X[;EW !Z:K[,%LO4?_I@8GACDJF[VZ/;;<W#*=4$ #[U-:E59TK)Q).X
M-&4"21\C:!4%X4Y*_  S2[YL");H@)@4,)3!N(&'8=A'4\%H%32JPB9),S6P
M$BF*V=6HU*A9ZX+72_-)*BR4?#M:R@B_,$G,2[P5%%9ET<P V78D[NTQ#[]!
MV#4/<[J.(,+"-2AW,$T]U$R*OIS\/ J3H)"@9"M.381&.A@AZWCU".JK!\Y3
MK[&1L+<%4VC8ICG3)X7Q2@)^WI]V^O(;O6T!N*QOH+BQO&2.KK!PHADQ;A_!
ME/H#R?LF/5*AE,#RS%J:#E"!Y3MU7)EW;=X)Q C-1$W:H81V/OTU=,N_]J+<
MTUG&G@KFZO'7$K3-@>G^"=,$C V-@[H42K*B^L9V*W>GYT(MP[2 SEL<'!1
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MQ4N\\(N2LG+G,3.PO@J4:SE8=S3Y-V*;=E,%0JT0G)JHKE+WKG8K+E[PWZ"
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MW)Q1&<PY2285UJ1*5>OX&'$SUFPKT&Q;*+"LY?)D0,)2@<"=1'5^-PM7;7(
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M*^:BV3YN9DXE9\@\=<GY;'SZ.L< W-/2E7K:<78FS&"2-!PBTAV%$KP9%%
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M8)!23>&D5UV[>48EFQ=QZX L[9HM#@9/M /3]-5#=N#;CK >EJZB'=1<;<^
MDD/;0^2L,RU67D=+4.W8RBD*XZS[481W)KV"N,CL_P XUB4SRPL3E!>4 5%"
MF%5,P 0.@ .N]VN^ACLW,H-550ON/R.)U4IG[%E-VU588ZI6(7D$C"R;JS3
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MR2:,P9RV9&:KS,N<#BHU*NB3W)VZ6Y.X@;AJ.S7>;B(F_P"ED?)<U!/>->9
M!IUGCXH95DYY)=.K4=[(K!6[82VUYS,*-Y5VJ?S'34?J#L106:SA4PI@)MP
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M*QHN6CU$_P 4Y<LEA+]//9"DDD&L0N#1-*/?(FCC/DT&B1%&*R28$,KL*/>
M[]#"/0=19S\RW3=9^"TV)N+LUG%&5I[E!1>1%>G<!Q^4QCJQ)ML1WR2K;>L.
M8IO$.YQS%O',<DS7742"2=MDS)*'[A[2F[0$1U#M;&9LWR >[H<*8''QX+M;
M:#J1]-WPEM/L3'#.3;F*^=5"[4VI4QK[1I+T\D<FT=0#QK%E.T,JY50.JDLL
MB*I14(?R&*(=VP;;ZE77;IV4_,6SI"TYA[JUKR_%5KHI]LA<ZS-)RX>7O7?>
M,LU/BKCN.B'"D=>DU)=]!HG@8]T[=-9%11!TD2":H)@@=5 R9SF,/:0NP[B&
MM)M+>0]0#2#P4B^L[G<K9O6<=5,5*N05K1>I'&$?AJG0!DLK5LZUVR+D%9XW
MEZ^S,R1!VE5H= 3L2NNPX@9=940(8 '8?37EO$2)&2X-_+Y?@J?:G7-NZ2*5
MQ,33Z5DU3XVL#T5[-Y95OWNK[8ZZTK]?"S61><:&G$W $ K%(%OQB/OU%-CD
M$I2[CZAJGEDZ=R&QX@YJP?NUQ([I.^!3J\EZE3H]'%*!W+[(]T;1]==,6;9F
M6L5:&9F*D]5>NUC'(FJF8H]Q4S!OOL4=M6 E>10Y*ONGS?Z@'Z>I<;73Y#$4
MXWQ_5Y)W*,'T(,JVDZ_XU7!I$Z93KR"[=N<4TV3/?^$(B)P[?36<<C0:G"JP
MAD<Y_JR&*[JQ$URE6F.FPS1/2UBLD<TCEJH5R9RHYF5B=K$SU:5-MV(F$QC
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M9Z',TG3J%OT:C#$EWJ/BB6Y*Y9=6+A5FY0_+M\XR$G2H:9-@'(N&V%$FY-"
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MNF-^:9#+I+@*#!I%/$$5')>9XY! YTR)J&,94X*$'8BPKJ@41V+VE HG/N4
M  #J ^NOQJS]2CY,9>9S7^E>S#K?;Y2'#1UYB7"E=.MPQIP  'D%/>#:>\EL
MATA!6H*RWO[;5XY@K[SQ1PK2#U(A8NR,#HN?(DY;^5P*?B4,J5+L[#B/;KZ'
MV'M@N]S#IF=0ZVYBO%?B[^Z7O^U[8^GU[!MFXAC7ZL"QSGUTG_2D'P'^5V07
MNDXC8I=UFBT+'K>,QNRA,4Y"<1S^2@5[3YKG^&ISA@WEW+IRWB%9*X,'DJY1
M=(295VJS8ODV%0""7]R;/:LMK70P!K0: #@*</!?Y9._NX;_ 'W?I]SW)UTZ
M[>YV%Q,9WZ=1H>I4^D\&YA650B"TJU<%DVZ/B1D52M5B%3V=MDQ1<,GQ4RF.
MHV.F;8H=ION$O=TW#5ZWU, .*^9EU7&B@:,Q?C>^9OY A=J%3[8*1L1"0]@K
ML5*JE$*F^V$%7C557H)A$.OUUDL5/]4QECJB (4NBU*JB(F$3P%?BXI01.&Q
M_P"*S:I*;&#UZ]=$3W[2[]W:'=^NP;_7Z_UCHB^Z(EHBB3/O^8O- _4,29(V
M_P#F?+Z(H\X2B(\,^)0CU'_LSX*_]%]7T13==G?XZI6N2 HJ"PKT\]!,=]C^
MTB':PD']A@(._P#3K9;,+KQA!PU 4]JBW=>GZ*ZZ'+R7D_D^0<)G*M0/X:.C
MJY:VT\9J[:Q+UJ19PXD$RD;.E13 IS+%33#?KN =-?K^*QD@V>W>XF@I@N5L
MHGZB923@<#Y%:S,%QJ6.82HY&N<Q$LPK,[&LG$'8FY2,I678O$#ME2"H!@45
M3%0XD,(;D$1V]=5^Y7#'S4G(>/$@J;8Q3QPZ8=3&UR&"?UBGJ#G*(MV4\'WB
M%L<I)24>Q=5&7=MSQ,;9H6,5(F94%5DRJ,BH+%453 0,IV^@CMK/;KNUH8W,
M9TA[D,4EM<!SB=!&7(IVXGG&>*EJ]>+^K#$AD6]EE9N38."J5UFP>>.-G#%.
MW360;H-7!#'2)U*4G<4=Q'4;<MQ8"614:SP6I]M<W,@D8YVDG(9()<^_+K+4
M5M8<?8,XL9"RICB6N,N_BLJ1,6]BZG/1RA1:$"/9D8&&30;_ ,50H )>XY ,
M7;KKB]4UW<ZPYQTJ^B[3=>L%R97QF,8@&E0$?>+H4]\H<3F^=AQKL<=A%2%2
M9NS$)/R#FTQ9&\@QDTR]IDSP:28G O02D/L( (CO,EO*1F.0U YJGW7<#9M-
MM""Y]*#C[2I^S-;*KB7"MDF:])HVF<O==&E,Y"'731"%CSI%>.'IWA3&>D+&
M)-3E.02@ *J]-]5UE;E]VV3*WK6G J%8=25_5G:T H?.#LJ,JM<H"9D#']U6
MG]KCI%&/5ER(+LTT&[1ZJ[%9%RB9D8W<8P)".^XZG[H(FQZF-:T5\OV_%6.Y
MLCI2$#+AY+.N4_:B2,W;&"+F9"4*XCQF1.NU;-"MB%(M(P[=0PO/,X*4WE.
M@.PC]-5XN(AP"V;;&Q[?UV@X<40..9O&SW&"E7R<\+$!"L%IU"2L;YHHB@_G
M$Q\3ANU6*HX28," "H&-]P;CMU'4&6=TCBT5#>7-0;J"<W;!;BC:G\*45>-W
MS[QNA>0V-^.>+KVRSA=,MSL3$MY"M%_*1=/6[@6G&+E^9+VP+N6B(G,@00.@
MG^]TU&DN):&)SSH'"JNX(+N%I<^,/:1RJCGM\,6WYR4J/XH(^L/9\[&/?0C4
MBY5#1D4W(<BP@ )MEG(HFW.;H(AL/KJ\L+EXMBPOPIE54]_N=PRFN-I . (R
M0^\F^)<3SZL+.B9 <.:=0<2F.HQ>O#"X91;>/%-I++RC%P@HU57E0V63%(R9
MP3'J AJCN++YR0O'J(PH.*L-N[FN(""UK0[GR4EX2Q9PBXYT27JW'J]II6O$
M*7YY];&+=JP&QRGMO;EC7KZ.CVBKQJHL;[D^XY.TH (B(:]BVJ]M0/32-WO
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MMG0W3A'7"AS4)VWBXHU@UN&( 67@?(263(W():HX3L$E^46?N$&@JN(AXR;
M0'24<V0[F;TZA@2[@,;[0*(AZ:ZT,LY6MDAD8YI%?VP5;NEO<VP'S3'1 X#5
MRYJ=&+#\/)QN3&+!2O%&<$J3B)07324>-TVOOTG"A5C$121,0Y0WZ#UU&GLC
MTG%M*JB<0+=^-!3\5/-\EI9D:/3"DU\L;;YIW&.9]PIY%&P3C0Z[3VR@' /%
M]HE$P&  ..H<D;G0&(?$0HUM,UC\'!6=_'<U18<8:HT1;K-2)3]V 47"ASJ
MK_-#\J@E$YC;I&,7<O[-?'-Y;IOGCB*?<NHMYF/C J-2.752I*Q7!#G$ *)P
M Q#$'M-V[B/7U]4]@#]X W]-$08Y\XT7#+UDQ+9$\C+1#G%V3K=>8E1JP?,'
M$=$VK#5_QE^(9C%29$).5B9>W-I5!\[((D%H*1"D,H)]$45<3>#L)Q[D59:[
M-J!=;DU"K#1K''5($'5+EHG'<91<AV^%6F?<R+"W9IDD%YFS+M3I$=OG9SJB
MJ.YAQ<:!$ /$-SDY7GG\C=/QS;H]K"SG.*(?7^&F(.+?I,:)5^.U)-,)1LG'
MN&[Y*7D9.78,2-B 15NDNHX[A,EVFUQB@>!45:M;9W0WD>@$^H$GD :X+SB<
MR^.68V>2^4UIM!X@LMC[+]SJM/3!"1=SF4ZTVM<FS47@'!P66,C4P0!D0QVH
M$.B"8F/]PJ&_-G?'9-QNF^"]TZAJK[*YK^X']J?]X$/8?T\?L\A'S'RE0728
M@M8*4Q!!Y<J*4>$.-LAQ/(3"=9B:A&UR1B<G4JN/9EQ")3C.7@;DSFG#JR*V
M^'% DNC$M(X6;^.22;B@Z,=)0Q3"!3=IVCV>^R=&[IC2<,0OSS_<?_<+#WT9
MA)H<'L<#J(?J#JYUJ:UR-5Z1,.94RC1<RN<>\B:=C^--8;/#8LJMAQK5VUN=
M3UL>GK<(U86@6B[2)95&(JOXCQ*E;K.VP**HN]O9'6/]>@MVVP<UM:G _P %
M_./<;YEQ$(<*@D@4H,3QHKF:_7S1J7B(Z4100:-&!631%-O&)K-156<O6K1,
M@ V6?*.!\I0,)0'H'IN.]4J$7Y-# '!+D.(B;8M8@=Q$.H[7BK=?Z=$1Y:(E
MHB#+EME*X8EJ-'FJ8^CX=Q:<^8CQW:;-*PQ9F/I=)NE@+$V>W.6JBJ#)/\1'
MD*<JSE5-!,OW'$.NB(=<A\G\@0V-[%)P^0:.RF:UC7/EOB)UU4V+YME.8H$B
MYC\?032$7?HMVR62&[59<@,SJJ+>$P(@8 '1%#K[E+RQEYRT05%LN($T(OCS
M6\Z1\U-5Y6PL(M9DI3C9!JD^G4P%Y3YJMHV%RA'1#Y-Z_ETVQE$03$HD$B*3
M&>>9;,V">0*=GCYR.M<%1K2Y?QTO76U<-&P<S6)Y&OI*LTI:3<>_=(1BCI<B
MPE50\Y2#W% IS$1U44!_DFG]=P&K5[;]G_!#/_5T1.O1$M$6CFV\FM&ODX@&
MH2JK=7V"SPSDK$'@ /MO?>S,FZ!J40#O[#;CHBK2R7BCF.\RO>)UK:)B<Q5-
M7CC!,RU.KMA1BS.:'6JADZ,SQ3\?%7.REHU&:MKVN/B@J\;N7)4#C[@ *)#$
M39YR<<J_*_&#R[@<JP_\P3TSQFR'<\@%<3\X^9R60ZGCV7EF$PGW2)4B$C)9
MDDLDBD0C4542',D82%UX<*E;+=])M3L!E[/WKS[Y_P""V9[IP[X\9";8\0+3
MH' G'%E;9Z7D:G7KC)?R[7FYIFV69+WSB+N[)BT=IHI.@.QEI)%8ZQR@.Z>N
M!^H6T2;GMU  12OV%?K+^TKZCVOT_P"_&[E=R: ^3/'F/P50COB#FZ5>Q4G7
ML?OG$A,6!A7(&H1YX.>L<@XCYAFA9["R\3DPQ2*"95#H+&:N41(8P*]A$Q4U
M\(V?Z?S,N1/*PZ0?VX+^LG?G]V6V7>SRPV4K=3810Z]).>>.*]$N&OB=NSKB
MO0'-<:NXC/U(M+)[:(A*[.JS7X]^_7@7$O(56RTU9U7[&Z@4(M1,JJS=%<5$
MUV)R$*X46-^ANWMB;91 NJ, ?!?QZ^LOU=O.\NXIXWG]*0C(FGVG#[>:] ?"
M:N96J&"JW6LMT*H8ODZ\L>)@*G39=Y-1[2LIQ\>HBH^>O5G2RDE^:5?)>0RR
MRCILFBY5-YEU #LG$G,#)?G>_P"E\P3&,>*,0%DR_:8P%, ;B40$#;=P$ =A
M#?;<?7TUBH2@6@'*.<N0X;_NAB$PCL.VQJF^$-AVV$1[?0-$4^"J0-PWZ@(
M(=IAZCU -@#<=$37MK9])5Z>91G8=\Z@99JS KDK8WO'+!RW:]K@2J @8%U
M^X2CV^NB*K?&F#<N560L#FUXWL<MB^9N6&)=7%*+FNR &;8[PLZI%_75K3F9
M"!=$NV3'R$L4#K;R!&QW2X$7(0IB)M\=.+>;Z[C:$QWE>"FTKTXO^9;)9<KM
M9UC,/&N&KJZO:^/\6M["I(IS,J_J3&:BVA(8Z18MJ1L)"+""1#&(LZD8QY0X
MIK?(J+N[2*F,167!^4IXERG+BZE[K7GR5(7)4\>Q-;23_#0<'6T3R#91@V_A
MHMT6ZAG#A90PE(CNX4% G#?B<4!$2AQKP:!!'N[NW^[&KB'?W"8>_P#7KZZ(
MI=R:H4N.\@&Z#XJ3;5!*?<"F M>D@$# /0Q![1ULM(FMN6.%:ZQ_W@B\,>%,
MNXZN=<@\7V6A(3E>EFKZK6./7>LHJ+DV<T=6-?"L]<D.\>-C^0HF$J92$[=N
M[IK]JR[1%+L4.H 5;[,1BJ*X<YD@>W!XQ"FC$^$^-G!^&>7J!_E*I0=ELKZ)
M&<L+Q/OC'ADE C(1-\Z6*"3!0J)@0,4P"<"^NN0%KM>T@!@! J:K8V[W+<F
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M@Z,_?*E*DI.-':7D-]W:)-R@;<-M8W49^8#V# Y?>N>VV]DEA<T4(:VF2/\
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M7,-: E$8E85DK=+RPR:S]A),(:!D7[M85G3BP3\0L2/<D(!#>-JV>@44RAN
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MS1?$J;9'E3MX5[BKR/G$:[;HYLFXD:Y.)M\7KA'SD>R=)+*-50*<4U"B ;&
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M?V+(^._BYC'$>*I>)JU303GJ^\EF-]DBKM7CVPM8\ZK>.!K)G5,Z9)'#J8!
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M/?Y+V/?%EENZYPX=4/(^0VJS&V2D_?6,BR<$2(LS)$VM^P;,S^(I2&!J@@!
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M]1_LI' N44ETU50(F<IA(M/BZS2,_D6PR5:Q\C7\87^D4Z]1N1FK"%8O[/D
M[V9@+5#7!)B["0=SL'!0\:1)=1(Z9T0$@+"5(I=$4X7"P0%*KTI9+ Y,TAX.
M.=2#I1-FL_%)NV#RG(U8-4'#IX[<' $T4$B'455$A"%$P@&B(4Y[D#4\M5-W
M7<80\[)2EQ@BK5*;EZ6@O"_S2UAF=Y90LG"2DC#R1YN+KYTWPIK@@@F80(=4
M# 8NB(D,1N[G(X^JR^1$U6-[<0S9:RM#&9E]O,$$R;Q,"19QC?M5 !." BD
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MU@_ZC_4!E&ECY!P!;^]8NV[;6X.:T)RDX4<3A2<E1563*L"@J*-<@-RG035
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M]6 !\-L2./R<6/V+UMIMK758&5KS'[UT5W@+PSJ\HXF(<[AO)O(Q>(5<#D=
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M]>+*C&KMG+,K+V,DG_-1$W/N$C?Q#&'[S===I9?6/>K<NG;L\A)S-/W@+VS
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M>-N#]8QQ:)N5O'/+!]@KLT^M\T$2I!?AW:C2RNMZ\1>55M:I7#6#;IJ) 4I
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M^*SC188.(R50,MYC+#Y%C*S?(F=A9^$;MI]@_A(=6L32*2<,43I_@&K$&P@
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MBKX&W8<[DXLP'VXB0#!L.X]HAKRZ9&Y@^4K0<U6MEH-,F,B;N5ITTO,(OU(
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M7U)N)3F.<2F$P%#;M*';V[_NB4H#L81$W7T$>FB+) -O3?\ V/Z-$4"<H?\
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M !49(" 0 *4$P%(" !2@ %V*'7]1T13TA_D$?^])_P"\#1$R\C%24H5]37*
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M$N):/%-_@QR@HTMSYP%AQW$1]:N87B710102426F2&J\ZN5=;O(B4RA0;']
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ML=4@+'!61"XP=BA(FQ0=K9%1]M9X69C&C^)FVI6X$3,E,,EBKIB0A2"50-@
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MGS-1ZYDS&^'9B::HWW+47=I6F5DB*QWTNSH$>TDK+('5*!D(]G'MWB?:=82
MHJ/87[M$0J\$X9I"7CGPP0*7L-SGN<H"B<9&10*N)7#>%I);O9Q;9HU\C=1V
M9,RPI@LX.7RJ&.H<YQ(K$A';Z"/]&B] JO@& ?IM_6'^SHO#0&E5]$?V"/\
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M"KFZ3RJH9O&97D+B/(&-4:P\)(-F[)W:!>F.FW1.Y6!!RU%=1/995=(1W22
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MQ+2PWNN2-_@;(TJKN[+LU4X]KCR9@UP9N9)^T;H,(BYOFL@FR\A2[-Q.0#'
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M#1O&2)(AU75\AS5%50Q5.S8/V:Z[\(2X()F!'RE;"4QA5(;8!T10OQ=XZV!
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M(Q"09J(N&*92 F"CM<AO4NW:'760M7/LR'8@%#>,AN.NT>MHH,.'[<4R*?\
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M1+\4JHS(<'2QQ!0"-V1! @!OW%-OJ5!NL;8P&\%R5];R1[V0TT7>U+1E'4%
MPDPRG)"/9KR3^-BY=9PJU;,/L&0L#M(JP*(.?WB-E/N, ]-;)]R,L>LE1;RR
MGDU/!.:)+A[96MAY"X]CZVLT4805J?$L",2N8&;%VO$OR),'*(IIE,<@@40
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MOU*G+A&X<4D6]\5?1ECK*=LL"MI@4D#.D#.XMVR:.2K1QP\NZQ1#R(@ &$1
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M.(#$NX8K6\B 9RO-?EJVI\<UDK062K\5/H2JRC9I]])@7;98%MRE*FF1,H"
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MMK>(-FI!(U!X_GW;F1.W*(C_  U'BAS!^N^OCO='_P"8F/\ B'_="E1W/S#
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M:Y :MXZCKCC2&LM+?P+;&5<:'B%O<,S4-W*,W"9DU7QTUC;:^8?4MD%]ME
MYYYK]O\ ]E&^V_;7>=X;CUF:&,!X_P"75X]1-<.1\$!;AM,3DY#0H5F2B7=A
M;N8M@1FTL!EVUF(UCRQT>6,C8J6D98ZB#93VS=%#R&=."BIL ]?@>T]LV]Y<
MB#HT>YX;6F%2<U_:GZI?5.][+M+'>=JO([JR9MQE>&R5#.F\,P%< &XD&N/N
M5I7"S '(A1]EDN-(VP5^V4_&SFV7F7(E:FS;'[Y\ZKLFMCZ>K]JJ)%%+A:(6
M.<1YGT,I-./$5R!")G\8:^V;%V8-O+2P#6W.GXK^0/UW^NLG>-[+')(1&2<=
M0-<:\/'V47K?X,SF7Y29M-&SM1I&+N4=3J+,)MTHM(:5"U%W#(L*L1H951PP
M:VNP12/?-,FRBHI/D5RJG*':F'UF"O2 (R%%^#=\OH[^\<ZI<\N+L37,_=R^
MS!63,F:+=X=B$<9LW735.?P) @B'B[$_*NX2$A?*J782%$!$ #8!Z:W*F48\
MD&Z;3 >1&Z9SG(G&1^PJ&,<X :=BS !C&ZB.PZ(B#)^Z']?^J.B+E_M?[?\
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MD62%(GB^XBLC0_R"/T_A)_[P-$32OQDRTBZG5'=-.J6,QRCT P%AG@F*(_\
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M9I=F IEHE/L%;I#+'>2+))(32;!5A(DAW;EHWD6J9D2)NR/B#V( MVAWB(@
M!OI#;N#2^3'!5%T8R\!I-:A"SRKQQ:"2.)Z'6"OHJJV6RDC9@8P[E8DRW;;
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M6RW7QG-MK=\LZ,%P:[W<%ONHW1Q.+A3!.P)EB==9LD_:'<-TQ%PW([;F6:'
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M& !3DKN=[+CN..2FBQ;9L#^-)!7AQU8?Q450GQ[9[QB>[Y*R'68K'^,:M%9
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M2V*DJMD861DW=8Q^N^R,SR-*5N%QW>XVUSMSRT_L>+(Q%"+SJ2^2-@53C%I
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MI=8J2/<M2U=*^+7(!YVH6;)E6H,],(Y/II[=+.+4^D7C[#</A:\56PTP2';
M#Z,F;W+L5W+!4? \23\JGW)E+JOFN66W;]P7U-RW8KB.M,>L:EI\Z8+;MY#0
M>L*NQH$UJ=\<'*"K,Z2XNE'QAG.(KE[OCYOC.UY?L=?@85.;:5*/QYD]I88Y
ME[Y.<QVRKZY$FK<J;M$C@"M52_>(R-FW&V9LSH+@.^;=9V=#QUB,]3/GZ5@0
MTW0><(P<DTK=\;'-&X<H*QE_^7<=5^&CLJ-YG(<E&9*:^RR578G,%!OM7L!8
M)> 7M*DO7Z_77+7P3,HZ*BH;N;)I@H(:NX+FWC@;$1J<!G^P5G=7D#<(@ .?
M[!6P?(GQXNG)G!,71:16FMKDHF_5RU/*J]N#"H-Y=C#)O2>R5=3<'8*M-)HN
MUTU3L9)J+=4A!,11)<B1PYVZ87RAPQ*J8I(WB0M^*H54;[XP^3B$=>XM_A_!
M5L'*#W',G<)V#N;."ECO*_B"2H+=#LMD186L@XHUA!M(%6?%D"N3G%1H5%1,
MAM6L]PU]J(Q_J!JA6XD9<$O.J.O/);ZA_%IR$F'I5L^QE O*3+"=XKL0VE+Y
M(V<C#)S[&N,ZI3;*!5V35(JC&=I[E8KSM\C4QB*D IO3.*^MXM@=9Z?]WU:U
MY8_:MLT,CKDSPNTM_!;EM\77(.8K67G=];4ZR9$D*A/J8=L;Z\NW\C5\ER-U
MJE@B[0SE%&B7X*4:1\,L!'J9!62$XE =E#:W;WNUK>;GMDD#GLLX7-ZP;AJH
M#4.Y@G@K*.=O3T3-U>*V/#+&=O:\XGL-,8H=/28YQWR!K>;>0SEM>&B.:;#?
M;;4751_F%G:ZS7HR5<(0[-TR [1Q*IIHM?X:B:2@%%/NNUB\WG=3&QEE.^U9
M"&BF@M)ZA',OJ*G!8E\,EJRTC=21EQU''_!P;Y8''[$S*%\6N=L=UN IE8QY
MB1O(*QT66H94C;RM#2W&*7C\CV&TVIS1ZZTBBH3Q,CQDDC[A1D=LJ=43(O!5
M1(0 HY=4C]$#C1F[,FQ%-4 806_]HC]RPWR:*\FGO;,Z8I;;I1@&E':@20>>
M&5$9LGP(LIOCH)Q7@*]5X7)-ID*K*9'D(^?>0R=AFHW(;*?L4X]N4:"4VK-/
M(-J/B=E5*Y34*0I#E[2B$_=;N)]XXP- B..?,#]RH-HL[VWM>G=R/=)7-QKQ
M.7+#[E9?B3%E4P]724VE*6M2!(N[D"?SG>[QD::(Y=K%,L4UDR!/V2>4;&']
MQ$7/C2VV(4 '41CM;0ZBL8VN$SL31#/SZS5>L'XZHDU2YZN4%M9LDPE/M^7;
MC7E[35,15:492;EY=)N%3>1[9VW([8HLP]RND@0SH#";N H#IGNOEG1MK36^
MA)R]I.&.2L);=D^R7SJ_[AL3=+.#O6*X<:9JGO(7/_F+:KA?J#%2F(V5#/2)
MZ*BBP[N7J>3K[$!C!>SM<\X\JKN%4R%"1$I+%V9"Z.G%HI[E,X\PID'.X#'W
M(C;2D6E[O!K,VGE6N6:T7D ;M]B875DHS4!C2GW+'I?-_DOB(,<Q@7V,E*S/
MY@O1+ PN<-+W')5X;$M-2@D:G1FTV[C'3QJSBGJZQ$(ARL_05^\S86XB;6YK
M+8;WN$DCB(C;VKHP,@9"X.ISPI48TI6@5>'21;7(YA/6#W>?Q'@C6Y!9\Y(P
M/+:4Q#A^PU^E,[(C7U'=IL-&E+VHT91N&[M>'"32$?6"/@6ZSB7@4$3"D1$Y
M4Q,)Q4.)1"GV5KKB#N;YTNCEMI*6@IA)^DTX5S&HG*N*V[G(]EWM3(AJCGE#
M9AF"PUKJ_ER&."WF4.7^8(+CAQBR,XN%,PBXRS 2+[(>7;A27-EHM1F(2GR<
MXP@OP;V4C@8.<A3T<5DV\SG^ 4Q@3[U?&4V=S"^WAL9&C]5H9J QTES1JYYF
MM>7@M%A>2OBCZ[2)WW,K2:?D:2&>0H,#Q0DU;GYRWM45 W>SYAQ)B/%4Y;*#
M0Y[)#_#BTC5**-CQ(KD<;[+O92=:%[;78D4H5@V<&2:(%<E%10SGL*-E!8!]
M]N38 T,BL#<1@TH9>K3 G%SBW@,:8@*9K,L4#W@N>[<VPD?_ "S'4\J-U?F-
M #Q28?*AR!1I-L3M;&D5#+JMDQ,;'E,DZ=+HO+7B^?J,JYMN1V\6X<"[4K\E
M/17G0.82IL$EBHF-N8N]U-M\+M]VW;6NKMUU;R.F>?\ EO$1<!R'J&'/):[M
MTEOL,NY15^9@>10?$1KI@WCAX9(JN%_-_(&1*KDRYY)OU-S+1:9Q_P >YD5R
M#CFCNJA%5Z[6B-DW%FP:\:(R$NVE;!"E8-E2&[RO"$?D*J0H]N]9)8M9#N$P
MD.NVW9T$+,,86V\;P\<2'2.=4XBN%<**0)7"XC93])\'4/@33,\QR69\=V8L
M]3%QR9CKD'2\WTNQY%C4\^XX=YJ803=L@I.J_C+K2Z.G7['8")U2F.%8YPW;
M.SLUBD?F(5 H%'64C6,M@YE \DUHH[2]UP[573IJ$)F:OD7Y=PB$\RKSG'^+
MAPSDN2PGFFTY"HK@&U@R2T;3MF05QD>>>,*Q(0LO5D(D$D%7S4[I61.DU5,Y
M3*D:';R.#+F60^J*$N:,CJX4''R5J(XAN<$6'0Z;7<J.-:X\#EQ5L(9_EY7B
MW8,NU2.0LV5JOB5G<Y.A-6#UO),+0_JZ<^RCY:JG5<3D:11!8':;(XBY,W#8
MHFW*(UW<,MS;1VSK4%T@N+0.S^"4CJ^P!WJY4X*IV>21YEZ]=+7RTJ*9/?2G
MX*J"G\]>6]XR':*)CG,^'\W,:)CBP91=SU,PPNFZMLG XTC+TIBQLR1L*S>/
ME?SCTT4JY1.JZ33+L"/N0,0+.RDD?OEY82./]/BN7,BDRZC!D>5/VJI%XV2P
MVVTNH #+=BK@,QSU 9>U."B?)=EZ(NF/RWK(N+;UA2=2BW5XSE$T!U5*S2+W
M;,97JP(X*>G))/VK>U4NXP+!D<ZABO'0O 07136,4NK8[=:!\@B?H;I(IAC_
M ,<_XJ3>6T>WV#;Z)U;B0T+13[A7/_BL#CK\BG(O*64*7&3=VQO/O)#)^'*2
M_P".\/C-['9"5H.1Z#$6.U9>4LI9@SN.CZ.\D!5,7V?M 14!)<Q%.S?4VTLK
M:WMXP[U3-<Q_D =(/(#V*%N,<,$D4K_5+;;:RZ+1B#,]^@ '^9K/26C&AJ1Q
M4[72XXX?\B,R-^1><,HXLRY3\G5AEQ@JE2N=OKCN9HKF&KKUD:AXUB55('+!
M+-83O&TLJ_827M#"(=S<A $*JQN97]NV.XD?[NYDE :1CZ)- :\9M:6X@FF&
M16O;V2NW6ZL'- MX0PM/Y3U!J-"<Z<<Z'#!"^UY$<N[5GGDQ3+]3N1N)[/F>
MLX I6):I96M6CZ9BI.PY+M, Z7JDU5[=.'<3EAI\2X>.Y Z)'!W)!( )$33
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M":9^Y1+.Q$-U-8/<.NZKP^HI3,"N6"@&I<U^84/'V[D?"/%,@P\WD'#U&=8
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M;@8>X-PW[N@FZ;[ZCR0Q.!B(!96I'CS7K*"NC.N/F5]$Z([E 2B.QMR[AON
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M(V2*+-K%Q;!".9-UO,"JK[V[5N0H&6$YQ[0$1$="_6=1S7B<X,S&."JA4E%
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M@#>X=>V;E=*")1( JNDDB.%# 4 +U,("0 Z:]::$'A5%U#"-52$348M@*45
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J_5T1(/4?]'U'7J<%Q'][^L->\%EP7/6*Q2T1+1$M$2T1+1$M$2T1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>pg68img1_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg68img1_424b4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ XP&B P$1  (1 0,1 ?_$ 1     & P$! 0
M      0%!@<)"@(#"  !"P$  00# 0$             !  #!08!!P@""1
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MMUFGM917Y)?$%H*I\KRT5^2-4&_&&<K<1I-L>3M)C@>=;?X>G_Q"XL/DBZ,
M&J$-$-$.1<;M/J":%03]45K7XZ\-2"GR,49-/+X*KP!Y4I^7I1.TH: V!#F7
MBH *-*D\?R3K,3M*!($4/2O\XH?#PK]3T:D!H3$ A;;I(HKB1XCX>?Y&G4&C
M!#JC7J->5*?'K&"4$+0X.A-33BKGX\M92@-B=G9(LN;R[2-/(0MMW<[ &UH7
MQ2M"\IM@4DCQ2H<]06:B6Y5NCFX.%H<0=8,=(.H\JE\MM!OM*T@;INK1#41L
MYN30EM>'%O7>[NNK4ZX[=KFZZZLU6ZZ[.?<<<6?%:W"23JXTI(HY4L$^C]&S
M#5Y(U:%IBJ)-9,F'&9Z1V.ORCKTHNTYNC8$WZ29[IW;*]I0&P)>DF>Z/;*]I
M0&P)>DF>Z/;*[_[6=D<"W+[3^_7.<@Q=B][@[68CLV_M=>5RIS+^-WG,=P/H
M]<GXD6,^W&G.SXCB6NE]MT"OJ@*-=:DX@9FO-CS]E"AHJAG5-SGU8KL!!K12
M&$<,(:1"$#BMLY!LMKO>3\V5]5)F=:6N32]#\8^-&J@3RQ,&GD*F/S;W3.PL
M+N=[7IEIQ^VQ>W;'MMLG/=<P;U=EVMC<';'';3<9S5_N2YQEV:5F4G)H?G,L
MNL#I:660GJIKFZV\>\R,R/F%CJEKLVS+I_IWBMB65;G,$,($,#/%$#"(71ER
MX%9>F9JL6[(<,KR[7&X.+C .I0'F)T@N)@X[$SVVONQ=H\KF^\VQ"Y8ZQ%RC
M!=RKIMIVH+D7"YM/6K(X^(7[="SVJSM^V)9O4BY8\84<IDB051TDBB^.K'?N
M-69+;;\FWFEGAQJ*#I=Q :TM :X49+L, #O'9O&)4+8^#.7+E<L[VN;)<)<B
ML%)0&)C%[>F#=.TC=$?<Q"8KNK]W5:=MNRKM&N^W>!W"_=T&19=8\9WIM&/&
M[7C*IN0;G85<L[Q3$Y..I?=9AS[%;XJ6FVV64+4 HJ*C35CR)QEZUXDYBZUJ
MV-R)(D[U&]P :>AU#:=Y!(&DN.\=N!T*I9WX.MM_"NPOME,YV=)K]VK:TDN
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MP+SIW2SQ_%LMQ2;+W%O=\NLBXQ<MQM[%WY=QO"I3MWER+;;G:,!;I31(!HD
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M2+X;YYSWU,U9/[5G;W_V?=MO]"NVMO\ "S^5Y/\ W5P_S$U<N<;/_P! F_\
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M"NE^^F]O7:G8:0E]N8I">DA05HVMX[9"E6@UE2ZZ2ZEQ$OH0D$38R(5>_H!
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M+A*64>8YYCKP"0E" -6&QY:L5CSA(O+KA0"U4-C-!;6BLE NF.CO$F,"3A"
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MY]QWW/8:P5OCN=,)<>D@-B>;0J^W.N?F5C:J51S&2VN#@UM!NM#A2&C!#1+
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MT>S'[QO@0QS?FK$]8.QT_G'>%"_GS(C\K.MP/BW!R[\N]*TP<F94)CU>R/\
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M]V/[PV.$.2.T#>9A*D]22]883(4/2/,N:01QYZ\_6[PT^G:;XU_Y"9^K3/\
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MKH=,HOFO1F&UJ6KU5!%'*U;3SXG\]3X-820.*@*=;"7$^OU% 4DT4!0A53P
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M3]KT@\.7'4B,1%8T:%S7W)*NF2X[ VKQ_((.-7W.)*H"+W/4X(L>"PT7):W
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M\C71";0.<%AY;A4HJJ0VJGJH3Z H>K7TZ&3*)I33DE"R&P%)(4'45!Z@ JI
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MQT:]O/RJ.#G;H$3 ##DYE[7L.<-!(@O) )B0"2O:\N@X>-B!CCWUEIW8;IA
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MZ06QO_*[MS_ZVVC45F#^7ZWD;#L;.;DT*0LX!NM&3IBFON;JA=KND4X7>Y^
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MJ=_4JOG>U@WR]\>G]>+IS-/]/R/177$S/(',.\OH<X#>/.GU[AJ"?LH 0?\
MFQ[&\OAQ^9J*LWZ%W.>^4;<OTS3J@.\$P%!Z-2T2HM7.?\FC _%,[D:MI<IW
M)V$T53@/P6VRJN/'A\&M(\5/WE1<_LK:W#_]VNYS[*L6)EGK(BOMI2ERO2M0
M<:/P4-2FE=:T($3SJ\H>@N=*5R%%#GF!:0VBB:*)%"KBGP\=#K*"N*4MU0+0
M#'05J>0OH=I7B/0H_ -))13>\XP*Z9=AV,7&'%>GVBQ3I,J<RRR2IE#K?E!3
M@YGS&RJFJ#FZFB(G2MC</[CT.O .A5JMQ\3E2;_(.*M-JML"UI=G.3F%L!@M
M<%.R$%/W0H*O#55MU-&L .A;JGUM'34I>XQQBFM7C\J_6"]X_P"? OJ5VJ1$
MFIC-+$=;1*5H/0I#;B AY ]8"M::,J)591U?BB V:E6)-9159,(+IKMVR-_/
M]E<?Q?()CTQS:B1-P],>1THEQ;6UYL^,RE"B5^S)4]TH4>!">&@:QQ-4"3'!
M.@!ODB',C'%L;]NSMEN,E:88FM+:Z3]S6@.('J$T"A3T:=-.6U@A@()JIJ :
M0[V*M3=N5J<C8%C:9">EA%IA=3:G$GH'D)I5-2H5UNJT4QI:*)V+0EU<36$F
M*ZV@.->SI2U5E:DT;#G%BJ2"3U D"H].G:C#0@=:$M-*<>2LH(*E$U21TD4%
M:%)()^#0J2/@I?1Y?6W4<!ZO2I/PUX]6DDBNX14J4I7E+7T(]9]/2.L<>%.'
M(Z223RWPE_U%MI46PAQ)) X\Z@\.N@\-));&I33BELH(9?\ */ )JEP"M54(
MH5&OAI)*B1[^#J3[S7>;IH*8-L4#P\?P08EX<==;\,?Y.IAJWO9*T#GL_P#D
M-3[WV H?PX3S^*@ U>R3'2531H70EJ_Z+&;?]H_;#_X6[K:A'D^L;?>P[&SF
MY-"D&_N<\Z8+T'Q'CJU'2HT:%FE5*UKQII+$!L6?F#X?WOCTDH#8MH=J:*(%
M>7@/0:Z] D&(P*!CC'6MB'UFOK)5R^&GU]>8",=:Q 1CK6X+ZB ":G][TZRE
M +:I"5TK7A6GQ_OM.IM/7VV@I[B-B./]V+;;D3_3?:=0F8"?5ZK["/LY_P!6
MHQRIK+D^I%YO"O3>+H?_ /ND#CJ9EG\VWWH[P03P-]WOCWU)A[G20H>\>[<R
M"%*#VZ"D@5^4G9W/SQU1>*A/U;UW,K-D, 9OHH*Z_;W6Y91[:[[.&^)<4"!U
M)'!-4T-#4ZX3@(8P76%-B3':L9J_+0Y.E!#D8DA@HJI0Z02A130>J=>14@:$
M0^F-084GC*&7WIN+WK(\+C9B]!FJQG$W4+D.H:*HK*YI 1(=:0CJ<">/'D-:
MXODRJQ@,(K?G#_J@ 4I=^<[O;5<Z?@:KT$O1UM3XSJD^2MA*2E*>*ND@T5YG
MK>M7EJ"I:VJI=(*W)545+7#=JC!J!IVCNK(+;<9W[I0I26^0'VOQ5U-',K#I
M55J<IN!WAH2A@[.9 ^VI#5ME*D. ^6AIEQ-$#F34*->.AO6>@]T%!=!IO=(_
MLO;GN%>IS8@8]/<1U!I*VX[JO7/!5?4((*:_4.@JJZU$[Y$(A>@+138/<#SX
MKMW9OW8NZ^?R&)=WMCV-V9YYMMRYR4EOJ840>E":<U@TKX:<IJB['2U-MO-F
MI?*<%-SL%VXP]A<&N.&_-L-XR84RVW)Z,VE2)MND(,=QR8X]UJ6L%SJ":^%?
M#5BI9-73"+Q'NJM7:]LGU-(*/$$]M5I._79:[;=;I3K8H.R[$9<V1CTTQ?+C
MF&^M;J&//0FCB6UJ4!4DCEINGJMXXZ8H]U3TJD,!BH];C9)_F(+B0&^E080T
M*-I<4.D\@"HGAS]&IH5.,1I49TANA (-CDP'E(F=:I#M"IL5*2BH(KT^)&O5
M35'E4A3F.G:N_P#L?[>;MO%NM9(#41]4%B2Q+F/*9*F6H[+H<<\Q72$]/2BA
MKX'58=^UUOBX(VNJ>ATF]H.W_:KE-CM:<7PN)9[,ILHL]I;M[+;00A#@C,A-
M$@< H%-/A.KLR95TE)$C%:891TUZS+^UF!6. W&?+CR)%V2&9/F%IEMP](43
MU4)\0I-.'IT33")Q2NE%32OD;B2G,BJ/$><IU:B2ZMSIHP@4XH5R)'A7EJ75
M2-,]0:^^!EL/YYV[JCE2FT;:YJT%G@%K;W"G!2QXFNNY_LH$C*5PA],-_%"X
MB^U+3'UNH(_1![ZB0BN@]!4: 5('UP?R-=;=+\;LKE$B(@8:$]&Y3X2YMC10
M(.RFW-:\_P!+W8BGU*Z@LH_(ZO\ C%;W@IK-GRRD&KJ>B[Z;Z.ZI7JJY\P1R
M\?R=6Y5:#=@2I_:YK$3_ ,Q"P'_*5?B^U^?+W4$?KQ=.?_WZ1KBAGD#F'>7T
M+=I/.GS[A%DO;%2F^+4GMBV80TYS2M5OM]WM<H \JLSH3K9^%!U%6;]$X\I[
MY4G<0/3L'WH[R8)*Z<Z\:?O<]2ZBB!%7+?\ )LTK/:EW#$H<,<=R5J\]ULD>
M43M5:/**J<PHUUI#BI^\J+G]E;/X?_NUW.?95B>V,-.N(*.M:V75%2DA2:)*
MJIX$!2E:U<XG>/.KVE<[(;0CV9".IQ:@"AW@L"M17@0!Q\->4EK=CMH+14I3
M9J$CC5E1)Y"H/%/Q:223^98K9LIM%RL=YB,S+?<8RHKH*:T"T*1YB"M/!;=?
M5T)64@K<( ]I%TE499BPD'D,.\HS+Q[M+")>2JOD>_SU6OVA+\RS+HRR_'#@
M46)0)"'FUD<13B!H"GL1Z8  .TIXYAK"-TDD<L2BW?'W<NW&8VKV_;Z%"Q+,
M[-#;-ME6QI#$2Y%M@I<BSV6T!M]MX$A7421X:.NEKZ5Y($>9"V^ZNZ9 .('.
M5#79.WC*=E]S,]M%WA-V5G)+%,7*CKC%:#>H%2RME?3T^SR62JA!Y:T_<Y-5
M2UD'#!;ALU?1UF!,8)T.WG;"YWW,+4TU%$E3UPCPF6G  A#34A"Y3Z034!IB
MI\=2]@D.K:W'% YJJ!1-PP'(K(>(6IJUV>%"C1"AB*TRP'6151#380*H)!(5
M3Z@UN5N%%!:.>XN<7'$Q3CLRE0TI\QFK"FZ=24%30/4"4N)'R.'RJ#0^G2O*
M43+K#+0>:2XE#J:I2E86EMPC_P"R'$H3QYG6(!)"Y,A2(8>4IU+AJ:!M)J/S
MJJ<@1X\-* 214S<5JC(0\@@**J=*RI0 IZP2X02#\?+3"R@#R8Q=2\L@]55$
M.) *0D$\0!6JJ4TDD%E28[1^Y)H5(]0J2>H$C@ H4(4=))44_?NN)/O+]X5&
MJ2K!-BB0H45_:@Q/G7CKJ[AB3ZH4N/MCWUH#/7\Q57O?8"A_UL,Z53AH70%O
M5Y7:IEW4?TWW';?)CFM"XJW[6;DF6./+RA<&B>?RQZ=0LS^8F\REF@&T'WR8
MI) Y\>5.'YNIPN='25$C0O'RSR"Q_FM8B=I65F4J%.!/U/RZTT<O"QUE8@-B
MS#B4^/3]BOUO1K*!6\.'J23PH?M>%=))#&W2H$JY>% /CKK,2L0">/8&X1[=
MOQLE/DJ\N/#W<VY?=<40D(0G+[0"5*)HD>MS/#4-F PM-6-4%)V<?ZK10VI
MY1"?MF49-:Y2/+EVS),@@2FR**1(AWB;%?000".EUHCCZ-2-'4!S&@Z=T=X(
M.L #S#W14C_N:B@>\G[;.L*4GVK<ZH2*DC\#V?U'QUU3>*G\AUPU04_D,?\
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M3]<Z+0RR2JE:U/V=))9A25<C6G/2266DDO#ARX?4X:SO.VE)"4CJ%4J!^O\
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0QOZS])]ZAO$^\_1??+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pg72img1_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg72img1_424b4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!3@(@ P$1  (1 0,1 ?_$ 1\    & P$! 0
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MF'X'RX/RG</#E=9"_8Y@(=?_ ."]&F!U3Y-'C96_\Q;[C?:Q(_-WKS^6J?\
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MW =IX##]M]9SH4>)9>H)0Q"BL40SSH!_&,R<\O0<+261_*#8<R9I.'A[30H
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MZC-]6_K)E(]ZV?\ 9S?T;$I?KQ^62L&_)^^Y?]7%_2,+2/S#Z.F'M061S_\
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M9$#+OD&7Q!\<3$#R&PK=Q@[B[[;;AXZS/5&^OT[L>X]0QP/<1V4&M+=06=V
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M;/.51M0/)?UV-AIB2DI"PUJ-JIHVQBH%==1UN?RJ%=EB3YD3E9@V<*F7,0P
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MHVN6F GYBLQ=RBXB59OY"JS:CQ&)GVC=8IUXM^JP41=IMW1 V$Q# (#L.P@
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MBB_:PM"F2L7)?UR2IB*$'H8 'IK*KYC>8$R"3;[*WOK4\)K:*=XG_6E]#"G
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MLHK)%, F22#<2]1(7?\ /V'1<J,]GV?M'#33S.=3L6;O-"?C.%M%4H"8!;&
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M4B4'ID0BG<W%L5"K.6*2YW;=(>]1,I0$=-1A"V:Y4P0 Q)2<@10$!(_1/[T
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M'4S9LXYHU81S1K'L&+=)HQ8L6R+-DR:($!-!JT:-B)-VS9%, *1,A2D*4-@
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MGBN/&^P8?G^.^.<8Y!B,0R-@:YMSA9JW$W>>>50UAN#?!505QA"WVPI6"/\
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M4% AD^^OVSS7OK798)MTVR[N#:10O=W%L+>WTRWR)+H$9S9J2(3IK0-BQO\
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MJJR9@5644-*Z:Z3\J[RUAZK21);2TBBN466^G"6BS.)(UD4L5A >*-2M*
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M+I8X%6*)U9P>4*(,S[="O9B6&7(CEG/&K!V$6>8CWB-B8%B(S!M?>UW*JTO
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M%_\ 5(O]'7';K\F-_P 47EE]//W-/]2>/=?/KS08OO6WD_['A_OVQ](.D_\
M5LG[\?LX^D77/R*BF-=CW?3?+7TX*F*=\JUEDKWPB!)55(%N7\ BL"2ATP62
M'#V83BDJ!#%\U(3D*(D-N41* [;@ @S*H4$#NPH**5[1BX_3\W_2TM5#"N(I
ME([!B&LQYXQY@^*8O+A).G,Y/.1CJ;1*XR5GK[>9C<H)Q-5K+(3/Y!8QC "B
MPE(V;@/<JH0H:JMRW2TVS3SV^F:NB,9O(:9! /3WCX1C(=7==]-]%VR3;U(Y
MOKCZ.UM8QJN;J?L6"( LR<!KH$!J"XQ Z,/R\SEVO+)8&G$K'SDPF0JM-"+N
MV=))BH!0*%@MS])U3J0X43,.Z4>V>N$1'JKW!JL,6][R 9]-GMI RXS5[B:Z
M5![J$]F,9!MWFOUC'[SO$WYH=.N,K:$\[<V)[3("T46KB:(2G?E7#SJO##CM
M6Y D]*T8<FVX#E56NF9):2RG97"Y?!;WBWKR+!F;?P!LW1(7;H !JPAZ:VN.
MAE4S..US4_:&+?:?)CH#:[C\H7-J^Y;R35[G<)'O96)[1SRR1_\ JT7%G8]D
MQB6R;.)8LXMHD4")M8YJW8MDTR]"D3;M$T42$* ;  %Z:MTM88QI0 )W  ?8
MSQTRUM+:PA$%B@@A'WL?@7]BM /BP:#J(C^N'Q'<=Q'T;^O1NH6@S(]/9APQ
MHV<E6/82S9>K/'H[AMX]>OCZ!T:1HPJ1@+$GWQD*]VM@/LX\*82&,<GLF-XF
M 1 1]'K]6EM&&702=(].%A(E]E2!^O?\+#=LU0J-U9*QMRJE;MD<N0R:S&RP
M<7.-5"& 0,4R,FU<EV'?42;;;.Y73<(KCT@8K=TV/9-Z73N]G;72TI]-&LW_
M &@;%7)+A1BN*=+SF%9F_<=+08YETW^'K,[C:ZLX$1$@RN.Y8TI1Y9L4PB)D
MC,T]P$0 Q?$*J7IJR5N9:/+;D<-# #Y0<<QG\E>F;.9[[HN?=-@W1^+;?.W+
M8_YI*7MZ=X5%RK3.F$5SE#DIQ])YN;ZJRSIBQF)0=9EQ!#.6%YK3$N_?(7W$
M0K.SR+5NG[3AY!++ 0H&,+?8-M0S?;ML]?RNJRV(J=<8.I5'WS@DY <=(KG6
MG'%9<=5^97ETA;S MEWWI.(:I-QLPT5Q;19#7<63<QY%7[]X&R-/!0DBW%)N
MU3R/6(BYT:QQ-KJ\\U(]BIN%<E=,72!]]R]Y1[T72!@$BR*A2+(J )3E*8!#
M5W9WUGN-LE[8.)+1QX6!R-,CW'CCK6T[OLV][?'N6T7<5Y83QB2*:(^!E;@"
M,RKK]\I(8=JKAT".WK_/U-1 PJ<62)J%23CS?2^4OIP\% %,%C/617A(\SI
M'RJ!G2;,52^\&;D."9UP2W[O**H8 [O#<=#F*&Y=1KIPPG5(JM5*O'36H(U
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M.IP$Z=V<TJ3)N'^D1X8":F_M!OOML(?;WUNPXT:$5 E:FJAJGOJU2/4,O1C
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M<M+1CJ8Q';+](8^L4QQYF+JR=9"CYJKIYV-5*;5KI;(U"R55MGY:!9())2*
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MX^LNXU_ 5,_OZ9C)'-YI#M2D$#=\+IKKCS!L-BBW*V:!]CMY[2-;4VX>6<W
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MLO\ 1\#\=?YF_P#+_)W]J]C_ %MZ'YS]=_-N?Q2?@X'Z9?K?_P GW;_@LO\
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MQYV"FZI-2M9LT6]@[%!/5H^9AY%(47T<_0/VJ(+I#V]!^Z(<NZ:J8@8AC%,
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MSMQO(H8@B.XCW ("'</I'??QZ#OZ0ZZG>Z6DY:::*)I9(V1B56I5F#,O#(5
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M'-/-Y-=/&;]K6R98CWP+-*(#^*T#NRH,6S,4IRF(H4ITS@)#D, &*8ANABB
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M_HVS7=_#[690T_[EUE]\_4>G_=X_@L)/FEY0_P"T>FS_ /-_XW&TO$K-A?\
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M#J8D$:10&N7I;H_ZP+=-_5_W/REGMI)>HYGFALKNM5M[&\:,WD7M J["(:"
M:ZV!*TSML7YB%:G?J @P@5ZO-N)S$;2X-[1#59SC:(B* \CSK/D9F-CWUT51
M%1F51J)4"J1P";;S"^R/$'^K+O>TS[ON$LJW]LJ7SPF">=;Z22ZU,BM$0L)5
M"VETUD2(*4!SQZ4A^NKL&X;=LME:6,EGN0NMMMYX[T0OML4=F\1UQ3J&G$DG
M+!$ABK;DMI#C$LW3E3A3C['5F.K-RE,RGM5TRW-60J%ZC,F3E.@;[%H-&KZ%
MF7L:QA4$DGR( C$K@!U6XJ^<8HGUC-A\H>OO,EK];[;HMF%G960"&![..9[9
MJ!6",2"Z^*1P#XAP..D=4>>WEEY*6>W6NQ[E<=507^[[C),HO%O9[*.]6CFW
MDECC#"(_M<4@I1F&O.IKI+_,,C"S$H[B:Q9IF/8S&"EZFUFTZS I.(C%<])S
M-A:6%C6R@S(:<+(^4R I7 HD3(54XE(4 ZOM7U9=S2TMX+ZXL()VCW/G-'S)
MC')=P"& 0O* S(FG6YK&59F*@DXX=N_US-LDOKM[&TW"YLDN-E-HLPAAYEMM
MUP;BXAN4B8I60DA&^D+*$C:D: 8,GYV8S@(*4@:E'YZF"S<AF:P.Y.^6R%D)
M!A+Y8I;J :1T6LS> =*"JTLL1=(!'O$"F4)LH8 "';_5YZZNIX;K=QTTD]M#
MMT*>[Q.H:.QN.8SR@QT>66/PNQ]OV2:9XLA];KH+9K&;;]B'55XM[-NUS-)?
M2PL]O-N%I)!%#:E7)%O#(X(%5T@:@I(IAJ2G/Q([+,#>)ILE[[;*M5V>*I>5
M<L%I#&MO1QXRQG>;"DL110Q4[)743B0$!$_F 7OV$1$+ZP^K==<_9Y;ZYM8X
M;>[F;<(X@^FZ@%P]W:ID%U&.8J&!H E:$TH<U??7#@$&^VVWVMZ[W6UVB[9-
M*R<VPOX;7W&>9#5BHFMR3S%;7KKX:$XQSASEKV4\*R]$AJQ/P-CM\)0Z]98Y
MU%T]>I,6%)3;%\R*FTT36MTHX6:%4:E."'NG<8G<8O03\OOJ\;OTCY@Q=3[E
M<6UQ96LMQ+'*LUPLTKS$$+)#E$%&8;Q.6 &&?,OZV.S==>4TO1]A;7=GOE[9
M6<$T/NUH;2#W9-#&WN 1<,&(!34@9=1%:#$4Q>8>.M]Q]BN Y TK*#NS87K[
MFHP+K&<Q ,H>]U 91W+1\)9BSA!=0+QDX>'(=XS!0ZJ8[[ ;;MV]]T3YJ=.]
M7;SO7EW>[4=LWRYY[B]$G,M)2 K20K&K+(=(H%8J*4%>W'-=L\R?)CK'HK8=
ME\Y]NWZ3>>FML>QB&WS1^[W\#NTRK,9"KVKI(U.;'S"::J#AB?(SG[3(G#\-
M2XBE66 GJ[3!QM&Q+9C2IJLO*F,T#P',E/RC0EA!XI$@"3A!) H+O"@N51/K
MKF5Q]6SJ.YZYDZDNKRUE2>[6Z>XYUPDRNJ$&-+< PZ6DX.6U(AI0TS['M?UP
M>E]J\M8.F-HVV\L-QL;1K."W$%I<PO;F0%99;V33-S0@HZ<EA+)XRX)R>Y?F
M-8P>VU69D*9E-G G;9&1?UZ/>5)1K9FMSM[:SLHN7.HJ5]'^YD0[0>,G"*[=
M<>\H'+[.J!OJQ=<C;%MDN-G-^&MB)&:;P<F%HW*CEZ6JS Z64AP,RO#&RA^N
MYT*>J7WM[/J"WL3'N0=(3:E[@7<T4D<;NWCA!5"'DB?5&2 H?CCD/(+(.I"0
M=-6XLVCE^]<M69EE')VC9PY56;M3.51%1P9ND<I!4-[1Q#<>HZ]N6-M):VT$
M,K%YTMHXV96*H610"1%2E">!KEW8^;.YW45YN%S=P*ZPW%Y-,%9JLBR,2JLW
M^$:AS8TSSSP4U-Q!P-# P-# P-# P-# P-# P-# P-# P-# Q[H<,\#$*<G/
M]R&F?\;,D'_D*&L#?'3Y@+)Q VDMEW2W+:?B[?DKCU/Y+NA\N-U93J9-[B0@
M<<[=?%^M':?DQV3_ "83_%"Y9_Y_V:OZE<?Z^7WF4=6\[?\ [GB_OSC[5]*_
MZOE_?<?27K#8TN!H8&*;\K_Z.^#W^>)7_P"XYF/4>?[7W<*'LGX,7)-X_F]8
MZ=C]G#,7L_#CS2\.8] 0* @ ; 8HD,'3M,0P;&(8NW:)3 .P@/00TT\1DJKD
M&(C@17Y:X,DYO1>>137I -.XTHI'K4U[:XKA?>)''?(LH-@F\80<7:3'%0UQ
MI2LA0+>*FP[*C8J6\@Y!14#;#NH93J'AJEN^FMLO!J96CG'!XB4(]5,<SW_R
M@\N>HIVO+S:[:'<7]NXMN9:3D\:\RV>+X:@U&6(LDN%TDDO#.*9R<SK"#7)8
ML]7V5V5IV7HV+F2,7D6B^1^O%=<2RBB4;(+H!YCLX@DH8 $/'4,[!N%J0]CN
M-T,J4E(F0#T*=-#Z:XJE\K=_VY='2?5>^V$*C*)_=[J( =A]YA>0]F9DKA@6
MEQS(I.:,4XD8<AL9V=SE>N9*G$+':,!1K%:+1Q@WKCDS213K5L8FDC2GUE J
M9B D" I"/:/=I(LNHXU)6]CD'ZJ(+3U .:^GNQ&3IKSDM0[1]3;3+IX>\[6%
M=N/%H+A U*9U44KEB60H_.=7S"+YKXTE266*X44)@BT'457)V]CE4BM^\H[A
M/M#M..Y@V#KH>[=2');J&O[V?P\*%AYY2 *^]=+QQTXFSFKZZ&XP8_!%R^F0
M52G>7T!!(+#L<*%Q_JS5V4A@ #@A(6F>L)DC?L3>7N Z<]RZA(#&_16'8( 1
M\KYX(=)>;]XU;KJNUM;<_?V6UVX)]3W$DY;X5]&"IN&T=8?+_"QG[DAEE,A1
M(M%RF25:37711#8R;B$QNQJQ54#>DAEC (=-'^;1E!]XO;UM1JP$NE:GC10H
MH.X5-!EAY_)Z#=*GJ[?-]WC.M)+@VR@_K;,0#3^IX4RQ-F-<!86P\F(8TQA3
M:@Z4* .9:+AD#3ST=Q$3OK"]][G'AS".XF5<&$1\=65ILFW6(K;QCF#@S>(C
MX3G\N-CTYY?=$=)EI.G]KLK6Y?\ ;)$3Z27]]E<M*W?^V#/$NCL(]VW7KN8>
MIAW\=S#UZZLD1AFYJU*99#XJG&P\9-9"'(% 2 6 ^:&]K3Z*TP-.8/ T,# T
M,# T,# T,# T,# T,# T,# T,# T,# T,# T,# T,# T,# T,# T,# T,# T
M,#'H?J?IZ8FX']8WV,(;VU_78_.6YX<@?Q;_ )SO-6]/*\ZM=8F+]/4>Z0<:
MZ;LIIQ6IRM4UVH\@'3L#,TYF'EHIH[1(OVHK^2*1S%*H)R^[O+E+V/H+IS=+
M UGLPLP3L?2SC23Q%:\:&G=CQMYL['M?5EWU#TCO#:+3<(980]*F-G"Z90N0
M8H5!"U%>\876_P Q?B:Y73;(FY G764(DBW)B"NKKJ+J[=K9(J64A,Y7$YNT
M 3 >X? -=?7S5ZEC@#2; _+0 ,_/HAIE524!/Q<:X\>1_4OCGIR>J868@!5-
MG(9#3+Q:'916E?"QRI7/$Y,\_P!&>-D7BF.^2,*V<D!5N:X8SQ[1%UTCANFJ
MBSNN:J^\43.'@8$]AWZ;ZI9?/YXV*)M#NP-#29CPX^S"V+&+ZB>[.*OU%;J*
M5_R5_EK(*'UX/!G3'H^%;R_MZ_AV!1#]#D:.F_ZP+_['?\:W\#A/]1;=O^8+
M?\2O\/C+\.6/?Z7,O?['8&_YQFA_6!?_ &._XYOX'!'ZB^[ 5/4%O^*7^'Q[
M^'''P^%<R\/_ -'8&_YQFC_K O\ ['?\<W\#@OZC.Z?\P6WXI/X?'OX<,?A_
MM;S!_L;@?_G%Z,>?TS"J[-(?_6M_ X']1G=/^8;;\4G\/CTN;\?F';ZN9?#Z
M?AN"-OT.1>C_ $^S]NS25_?6_@<#^HQNG_,%M^*3^'QG^&S'_P#2YE__ &+P
M3_SBM#]/LW^QI/QK?P&$'ZCFY@T_."W_ !*_P^-@9GH0_P"UW+H?9C<%?\XG
M1#S]N#_]&?\ '-_ 8']1S<Z_^(;;\2O\/C+\,M"_I>RW_L;@K_G$:7^GNX[=
MF?\ '/\ P& ?J.[D!7\X;;\2O\/C(,R4$?&OY<#U?ZVX*Z__ .1.A^GJX_V,
M_P".;^ PC^H_N/\ S#;?BE_A\9?AAH@^%>RV/_T9@S]/\8?II:^?%PP_U,X_
M]<W\!A+?4AW%33\X;;\4O\/C(N7J.(_T.Y:#Z?AN#1_2Y#>G3<GGC-(:MLTF
MH<"L[*1\/(SP@_4CW*M/S@M3$>*M"A!/8?V_*F-A<L48-NVNY:WZ[=L5@_Q'
M['(7Q'0_3I?/%RIMIE8$YD3L"P[ 3R.SO[<-GZD-US>:N_VJL!EIB44;M/[?
MVGLPV+9R*Q=16B<C;ZCR2@XM4Q2(S2^%X1W7ESFV[4T+%'90>0:RIMPV*5QN
M/HU;V?G'?7Z_0[9"LOS&NTYA/<$"EB?1I&(ES]36YL59KS?65%%2XL9F11WL
M0U0!VT!PPB\W.,YA  <9QZAN&^)8';\\,G#JX7S$ZD8?ZEH3WS-3X^7BF3ZJ
MVVL"6ZKMA0\!97!/Q8W%YJ\:S>#C-_7P_L2P?7[']DS2UZ_ZH8T390S=PF;^
M#PF3ZK&UH-7YUVX7]597 ^+#DKG*3"MPD BJG"\B;/)B'=[A 82CY9V1/INL
MJ@RR,L=% H#U4/VD /$0U'O/,KJ#;XC-?;/#%$.)>[1#^Q=5)]8KW<<.6OU4
M;2\<);]3Q/7AIL;D_+P^,XE$N0*G]RK6LQ,U0W [:0KF(8YXF(>)5F3[/#=V
MW.'@)5"%, ]-M9Y?/.=QJBVDR1]C+,Q4^H\GLX'%XWU+[Q33\X(*4[8 I_8M
M,&'PC&87VH"/2$RG](?"L, (?9_L^#X:5^G&[_V-)^-;^!PS_4TO*T_."V_%
M+_#XW?7BHC]S#91'_P"B<-?W^].?ILO.W9I/QK?P.#/U-+JE?SAMOQ2_P^,@
MNM4'_P "Y2V]?PG#?]_K0_3;>?[&D_&M_ X1_4WNO^8+;\4O\-C,+E5!_P#
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MI1I,L7C#'P65S-R=6J[TD*XA$B-Q02(1?WH5CAW$ FXL37_4C+6&P@ /[I,
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MZJCAI[Y!>P"M"3 64?"I.7I[L&WG1M&U+JZSVG>MBID7O8/XM7A3WBVY]?B
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M^F_Y6F!^GOR?_P"8]K_&'[F!^^(\*?\ *"I/[:6_F;H?GOTW_*TP/T]^3_\
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M"..:E'V9U+RECDEX*BTR-"P7:=:H)KOD(U1TDPC82$;KB1!Y:[5*+$91R)A
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M%/\ @8'[WSG;]E ?R!<OZU-#]%?47S[? _J2^9O\KV/XI_P,#][YSM^R@/Y
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MN\P  B7UCL [CZP$=M2 PH,\1F4YY8/HJ"!A$3 /3H;H ;[^'JT[&PUC/MQ
M9&TG(_%B>N.A]\]8=,8=_P"R'6@Z==]WA?T U3=:,#TGN !S]W/V1B[Z1\/4
M]BS9*+@$GNR.%2U*A^!? 7AU>9M#??;_ &VU_P#1 0U&Z<H.H=W/ZC;_ /1W
MP]U"*=.;2OWRR7X([CST/V,\1NW4   NX;%]/=X^&X:VM17LKC"2BIPKME>T
M2] V$?2/3;PU(C4D4 SPPQ"^T:#'7RIXNHMVXX8(L\)B1GR+RQ7L80\(KAB&
MO T:1;5:R9RSG]9,I31JXNULL^]@OA,9&I]Q_=XQ-\FZ>%.W*0 \Y[GU=U'M
M77&Y;79[G^1]HEO^>;EE+)S+>TC1(AJ(0%SJ\-:EA0#5CN>V=.[3N/1]AN+6
M:;CO$=HP]V+!9*&YD((4>(^ @J:9J0>&)"N_%GAI#VZV3SNP/:'C6FYB9<6Y
MR"<Y#2LDDUR1>)RM3-5R9'VQ,OP^8J-5Q3+3#J4,D/N7Q&#3[@*BZ -1MK\R
M_,=K6&S,1O-_O+5KV&4QLFFV5)_>D XAY)8XDAJ,^>0!48E[KT!T'!/-=QN+
M;9K&;W:2)75N9=71AY!U&H(A221Y:5T<D%J#"GF7 7%+%>/<C7U?$%F:6JK0
M-I9TO'EFN5CJD1;6R5[H55KV0U2.KE.W6>-'-[(Z.HXCP;0$SL11KV%25**>
MF.O/,_J;?=NZ;CW")K:^-K)-.@5_=RT,IDMY-,<:QR4C"Z'+.#75G@=1^7WE
MQT[L.X;VUK(D]JLXBCD9E-QH"<N:,/)(7CJQ.M-*'N[,1W@[CKCZTX/P%;IS
M!\G:HG*$_ER)S/GD<JNJQ&X)J]-G4HZ-M[>N@JG"H#"QBBCU=65(NTE/(]S0
M*5P;?5_U?U[U1M'5FXVUAN02YV^TM#:V;0(YO9+A=;Q4<@^TJ@: 6J<\L9;H
M_H;8-UZ9VZ^N-L68W]Y<I<3B21?=889DB$O@!^\9BQ;(*M<2.K@SCW(VFS5_
M$/'Y;,RE.R70,:6>,9YNF85[$8ZGJ)!V>=Y"2"YGI46P2D_*.V+10V\!!(QV
MS]-558#:J4Z\ZS%G:S[YO,&V1R6\EVC/9J]9[:XE0;;6(E>6H592I/-F,NE1
M1<6UYT!T9#<WEEL6TIN$MG/;0!!,[%X;A5=[Y2]#KJYB+#P0K%J>FK#XBL5<
M7[O'4&K-*\QOKO%F',GK41E4I"PS%@SHHTY172FI6"?@*M/P$_+FAZ>U":!M
M$N4'1TG9#EW8H 4*NZZS\Q;&[O\ >Y9H[1-VO[,3ZDTQVBRV:3$ R(Z*H<A"
MY7237B3B7#TCT#?2P[):VZ7OY.MKUH60T>Z=;MXA1%=&+,GBT:B: 'A@GE_'
M'&#&&&++-)U65R@VQK=Y*.IF,+/DUK7@K$M<KC16=N83#RB/7]@G6U?(H[03
M SXRY3H)BL8ATUR'E=/]6>8?4'4\*6TZV=]>6RK=31ISQ+%%'<,C(DX2(%DH
MY"*H"YCPTHQU%TCT%L/2DS7,?O4=E.8[:!FY302W4D'.UO"TDK+$Y*:I"2&%
M"=5<0ARRX_XNQ7BX\]CBN/F(Q.9+/3SVRT6MW(R%SB%W5I>5TU$18NG=3M%5
MB(:,0:R*Y$F<O'R"/<Y(HB]1,39^5WF-U%O?5)M>H98I;1]K:5(U%/=[A0G.
M6<GQQ&8Y)& 86!H#X3C$^8GE[L>U]+&_V*W"71W!8C)JKSH#KY#6XJ5F,/%I
M"1*O=GBR,5$6=[2;AC.MP%;J=&2XR86<AF0T/CJP1U;%MQVD<BSE<S% 6ALM
M--,;Y+L-J>G96)@9%TRL[=L"9G D\DG.-RW2%-Y@WR[GF:]7J6^1;#F31J];
MI(P8WC]IK=$4+$:AH&U4H:G>;+:-<;9^38+6);*3IZT=KM8XG=2T%Q.U4>@T
MS2R4E?[R8".NK+"+-L6V#,A<N<JV.#GJ;1YVH8==8IL%"K>)Y^1F6RUCQLA.
M(T>.OC>5J)V;ULZ51DE ;^85%10>PP]P:LVW"^ZVZ=V#IK:IQ<[VFX722V\E
MS=1\KPSE3(RM&ZE,M"D^+(4SQ#AVR#HW?=ZZ@W!/=]L_)=@8+E+>V?F:5BYT
M:C45HXJK$9@UK0XJ7R=M4#D3%^%,E0M*B<>M[9D3D^-?JL4@R2"&HJ5YJDM!
M1"JS%G'MWZ45,3DDF10B)$4CF.DB4B1"D#JWEQ:[SLW4F\=/7M_)>SQ;?M@E
MED:349M)5DI(Q92  M 144)%<<T\Q;O9M]Z:V?J/;;!;+;VW?<#;PJB " C4
M9#HKJ5GJ=1R&8!IGBEO7_I:[-<,O/G1O969@P/80>T=_KQQB(L\<4H&;Q@J1
MVCT'M'JQYI![3VD8!J%H. Q)O^\DM_QSL_[GK_6-E_\ N$W^XX?]*.-<G_V_
M;_>D7Q^[+CZ+?R7_ *<0.67_ +P'-0_^2>/M?,SS+&K>K2GWVUPD>K4<?43I
MK.PD_?/N8^E/6'QIL#0P,4WY7_T=\'O\\2O_ -QS,>H\_P!K[N%#V3\&-G)Q
M(+3E?AYB];K'3V:Y3(TRFJ4!;.F6':9+61@U4 P=JBIIYZT4(3<=_*[MAVUE
M=]K/N.WV! ,3RLS=GL"H^,XXAYG*VY]4=']*L ;6]WN6YEJ?O=NM7N$]9YI2
M@XUS' XN*;Q'Z>OVQZC^CK7Q,60$\<_D-,=L!JH/;0?'3/'@>(?9#2SP. >!
MQ3CFC2>-5LH];5Y%F>1R;69?,J-8H2YO\>6>)F7,8L_DD8BVL)2(]U;KQL69
M5PBX54;* @412,<I=93JG\C"RU[Q%S(12E 6/P 9XI-Z@L3%&^XDAA[%./[+
M@N7?CBN9M\L1"Q%C;#E2?RFU07\H:IDCF3:GL"X.53_M9XS@(V-9.0/]P9-5
MPHF8.@[AKF!WGI.SD#VVU2, ::BA(^48S&K9HG&;OGP+Y?'PQT(;91^7+:L1
M/,#V?%N-*ICRKL(6ZQ6-FQZZRIL@@YED*\TL]>M%9D8]L1TG+R9&[IR\6:NP
M*Y^^=Y%/:VEGU+T[NFV3<R%EM8=.I#&>)KIH ,^'8,3Y-UZ:GA:UE@TRK3(-
M4&OI![,5(6SUP-9D>TC W%'%F0HMB8[!^VQ!Q<=YQ33$A1*9&8M;2OK,7#K;
M?OW4.<1WW,/CJB_.:_G4KM&TJUF#12R 5I\ H,-27FVQ1B*TMG9*<0I<5/'/
M/XL2YP'M^*H?DXXK.(^'#_'#J[5&=<W_ "3^ R^8B7HK*%,WDXB#>J6H[BMA
M#VB2'RDV47[JH+H"J&34( B6ZZ6O=QNMPE%]MJ6?T=-:E?$?4,Q@;1<R+?&.
M.W/(EXLPTF+LH <SWY#%],6\/,3,Z[*'REB''D_<I6^9(LCV7<,$Y-=XQLUZ
MG9V%47>' IS.2Q#Y JA1#[V8O;N.PB,C9>A]LM[("_L[7WPS2L3RU8D,[$$D
M,14@U.?;F,>JNM?.SJZ]W6+\T=VW*':XMMV^ 5<1"MM:K#(%55)H&%%U#Q"A
M)Q)?XIG&3_@-QQ_L E^ZU;_F=T]_(K7\4N,M^F'S/_VYN/XQ?N8'XIG&3_@,
MQQ_L E^ZT/S.Z>_D5K^*7 _3#YG_ .W-R_&+]S")9.&_&:<@9B()A''Z)Y2*
MDHPBS>%0161._8KMDETUC& R2C950%"&*(&*8H"'4-1[OH_IQK:6*2QM2G+9
MOVH<5X<.W^RHQGNK/,#KWJSIJ\Z6WC>+Z;:MSMY;26*1U,;I/$Z5D4*6*H2'
MH@+54$<,5\X@<=./^0>,N(;):L,T*8LRE85AIZ:=0Q/B$E,5F8E*R_D5'J9T
MW(N7*T3Y@JE,4QCCW (#UU6;#TQT[N&SPW+VD2S,M"$U1C(TX*U"?34GTXQ'
MD9YY>:^X^4W3\MSU%NDVX6UE[M(TLJB&0VDCVQJJHP<?19*R4*TJ2:XGG&C=
M[BK,$_@Q&9GYVAR]$)D_'A;!*.9N6I*+.=3K-HIB4U(*+RLC7B.'35U' X44
M5:E441[A(4@!8;69-GZ@/3\?^KWM>;&*DB.C:=()S(K4YYX[5U8UIU;Y?VGF
MA<10P]1V>\OM]]R8UCBN.9;M<VUURXU6-?"LD,JJHU$*Y SQ:</ /'P#Q\?M
M_3K9QUY:U-309]^.2B-HARF]I<CG7,9<>WUX]TK P-# P-# P-# P-# P-#
MP-# P-# P-# P-# P-# P-# P-# P-# QZ'B'^B+^GIM^/\ <M]K"3[:T[\?
MFQ_,], ?,A^;H ^)8!??[>0..^O8_11!Z0Z5':9:?"2Q']Z<><^H(V'4.]5[
MS]O'%/S";[;CXCZ!^D==H9PRF9 60M]Z"3GF*@9C'-M)5-9X @?'C>F<2F 2
M^.X!U\!](#UZ;"'IT&)3B&J>% 26[]('M4[:<#D<+,;:=0H1H+Y&OA!H3\?9
M@\1PF<H#N #Z0$0]?V>FELDJDZ%9BNBND5 +C4JDC@Q )TG,=N$BI8"AS%>&
M5.\GL&,A AS (!U =QZ[=0$.W;<>N^D\YXB><0E$5O%EX7KIIWUIP&8[<(D7
M7$K@C2YH,^)&,A$2#MV[B/J'</SPW#?4@.P022'P,ZJ./%ZT-*5TY&K4H.W$
M*2(Z22R!@:4)HV?<IS(]-,;@4)L'LAOL'Z\/I#PWWW';3Z/&8C+$ZR0 $ZD.
MI2 2IH1W$$'U8:,,G,$0%7/=G\?=\.-Q%  /9+X]?NOM>H=&8Y6;Z-&=2 :J
M-0-1WCY>XX::B'2^1'?E@Z57V2"(%+W"! [C@'M=O<(=?44-]+<\D$R^'2NH
MURR^[Z.. H+U*9Z8RY_6@TK\?9@T0Y1V,42G+N(;E, @/KV$!$-/N!4HIU&M
M/#4YZ0_$"GLD'Y,,!'+%:$,!VX-)J[#N!3;"(;[CT]6^VF60U 4AJFGA(:GK
MIP^&F""/(0@!J305RSP<*N'F F)R .Y@[.XO?L4H#]SOW; !P_/U-5E+"($&
M3233MR[^X^C$24,8EFH>614&G821]D8.@L8  0* E'KW;[ 'H'?<?1IP \OF
M4.G37AV5I]D8CD5=T!&J,5;/L]'?@XDN ;[==NAR@/W(AZ#!Z!VZZ6E"R1U
M>1]" Y:FTZJ#X/ERPE5+9BG"N9I7U=_P85&ZP' JA0*8O782F P"7;8/ >N@
MK:Q50WQ&N(SQLLC(U P&HU-,CF/_ "=F%))4IB;=OMCN(!W;".VV_3U!Z]/H
MC5).14@$'(Y]P.9]-.&(CY^ 9DJ3EF*>OAZN_$[\<5Q_#WALHAM_9$K0!_)I
M?X.J'J]@.EK^O\F;[(Q9=-Q.-\MJC+F85;2H X5P (["/O\ G'T[= M]=W_3
MT.G'#=0[N!Q$>W_Z.^'NI8V_(UA_G-[_ '\6(R05#;M'8 +N(F'H!2!U[C>
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M;N) 9H8G1+%G=01<A*B0TJ SZ9*@TXG%!%T/LTMSSHUG06K^R[H?>-(;*.G
MG*E:XM$QX:X.R1AS =5M6.;KQJ83-.I=OG\7SC>N3F:+/.(/.9MO84AO=0Q\
MCDQ:6O/U*CF48F5B$H>,.DDJQ=N4FNV:N>N>H=JZEN]QMKJ.[;WQX@ZATAT\
MF&I"$D4#$MQ[\P"<7-MTIM&X[0EM)$(']RCD"NRZQ6:04R[2!W?!BL66N"&
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M?C_X=OLC'+NG5IO5O^^#"A:S .$^/IBAL'Q#.8"/K_GRK@]?L@&ATTP7J3>
M>)BV_P#T>3[.'>I58[+8Z!63WF]H.T^.*OQ#,XC)/[@YA*)R)]A%S[&%,H*C
ML4JAP 2D%3P+W"'=Z-;)KA8GHC(FYNI6)'8 LQXJ.YJ9UX4QA;B"<1>\PJ[1
MJX5R$+"F1TY=N>+Q4KD/G&YGK;*F8]Q=-Y?HE.CI&#S<2BH.,S1E#P4Q0L\>
M\)-2<P%564IM=K!$5)0D:,LM%-?=3K*%$0-S&]Z*V+;4N+BZW2Y399+A(Y+,
MR1M;^\W"E&#J/&WTD^M4KH#U;C3'0+/JK<]Q>"WL]L@EWCW=BDVB1976$.]%
M8^%98TCIK&92B8*6?F#D6R4>WXVB*AB3&./,DQ\J-SJV-*2[@(VS34Y.5>;E
M;LLK(34L[)/>?46;9H5!0D?'-!61;-T@5,.K?:O+K:K7=;?=)]PN=PGL)H>7
M-<2QF2"*V2<):K2@T-)*#(2-1)&9.(U[YBWTEC-9Q64=KM][!*E(HW$=U-,J
M!WIQ# J2> [L.>3Y$\@IK',W*O$*H:COUGF+)9XE$QZ,BD]GL$U_$BS!..^+
M&FDEC8RIJ!RN@;"U(] Z@G!0X) F/HOI*/J%+&XN6.Y1$3+%56 6.^6]TN11
M:FXD[&/@'PXBR]8]3R=/O<0VJMMDL?(+,I4,SV\MMJ'%J<B@H5!UBN'03G1F
M%TE7U9>DX3L5AILNYFL<72<QLJ\MF.[3(PM>A?C%8?ISB3%R^:LZNQ<-F\BW
M>MFS]'WHJ/F;#IB3R>V>&[GBCW6_MQ>P<Z>$21K#<VYGD9D8U+!*L8B!1GK4
M56F'Y/,[<5M8KAK&TO9K4\J!I$=IK::*WAC(CH O^#U@G@/3B1+9R'Y4XQ4J
MSNW4K'E5O32[5%*Q74U=8NLCY.L_'AFS;52-RD1K97PNDZNC,-E%#(L8X)18
M$U5%%S)&$*K:>B.A]Y>[:RW.:7;45]$+.HM;1+\EBL1(XLRZ<R0*'(5P]O/6
M'7&Q)!/O.WI VJW6:X52UQ,8(U9*A<]"^$J* UQ$K?E'DISC)+&C^*HLPE'T
MQWCJ,O<C!23R[0>.GTFXD%:FP7^-%JJ:+9P_60:R"T8I*M&JHH).2D[0#4W/
ME5T_%U=)O\]Q+;WK7BW'*66#EM/H14"_1LY#*J@4D"=E*UKD?TG=0?F]^1$B
MCDB6U,8E,-QK1"S/(YTR(H&IB:,C/Q-:4P[\$9 SM.+US$N,J=5LDQD76\IH
MO\;6*':NH*UTFWKP-IOJ-Q=.IN"$(Z)=U!B_:NTGC)Q'+-BJ)J@;Q/KKIKH^
M)9^H=WOFL+^6>UI.&\5M+&9HDY:A7;5K=B]5(8$Z1AOHSJ#JRX2VZ>V:R-_9
MQQW3F,K1+N.3E22),Q*CD,%&D Z@WM'+#@MV3,^X@S/7,C6RI8Y@[$SQ[*46
MIX]&$K-HQC"XK/#SV/I"FHU2&GYEN$.BR=2!#^^NS/'"ZIW:AU#'\P6-IZ;Z
M/ZFZ0N^E]KW.YO%DOX[R:Z9@+MY!HD9U+!%$B%8S&::53(YBF']ZW[J?I?K&
MPZ@W3;DMKF"UEM8K55/NW*8N@4T+$QN'D$E#5G-1E@]'\B<LV&HV&-:8EPU*
MX'ID-6D9+#"E*D#8JJKN4LT@K7+FS:?6I*Z*W"5L\NY3/(_$G"CM!8S58HM0
M*F5,GEUL&V[E;;AN6]7J]7W,H*W@EB:Y8\@\R%,F@Y,,4>E@8T;5I*]N%?I"
MWZ7:[G;+/9[<]-VL"DV0BD%O62Y CD:A$G-)E!4\QUR.H\,'7W)S,N:75KD[
M5C?!&1W\!"VBW,)*PT&*:_@HKJD5&PUA1H<<K8HN#7AFQ6Z+AK$/$)0&S\QU
MVB '[@!5OY4['TJEA;1;ON=FUY-;Q2!62EZ_-:42R&LA65M85F7EKI0UXC#5
M]YE[WU.;Z*?;;#<6LHKB>/F*U+9&BC1@@"H"4 ).K7[0H<CALU[ESEB&2,RD
M(BB7&'/&8Q18URV04T:%82F)ZDVH=&M+%&#L$&]<RHUIF1L^3767CY4H!Y[<
M_:4 E[MY0],;U''-+=2\T27[R.LMN7YMW.)94*/%+6C %2N@@'VL1;#S2ZJV
M>:2+W8>[2+:K'$T<W*Y=O#I@96CEB(\!*MJ+ G[TX]8\O\YQ4O*S:4C457\R
MWI$98T'].8GBYR(HD1;(!K7IB$\Q..4A9R%O$DTDFI4TR+(*E @)"0H@J[\H
M>EKG93MW-E=429U\:^$R&W"R$CV70P<#Q!'$5Q%3S>ZIMKU;WE*MU((H7;2=
M1"22N5&0U1L) *@ U!K4YX3[OR:R#=,:HX7)4L8T+&;!PT<,ZAC^G/H862S*
M;>6<'"DG)34Q+OW3F3?**++.E55#)=I ,4A"@$GIWRTV/:NI4ZNO=VNK_>C$
M%!GEB(==#*J@+2@C5=)H *J2!B-OOF3N^X=-CHZ#;+3;]O4EE6-) [DO&\T@
MU ^TZ FIKXABNNP@)0, E$Q2J%[BB7N3-OVJ% P!W)GVZ&#<!UU,J78F/E\L
M,=;%@JI\-34=Q SQS,JJH2Q9M0K'I5F,@/"F2T-.-<29_O(K?\<[/^YZ_P!8
MJ7_[AM_N2'_2CC6)_P#;]O\ >D7^C+CZ+?R7P-^(/+?Z/F YI'_R3QY^KKYC
M>8ZAM_AC/!;&)/@'BKZ\?4/ILTL'_?,?2GK&XT^!H8&*;\K_ .CO@]_GB5_^
MXYF/4>?[7W<*'LGX,7!?,VL@T<L'S9!XR>H+-'K-TB1PU=M')#(NFCINJ IK
MMW*)A(<A@$IBB(" AHQ&DL31R -&PH0>&(JQ1R*VM5;4K(0P#*4<4D4J<CK2
MJ&O $TQ06-DK%P;>'K\^A*6CA\_D'*U5MK1N\E+!QP6D'(N/JI;FC<KIW)XC
M*X7/[A)IE,>((((KAY0$/K%PR7?2UQ[O<:Y]C=C20?\ NZ\:2>BIR(X#CC@E
MM/NGD?.=INTFN?*624R03QJ9;G:W9R5ADB );;P20+G_  0]OPC%[H.;AK+$
MQT_7I6,G(26;)O8R8AGS:3BG[58H'379/VAU6[E(Y1Z"4PZV$5W!<6XN+=@\
M##(CM!X'U8[G:;C!NEJM_:3036\@U!X6$T9KGE-'X*XKGR5R<[H;W#5:C+!3
M\?R>4+Q-5LN6+RPBGL/CF)A*9-6J<=QQ)IRPBSVFQ,XL(^/3<+D0,=4QU"+%
M3\HR3Q]6)T(^C.((LT=@MQQF:99RDC4\S-,9.W%C8.J#%K8G@K<]L-LCTZ<[
MM=-8O&<-&+3RIXQ=Z[>)>Y&2 SP@ T/VB!49#Y<*5=9S)'JQ4>Z<T<F+!D5M
M2L:X%2EV>0IM0Z;1O#VBFR,978VWH2$TVM3:LIKVR;FGU!DV)'JC1(I$90A
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M*UH\F7BDMJO&/31B'XY4 /KPJ/S!ZZZ:^BZ_Z<E>T7+WS9F-];OV:IH'I<0
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M'[433'3:JV>(NU8KUQKZYW,':(:.GHA=1,Z*BC"3:INFXJHJ%*HDL4BFQRB
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MNIA&&>..?DI%D=1*I5@:UQGWZ=\Q-IV9Y(6E&VK&TEP$F"%5$FE9'1)6)RH
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M]O\ >D7^C+CZ*_R7O_% Y<?^\!S3_4ICS7S%\P,^H(R.'NJ?8Q]0^G/\A?\
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MCFOEKGNL6Y V.+1A^A5"BH89D7\3*2*C]Q*.[%=KW'3D>4S>=@_X[AVJ!D%
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MM.,@=)".QA2\!V^^%WW]&WM:6KBH"\]CW<DY_P#2PV=.G+57]:<9 <@]043
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M L58S)RE&8Y3Z&"4X^ @@\<\18NL=^M)99(+PAIO;J[(6R934 'B&/KXX?\
M"<QN4<+,VR?CN061&\S>'3"0L\BK,MWBKN5BHPD)$2\<F]:.$*Y+PT(0K)FZ
MC",UFC,I44C$3*4H,R^7_2=Q:Q6TEIX88G5#IE#*9&U.^K15G9JDZJBI/ASP
MTG7'4,5Q+<"[+-,Z%P6C(81C2B>)JZ5&0X-WFN&M&YQRY'S*UD897N[2Q.X6
MIUYU/L;,]:32T%1'T-*4R)/)MU$WHM*O)UU@NR*!]TE6B9MQVZW;]-;#<6@V
M^>SCDL_>))RK1R$-+(AC9V\&9 +$=Q)XXJVZDW96:5+IEN3;I"'$D8811N)
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MMV>^Y3M=FLE/!$*C.NI4K:3K:J$D$P1[$KQA&0MI,\N4'2KP-W:[@H***G.
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MBVU@Q3R J"PVYGBG,M<E:I8C,F6[">!JLV(XB[55WC%X9%1_#N7J!1.F<?
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MQODI4GK%^=*?:B-6AK%',D_XW4 2,132%,024(477FT17P.^6SM<0I&*%$!
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ME;S\!LB/^D5;XP,>_B@K_P"4H[_Y%O%C]QH_T+=8?NL?\\N?X7 _KN]$G/\
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M !&^_"P7]='HTYC:-VI^MVW#7M_"A&_1GP.V\M\UR5>[BG-5F&*Z'6ZF<Y#
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M\%_CF #ZNFP>&G!Y?;^F?,A/_P#)[A_"82/K3]%,?#%?5_W=MI^PE<;PQD4
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MJHRQ:R:M=9KL>ZDYJ>BV#-H0QU5%7B)SB(?<HHH(G4<.'"IO9(FF4RAS"
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M-=345FYR/8F)N -17*N_54VW!)".; L^75'T%(F8P^K5K>;K96*ZII(U [V
M/RG#2P3. %1Z$=QP8K]CA+9$MIRO2365BW6X)N6QMQ(J0>U5LY1,!7#)ZW.
ME506*19(X"4Q0$-.V5W:WL7O-HP:-NXUPTX:T;DR J6RS%/LX/F>,B+ V.\9
MD<F$ *W.Z0*N(CT  1,H"@B/JVU(,\*G2SJ#6G'MPL(Y&H E?5@UL("!1#81
M';8>@[Z<J*983Q-!QQ1?/V,[-G#(U=D,:Y(1(CC6(693]>83[N&=04XM.-)I
M"U12S&*D0E9-Y'QRL29(J[0I/,[3K]@JI#H^D.K>G-N@GV^_@CN+IKA&U@AR
MJZ'4H5$BT 8ACX3\8&,7U3TMOVY[I:;A87#0VJ02HT9JJL=:$$MH/$5 \<?
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M[+1V,'6&;;96"=LQ-^&^\6K-+ZN0%(H>/COEJ\BM(/X5NJ\"55L30R1$RIK
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M%8UDZ6?R3$DI'1:J"8NB$,=81,JH;M#N'PN'ZIN8-ODFENG2/EG(&F;$#[)
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M'U4B)I\&+1OJO>04"AKNRN4J*E$NKC4/768"OPX!/F<8;..Q<468QO2'U4?
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M+)QQS#7#+^?3EYI% Q@4<5APVL)0*4!-W'9LCFE41VZ[*-B"'IU%?8MQM1S
M.8AX&-B2/6/3V8\R]6_5I\[^E 7W78+RYLTKIN+?ER(M.+-P< Y4I0Y'#>J6
M5,P8ED!+4+Y?J&^0-V*L64S+Q1?8'JDYB7!P;*$ 1^Y.D(:@F[OK2HEYNH<
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MS#U$P@&XCZ1UEN82BL*9CN])Q:PKHA$1KK/?@JD10IEP'RE"G*(F-N(;" @
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M/7AUU2X5>YLG"U9L,=8"-%RMWI&3DAG+!8QC&*C(LQ CM@J?8>TBZ:9C;#L
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M! 4_;$A3")E-AZ!L&_YV@SD-1(VTX.,E02O%N/V, I%D^S[T82G'L[-MSB4
MW'M]8!MU'PT[F1[!X8<*QN!R7%1QQL.AWE#=-78YA NP#O[(^UMN =H=.OV-
M'''I.E$;XZX*-C&X<.RT[:\,)+]=DBNPCWCMNV<29'OPV.=+(E>2(,4BJO\
MW%LH8#N09I'*=7L 03*8!-MOIK3+,#(R4@4TS'WW9AZ!Y(0P>9F9C7B*T]=,
M,Z6QG1+2F)9JJQ3H^P@+E1FDFZ+TV[@71 IRG#T" [Z!EEBIRF9/4:5]??A,
MD5O+4%5->/;7U]GR8@&Y<.<76]LJU6(L*8^8";6<9LK+')E,&Q2IIS3=TLV
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M]N5>'''8(-XAZ8VT022,&F7Q4/'U_!ANY9Y#XN<,7?D!#)>2ENDNBFFV=IG
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M9WSYDG(-7JL2Y>*JLE$14,.I%_T+MUUX;6YFCL6@2*1(VHKI&FB-6X^%$&D
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M'@?][;[6!2LY*^SX>&/SB/F8=O[XS\X(2;=GU:>;" [AM^$;C?Z=?1ORT_\
MMYTU^]#[)QY,ZF!'4^\ \?[>.5_&[):>&N1&"\M+RTO",<;Y=QW<Y>5@"'5F
M6D% 6N+D+ >,12,51PZ5@T7!"I%$!5[NSIW:ZSO%I)N.WW-A;L%DE@=?A((
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MCQ%HK$#(,G"\$T(C557HMHT5VCAR8&-MZ.ZBMN5))$;C;(Y$YUHQHTTH'[8
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MV3V/<APF,\QUC&62H6Q4I&Z92Q'8(NDHW#,ENM-C@%&=5JLPN5*+;H1%?=*
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M_?\ 'E%R;#.JODBE5^_P"RI71(RWQ+2:9IKB7M][:&>)J+,W8%WV61,10 Z
M;;3>W;C>[9/[W:O);W7ZIC3NX=N"OK6VW*,6E[''+;']3I)'H/9BND?P&X7,
M7Q7K;CS1W+H3&.5M(.;',,$3;[@<L1*3KN- @&\ %'M#PVU=3=:]3.FF6\;E
MGN!'RXJDZ0Z>5M4%F X[V!%/5BTM8KE:ID %=J-8@ZI!,Q$&T)7(>.@8I/N
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M86?A4B_!W U)JY>R[])HJ=-$"N%;B7K'?([MNG7N;2:>.8QF\R6/1REF5!P
M:KG.N>8XC$,=,[<D/OZ+(&2M$;,M0Z6R[ I'&F?97$LVSY66 Z//8KQ8K'\K
M;M,YKG>0L ER)KB-+9X5P,.([%-LX]QE6*)69A-X^K<<R3+=$1G8Q*+!!=9J
MHJ( D6LAZ^WV[8DRVR+94(C)H;@G+2WH[4-*&HP+CI/;D@2YD29FF&N@%-%<
MM)'812OJP4RCQ#XJ6"0K5^K>#>2MJAGE6X08D<8GXXS-2D[%"6K,_'RO7V3S
MY:'2F.Y,5(J:5< U:,C,6Z4W/$>*+/VA3$2 MMZSZFEAEMWN88;BDLR3R"FB
M-6-;1%^^#FOC%=*D87<=-[*JPA(YB2/$ ?[,Z8E.L?+(X_TVH7A4)++%YJ[*
M.L>-,N95:T**M4N,Q#<@L<0CEY@O%;['KNSMG3C&;\\E%6FL2MD0D4#N6_WI
M4#-E8E[U[NES=*$C2*9GAF1 QH (:$.XRR.5" >!Q.M.EK"-2ZEVA%O*A!'
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MS)D[_P J1?Z,N/HM_)H2F4XD\K3%(<Y"\_<X@) 'J;^=C'0  ^@=?(KS^_\
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MW:7WBUABMD>50Y%=2IRJ%5 J=2R^$9DE0O%AB0=HW<V*213RM<,L;%>!#.9
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M/DJ:R/D-YF2CY8DF,WAFIFN*N)+NJYRBU:Q&068)IF)#S4@V58(D6<%)LW5
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MDX*?7B6"13+R+^$1=IO0;I 999)%0B93'$ ';>7N^66U[^\UTR1Q2C1K>M%
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M03ZQPI]O'VP0/%F;K&+^$&.I9*TS4OC.?@H#+\A3[I;*]"#7W%2NL[84I-M
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M51  2&CG\M;8VDL:O*R3+&D8^B/+*7<ETE05I0O*8R#ERP/OL\/OUW-#+&9
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M8&^]HM/L98L(+ZZB0!&I0=P/VL0I7/E4</(5=N^E8K)-](57O(QN63; >(.
M#L"+B-KHUU%XB&W4JHF*;P$!#4^?KOJ*X7EPR&$$4]E>W+B5RPIMSOI25C'K
MR'PGAB4,L\ N,^4X&"JT;328C7JL6K&5NQX?384^1C&2JOO1XU\S39.82RL%
M7!Q5$DBV<G!4QC$.0QC"+6V=5[WM$M4F:0MQ5C4/Z#7AWY8**]EA-:U3M']G
M#%.0^2SB287(%GSIE>>BV[@3>XN*EB])V< ,/W$@YKLB#<Q@#J9-$!#Q#KJ_
M;S&WTK188@3VUQ(.[,PHJ>+X\7WP+PKX[\;%!?8IH"+6U>Y^Y.+]:'J]EO"S
M(XE\YBTFI(3A!1KD2^VVCDFC<VP;D'65W??MWWB$Q[A(IA[%4@<>-:4/=3%>
M][+>:HY00H^#%H%5A]M(A2 <Y0 =PZ"/AXE].WV!UG%)>(QMFA&D^H=E?M\<
M-22/0)7P@>C'ASB)$TS@/=L4 4)[(D, >._B8OH'Z-2$'A SPT'89 Y8]5,
M>4F=8WFK^R)2!W  @&P&Z; 4/L:9;Q%:YZ"=/HKQ_L.'+=5S-,\\>@9-/N;B
MH=0W9MN/<8PB ]>OB;;T:56HX#XAA!=CQX8R*?RA(8B?FB;V! ?9, >OIMN
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MBBYLDX/ 46$].9"Q;/8NB"-,10<CDQNC)56U#DKR4'DTXCEVSB/.91 R"I3
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MU;9*#PUX^C5<BA#(&*AW]@??1'NWZ_L0#IOOKB7-C)R/V<;YSI7EIFN-AU7
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MC04#D/L!13*"@E / 5 ]&P"&VEI/$%%3\A^YAS2>[ <$,('()#E P@83F$P
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M0^YB@/;T'8W4=NOV-)62(&NN/]FOW<#2Q[,;/=S=Y?-)Y@=3%[0[3;_2/0!
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M<?$WX6/1BORE0!+WV7YB9AZ]GF$RV&W4=^W>K^O1L?(Y?\I_(##LJL0_\_!
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/&_Z/X6'- ^<O_2_!Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>pg72img2_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg72img2_424b4.jpg
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M$C A<8&AL7)005%AP1- \-'A(I+2H],4- 4@0B-T%?%2<\(SPV*BLI-4$P$
M @ "!PD! 0         ! !'P(1 Q05%AD?$@,%!Q@:&QP='A0/_:  P# 0 "
M$0,1   !Z[[EAP                              DG6RP%T-??OK5N'-
MZ4S^M'@ /G@VH-@]PX4=FGIEJ^3                        1QLX_*I;,
M4D[5RQCM8K?=VO?A9-*   27')5#-4>C?5)4\J      ZB2P!P9O!&1V3@
M            $8[6+R&W%$).U<L8[6*X$BK7&L2G   ).X4BA:HO2OJDJ>5
M     1 #9S]&M$M@              $8[6+R&W%$).U<L8[6*X$BK7&L2G
M ).X4BA:HO2OJDJ>5""3KR+D??S#._A   Q/GF25H=H     :#^K1?B?OS]
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M;G7EXC*&3&39G#@     *VR;FY'S];A&^A7XS30BRA7PG AXX<V(_)<@YL
M$8[6+R&W%$).U<L8[6*X$BK7&L2G+>0*P14.>U]<2 6'=FN+,Z8O0WG"3N%(
MH6J+TKZI*GE756=J@*OEH   "HVQ$+<Z\O%5:/NV:;%KL   #5N)V]L[O#WZ
M4Q<0QQ8CD_63'[$JKH2.1H62*ADUG#GX-@-6)%(-)P-$-=-N/J3CM8O(;<40
MD[5RQCM8K@2*M>?F]4WSK"U=/Z'.HI9E76*B4OL;$ICUT6U3\G<*10M47I7U
M25/*NL@[-R-"*BT   !4;8B%N=>7@      #%^,7]_?W ^LG#'#@RC^&:?<Q
MS /Z?$X$D UDR3[&6<'M8O(;<40D[5RQCM8K@2*M?A8E.=G]+W?&?9XM"K/J
MJX]?6+:>$SGJ1O>@9.X4BA:HO2OJDJ>5=81V>G5\3 7A   *C;$0MSKR\
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MG+Q5M9VZ\[I==%M4_)W"D4+5%Z5]4E3RKJ0.V\J>8A;L   J-L1"W.O+P
M             !&.UB\AMQ1"3M7+&.UBN!(JUQK$IR_U6VQ#W?CM8IG">R2H
M+EBKN<&F%AUQ)W"D4+5%Z5]4E3RJ@1?TIT81=(   J-L1"W.O+P
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M=KWBE*0L+**+(+%A)5-?T&O\!^@D6R[;7QA.U^HU_@/T$BV7;:^,)VOU&O\
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M<0(I)CX209YYR/8%#\13TEQ2\-44@]*-;;J3/^-F7TYXE1ELR C2JR56J.%
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MD57=[DSU)B?\#M_V1V-D_&A^*-W+FJ$^J:U-Y;:LI$3>'SMMJ>3/L)5?MRP
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MK=/H=?Y7'G6Z?0Z_RN/.MT^AU_E<>=;I]#K_ "N.+%KK^ZD)RL!8/B086?\
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M6/.IOH .LL>=3?0 =98\ZF^@ ZRQYU-] !UECSJ;Z #K+'G4WT '66/.IOH
M.LL>=3?0 =98\ZF^@ ZRQYU-] !UECSJ;Z #K+'G4WT '66/.IOH .LL>=3?
M0 =98\ZF^@ ZRQYU-] !UECSJ;Z #K+'G4WT '66/.IOH .LL>=3?0 =98\Z
MF^@ ZRQYU-] !UECSJ;Z #K+'G4WT '66/.IOH .LL>=3?0 =98\ZF^@ ZRQ
MYU-] !UECSJ;Z #K+'G4WT '66/.IOH .LL>=3?0 =98\ZF^@ ZRQYU-] !U
MECSJ;Z #K+'G4WT '66/.IOH .LL>=3?0 =98\ZF^@ ZRQYU-] !UECSJ;Z
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M^%;G8T?*[C6>3OG>2JMC(/-F9NHV[%!;:PY/C0KJCA-5:MQF[K9WQ6V-;/\
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M74-5*1LUJ:T9O,**7//9LKXC"4CZE2:2L*:G9MRT:SR>)NWA6YV-'RM 3_\
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ML]6/6>K'K/5CUGJQZSU8]9ZL>L]6/6>K'K/5CUAO'\(__]H # ,!  (1 Q$
M !#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ Y9TDDM"222222222222222222222223J*I)))H      )
M      #15)))!      !(!                :*I))((!!P   [;;;;;8
M         #15)))!  (   #B      !U! ) (!   :*HU)(((!   !@"
M  /  !      #15%I-!!     , 0      ] )       :*HI#H((!   !@/_
M /\ _P#\ *X() ! !  #14U8[!!!(   ,       !X))( ))!)(:*C9,X(((
M   !@       .I!((( (  #15&9S!  (   ,       !()))) )(( :*IC/8
M(()   !@       (( ) (  ! #15)I9!!!    ,                  :*H
M]/H((!   !@                 #15)I;!! (   ,
M:*I%$8((!   !@                 #15I))!  (   !@
M   :*MS)(( (    ^@                #15)))! !)! ('1Q()!!(
M      :*I))(( !) !!( )!) (           #15)))!     ! !(!)
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M1(D2)$B1(D2)$B1(D2)$CWA$B1(D2)$B1(D2( *PE/\ .9@00>Q$+\/=$!T
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MMK.W&NX(FOE8,64M6<M%:KMO'*L#<D1&')Y(@T'\0EZ$EQ0)P -U8DXQ/7P
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M00#\!DG725BPL$HZ =JN86!5H5849A.0?N[*W6V@069TQ<Q_>SWWY.]PC?\
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MJ:"6;,H*"+H06VT %N;EK_QXEO=B1[Z(JU"2\ 55(JAY1-53  \!1D*0@"[
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M5O\ (16_R$5O\A%;_(16_P A%;_(16_R$5O\A%;_ "$5O\A%;_(16_R$5O\
M(16_R$5O\A%;_(16_P A%;_(16_R$5O\A%;_ "$5O\A%;_(16_R$5O\ (16_
LR$5O\A%;_(16_P A%;_(16_R$5O\A%;_ "$5O\A%;_(16_R$'6*;H^2?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>pg72img3_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg72img3_424b4.jpg
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M  $" P8' 0$!         1$ (? Q81!!47&1L2 P0*'1X?%0@<'_V@ , P$
M A$#$0   >KN[(6/J_.=_<8 ''?GKCGL                         "3M
M7+&.UBDKWI6_GE'8'6X( &;@V(B@EQ?:*SWT[5;)P
M    (:W</D^MR)R=JY8QVL5ON]7?PLBE@  )+CLHC.H_I'U%57*      .EH
ML(?(W(B@[2P              "%]W!Y)[?B4G:N6,=K%<"15KC6)3@  $G<*
M11A3WTOZBJKE      &H&*<R?0X0W<               A?=P>2>WXE)VKEC
M':Q7 D5:XUB4X  !)W"D484]]+^HJJY0().O$MSDP1ST^"  !PV1)'%D@P=7
M9SMK6    CC]_+0?G[8G\_0         !"^[@\D]OQ*3M7+&.UBN!(JUQK$I
MP  "3N%(HPI[Z7]155R@ 4_+@   %5MR+VITY0(RADQDV9PX   #^'\/T"%O
MW\R3 _/VO!HQR1^CG3 )I*\F*;\:T62+$@ $+[N#R3V_$I.U<L8[6*X$BK7\
M6%3W8A4]O1+W>!4.>U\ ).X4BC"GOI?U%57*(+)T-?*OEP   "JVY%[4Z<H$
M90R8R;,X<     !%_5U?MY_>:YFS'YLA@'/$9$C'S-<.:,8D<Y,  $+[N#R3
MV_$I.U<L8[6*X$BK7&L2G+F5[8VC=/EULE\-^_GUS.OLZ_M:DG<*11A3WTOZ
MBJKE'5@=IYU$$]%_0  "JVY%[4Z<H%7Z5N>7Y_ 0   .!Y?4VKN</=9''A!W
M>T?OY_><X>[#9EFAD_$'DQ$7'%FPGY+1G+   A?=P>2>WXE)VKEC':Q7 D5:
MXUB4YV"U5;6J[VA22QZTN-7]B76KJR^F/Z%^<).X4BC"GOI?U%57*.K [3P4
M_+@   %5MR+VITY0.+TMSE-W3    Q<.9^,K/A$'<.&Y?K+A]J6UE-](Q+0%
M.R<CC#X',&K$EE?BPI&AP1MYF$X;N#R3V_$I.U<L8[6*X$BK7&L2G+]5=:WQ
M]>:%V?5=D(C,;)0^9];MO4W)W"D484]]+^HJJY1U0G:\0@1<7    *K;D7M3
MIR@        89BF$?H^9]S['Z/F?$'%'[.?.//Z?4^A&&[@\D]OQ*3M7+&.U
MBN!(JUQK$IR^%8VGI72YE1)Y7]V:YLNTL)G/4#?GSW)W"D484]]+^HJJY1UL
M'9.=<1L!?T   JMN1>U.G*       !#->6#DYL.O3V"5;-P(S+.%&S;2=B!"
MP1JYP1BG-G8@ "%]W!Y)[?B4G:N6,=K%<"15KC6)3G9K3=UQUUN/0^SJL[ *
MLMCZ?GKK[M2I9.X4BC"GOI?U%57**)E[ 4_+@   %5MR+VITY0       *U'
MV)9(V-F.--H-.-@/R<<<V89\3[FJFU'T)3!"^[@\D]OQ*3M7+&.UBN!(JU_%
MA4]V1U#<D/\ ?CU-K!KJPT4EU@HK+>O>U:DD[A2*,*>^E_455<HZ13NZ*]&@
MEPP  #KFGL5LYP^WR>+URN'W*O)V@     *T&62(1(9)HQ.9I!KYL)^#A39#
MD"+3?#02;29@0ONX/)/;\2D[5RQCM8K@2*M<:Q*<[!ZJMO\ '[^=?=J5+8R)
M3"^U7VKT^W[\]2=PI%&%/?2_J*JN4=8)V?%%CA3L#   (AX\5E[L2H0!(="?
MX]O@               0ONX/)/;\2D[5RQCM8K@2*M<:Q*<N37UB\WK;5&[*
MK"^=86IMFCO]<%NTY)W"D484]]+^HJJY1U;G:0"GY<    B'CQ67NQ*AU@VI
M&;?PWK_/]_)>XNWLNME              $+[N#R3V_$I.U<L8[6*X$BK7&L2
MG+\5?:VH;_.IM8-=7OK*TMZYG4ZUK@IF3N%(HPI[Z7]155RCI\.X,IL:R7O
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M@  $G<*11A3WTOZBJKE  @\F@R #^&D&\  A(FT $*$U@ TTXDD@
M  $+[N#R3V_$I.U<L8[6*X$BK7&L2G   ).X4BC"GOI?U%57*    *C%1C>2
M5BMIRQ/)54^1,9!!(9VB&Q             $+[N#R3V_$I.U<L8[6*U'1B/,
MVE06+[\@ "08;84>UG>_J*JN4    8Y\313?S33:C+,,^A]S'!FGZ
M      (7W<'DGM^)2=JY8QVL7U?EJ.E$.9Z<?  ^>#;KQPYYS6EO=F,7Z8
M                     &G9O'55+>5)VKE
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M19BE"&A5;)"X'(;7,36*8M6GI]O:;8,#.<KMPQ+W>6QU-RP;[6L3<J16)I!
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M@ZC7K".;VBW6="O]+VIAQ9<)#2S(=R,Y8^P5%R@A+:B6U>H93"!"$9H_@/\
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METIKKIK&JX ^R?1#NH;RSY!<T/%=;0X$?T>E,9]/Y1S)Y>+I8(7X4=Z?UO\
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M'<4G_IX\&6'<4G_IX\&6'<4G_IX\&6'<4G_IX3I,61'U?1XX2"U?R<1K<_\
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M7DK>W)N+[[K/U+OD)_W';_NCL;-^VS?)-AR[8/5R+)KJK=VW)TJ'"E#C194
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M7Z+ES5,*J5==FL=L1?V*-SQ6,:)L9?J^>.T;$:C/HY(B8$\M=!(\!BR0N)$
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MM97O7:U8A&D2LWCPFM%_&*M>Q[5?J=K:K5:G,[4JM__:  @! 0,!/R'8AW-
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MZNY#!0BF[K/B-%RS1_O!*DL."W1DZ 0 (A(C9$;(E F$  " "P!MN\%S8_X
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MI2ZE+J4NI2BX6_\ 04).9'(0"MS&QH2C["$[P9-KDV:V 'JQA&17 3F,?^#
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M$C:&V0+AX8<%N^^N$H9M4 SJ'SSYU.89J",GK/NC!P0Z? [,2[E"T#,80NS
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M"Q-\S8KI#*60-V:)X?Y>*A9<(;B_R7)]C8S.2O9'9YN;M F2@"#@)+(S=WE
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MDDD&       @$               #HJDDD@P$F__ /\ [9[;;;8P
M  !T522208 "   # $    " +02 22"0  .BK522#" 0   8 @     "\202
M22   !T51F6080"   # +_\ _P#^^!;!!!      Z*HG+(,(!   !@.    (
MP)I )  ()  '15'87!A!(   ,                  Z*HC)X, )   !@
M    *8!((( (  '15 I9!@ (   ,       !))))))!)( Z*L;+8, )   !:
MT      )(()!(  ! '15));!A     & @                Z*I=$X,(!
M  P&+P              '15(Y3!A (   &!P6               Z*J#!8,
M!    &P"P              '14F9)!@ (     P6               Z*B9)
M(, (     .8"2290          '15)))!@!(  ( !!&(  (           Z*
MI))(, !  !  ( !              '15)))!@    ) ( !)
M Z+?))(,     ((                 '1;FVVQ?_P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ Z
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M2X?0%^*FK/(MJ0U+**GH"CIS!7('+KR7!\&@YIA_<[V'P\:: LL7)ZLMR!1
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M?NOFOW7S2"8[]WO !NB01J*.BSS#R"A98Z!$Y-GF']>RF Y6.QY&/\7^O93
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M4;"(D43,MS"<P0DABC5V540)0-S( 8!#6/\ %]#9CFZH8"(]1EV2F'8(4^V
M,RY%)!,@IDPR04G)@Y?PTP'*QV-CFM_ 6"$@@2$"-%B\E8A&0P"!*R!"J;O$
M*ZL$ [L)R#%VGXZJQ!0&1( 2L?XOH;,>7* N26RM,6W;,-X*P[C_ (:8#E8[
M%(IB^!)4; %U:S\12 B@ Q(D6%/(-B>+<E  2VY9W5* QX.(1# 2-F=FB3<Y
M@5@B$,@@"KL8_P 7SK,BTDFD7V02TD2&XV\^:3XHD&$L$CGOV8;P5AW'_#3
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E1(D2/52)$B1(D2)$B1(D2)$B1(D2)$B1(D2)&X]ACFW_ %__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>pg73img1_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg73img1_424b4.jpg
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M P$          1$ (3%181 @\$&1\4!0<:&QT3"!X<'_V@ , P$  A$#$0
M >KN[(6/J_.=_<8 ''?GKCGO>=?)V9QCI@                       <1[
M\]54LY4G:N6,=K%)7O2M_/*.P.MP0 ,W!L1%!+BU>-SKU?5)+       *^DY
MGR.).*-_              -+S^/'G<L.D[5RQCM8K?=ZN_A9%+ 37')+&':X
M?![.L)+CLHK_ %5]&^KZI)8!!I!!,I80    Z^#2#<#@R+3M\
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M+F"3N%(J^5+])^KZI)96DW\^I0@W8[$P     55EO+M5$NH
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M7&L2G!]_/KMDHN_*\RR(4:LJL!)W"D5?*E^D_5]4DLJ,6),PK>:&7P
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MJ^J26 "'SA3>C#-/-\(X)'(L)3!'!(Y'!(YPYPYN!&Y)!&Y) (X)'(]+!
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MD/F='U45/*@                       -,S^/(9<40D[5R@
M                   2/K9/_]H " $!  $% L+++S+ND.PZ0[#I#L.D.PZ0
M[ ]&K2X1EC-DT@^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^
M)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*
MD0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B
M'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B'Q*D0^)4B"__P J
MOZ!"$OHP12.'2=WL>D;#9YKD8\UR,>:Y&/-<C'FN1@J7O=*3"+MAK9I1_2^W
M>]3X;'GG-)A1:BN")Y0+B9#)V6+L_?9)Z="7T8()2B>(8MVG<R='%R;5S.NP
MCE,Q9I1_2\7:4.S?+6K5=Z7J%.I#,CEW8S_3&7R*5J='9F>ZI-$"T!J71%WM
M4/NA,\>E??9)Z="7T8(9Z&P0&E$+I*XH2&[59S0NDRPBO.Z4?TO%04V9TIB@
M]RS4GU=WEW=$K(VOO_HMM;EL5G3',3)/-6Z)K%^L,<0KS-68E<VVZOP?_>NI
M\>1PR9ZDIHJF5ZEVHE,5D;O(+/KDGIT)?1@AGH;!*58>J?4!#<V:HLS<QS'"
M*\[I1_2\=1-.E4J<FK2F1IG[4^%&F3[VI6CVI6CVI6CVI6CVI6CVI6CVI6CV
MI6CVI6C3YC='4GR6H'DM0/):@+XFJ2((F<<HCG9O,(B<A5AZB[%(KU>G<.7"
MFG41I7VQA>\BC#$@99'#F"64\@Q/J\?AD<BQOUR3TZ$OHP0ST-@TQTMT:&Y/
M,FM!,D![=(L(KSNE']+QECLK8HVQZO/SJX3F3WK]5.QTL^AZ_P"-#?2^+2X:
MA&NOU+E%Z1([ZA/:->S/"ITNG$X/ARYTUB<&]R.U=--:K-9K,S[F+$6G6HD_
M>HPG5ZEO2==")8[/996I:IRA)VM<N+N@>J$DE,C>M4G2V77ZO2],1A)/3H2^
MC!#/0V$)40(L/A&AD?>-16EK9)5A%>=TH_I8>9U"8ZK:W9K?$+KTOIB*[3"]
M5J3ZN['2SZ'K_C0WTO@\S.-1\T[46+IS&5]0OQ'U5MI7!4WH%U36-E/LLC<=
M+,K%(M4)$:1O3N3,SO%O2&GJ2%J:VRIZ<A455C9;J$M;:G-5L[0O4)(K&$&,
MD].A+Z,$,]#8)ZG6GW62!RKJ"KD2V5817G=*/Z6-8&9_<$&EECP7!9HQ'R:*
MLVDT@0.DYB2%NU4['2SZ'$B]4WMB34!J0?ZZC#_7485032JF^/2(RU.7/4A7
M^NHP_P!=1@P'SNZ4]TDGIT)?1@AGH; FEUQQ<,U"L,U65(%DUPBO.Z4?TL:R
ME'NZ'3LBJ:&OIYB5F;]09NE<YR^O*O53L=+/L4D].A+Z,$,]#80QOC#DZR6&
MZ0]<GRB-*)'A%>=TH_I8UY7LB1NT[,:38:X*$*1"GF4"<%NI/J[L5FD4(7+8
M:R(8UJQ]@DGIT)?1@AGH;#3MICJ>/$71S32&ZK1Y!&9KA%>=TH_I8U7JYVLN
MEE[P;!)='Z2J-->DSLB7SF%1MKU4[)VD141U:]Z(\+M;(P7W^2>G0E]&"&>A
ML(5.E4.N,U3,7R^22!?*'K"*\[I1_2QJ7!D4^1PIB;HU'INXN#1$(YJ;*%SS
M.724J-5.TUF]"]^DGIT)?1@AGH; LN\XQPTNCK2URZ-'Q-]PBO.Z4?TL?^AV
MZ*V%Z25;JZ>W76V6HM2X0Y':CJ"+YIVD]C*J71IS;M86QM@;LM?8?WR2>G0E
M]&"&>AL"C3"#6^8Q>2%39^5R21X17G=*/Z6-:TTC61W350M60M\9TT@:&;1H
MEF5SN(1IMU.[66>EM,7=I(@*=6E66=[DGIT)?1@AGH;!!E\](*O+(GU@,(,G
M.$5YW2C^EC6>UZL3Z;)"$4,DZB]+'H_+)\H=)RHF5^JG:J""59'M9IX-%2"4
MC5WN2>G0E]&"&>AL$Y684.Z[2J(..H,?11F4817G=*/Z6-?'-$\B$,KE'HTY
M+R6I BU2BJY;J$\-"F?=O%7N30LR)3V^3.W>I)Z="7T8(9Z&P+NI89;(I.OK
MJ#-+3K<(KSNE']+$RT?:YF\,+48QM+PA.<VILTD;6T_4"/,"/43N#3_7OIM4
MIKK^Z23TZ$OHP0ST-@A.+3K3I,9('3590W*IMA%>=TH_I>*LL\U*T&:B%N<Y
MI-O=3N#_ *>.;G)/;R:CV\FH]O)J/;R:CV\FHA.D,MCNH?=))Z="7T8(9Z&P
MATBBS&7:Z1>]NE:QO7OF$5YW2C^E_0[3EL:)'JI/X2@G'O7I&/>O2,>]>D8]
MZ](Q[UZ1CWKTC'O7I&/>O2,>]>D8]Z](Q[UZ1CWKTC'O7I&/>O2,>]>D8]Z]
M(Q[UZ1CWKTC'O7I&/>O2,>]>D8]Z](Q[UZ1ADU-T]DKCW.2>G0E]&"&>AL$M
MQ-BIQ:)5)$.K"YO<)MA%>=TH_I?T.D)9W>0R33R/R9X\IQ8*(=%CR(OIO%HU
M'?*<6%FF46LEWE.+":Z61:8QORG%AY3BPCFF46CX\IQ8.VF46='SRG%@X0B+
M+T$>T]BS P>4XL$VF4632KRG%A*=,HM)F[RG%AY3BPC6F46CA/E.+!3IRQ&2
M_N<D].A+Z,$,]#8:<QR-+6XS3Z G(Y8X,CF]X17G=*/Z7].H$:D;Q*1(B:J&
M#2]J<&>)BQBF_N\-76&02&/,I"E,SC1B*R>+I1+84^GO\+0.C5$9\P+GU#IZ
MQN+=);J;UKA!=126@:EQ&2OJS3)I<V6+3!I.?8O&89+T.HP7PR0*WR((G1LB
M?<I)Z="7T8(9Z&PTZ?8>DCCFZ:+NL?DQ,=3N^$5YW2C^E_3-YG2&IV[5:('M
M)DRBA1;+)XY(T$CUK@3$T,NKVG3VVD2^+*G.Z<0ZQ+74B 6CSO#>H>XT"Z:C
MU$@;B:HU @R._P!SH4FK(YO'8JO(U4TU54?-2X+'J)M6-.%!5L_@]]5FJ6GZ
M-#6<10J.ES:'G.!>HT!-1^?(3OIM2(NX3+N<D].A+Z,&FJTE10XDU,;]53:1
MN+:4?TOZ9_#G&7D.NA;LYM2#2A6JFD2T[=(S%F?0U:@67?\ GHRI</AQ<2/3
M:-J&MB2_^=\LR*]%U"UO1Z1*O,KCHFOC\40Z/+VJU3H'10?(H6<]&?'DHMG=
MM"USV\(M%E!2I-_YX+3&$Z%EEMCEI^ZK6SV/,\P)-!%Q:>[08\XZ':1GQ*1=
MSDGIT)?1@LOO*O1:DDJR/-NGP\VZ?#S;I\/-NGP\VZ?"Z=0]%202-UDRW2NZ
MVS4CJ3<.I-PZDW#J3<.I-PZDW#J3<.I-PZDW#J3<.I-PZDW#J3<.I-PZDW#J
M3<.I-PZDW#J3<.I-PZDW#J3<.I-PZDW#J3<.I-PZDW#J3<.I-PZDW#J3<.I-
MPZDW#J3<.I-PZDW#J3<.I-PZDW#J3<.I-PZDW#J3<.I-PZDW#J3<.I-PZDW#
MJ3<)&X(*QX)?1F5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@R
ML,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5
MA@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL
M,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,&5A@RL,"9-$?*/__:
M  @! @ !!0+LC;_\B^KECJY8ZN6.KECJY8ZN6.KECJY8ZN6.KECJY8ZN6.KE
MCJY8ZN6.KECJY8ZN6.KECJY8ZN6.KECJY8ZN6.KECJY8ZN6.KECJY8ZN6.KE
MCJY8ZN6.KECJY8ZN6.KECJY8ZN6.KECJY8ZN6.KECJY8ZN6.KECJY8ZN6.KE
MBUV+NN%>,*4K=4AN+MIE$PRB891,,HF&43"]"FOHJ37)[U?+?<2^(*\8-UM+
ME.)KLWDE$G%GEX.5M*IU?+?<2^(*\8-G,8&4K<6C*,N-9"3"6_!QY97RW?R2
MKCS2(T898K0'HJ=N7Q!7C!LYC"^M;;$QMQIS*H-4M^#CRROEOI2GT3&=7L'5
M[!U>P=7L'5[!U>P=7L'5[!U>P2=ISRKRZ:/+IH\NFA4Q'D)F(PPUH[,E<K3V
M=P+X@KQ@V<Q@>KJ2>;<WG&MYMIJ3!QY97RW;NWT./_/CW_%[)2;<00OE;DG5
M-S@>MKVY?$%>,&SF,'&USJ$UTE5)VD\Y0BP<>65\MV[M]#C_ ,^/?\7L]E*]
MQ+X@KQ@V<QA=N[NU*4&JQ(6BP<>65\MV[M]"LJX](C(E2%+ORX;\N&_+AORX
M;\N&_+AORX-1LGJ]]T+X@KQ@V<QA=^-7!JK1DL-+;L''EE?+=N[?8B^(*\8-
MG,8.!JPDA&X/V6:[5EJ3!QY97RW;V/"ZRQ:?>I:/L!?$%>,&SF,'8]7<JNS;
MPX,BLU8W8./+*^6[@2FJL9^B*!T-57OY?$%>,&SF,'%LL<!1DH4@2)2D2?!Q
MY97RW<F3G^_%\05XP;.8PK6EM"GI6><@66KDV#CRROENY-ZJU&I*,933' JP
MA9WPOB"O&#9S&%:4NH:WK4E6Y+8D28./+*^6[FDYMT).N<+K+K*][+X@KQ@V
M<Q@9O?YI<NHN8*74;<''EE?+=SMNK9=U9Q#Y=6\WO9?$%>,&SF,+J[MI!;VO
M*:E1BQ%@X\LKY;NJLA*NHL;Z)2>]%\05XP;.8PK3;3*(R@U-V[BX\LKY;NQW
M_&^G=NV=T+X@KQ@V<Q@9;6XNU'1*2QVFV-V#CRROEN[)W$HI-U%".HH1U%".
MHH1U%"%SRC4MW="^(*\8-G,8."1:IK4E;0U"6:6FP<>65\M]Q+X@KQ@V<QA?
MO5L*/1(S&,LTINP<>65\M]Q+X@KQ@V<Q@[*UA9M'5TM,0E*"4V#CRROEON)?
M$%>,&SF,'9,OO5DDR$A4CN5W$8./+*^6^XE\05XP2F_XG4K2ZGU.9] KY;[B
M7Q!7C8$JCB1U0\=4/'5#QU0\=4/%[BHOI6NT*^6W;ANW#=N&[<-VX;MPW;AN
MW#=N&[<-VX;MPW;ANW#=N&[<-VX;MPW;ANW#=N&[<-VX;MPW;ANW#=N&[<-V
MX;MPW;ANW#=N&[<-VX;MPW;ANW#=N&[<-VX;MPW;ANW#=N&[<-VX;MPW;@7;
M=_H*\;:<-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPV
MG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<
M-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPVG#:<-IPK4[_;_]H
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M=8P"'AR/\9[9A9ZS]0?A79VH8AHU:XCD(B*>=/[IX&)[Q6VH_B*DV6)$RMQ
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M*420)A7=^VR;3A[6RO'Q9<,_S';^*.QH;UGJ?&Q_D7%O C!F38$(AHT:09H
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MZ" S-K9,&( 16[8(L9^R1@T<FW&@@&OZ6!8G4:W(4N=55LV4 !XP9,N#&D2
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MLAXN5O$[<[>/@R!APN./7TU2!:1BE&GW*U/QO&B[;4X_G_.R:6'+#!DFDP)
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M(3(%6D L_$3ITZ=.G3IT\,8$?,(0C?+#<9,F65L&5$X0PC%.Y\# V!>8I?R
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M/A<>0DW(*AE;8X2P6DJP!9>G]C7"EX(YODP$"! @0($"! @0($"! @0($"!
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M?__:  P# 0 "$0,1   0M)))]0                        M%"))/=
M    $ $               HNDBLGH @@    $ @              %%4AYD%
M  D            "T@@DD    HJD!<@H  9))))*2_     $$DDD@   %%4C
MTD% $       &( @  &W@  $  @ HJD?4@H@$@      Q D@    $@   $ %
M%4B2D% D       #Z2R2@          HJD&L@H$
M  %%4G>D% @D                      HJD5<@HD@     %\
M     %%4A!D%$D@      @               HJDJD@HD$@     $D
M        %%4B8D% @       %H              HJD(T@H$$       *
M           %%4A^D% @D       &0             HJDN$@H$ @
M%  !          %%4BJD%  @        /_\ ^          **I 7(* !!)))
M))))))))(         !15(!9!0 )))!!(())))()          **I)M(*
M!    !(  )((         !15(79!0 !) ))))))))!)          *+?))(*
M  ())((!!)!((           !1;FVVQVVVVVVVVVVVVVVVVVVVVVVVVW:
M                            #__:  @! 0,!/Q#8:EZN HK\, N]=NW;
MMTIF47H%1@8+FPV/? ;]\ "M$6\FJ5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E
M2I4J5*E2I4J?DJ5*E2I4J5*E2I4F^W7^^5UL MMR)/P6FJQ"O1&#HV71/ZG8
MDK--&\08,&#!?7N]T!]B%4K0Y/1XIZFC+P,+P25>(HX<1?#)4FFA$ 3(1/ (
MHA2N46O%V D!W+:0HIX?"'%U^>1SN=E^+4=%"7\B Q(R$$D":H%F )3"-LX7
M:$B 08915S .,@,4]TJ_38>EX<.#J0R1M$8W0DVI.&D%2N*:0303]A<)I:DU
MWFND+0RD]A;\0T7!2H*066;FAV.H2HS-I+?3 _)UD\B5H(-<%ZY2?RC^"^:0
M],2XA>*X$/)9 8EC,6Z $>^M:4-(=@56B;T._6Y<L)!'[(1U^"G40DFLFX,P
M C8Z(JB/E1Q%UOF=\6G>+40Y<<HI=2<JBFJ@Y*4#H)(:+H99JS\+%D2<%'6)
MA 4D%E@&!5*R)U1<SV>=3/\ T/S>&SPLIZ<6+&"<N>M15CS%W1T!YOYY2#!:
MR:R)4?7%;Y-0\[?G%!,\!KR# ^VZE_& ,2P$3A4<8W.($7I1;&U"8-8:ZHE,
MS_1_XD00'I^)40E_+/?+227DE89!TGG/?$C*4!1*+[8083\4W[]^_?OW[][^
M0 VEXN,U&8SMH4*%J/IQ6V'[H&$;TN.?8 )X!BAC^0 2.3[QUA=*ON:M.3HO
MN!P5\!':W1$"!.X'5Z_-:1G(:L1#6AO475?GH$\A2"4)U0RHP_!G+WQR3]4D
MUQTLM_6VO3U5=]Q3DEPD)^8#$L8S:PSANBXB>:B/F83KE$V6 #+O3(^1H+,C
M0 WZ(0E 77"0%-I%3CF67(>T=2*3O^B;!)I&)^!^#DI-(3/C2MB$NSONAQ 4
MFNX0-"&PTY2PV&UPA,30*>P\J]F*,8@JQ/);:PFC%/FCLM<W$N0)&J0!8\Y
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M4Y)L6;L 7"RX6$WHSS6'R "T-'AE_<,48'JX3^+/23P@@6$/#P'JO@BY0*O
MEB'Q@&)8Y#<39;MLES%:I^?-)J[BU=/F<$)S!)E9(]"-^B$_;Z#9_.U1HC1:
M>/"$O7#2*)#\Y73$O@B<2'@1<PDZ$Q[88K%O'SY\^??"[%J;A*B!WQ@#$L0
MB4(+R5LVV,VG+2=IH.\KD44<YI'IBC,$)2/X:(0/++Z7_K*A5X$5\XS$=UGQ
MF3P\B1(D2)$B1(D2)$B1(D2)$B1(D2$!\X][42 46/%@8EA,LAXN.:Q8<1C3
M=#P\.-6*(X4%;)%;*W"5]1?A:(0PYF!;[Z(VG?"?Q@6\+>(   [!O#:B^XS8
MNN2Q7S \W+S.6N[#>,39.)"\B^2SB"C?0:PN4@NP%YEL-F^)^*#=Z=^=&^@#
MFIS\E]XA"C?5 @'UP"P-ROG)[DAV]K+'8;_D3WH^P*(@HWZR]:];X@(2Y#L-
MF\P7:7SG!8]RMAMK0H[_ ,8P BP*?% 8E@;A'9#\$A^I?0 F=1E+?3'7.,>:
M!6/DRQ?QT0@) &-S":6+L3\Q+#X&Z'2):9ZS5L'<72H T<%H6E2\DALTYPF!
MJK5:+@U9,:50)S TIA;06P,8,C44J7=B6N1#%Z=Q'0,84-(#(97-$Q4W"[[W
MP(G*F,04I[Z:8&9U<X\C6 ,U9,6)19V[)/[2"BGG_P!6$UZPUT\7I%9*T2Q%
M:&D*! J#*V\XL1P"E>1Y;#[V@]D#9M1C?VN!P]-J[4BQO+G%:2Z\4!B6)4<%
M/ML!EDN2A^%^CV5<9DRII7=D:KI'Y.B<?\-$)%]#!_)4@H((JDG-JF+OH#7K
MK!C"PX@]NZ@458ZTP3A!0HI0HAP?DBV99@Z@#\T]NA.:CCAW41QGUN;AFR@*
ML8PDF$*0B5%P>5BN'K3KA;10'#G]HY1#,50>^R)>>!6ICBKV.(TR#8\(EMH9
MV52([Q60[U"1F4T5WY&<J#9?<<!TKBT;_G1G/%TTD()1*T<"#D6X;(Y]\N%^
MED+X(F'3 U36I= O!F<B6HB2Q5[@J44,ZLJ]"R!I<A:@AP55$VP-MA1-\ZKE
M$#Y=L4 A!9H,9C8*#PA1A0.0$!#*P$$O#@8B!9Z*XB;U(IC6'JFY1W( 8DB0
MBB.^I\(8X:;J:#!OP))+;$'GT\"#8#K"?HR.+%Q=V\QP6_56%6M%W"CE9:S(
M8T.G>?DV# $Z>(&NJ?$&$%%=;DC](00E03 0E#)_;X.9Y/4,9!AC2M?.,VW$
M*DQ13"(VB8%Q&B 8VR7#6CXF:/,7LPB ?Z*RJ+!/<TI2_B;<ST2 C[LEJ82E
MI/&66;JLZTK8/3:=G9&O;V&BHUV[;H4]$K$BP;(&=Q8J(-P]T:5(%2H$,N@]
MN%&1C):N,JH=XCG:8S#F[&O?B*];" ;1.---2,2-14]6$?32P,_$PVI]2]%=
M$ I;P!B&&VDJI523D1!I<3004@[Q()??=.'#APX::&(R1AH%Y@M*?(281@(4
MGW$^A[$O,0S:5 #'R8H4*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A0
MI^0H4*%"A0H4*%"A18.[ )*N  57R>)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$
MB1(D2)$B1(D2)XJ)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$,/^8^&#GX/4/__:
M  @! @,!/Q#;H-:#6@UH-:#2)CL6XLAB@F"?+!!!!!!!!!!!!!!!!!!!!!!!
M!!!!!!!!!!!!!!!!!!!!-X000000))G,"0?[N 3!5  NJL :K8HRH I4TI0H
MYLZ#F]H?NNT/W7:'[KM#]UVA^Z0VK943]*K]C4OX4F0#_$P'*S<1KAF;S+B6
M3< W1((U%'19]0W):*"%L(6 HB3)B0W.U0@2G,$1$  @(FTH6&.@1/1L^H5P
MS-YEQ+)N <+CL;9XRG"$BGE"C09E109<@5O3(@5 RJF(M1!R+ E@(#9Q_-KA
MF;R#E;:4F-U8+8TTDH18@1 4LLX$#+-F'8&/"F>3!&?@.)9-P#A<=C:O4&<4
M$&J(_=1&]M$5QAB"42LBXZ0BBX@RB2W5))V\?S:X9FWEB'%E\KW)$#R%SKA3
M_:X4_P!KA3_:X4_VN%/]KA3_ &N%/]KA3_:X4_VHH@]].043(EEC7!O^5P;_
M )7!O^5 3V@#(0R0,(Q@E8WTHHAT:I?R-D]SP) +<;H'3P/$LFX!PN.QM0M@
ML;>'"#S*2YU/HTP^95@%;L))65:N8N)('*$(6N,WF=O'\VN&9O('3W*@VERD
MA%>5,_JIE3KU">LK)K)BH4) $$PD EB?0\!Q+)N <+CL;9/.5F8D@A QL1CR
M 501(@)!&;(1%%]E8&+X800%)(!;./YM<,S>0NGN7C'*05)$CR8M;EX'B63<
M X7'8V@F* MQ8P3*)FF3<.L%0/.K(N5"JL3( DQ5C-X$  $A+LX_FUPS-X1T
M$*3D7: 4@2@P<FA&V8P*RV&_):?@ERY<N7+EP-JX'$IDN,%S1&3PG$LFX!PN
M.QMBR;,)@#)#C.$<ZQ$ 6;<Y![@8EZC"2).%="E< XG1V\?S:X9F\R=Q+)N
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0)$B1(D2)$CD>X8]7/^?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>pg77img1_424b4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg77img1_424b4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!2@&V P$1  (1 0,1 ?_$ .D   $$ P$! 0
M       ! @<( P4&"00* 0 !! ,! 0               @,$!0$&!P@)$  !
M! $# @,$ PL&"@4)!@<! @,$!08 $0<A$C$3"$%1(A1AT15Q@9$R0E*2(U,6
M"?"AL=57E\'AHC-#)%24%QAB<I,E)O'"TF-$)S<9*8)SHS5%532DE<56AR@1
M  $# @,%! <%!04$!@D#!0$  @,1!"$2!3%!41,&87$4!_"!D:&Q(C+!X5(C
M%=%"8I(S\7)3%@B"PB0THK+2LS5UXD-C<Y-E-A<W1"4)9%4G1QC_V@ , P$
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M4V!%2D\YW]JY^FKZ]9RMX!%2CS7?VKGZ:OKT@M;78$5*/->_:.?IJ^O6,K>
M6:E'FO?M'?TU_=]_NT96\ BI1YKWCYCFW_75]>C*W@$5*7SGNOZQS]-7UZQE
M;P"@%AXH\]W]JY^FKZ]9RC@%D-((Q*0NO#Q=<&WO6H?X=&5O *=4H+KPWW<=
M&W0[K7T^[UZ>.C*W@$5*/->\?-<VZ?EJ]O0>WVG1E;P"*E'FO?M'/;^6KV>/
MM]FC*W@$5*/.=_:N?IJ^O1E;P"*E'FO?M'/TU?7].C*. 6*E'G._M7/;^6KV
M>/M]FC*W@%FI0771XNN#[JU>W[^C*W@$5*/.=_:N?IJ^O1E;P"*E'G._M7/T
MU>\?3K.493@$$G*4GG._M7/#\]7N/TZB,:WY\!N^*BL)H[U?$+$/'5N_Z2I1
M2G5>_:%A+IVA0D*2K9*>WN4I"$A9;2A2EK2A*5%Y2&@%J5M\1 Z^.D2.R,+N
M 66BK@%YD<1?Q7?3/R[G]3@U91<RT%=?<TY]Z=,=Y,RWC.XJN)<EYGP"QGUV
M3<?5.:>:["^VHBZUY##11NZ$CM7UV.&O;EP(.'M3Q8!N4ZXYZY.",K]8&4^B
M6KLKE[F?$\4E99:)D4;T;$76ZV%C5M9X[5Y&ED54O(JJBRN!+>A%XOMM.E3B
M.W?2<QKM ]>WUK&1O!:? ?79Q-R-D>>PJ+&^5U\<X'9\IXYDW.CN"S8_$C&0
M<-5[]GG\")DI*Y39IEU3\)@J0D/2VG$,C8))2'-:T@X?-AC[$K(*[%']C_$]
MX/QOTZ<@>K/-, YOPO@O!,'Q3DR+E^1<>R843.L1S3)&L9HIF$J$MU,Y<J7+
M8>5%);DMQGTNN)2E03HYA#@'4%0=XW;_ %I#V # 8J;L6]9/"N71?4.ZU;6%
M YZ88T*WY;;O8(K)%=C=SA,7D*CO*ICS4&4Q/Q.2%)<:"0J4DM[K(4-&>M&D
M@.P.VO>$WV[E7WA'^*+PWZC>4+_B_AOB3U*YC(P^RP&ASW*(?$MPC!N.)')&
M'UF=8H_E^1%]A5._,QRQ:EK;4%=BU$*45!6RAMR$_+N[1O""*#,59WEWU7<4
M<,<Q^G7@W-';=K/O5#:<F57&\>-5R)E4[8\5XBYG67Q;J=$\T533E&VA<=1*
ME.O.%/0C6<V5M"1[0@"N(40^G+^)!Z:O4MQ)RAS/A=AE]#B7"\%VWSV-GN,2
ML?RF+B[E5,OJ.\KJ1QU<B=!R6$TM%;+1WI?\A:5 *&P3S/F !%#VCTV)J9I'
M>H/C?QEO2,YQ%Q#S4N+R]&PKFWE'.>*\?BR.,[J)?XO:\:-4-GFECFV/N1Q-
MH\8Q^LR*))^;==["VXMSX0G;20[YBT.W8I!B<-H5@O4K_$&]/?I;Y#X-XVY%
MG9;:9'S_ "EIPMW$\;FW]'#K9EK74]1>9A;0&Y1HJZRL;=MF%(5W%QWS$H/P
MJ(S4/&;#F <>Y.Q T/"JUF-?Q&/3OE_IHX-]5E-*S![BWU%9_C?&7&JI>,S(
MN03<HRG.+/$H$>SK/B^R8+5K4.AUU2N_R>Q?BK;2FRAQ[1MQ]B<+2,%SU/\
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M#$LKO-XN<XQ,H,D8QAG'I5W693$JI:?,M*J_KZ]WY.0VSV.NMK0DDI&DB2A
M<6XCCO62T\% #'\9KTB*XCX=YJ7%Y@:PKF?E;..+*%$KC"X9R*CN.,F\?D9E
M=YY1;_\ A/%J:NR.(M,G924(675)2$DC ?4Y7$4IQV'[>)6<I5@O49_$.].O
MI=Y$X.XPY&GY=:9%S[\DC"7<,QB?F%9%B3Y]97T]UE-C6=L"C@Y#/ND,QRZK
MMDE*E E23LH31D9PX95@,<=@V+#CG\1'TZY;Z:.!_5E3R<K7Q%ZC,]Q?C?C:
M0,>GMWTK(,JRRXP> )M4XR1#B"]IG_-=<5V-)2-_$:5S&$$M<,.U8RN!H05R
M-5_%)]*MUR;ZQ^(FKG+8^<>AFGRS+.:JN9B]I#B6=!AT.0YD[_'4PH0<VET3
M<,KEA@A+!6@G8*3NVV8/ (/RX8]O=P[0E%CAC1:H?Q3N!+D\RL8%@//W)]KP
M#6\4WW)U1QUQC/R.WHL>Y>X^7R;C&1(B-N1FE4K&+,A4Y_I\NZKM4E1T_7#!
M)H5ML$_B:<+9OQ?@'.4GC#GGC_A_D?/N.L)Q/.^1>.)V+T]JKDOYDXSDL2;.
MF.B?B9GH;CKG ,M(D.)01\0.F@YPS5(+MPV8?>LD4VJSW"WJ(X_YXN^8Z7C\
MV\Y'!O)$WB/+[Y^ J-CUAF])"C2LA@X[,4I0L4TTF5Y$E2"4MO HWW!TXTN.
MT46"**>OY?SC2S])6#])2?R_FU$9^_ZOBHK"*.]7Q"0>.K9_TE2REU =]06$
MNGUA9XRD)DQUN+#;:'V5K6HA(0E#B5%1400-MO;I$N,;AV+(-#5?GP_AO_PX
M<]PC$,SSSU15?)L/)^._79ZL_47PKP%,OZ;]Q9D_,LSMI?&_*4NOHWYS-S<7
MU?+*H?GRV3'2O]8V@['5-RLHP&)/#XI]TS2=NX*-*/T6^OC$J7@?U7FHILA]
M0%1ZRK_U)\@^G^OH8-?R-7TG.EH_AO)F(OYY+O4U]U6X1@$YA^(T9$B/V5[0
M2@AM*1DQ@X8[>"RV5N:G8IFQG@KF3'_67D>9<$>F7FOA3@[*7>5I_J]XIS[.
ML3L. /4*S?4,^/5V?%.*L6]VNMY#R?(YJS.E+9@-O-O+4Z#TUDQ4V53O,914
MFYW]#_J^S7TC>O[@CTR\%^H+ ?3]R'PWA57POZ6>;,\Q7)[V'S/6<R8[D&3R
M>(&4Y%+KL1XT&)5RRU%EV :4ED%IML[)4W+;ET>-:X)+GM-!ZU<GUG>D#U09
M1ZA^/X7"/'LBYX3]:O!/$GIT]<M_7VM+3-\74G&-QCMH]G<EF64S+2=9X?-N
M*9EB-YVY4DJ"0@;YBA+,"-RC5PPXK3>GSTY\M< ?Q-/6KR/D/I6]1.0\><\>
MH?B;)>%>3N,,MQ"OX;K,+QSB>!@=J_GV.NY; F37:^?$/DI3"6$M(W'CJ87.
M% ",M,4S<,YD8XM.Q6L]=GIXYEY:]>?\+7E;C[!K#+< X.R#U;6'+&85\VMA
MQL+BYSPBYAF!S[1J9/AS5&\OV@SM$;D$+_' 3\6HTD0?L"5"#&TU7FQQS_#L
M]8..X9Z',-H./UXEB?,_&6%\+?Q":>QL:YFVPC#.)^29?(-'<J^6MGHLN7D-
M/(FTK;<5Q[9N<DKV'< W';N8"=Y4ETS":'<ICQ?^'IS!E>0\3XER!P_95G&#
M?K$_B77&<A^=CJX5)PUSGQ]38KQ3D 9BV3CKT&\>\Y,5#:5O,>3\:4]B-\\N
M3U4'MWHYK:;5%>&>A3UV9GQGB5SZA</=MN:<5]5/I:XNH)-3;5DM^N])GIQN
MUQO^)CK\JP$&6,@5:3+EYM01)<04I4SW-I05F,FH -:)(E9M6]X7]*/JFH_3
MAZ./X;4GTVYS45_I0]4^-<@Y9ZELAOL4<XGRKB?!N3\MY*J[K"DQ[1V^NLBO
MZZ\CLN5CL2*&'PXGO^%.YRS3"JR9F%Q/8E]1'\.KU(9GQYZW.6^...;9KU +
M]7/J.RKAS%G<@K*USG3TT\_8K!P;D##7+A<XIJX^2PG#,KV)#C:V;*"TMQ(2
M2='+(XHYS*XG!31Z+O2#ZBN*^1?XJMME_%UUB=-SQP#Z7<4X85(GTLS]ZK_!
M_3%:8'F=; <BV#AAR,4R1]FN=4^AI+CJBIGO;)4#)C2A0969059_CGTOYN[_
M  ?J?TR9IQS*:Y7K_2'*Q!7'3LR!)N*KD^FP^;88NQ&G&6:R)<Q<YA0GHSC4
ME:6WD#9:$[Z=$;:T.;9P2*YG9AO*L_Z".#Y/I\]'O 7$]Q465-EU5Q[23.2F
MKN8U.R"3R9>Q5VN;7V36##CS-G?6&3S'5R74K6%'KW$:=Y/>DG:K?J45J*CM
MNH[GM&PW/N'L&I;11H'8L)NLH2Z%$.U&A VI-"EI=9&!0C2LS>*PC1F;Q0C1
MF;Q0C1F;Q0C1F;Q0C1F;Q0C1F;Q0C1F;Q0C1F;Q0C1F;Q0C1F;Q0C1F;Q0C1
MF;Q0HMYKNL[QKB/E#(^+,4E9MR= PK(#QMB##S'=E.<,T4HX_4-_,OUT>'!E
MVCC;<I;KS:=OB2O<:@.)YSBT4;7'M]-R7N7A%QC_  ^_5SZ?,M]&^5PIE!R%
M$MN)>4?3OZAXN$8E#QC(\)Q'FB#9YI>9YF=@Y>,.91)QKE!82IQ)D2'FY3J^
MQ6^YS4$D4.'I@LX&I5L/X:BO4]Z?N,.+?1#S!Z4,NIGN%(=M@\_U 561XNO@
MK-L.K+J39X[E>(.MSSE,B=DT9UI4JJ?B,.QIS:U>9V$#2<H<,XJ"<>U!X[E4
M3U,>C3U0Y9_#]_C$\3XSQ#<9)RAZCO5;<9UPIBOSU(W9<D8E*S?C:W9R6M>E
M6WV9"2_44\I2D2W8[R6F5)_&V!4:D@+(()'<NS];'H\]4N3^HG HO G&CN0<
M*>M/@[B;T[^N:\A7-)5L<:8_Q-D6/6S&:.M/OIDS[R9C#MO2%+'G]WZI>_Y6
MHK;'.*C9CV*3S6#>L7*_IIY2P?\ BX\A>I2'Z5?4%RYP;E/I5]-_$W'V1^G[
M+\?JXN.YKQOF=A+OHV>Q;C*J!]['(=:MI2XY9E,J;!"0=ANCP6-:BNS'#TVI
M7,916?\ 6]P/S1S%Z[OX6G+_ !_QY9Y#QYPH_P"K"SY?R)J36P6>/4<G<'OX
M?B34]B6_%D.&TR IB)3$9?\ UAW6$-_'I4EED%=^Y8$K.*\Y, _AT>L;%,2]
M$. U&"G&,(YCXEPGA7^(C42[>M5.Q#'.*.29_(^-W):@V:X\Z3;5$V91J=B+
M><0B7V=A0$J&18U;5!E97:I(Q'T \UY-DO$V'<@<.7L/BV9ZO?XDUYR$Y*E4
M/DU/$G/& 8_B_'62MQ4VBWUU63".1#:;;7*8+/<XEM0&CP-6@MVGBCF,XX*.
M\<]!WK;S'BS";/G?!E6O,^*^K#TN<7XW(K950ZQ6>DCTZVKM='Y1FMR;A<1]
MK)K"QG74V+WBQ\M3*2V>S;6? 5J CFL6_P"%_2CZJ,<]-/HU_AN7'IVS2EA^
MDWU3T'(.6>I2RN<-3Q#EW%.%<KY;G]-;8NF/;3,BM\AR%B^91]F/PHJ&'F5]
M[A 3W8&GN)KN".:S:OC]2?\ #D]2^8\>>MWE?C_CJS5ZA!ZP?4%E'%&--6]7
M4*YV],W.^+U.&YWAC%L+-7D0\CK/^](:9JFE1[&"A*D)!ZN16O*=G]21)(RF
MU3EZ)O2%ZA>+^1/XI]YF/%=YB%3SYZ?_ $N8IPZ[(L:AUO-LFP?TQV^#Y13P
M7X=H_*B3<>S)T07EOI8:><W<2HME)+U<:)CF-H,5;'CCTTYK(_A XYZ9.1L!
ME+Y8@^D:5C:<&EOP/MROY0Q_%K"QPZB:G1Y$FO9L8&9PH2X<EN0E"%MH*EHZ
MG3,M:XC"JP2UQPXJR/H)X-5Z=?2#P/Q=84MG0YE78)577*$6]E,V.26'*>2L
MIN<ZO,HM([TEFRR&SNY3BI+J7GDE0&R]N@EVY!)([/@DNVX;%;X?5_2-2'_2
M4S+]*/J_\W4)G[_J^*A-_>[OM"8/'5N_Z2K,I=0'?4%A+I^H2<S>(3DG8@_#
MT/Y20M/WTGHH?1K#J$427N&4T(K1"BHJ&ZDJ3OU2@!E)Z>X>&F<@43,_@FK"
M2!W*+@3U'F!2EHV]C:T_& ? ['J-&0);'N#JT2I*PCN24-!S\=I(24DCP*P?
MUFX]FLY G>:Y![E_ I0*%_"OL_5GM\3NH_DDCP]NEQQLS?,<*)39*FA6,*0T
MDE@B.I_X5]KDEEP]A'12]E(6'$C8#;KHGBY;<VQHWI4LL<! F<&D[*X+XY-_
M35CDIB=<5U4MF,)"X\VSJ(3L&,ZZ(J9,E+SZ7T,ID*VW4D#<ZHS>VG,+.8S-
MWJ\L]!U>\8V6"UG?$\T:6M)#CMH#O-%L5%I0"FE,K0K8,EI07^J2D GO22A2
M7'-U CQWU<0-$HS"A:J6[CD@>^)X+7Q_4#@6]XW)I&Z2V3L%=2?9]'7[^G9&
M1FF0]]/M4"-SY(Q+&*Q.V'<:8&GK69MQ3:0E)0 /#N2%?@TUD[TO\S\)37%%
MP@J*=P-OA':/_+HR=ZP2\;DSINVK?JRHK2-_'NZ'IX>S1D':C,_@D4E*NCB0
MXG<OI^,#M>'AT'@K1D",S^"/'JH]3L3UWZGKMO[QOHR#M6,S^"-.B@ "E,<,
M@J15&LX)>9O$(TB0B*G,^6NRJ,[>(2]JM^W;J 5;?0" 3]XJ'X=*+7-9G(HS
MBE4)321K%"HAVHW'O&BAX(&U)W)_.'X=%"I.9O%'<G\X?ATEX=E-!BC,WBCX
M??\ SC47\[\/N1G;Q"/A]_\ .-'YWX?<C.WB$?#[_P"<:/SOP^Y&=O$(^'W_
M ,XT?G?A]R,[>(1\/O\ YQH_._#[D9V\0CX??_.-'YWX?<C.WB$?#[_YQH_.
M_#[D9V\0CX??_.-'YWX?<C.WB$?#[_YQH_._#[D9V\0CX??_ #C1^=^'W(SM
MXA'P^_\ G&C\[\/N1G;Q"/A]_P#.-'YWX?<C.WB$?#[_ .<:/SOP^Y&=O$)"
MZ-P%?%V=$'I\(\=.ACR*D&JSF;Q"%+[OB<(&_4EL_']T_P#2UG(\[BLYF\4I
M4DI2D'=M"BMH*\4O'Q61["3HR.X%&9O$)"L$[E0)]O7V^)_GT9'\"L9F\4J5
MA"RE6SR=NC3QV9^@CR=AW#Z=9SR?A*:YA[$T/#<=S;8V\-U. _0?U.R?P]-&
M9YVM)]2!(>Q?1\TH'??P._B#X?1[=&>3\)]B.8>Q)\QMW$.[ESH1V ?1U]VC
M/+^$^Q',/8L2G M2%NJ*E-K"FE [E)2>X=?9OMM]_1GE_"49W=B%K[W%/ A"
MG'O/\I.WEM+V([FP?A[UCQZ:,\OX2CF.[$XN*6I:W5=R%E*W$?JQW=G@/AZ[
M[]?O:.9+^$HSGL2**20M:PI24AI1_.=3U<>'O#@(&_T:"9'84*2][B$WN1^<
M/PZQD?P*:J_@GI4D!9[O%"D'K[%_"=-21R$8 IR-U"<V 2(&Z&P.OEH#8^XD
MDC\.^I$37#;5/YV<0G['KT\!W';KLD$;G8==AOIQV(RC:4W(YI;@0D^GZ/\
MS3J(UK@]T9'YAI0;SBHC6GYC3##XA,'CJU?])5D4OM&J]^T+!V%&G%#1H0C0
MA&A"-"$NA'[S?[P2*[2A04LM@@?&$!93LH$?"?>>FI%__P H>[[$SU S/-$/
MX@OS*?Q1)4I'J5]3*69$M@-^F#CFP9CQID^&TN3(Y B/.O(2Q(2B.^2G8J W
M5X:XGJ=RZVO 6G:^B]H= :>#T[8.+02'5V;Z;5^C#BD=W%G&:AW$)P?%T=RB
M5*4I=3#=5W+42MQ06L[J/4ZZ7HMT^2U&\T7EWJV$1Z]JP& !^TKO3]SVD??'
MB/O:L[8N)>7<0M6THUT6V' /_P"N4FI2F(.DNVIF7:$FDII&A"-"$:$(T(1_
M+^7W=8O_ ,Y\3!N 26_456_)>2^9)G,]GPWQ+QQB&62*7C^JSVYNLLS%['HT
M=J]O9-2B)70V(;RGWFQ7]Q[B!NK3VHN\/9->_8X@#U<5:1@EM MP6?6MN=N$
M^'MM^G_O8G#^;[+Z:!K.G@ $.K3\/W)/A4@:]:O]B?#O][,[^J]9_6=/X._D
M^Y'A>Q/\KUJ?V(\/_P![,_\ JO6/UFP_B_D^Y'A>SWH\KUJ?V(\/_P![,_\
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MFP_B_D^Y'A>SWH\GUJ?V(\/?WLS_ .J]'ZS8?Q?R?<CPIX>]'E>M3^Q'A_\
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M_P 7XK/+CX!'S\G^13]>CP[/\4^PI-(0CY^3]'Z2/KT>'9_BGV%'Y*/GY/\
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MMU ]IW(^]I"PC0I3/I"30E)?\>B;_P 8M_[C/M42X^Q5NP%_R?6ORFH?B_\
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MI+7"W+_E[J#@MQJ<J]+[_OZ:F_\ '+;^XW[5%N=W=^U5/IW_ "O67R8%$].
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MNL,5-2S/CT4#)8SGEN69<F63JH;2V76VEAOL0-QOKVS;-M-,T%C)XP^4-)-
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M7?4MV)A!-$.6UC",HQKLQJI[NKF/0TUO=OK:+%-66ELXCO2 I,"*N4TSY96
MXX^\VE"?>I7ATULNJEL5AF>:8+1H!/?7[9"#1KMB\NJ;(X*(&7\F"BDSI/(.
M66K.2"MF"J;Q>J$65*F6MO7O(4<A:MI[2&D-J0Y':? "BDD*UY;Z\OYQ?5M@
M'1\NAQ[2O2_0UE('1ZU)%S&1'*(R:"K:'/F&-<=A%%!V68O N+/!,OK<"B<D
MX#"M+"RRCC>%(<I9^1RK^(H(R"2W/=3)1*BN-(\YEY:0V E23V]HUK73NG7E
MR[GQO(D_#0?%-=?^9O3?3=T()LD[[@4+22.37'"@.:FS&BMW0SZY[TRXGQ([
M4&\Y0^V;ZYJ'X\65,'&-$9\FTQFLF9<ZB*[.3CS2T1G?*6X%MH\OM4G<GIND
M6>JB?-,T\QOP7GO6^M>B=.ZQ??07=+9L3' M83F<]E'-H":!I/K[%7NMSZ]3
M;-/76.V<=3=580+/%:Z/#=4YE2;UGY&W@KD+$QRGE5PV"U)'E!X ^!&I\7FE
M=Z?J8T9]DVF:F?F'AMIE^U<TU7R:UGJG0&]?V-V9]*TZ*8Y7-8WF<S'&KLS<
MM-P-5)&90LCKZ[&,HI40*V[AS83$UK(('S'[LUKTMHV+(EQDK%=8R6CY;4GJ
ME)'0$[C4GS$T6;J31&WX<8ZLS8"O[$?Z0^M?T;J'5]*EA'+OI&D?,?RZ-RT&
M'S5/<MK+LLBBUN,7-;?R[O,\'%E<O6-]9M(RJQJ569EL"+1129EA05ZG TX^
MZDJ4C;S$IURSRVUF?2M0_3Y&YVAQ&8FA]E%[FZ\Z<9J.EPM#S&YGS- ;7, *
M8FN&U6=Y!J9/+_%<;/\ $<LS.-F</%)0JZ;!;UFF@VML^&/MVNL:H),62^S,
M<_5.DDMA.P&O1PYE\*!Q:#ZUQG2V6NB7#I)7\T5/RD4IZQ78I>XQPO&N.<*I
M,8QVF8IF6H,"1:-NO%^SG7#S:'KJ5=SE;N6-A)D+6E2U[]A_%Z=-2XK&:TQH
M7GV*CZGUJ&_.6$\DC>,?BN\\]C=14E"MUE>Q6GXCU 2]VA/FH3[!TUL4$'*%
M:UKV+6)(3*-J9YZ/#N1^D-$T',.:NQ.1-Y3,@QP3?.;_ #A^'_%IC*Y)Y1XH
M\YO\X?A_Q:4&.)H=BP8C1'G-_G)_2&EOBRBHQ2A%45)HE#K>_5Q 2.JCW;GM
M'4]H'52]O >TZ;#37YQ1O%-OCD:/D&9RR;H^ DE*>Y1=4I)26FT=X)4@@*2Y
MWI [5;;]?=I>6#\9]B&Q7'[S:>M,\UGL2H.#N4A#@!Z#L65!)W]_PZ4V)DAI
M&ZKJ<$IT,@;5HJ5\4^TK:J!/M;-[RH577S9\AU"5/N-M18[CCBFX[?ZQ]80#
M\*=_?X#57/=.@DR%M41VM_*:1Q5]:90WU+E6.U67X_.9M*:]@M3H-C''ELO1
M4%+"P LCO<:?/:L)W[5;@ZEVTS)" <"?<L7.G:A$&NGCRXX8UJMGYS.RCYG<
M$)<6XIMMQQ+;;3GDN%92.[N\SP '4;GV:=N&1VD@(-:XK$DFH1QT\/\ ETVY
MON7,9VZA&#YJGO05#$<F0H!04%*-%./>TH?"ME22-CX[[[@:F7$ =K&E2UVS
M,_[QBKFS$P2$C'##@HY4D_\ RXVT]=O^7L]=O'_NMSJ/HUN]F_\ _P ]W;/_
M )RS_<6H<W_BMG[WVJ^Q]FN<)4>U.]NL;E8--&U.Y."2H[-_$KW;[#QV\?9I
MK:H_B&38-VIR0D]Q'?W(W"VE(4%@CQ5W?BEOZ1H3;[:7(7T^4"J5*UI4E2$)
M6XG<H[D%PA(![T!(._Q)WZ^P]?9J/+L*1#N[U3+G5WU6XME-#:\>S\:L.,[6
M:Q]NI^2:<R3'ZXN)"VI"%$)=86HA(D#9P[[$;;ZJKHU8[U*VA^L+G'E=CJRE
MY*&R\7%N%*D!UYX]ZW76VB>P!P^(!*=5:F*C7J,RKFAI;,_@O%X.;9]036E4
M#\:-=5T] #H^:J<K<D]M)8TLQ/1*22I9"3TVVT(5JN-;W,\BQ:FL.2,-<X\S
M5Z*TK),7=LXUI%A6;[/=(?CRHFZ/(><22T-R6DGM  )T(4E0F(\J),?D3C$D
M16_+C@-E:Y'Q^(VW44=OWC[="%Y\^H[D/U+QLZH<8POANY:X8#[3N69]7V/S
M=O;I&P5%CPZ5]%O20&-U%SRDJ+B%D;#0A6DXSR1.2T44]V+M(B140HE=0P+B
MH1%B1=^UF7%N6&9JY8*B5$E7<K<[]=8+\J%-*,AG,?9+*$F,FED(GQI(92A;
MK>VSC7?XJ4=M@-'-[2BBLU1<E8=;QFD(EOU]A(CHWCR1Y:'9))#CCLEW]6K?
MW'XMOHU;6%VR.(M=^)0+IP;( =M%W$1QJ4XJ/$DL3WT-M/%IA32%>2IU+9 *
MEA*UGN^';QU<1WL1WJ)X.>?Z 5EV+:E]>U86M"V]P2@I)!;<(W'>GV_3IXR"
M7YQLHE<F2#\N3ZTW??KL$_0/#^1TE91H0C0A'YWW]-3?^.6W]QOVJ-/M'J^U
M46S"4(OJGY%6M"5'_@=QA^-N/'-\E]VMQZ@_^C=$_P#-+K_=5WI.P%=)]KQN
MN[#W7<'X@#]T'?IJ)JS(>??\*0? +=6LBF'R+(W>,- ):CO A0*-W-QW ]5+
MV_SJU?G'J-&JPV\ATMC_ *76SP>XNHB.26WG8&X-SM^(7 7M# 5C>60,,<_<
MJ]R3R5RL@IXZ46!LDN-K<MG7@E2W'U=I"OA)V4=NNM?U/18+<Y; 4'9Z%6U_
M>QC4JM(VK<Q(-8_24E)E<"-F$R#$8^9N+>)'>^>LF]B;-8(5)^<<V \$?>U#
MM.GXI6\^Y:*MQ2KC5I&:E:EQ^02"JRY'DF'_ "K"LEA-6#<>?&1%9G);=,.W
MW#,-,>.?AC3T)5NF*%*<4@%0! )$UH@MCECI5:]JEQ%=ZR2#^\NC5=0NYQ#K
M9>6AMIH^4TID>8 % DJZ((;&VIL0+R)-P5A<F.K864S46'[7A^R*\#[_ #$G
M_#J2H_)<C[9C#_V=[])'UZ0_%J.0Y'VU&_V=[])'UZ9H$>'<E^VHQW_U=[Z/
MB3]>EQO8PU?L2V0N:#W)R;N*D[_*R% ;_"E8'7P^+;?O0I!(*3T(.I&6*38H
M[)N5+P-4OV]%("1"=3L5%1![2I2NI(W)V2!L !T&CD0QN!-*J3J5P9G1-W4/
MV*OOJ4GV%CQXW74CIB2+*_J83L)WO2B_9<=4#6O36278,9A9#JU)&ZN@UIG7
M%ZZ"P(C.-"MKZ:T^#.)'A5WS65F-38P:&!_W73NU=35M87.9BU[U(@1%MWCL
M'((;#RYLJYL5"2P9+P"1^,CH"?)[]2NM2UT:3&"Y[Q79V]B] :9J5IT[TO=Z
MO,!X9H<T'<'9>^E<56K),9RUJSO*Z'C6;_OZY;8D[QQD%=<^1BV)5\1+$3+8
M66PT]@NKB;8>8MR9LOO:6V$$!.NB=.Z7J6CZK&RYC<(G$;01]@7R>ZLU>[ZC
MZOO[FZF(M7O.2I%/J.RO8KN6=5*O<=:IY=W/KYDF!7B=<T;JF)];910GSW8"
MU_"7''$D$KWZ'7IS3K/3Y[MS" ).6W#U+F&CZG;=)ZA-)U8Q]Q85^4Y2X8G#
M9EPV;U$>7JK<3#51#J&<HR\5;MTW:681(RZRI*Z2+.73MR$=KC[DYZN#CA2.
MC:0T/\YKSEU?T]EZK+H1\N9>W^ANKM3ZB\I;]W3=PV+01$X<O,&FE#^Z:G=Q
M4K29L?(L5-I!B&-&M*5-TRQ-857&O=<:,PNV3*U%)=+B/).X5NX"H ;Z[O>6
M-N.AK>.0#FBVQ[\5YA\O]3EZ6ZVTN=IRLO) 3VC/E^*B_CZ/@\>:NHAW5949
M)=(R'&FK6<Q89;?UEED,,Y)>XNB<8BH=&NP2/,1NHH;;(3OOKQW"1I_4CBRG
MU'XK["=1S-9:Z?"XD"9C,*4K4;N*M1Z<IL6OXS@QC#08Z;6]?C=@0J6@R);;
M3R%I24J:4%1^XI]BE$:]6=.QYXHY'?O,:?:*KS9U'IT$=Y/\P YKJ;.)4VJN
M87<K_4Y1/<=R5]2=R=SOUWUT&ML& 246I0Z'!=N-7"OJ1]L1?]G>_31]>JVH
MW;$WR'##@C[8B_[.]^FCZ]&U')<E^V(W^SO_ *:/KT<H< L<EW8C[8C?[._^
MFD_S [Z.37"@2XX"YX::4)2_:\8 GY=\=#L5*"4@['Q4>@&XU@O;%B_8HUX.
M1)D39<Q,F',C,AZ&]+B3(T:62V?EGG(K08EI4I24-F.N0%]Q_%*=]CI#KZSE
M;R7$"N]2HHW"#Q#15P5;\/PKD^FSG&\AF\P+S3"F& Q85"FVT?-+$!13-78(
M<_[VF*=0^N0G9*65J2$Z9I8?XC?:/VI!%],?D8ZG<?V*RR[9KRD+2RX^@-MK
M2IDA3;B'OUC;"9"26O.CI6 M)ZI/CIV*6SA=F8YI)%-H_:H\\&IVC><^-P;6
MFPTQ]2Y_*)5M98[>5^+6+-#=283T)FXFL)GPZQ]YI2O.?C;'SEQT;K1^0I8
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M@_"H$M[ CS!^V:45@>2CQ43X 'II_4HFEEJ][B#"PL'<XU)/:$NXN/\ B&-
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MI;'@:T!._@K)\(>IK%.:H4]2:Z?BUQ7R%PE&9(AO4D]99$H?9=E%="9#900
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M:*C?\1F'@-OZ5,\Q+DGF&LX8QS(_L%=AD=L6EOW,&LN&;BPH*6IC*^T9SEG
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M56,6CQW&^9L)1C'(E/,A[F6T_=A"4Y!5I4.T.C??QWUO73+M7NF Z@6DTW-
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M2VT&(46V?IH\5-Q-B]>QUS=2=^FF](LAIT;60@@#CBM4ZPZS_6FFZ+FDN&X
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MX9JC-O[=B]4]':?;W0EG(<+&*)SF#-C@*D\74IP7&\X0<K98J[VO;SN7C=U
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MD$U% ^$2WG;.GC=JH+KR0RVW;-,N%83,.ZEC9.Y &N*]9=+===(W;X] #AM
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M$N%7 4&P$ @J\.+<4XWB$-<2H;\MZU?@*L'PF(P_(E)?[Y$4!(:2U'"D!.P
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M,USA]/;]-%'ZZZ^M>G=.AALIN5</H'92*[,=^\XJUV$^GS@BHEMS<JF89<9
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M6C:1TG$>I9M+I^5$P. (XMS;"/L7>VL]C&YV08?#QB"<?=H)#]$Q'JK:'-7
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M]9\,D&/O'_2]GT;%6_T_1IKF6?%'ADO[OO>R0?T#IMSK0G;7VH\+WH_=]_\
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MCK*UC&(#J@XM![VGG_)\LB(E):4H=@5\ON%>SQU7EEP/Q>TI8U!AWJO'JO\
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M6]S?:$H]</IU) $KD$D[; <0<EDG<[#8"@Z[G2_\J3?C9_.U9Y$7XF^T)/\
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MRP$[@NE]I^Y]6IK_ .BE)?=J'#^]WIB7:DTZFD:$(T(1H0C0A&A"-"$:$)0
MH@';8G8[[@;'H=R.H&A9&U9E.K);/</-0%-^:-@XA"!^K0W("?-#:ONZ%+0I
MU2E*)6H @@I"RI0[C^M1YH 0^U(<^-14@+'L.L ',*;$+$ &ALVM7P EM1V<
M+?Z@QF4-!75/D-#8>[NTY05J!BL+,7'"X"EY;89 2 ESM:6B26I$DMI*5*1V
MO,)[T>#J^O0:2YK3B1CQ6<5A2HI+A1L%.J[RM86 A02@-.,MM.(2A:.T I7W
MH 3X:26@BAV(3^[9)"E%7S 2E]/:VH%"%A]I*QVAM89DHZ)[2DH(!&D.C#B
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M/PC:ZE?578O)'U8Y-*Y*YH@872-B8FC,;%X<= \XKM;1QD6KSB$$LM_+H*'
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M,^"LT=P+'*:/E<NG>;AWEM8W+T:,B7YA068JHK:TOR&74D%!^(^S7S@\T/\
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M3]S3O)?,W*W"N\[$CF!SQ&VI>5 W*/*8I4N8Y1.-RK)8\F78!8\N$AS=*R%
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M%717E4FI2PNNGWLQ4V8O+A$:@QU/QEML-O/-E>X4=4+M6;(X.K7T.([<=O!
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MV6&U*#8Z;*6EQ(W!WU]4-&UN>[ALF$9'WD!D!.- T+S9J4MO'JL=E+$YSB2
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MYWYAXK<D*<7+<D.)V<\T$GL4>[N4GN]F^N)]7:[*79:[?3@O773/3UC:-S,
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MY#*)(<8K[=<)Y,1Q?:A\L+[%* U!?ITP^@$K%6<<%AE93B<"1719^4X]#DW
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,]_U?%06_O=WVA?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
